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Aim of the thesis 
 
The main scope of the PhD research project described in this thesis was the synthesis and the 
characterization of pseudo-glycodendrimers as potential ligands of the receptor DC-SIGN. DC-SIGN is 
a lectin expressed at the surface of immature Dendritic Cells (DCs), and it is the first target of several 
pathogens that attack the human body following the mucosal-entry pathway. HIV virus belongs to this 
category; therefore, constructs able to antagonize the interaction between the receptor and the virus, 
such as the ones here envisaged, may in principle act as anti-adhesive pharmaceutical drugs. 
In Chapter 1, the immunobiology of DCs will be introduced. The DC-SIGN receptor and its 
immunological activity will be presented, as well as its deficient role in HIV infection. Natural DC-
SIGN ligands will be shown, since mimicking natural compounds able to bind to DC-SIGN is a way to 
produce active ligands. The state of the art related to known artificial DC-SIGN ligands will be 
described. Also the topic of multivalency will be explained; a brief thermodynamic overview will 
underline how multivalent ligands are involved in strong binding events with their target receptors. 
Few examples of compounds that exploit the chelating-multivalent effect will be described. The 
possibility of producing multivalent compounds able to chelate DC-SIGN was indeed the main goal of 
my thesis. The distance between DC-SIGN binding sites is known to be about 4 nm. 
In Chapter 2, the design of multivalent compounds potentially able to bridge two DC-SIGN binding 
sites will be presented. My project started from the results obtained by N. Varga in his PhD thesis 
(2012): he developed multivalent constructs active towards DC-SIGN but not able to chelate it. The 
library of hexavalent and divalent glycodendrimers that I’ve produced with the aim to chelate DC-
SIGN will be here present, together with the synthetic pathways followed to achieve it. Our approach 
envisaged to control the relative disposition of active ligands using molecular rods. Active ligands, 
overall valency, rod length and system flexibility are all parameters that we varied in order to dissect 
their relative contribution in affecting compounds performances. The ability of these glycodendrimers 
to effectively chelate DC-SIGN was first confirmed through computational models. Two biological 
tests were performed in order to evaluate their activity as DC-SIGN ligands and as inhibitors of the 
DC-SIGN-mediated HIV infection. Former tests were performed through SPR inhibition assays, 
evaluating the ability of compounds to inhibit the DC-SIGN binding to a high mannosylated surface. 
Trans-infection inhibition assays were conducted in vitro on a cellular model of HIV infections. 
Biological assays revealed that a good combination of active monovalent ligands, medium valency and 
appropriate size of the rod can lead to efficient DC-SIGN ligands. The rational design that we’ve tried 
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to implement led to one of the most potent inhibitors of the DC-SIGN-mediated HIV adhesion, up to 
date. Remarkably, cytotoxicity of these glycodendrimers was excluded.  
Since DC-SIGN is able to internalize bound antigens and route them to intracellular compartments to 
start generating an immunological response, the behavior of glycodendrimers once interacting with 
DC-SIGN and DCs was investigated and it will be presented in Chapter 3. Exploiting the intrinsic 
fluorescence of the rods, the most active compound was chosen to perform confocal microscopy 
experiments. The compound was demonstrated to bind selectively to the Carbohydrate Recognition 
Domain of DC-SIGN, as expected, and not to its neck. Internalization studies on tested compounds will 
also be described, showing that they are internalized inside DCs and, particularly, that they are routed 
to lysosomes.  
In Chapter 4, the morphological behavior of the glycodendrimers in water will be evaluated. Their 
amphiphilic structure suggested that they could in principle self-assemble as aggregates in aqueous 
solution. Several analytical techniques were used, in collaboration with other groups. Results 
demonstrated that all compounds are mainly monomers in solution, but that a small amount of the 
sample (< 10 %) generally fails to dissolve and it gives rise to large aggregates of hundred nm-sized 
diameters. We realized that these aggregates can be almost totally removed through centrifugation and 
that, once pelleted, they do not form anymore. If this holds true, biological performances described in 
Chapter 3 naturally arise only from monomers. 
Finally, in Chapter 5, slight modifications of the monovalent ligands in order to improve their activity 
but also selectivity towards DC-SIGN will be described. In particular, a previous PhD thesis (N. Varga, 
2012) suggested that the presence of an amino group, normally protonated at physiological pH, should 
lead to less active species towards Langerin. Langerin is another lectin expressed on Denditic Cells, 
still able to perform an efficient action against HIV virus; it presents two Lysine residues in its active 
site, that should generate electrostatic repulsions with positively-charged compounds. Pursuing this 
issue, a monovalent ligand totally selective for DC-SIGN (i.e. not binding Langerin) was produced. 
Multivalent constructs bearing multiple –NH2 groups were synthesised. The evaluation of their 
biological behavior is still ongoing.  
 
To go along with the habits of the different disciplines, the experimental parts describing synthesis will 
be at the end of each related chapter (Chapter 2 and Chapter 3). On the contrary, experimental details 
describing biological and physical investigations have been inserted before corresponding results 
(Chaper 2.6, Chapter 3, Chapter 4). 
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Introduction 
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1.1 Immunobiology of Dendritic Cells 
The body’s answer to danger and disease is the immune system, which is constituted by two 
subsystems: the innate (non-specific) and the adaptive (specific) ones. The former, through 
inflammatory and phagocytic barriers, recognizes pathogens and/or tissue injuries and signals the 
presence of danger to cells of the adaptive immune system that, in turn, activates to produce 
antibodies specifically against a particular antigena and to establish an immunological memory -
meaning that there will be a quicker answer to the antigen during a second exposure.1,2 The adaptive 
immune system is driven by lymphocytes; in particular, B lymphocytes (or B cells) are involved in 
the so-called humoral response, whilst T lymphocytes (or T cells) are involved in the cell-mediated 
response. Both classes of lymphocytes recognize antigens through surface receptors. Surface 
antibodies on B cells are specific for recognizing a certain antigen; this recognition process 
mediates the activation of B cells, that start producing a large quantity of antibodies to block the 
harmful effects of that specific antigen. T cells don’t recognize a free antigen, but they need it to 
have been processed (i.e. divided in short peptides) by other cells. T cell receptors (TCRs) mediate 
the interaction between T cells and antigens presented at the surface of Antigen Presenting Cells 
(APCs) as Major Hystocompatibility (MHC) complexes. Every nucleated cell, when altered (e.g. 
tumoral or infected), can present its endogenous antigen as MHC type I complex to CD8+ Cytotoxic 
T cells  (CTLs), that are therefore activated to destroy them. In contrast, the role of the so-called 
professional APCs is to process exogenous captured antigens as MHC type II complexes and to 
present them to CD4+ T helper cells (Th). Once activated, Th cells can trigger the activities of 
macrophages (MF)b and natural killer (NK) cells,c secrete cytokines and help B cells to make the 
appropriate antibodies.3 T helper cells can also contribute to stimulate the CTL response.4 
Dendritic Cells (DCs) are Antigen Presenting Cells, whose major role is to present antigens 
to the lymphocytes. Being located on human skin and mucosal tissues, they are sentinels for the 
human body. After pathogen uptake, immature Dendritic Cells (iDCs) process it and complex its 
fragments on the MHC, and start migrating from the periphery into the T cell area of the lymphoid 
organs, releasing chemokynesd to attract T and B cells.5 They therefore evolve from immature 
antigen capturing cells to proper mature antigen presenting cells. Interestingly, MHC complexes on 
DCs are 10-100 times higher than on other APCs.6 Antigens processed on MHC are then presented 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
a Antigen: any substance that is capable, under appropriate conditions, of inducing the formation of 
antibodies and reacting specifically with the antibodies so produced. 
b Macrophage: a type of white blood cell that recognizes, engulfs and destroys target cells.	  c	  Natural killer Cell: a type of lymphocyte that can react against and destroy another cell without prior 
sensitization to it.	  
d Chemokynes: small protein molecules that act as chemoattractants, leading to the migration of immune 
cells to an infection site so they can target and destroy pathogens. 
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to select T cells, stimulating a strong immune response (Figure 1.1). Immature DCs accumulate 
MHC class II molecules in lysosome-related intracellular compartments and MHC class I in the 
endoplasmatic reticulum. The interaction between dendritic and T cells is mediated by several 
adhesion proteins, like ICAM3 (which stands for intracellular adhesion molecule 3).  
 
  
Figure 1.1 The life cycle of DCs. Immature Dendritic Cells bind antigens and present their fragments to T-
lymphocytes, after a maturation process. Once activated, T cells can stimulate the activities of macrophages (MF), 
natural killer (NK) cells and Cytotoxic T cells (CTL) and help B cells to produce the appropriate antibodies (ab).4 
 
DCs can uptake pathogens by macropinocytosis7 - in which the uptake of extracellular fluid and 
solutes is mediated by membrane ruffling- and phagocytosis,8 and through surface pathogen 
recognition receptors (PRR)7 that trigger adsorptive endocytosis. Macropinocytosis and receptor-
mediated antigen uptake are so efficient that nano- and picomolar concentrations of antigen suffice; 
remarkably, other APCs typically need micromolar antigen concentrations. 
C-type lectins are a subset of DCs surface receptors that specifically interact with carbohydrate 
moieties.9 They possess a carbohydrate recognition domain (CRD) that includes Ca++ ions involved 
both in ligand binding and in the maintenance of the active folding of the CRD itself.10 Besides the 
metal ion coordination by hydroxyl groups on the sugar, the interaction between the lectin and the 
sugars is driven also by hydrogen bonds and ionic and hydrophobic interactions.11 C-type lectins 
specificity arises from their ability to recognize even slight differences in the arrangement, spacing 
and branching of the carbohydrate residues of their ligands. Several pathogens present carbohydrate 
residues at their surface that differ significantly from the glycans of mammalians; therefore humans 
lectin can interact with them and recognize them as non-self signals. Once recognized a pathogen, 
lectins internalize it to lysosomes where it is are processed for presentation to T lymphocytes. 
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Toll-like receptors (TLR) are another class of DCs receptors, which recognize specific pathogen-
derived components, such as lipoproteins, lipopolysaccharide, and bacterial DNA. After the 
recognition process, they activate intracellular signalling cascades ending in the production of 
proinflammatory cytokines that activate T cells.12 
 
1.2 The C-type lectin DC-SIGN and its role in HIV-1 infection. 
Dendritic cell-specific ICAM-3 grabbing non-integrin, known as DC-SIGN, is a tetrameric 
transmembrane C-type lectin expressed at the surface of DCs present in dermal and submucosal 
tissues and in the blood too.13 DC-SIGN presents a CRD that is selective for fucose- and mannose-
based carbohydrates. The CRD is separated from the transmembrane region (TM) by a neck 
domain, which is made by seven complete and one incomplete tandem repeats. Finally, a 
cytoplasmatic tail is present, which contains also the di-leucine (LL) motif and the tri-acidic (EEE) 
clusters designated for the internalization processes (Figure 1.2). Interestingly, the neck domain is 
needed by the receptor to oligomerize and form tetramers,14 which increases the affinity but also the 
selectivity of the receptor towards its binding partner (see Paragraph 1.5). 
 
 
Figure 1.2 Two ways of representing the monomeric DC-SIGN structure. 
 
Interacting with the adhesion receptors ICAM-3 on T-lymphocytes and ICAM-2 on both blood and 
lymphatic vessels, DC-SIGN mediates DCs-T cells interactions and trans-endothelial migration of 
DCs, respectively; both ICAM2 and ICAM3 are heavily glycosylated glycoproteins. DC-SIGN is 
also responsible for the recognition of several pathogens, like viruses (Hepatitis C, Ebola, 
Cytomegalovirus, Dengue, SARS), bacteria (Mycobacterium tuberculosis, Klebsiella pneumonae, 
Helicobacter pylori), yiest (Candida albicans), and parasites (Leishmania spp, Schistosoma 
mansoni).15 Instead of being processed as MHC complexes and stimulate an immunological 
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response,16 some of these pathogens hijack the DCs to disseminate the infection in the human body. 
Human Immunodeficiency Virus type I (HIV-1) belongs to this category, leading to the severe 
disease known as the Acquired Immune Deficiency Syndrome (AIDS).17 The interaction between 
DC-SIGN and HIV-1 is mediated by the virus highly-mannosylated glycoprotein gp120.18,19After 
the recognition process, HIV-1 is internalized into acidic non-lysosomal organelles of DCs,20 where 
it remains stable and is somehow protected. Indeed, instead of being degraded, the virus is 
presented to CD4+ T cells in the lymphoid tissues, resulting in a productive infection of T cells. 
CD4, together with the CCR5, represents a receptor complex on T cells needed for the virus entry. 
If the infection occurs fast and independently of de novo virus synthesis, it is referred to as trans 
infection (Figure 1.3a). It can also be possible that, several days after HIV-1 infection, progeny 
virions produced in DCs infect target cells. In that case, DCs would be infected in cis, after the 
interaction between the virus and CD4 and co-receptors expressed on them (Figure 1.3b).21 Betts 
and co-workers demonstrated the presence of HIV-1-specific CD4+ and CD8+ T cells in twenty-
three HIV-1 infected patients, suggesting that DCs should also be able to process the virus as MHCI 
and MHCII complexes. However, this immunological response can only be able to delay the 
progression of the AIDS, but not to inhibit the replication of the virus itself.22  
 
 
Figure 1.3 Trans (a) and cis (b) infections of T cells mediated by DC-SIGN.23 
 
At low virus titre, which should mimic the in vivo HIV-1 levels, T cells are not infected in the 
absence of DC-SIGN+ DCs, thus underlying that DC-SIGN not only transmits HIV-1 to T cells, but 
Chapter 1 
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it also enhances the infection.18 The mechanism of DC-SIGN mediated enhancement of HIV-1 
infectivity is still not totally clear. It can be possible that, after binding to DC-SIGN, gp120 
undergoes conformational changes that enhance its efficiency in interacting with T-cells. It might 
also be that internalized HIV-1, exposed to low pH media, increases its infectivity.20 Finally, it can 
be a matter of concentration of virus particles at the interface between Dendritic and T cells.24 
Remarkably, HIV-1 is able to retain its infectivity 4 days after having interacted with DCs in vitro.  
 
1.2.1 DC-SIGN natural ligands 
Glycan array is a common technology used to evaluate the binding of a fluorescently-tagged 
receptor to glycans immobilized on a plate.25 Van Liempt et al. performed this assay to evaluate the 
interaction between DC-SIGN and a library of mannosylated and fucosylated compounds.26 
Concerning mannose ligands, DC-SIGN was found to have the highest affinity for the structure 
(Man)9(GlcNAc)2 (Scheme 1.1) and lower affinities as the number of mannose units decreases 
(Figure 1.4 bottom). Among the fucosylated compounds, Lewis B (Fucα1-2Galβ1-3(Fucα1-
4)GlcNAcβ; Leb) was the best ligand; interestingly, diantennary N-glycans as Bi-LDN and Bi-LeX 
doubled their affinity compared to the individual ones (Figure 1.4). These results were obtained by 
using chimeric DC-SIGN/Fc, which has as a dimeric carbohydrate-binding domain assembled on 
the Fc domain of human IgG1. However, they are comparable to the ones obtained by Guo et al. 
using a renatured tetramer of DC-SIGN.27 
 
 
Scheme 1.1 Structure of (Man)9(GlcNAc)2.27 
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Figure 1.4 Data obtained from the glycan array; carbohydrate structures are schematically represented. Affinity is 
expressed as S/N = !"#$%&  (!"#$%&'(&)(&)!"#$% . Relative binding is calculated respect of the highest one (Bi-LDNF).27 
 
Remarkably, also simpler fragments of Man9 where found to be active DC-SIGN ligands (Scheme 
1.2).28 In particular, above all, linear trivalent and tetravalent mannose derivatives 4 and 5 
approached the binding affinity of Man9 itself. This suggests the importance of the Manα1-2Man 
residue in binding the DC-SIGN CRD (over e.g. the 3,6-branched Man or Manα1-6Man residue, 
see compounds 3 and 7). Also Mannose alone (compound 6) had a remarkable ability to bind the 
lectin in this surface assay. The lower activity of the branched trisaccharide 3 compared to mannose 
6 was probably due to steric constraints.29  
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Scheme 1.2 Evaluation of the interaction between DC-SIGN and Man9 or its fragments (compounds 1-7). The amount 
of (fluorescently tagged) bound protein on the oligosaccharide is measured as fluorescence units.28 
 
LewisX is known to be expressed, for instance, at the surface of the Gram-negative bacterium H. 
pylori, which induces peptic ulcers and gastric carcinoma; Lex, Ley, Lea, Leb are also blood group 
epitopes.30 High mannose type glycans are found on the HIV-1 glycoprotein gp120,19 on the 
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Mycobacterium tuberculosis and the yeast Candida albicans.23 In 2011, Sabatte et al. demonstrated 
that semen clusterin, and not serum one, is a natural potent DC-SIGN ligand (KD = 76 nM). 
Clusterin is a protein involved in a variety of physiological and pathological processes (e.g. 
inflammation, atherosclerosis, cancer), and semen clusterin contains highly fucosylated glycans in 
high concentration, as demonstrated by MALDI-MS analysis.31 
 
1.3 The role of other proteins in HIV infection 
DC-SIGN seems to be the major HIV-1 receptor located on DCs, responsible for sequestering the 
virus and transferring it to CD4+ T cells. However, other proteins and receptors are involved in the 
virus-cell attachment process. First of all, virus accumulation on cell surfaces can be driven by an 
interaction between positively charged regions on the virus envelope and negatively charged 
proteoglycans on the cell membrane.32 Other DC receptors, like CD4, glycospingholipid galactosyl 
ceramide33 and the mannose receptor34, might be involved in HIV-1 capture. 
As already stated above (see Paragraph 1.2), also receptors located on T cells (CD4, CCR5 and 
CXR4 coreceptors) are essentials for the binding between HIV-1 and the target T cells. This 
binding induces conformational modifications in the virus gp41 envelope glycoprotein, which 
forces its amino-terminal fusion peptides into the target cell membrane, thus leading the virus-cell 
fusion process to occur.35  
 
1.3.1 Langerin 
Langerin is a C-type lectin specific for mannose exclusively expressed on Langheran Cells (LCs), 
which are a subset of immature Dendritic Cells (iDCs). Found in the epidermis of the skin and in 
mucosal stratified epithelia, LCs are the first Dendritic Cells encountered by external pathogens, as 
HIV virus (Figure 1.5). 36 Langerin has an extracellular region consisting of a carbohydrate 
recognition domain and a neck, which stabilizes the formation of rigid trimers where the three 
CRDs are in fixed positions and the sugar binding sites are separated by a distance of 41.5 Å 
(Figure 1.6).37  
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Figure 1.5 Specific localization of the Langheran Cells 
and the DC-SIGN+ Dendritic Cells. 
Figure 1.6 Side view of Langerin in its trimeric 
arrangement. 
 
As DC-SIGN, also Lagerin possesses a CRD that recognizes fucose and high mannose structures; 
therefore, it is able to bind gp120 on HIV-1 surface. Langerin was found to be a natural barrier 
against HIV-1, serving as a sort of scavenger receptor that mediates virus degradation inside 
Langheran Cells.38 Indeed, LCs where not able to transfer HIV-1 to T cells, except when using high 
concentrations of the virus (i.e. 10000 Tissue Culture Infective Doses, whereas in vivo HIV-1 levels 
are lower). The virus clearance probably happens after its internalization inside Birbeck granules, 
which are pentalamellar cytoplasmatic organelles. 39 Even if it is not known if Birbeck granules 
promote antigen processing, it is possible that they route captured HIV-1 to lysosomes for 
degradation. 
The main difference between the carbohydrate recognition domains of DC-SIGN and Langerin is 
that Langerin CRD presents two lysine residues (Lys299 and Lys313) in its sugar binding site, close 
to the Ca++ ion.40 This is the reason why Langerin accommodates positively charged sulfated sugars 
in its CRD (see Chapter 5).  
 
1.4 DC-SIGN as a therapeutic target 
Since AIDS curative treatments or preventive vaccines against HIV-1 virus are still a challenge, 
avoiding virus-body attachment is a way of preventing HIV-1 infection.41 In this field, DC-SIGN is 
a suitable target; indeed, synthesising artificial molecules that mimic the cluster presentation of 
gp120 on HIV-1 and can occupy DC-SIGN binding sites antagonizing the virus is a way of 
producing anti-adhesive drugs. From a biological point of view, these molecules should be strong 
41.5 Å 
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and selective DC-SIGN binders. Non-selective compounds can be detrimental for the curative 
purpose if they bind other receptors that are able to contrast HIV-1, like Lingerin (see Paragraph 
1.3.1).38 From a pharmaceutical point of view, they could be formulated as a topic gel, possibly 
colourless and odourless, which confers sustained protection from HIV after a single dose.  
In principle, HIV infection can be blocked also antagonizing the other receptors involved in the 
virus dissemination (see Paragraph 1.3).42,43 Indeed, HIV-1 infection of T cells can be prohibited by 
blocking the interaction between the virus and either the CD4 receptor or the CCR5 and CXCR4 
coreceptors. Also the fusion process between HIV-1 and target cell occurring after membranes 
coalescence mediated by gp41 on the virus can be prevented. However, interaction with DC-SIGN 
is the first adhesion event and blocking it may be more efficient in reducing viral load.  
Beside HIV, DC-SIGN ligands can prevent the adhesion of other pathogens that use this receptor to 
attack the human body, like Ebola and Dengue viruses.23 
 
1.4.1 Artificial DC-SIGN ligands 
Artificial glycomimetic compounds, which imitate the structure of natural DC-SIGN ligands (e.g. 
LeX and (Man)9(GlcNac)2, see paragraph 1.2.1), can be active DC-SIGN binders, thus antagonists 
of HIV-1 attachment on DCs. The use of glycomimetics instead of complex oligosaccharides 
should lead to compounds more easily synthesised, as well as more metabolically stable. 
Glycomimetic compounds should maintain the anchoring moieties that allow their main binding 
with the receptor, but can also present other elements that favour their accommodation in the 
binding sites thanks to further non-covalent interactions. In that way, it may also be possible to tune 
their selectivity towards DC-SIGN relative to other C-type lectins. 
In the following paragraphs, a number of artificial carbohydate and non-carbohydrate molecules 
synthesised as DC-SIGN ligands will be presented; their affinity towards the target receptor will be 
expressed as IC50 and/or KD. 
 
1.4.1.1 Fucose based 
Fucosed-based ligands where designed and synthesised as mimics of the natural DC-SIGN binder 
Lewis X (compound 1.1 in Scheme 1.3). Unless differently stated, all fucose-based compounds here 
presented were tested as DC-SIGN inhibitors thorough an SPR inhibition assay, by evaluating their 
ability to inhibit binding of DC-SIGN to Man-BSA (Manα1-3[Manα1-6]Man, 15 trimannose 
residues, on average). The fucose moiety was maintained as the chelator of Ca2+ ions on the 
receptor binding site. Compound 1.2 was obtained by replacing the galactose sub-unit with a 
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cyclohexyl mimic and the central N-acetyl-glucosamine (Glc-NAc) with a 2-amino-
cyclohexanecarboxylic acid (Scheme 1.3).44 
 
 
Scheme 1.3 First Lewis X mimic 1.2. IC50 values were obtained through SPR inhibition assays, using BSA-mannotriose 
as competitor.44 
 
No further affinity improvements were obtained by replacing the galactose mimic with aromatic 
systems –which, on the contrary, were expected given its interaction with lipophilic protein areas 
suggested by docking studies-, nor varying the configuration of the 2-amino-cyclohexanecarboxylic 
acid to find the most efficient one. Within the synthesised library of compounds with the general 
structures depicted in Scheme 1.4, 1.3 was the most active ligand. Compound 1.4 was produced by 
using the commercially available β-alanine as the central building block and, despite its simplicity, 
proved to have an affinity similar to that of LeX (Scheme 1.4).  
 
 
Scheme 1.4 The most interesting compounds within a new library of fucose based glycomimetics whose general 
structure is indicated in the left. IC50 values were obtained through SPR inhibition assays, using BSA-mannotriose as 
competitor.44 
 
Compounds 1.3 and 1.4 were selected to build multivalent derivatives; thus, they were 
functionalized with linkers or functional groups suitable for the conjugation on a multivalent 
scaffold. The tetravalent presentations 1.5 and 1.6 of the weak carbohydrate DC-SIGN antagonists 
on a pentaerythritol-based core improved their affinity up to one order of magnitude (Scheme 
1.5).45 IC50 were evaluated through SPR inhibition assays, using Man-BSA as competitor. 
Lewis X 1.1
IC50 = 800 µM
1.2
IC50 = 350 µM
1.3
IC50 = 470 µM
1.4
IC50 around 1 mM
General 
structure
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Scheme 1.5 Tetravalent presentations of selected fucose based ligands. IC50 values were obtained through SPR 
inhibition assays, using BSA-mannotriose as competitor.45 
 
Compound 1.4 was used also to decorate gold nanoparticles. Particles containing 50 % of 
fucosylated amide had a similar behaviour of gold nanoparticles bearing Lewis X (10 % LeX-
loading). They both displayed IC50 values around 12 ng/mL, measured by inhibiting the binding of 
fluorescent gp120 to DC-SIGN. 46 
 
1.4.1.2 Mannose based 
In the Bernardi group, compound 1.7 (Scheme 1.6) was synthesis to mimic the Manα1-2Man 
residue of  (Man)9(GlcNAc)2; authors demonstrated that the two compounds share the same three-
dimensional structure and conformational behaviour (NMR and docking studies), but 1.7 is more 
stable to hydrolysis mediated by jack-bean mannosidase and also less cytotoxic.47 Compound 1.7 
consists of one mannose residue, involved in the direct chelation of Ca2+ in the receptor binding 
site,48 and one conformationally locked cyclohexyl moiety (i.e. a pseudo mannose) substituted with 
two methyl ester groups (Scheme 1.6); it allowed an increase of affinity towards DC-SIGN by 
almost a factor of two with respect to mannose (IC50 = 1.0 mM vs 1.8 mM, obtained through SPR 
inhibition assays, using ManBSA as competitor). This suggests an additional and positive 
interaction of the substituted cyclohexyl in the DC-SIGN CRD. 
 
1.5
IC50 = 30 µM
1.6
IC50 = 150 µM
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Scheme 1.6 Structure of the pseudo-dimannoside 1.7. IC50 values were obtained through SPR inhibition assays, using 
BSA-Mannotriose as competitor.47 
 
The same research group, by adding a third mannose moiety to compound 1.7, obtained the pseudo-
trimannoside 1.8 (Scheme 1.7).49 The presence of another mannose unite in the DC-SIGN binding 
site allowed to increase the affinity toward the receptor by about one order of magnitude, as 
measured in the inhibition assay.   
 
 
Scheme 1.7 Structure of the pseudo-trimannoside 1.8. IC50 values were obtained through SPR inhibition assays, using 
BSA-mannotriose as competitor.49 
 
However, the synthesis of 1.8 is rather long and complicated. Additionally, later studies showed 
that the high affinity measured by SPR inhibition study for 1.8 depended on the format of the assay 
(i.e. protein soluble in solution) and derived mostly by dimerization of the DC-SIGN tetramer. 
These results were confirmed by calculating the stoichiometry associated to the interaction through 
Isothermal Titration Calorimetry and by detecting the dimer through Analytical 
Ultracentrifugation.50 Therefore, other type of modifications of compound 1.7 is desirable. In order 
to gain additional positive contacts between the artificial compounds and the DC-SIGN binding 
site, the methyl esters groups in 1.7 were replaced by aromatic amides and benzyl amides, obtaining 
two new different libraries of DC-SIGN ligands.51,52 Among all, compound 1.9 was found to be the 
most interesting one: having an IC50 = 325 µM (SPR inhibition assay using Man-BSA as 
competitor, Scheme 1.8), it approaches the activity of the pseudo-trimannoside. It is equipped with 
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two additional hydroxyl groups that help improving its solubility in water. Remarkably, 1.9 has also 
a good selectivity vs Langerin. 
 
 
Scheme 1.8 Structure of the bisamide 1.9. IC50 values were obtained through SPR inhibition assays, using BSA-
mannotriose as competitor.52 
 
Compounds 1.8, 1.7 and 1.9 were used to decorate multivalent polyalkyne scaffolds, thus obtaining 
multivalent ligands with an improved affinity toward DC-SIGN relative to their monovalent 
counterparts (Scheme 1.9).53,54,55 Compound 1.9 gave the best affinity improvements, even if, 
increasing its valency up to 9, it showed a rather low solubility in water (< 300 µM).55  
Remarkably, a 32-valent presentation of 1.8 on a 3rd generation of Boltorn type dendrimer (G3-(ps-
tri)32, Scheme 1.10)54 was just 4 times as active as a 4-times presentation on a tetravalent dendron53 
(Polyman2, Scheme 1.10). All IC50 values were obtained through SPR inhibition assays vs Man-
BSA.  
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Scheme 1.9 Multivalent presentations of compounds 1.7, 1.8 and 1.9. IC50 values were obtained through SPR inhibition 
assays, using BSA-mannotriose as competitor.55 
 
 
Scheme 1.10 4-valent (G3-(ps-tri)32, left) and 32-valent (Polyman2, right) presentations of compound 1.8. IC50 values 
were obtained through SPR inhibition assays, using BSA-mannotriose as competitor.53,54 
 
= 1.7, IC50 = 39 µ!
= 1.8, IC50 = 51 µ!
= 1.9, IC50 = 5.7 µ!
= 1.7, IC50 = 136  µ!
= 1.8, IC50 = 112  µ!
= 1.9, IC50 = 12 µ!
= 1.7, IC50 = 14  µ!
= 1.9, not soluble
G3-(ps-tri)32
IC50 = 5 µM
Polyman2
IC50 = 1.25 µM
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The group of Kiessling used a library of Shikimic acid derivatives to discover glycomimetic DC-
SIGN antagonists.56  Shikimic acid is a mannose mimic, since it presents three hydroxyl groups that 
match the configuration of the mannose hydroxyl groups in positions 2, 3 and 4. In has three points 
of variations where different substituents can be used to modulate final affinity and selectivity 
toward DC-SIGN (Scheme 1.11). 
 
 
Scheme 1.11 Shikimic acid and its derivatives are mannose-mimetics. IC50 values were obtained through inhibition 
assays, using Man-BSA as competitor.56 
 
Compound 1.10 (Scheme 1.12 A) was found to be the most active towards DC-SIGN (IC50 = 3.2 
mM, evaluating its ability to inhibit binding of fluorescent Man-BSA bearing 20-25 copies of 
mannose to DC-SIGN). It didn’t show any affinity improvement relative to mannose itself but, 
interestingly, it was selective against Mannose Binding Protein-A. Through 1H-15N HSQC NMR 
experiments, the authors demonstrated that compound 1.10, besides having a binding mode 
analogous to that of saccharide ligands (ManNAc and Fuc were tested), is also involved in the 
recognition of adjacent secondary sites.57 
By decorating a ROMP-generated polymeric backbone with compound 1.10, a powerful multivalent 
ligand 1.11 was obtained (IC50 = 2.9 µM, inhibition assay vs Man-BSA, Scheme 1.12 B). The 
degree of polymerization (29) was chosen to generate a multivalent structure able to bind 
simultaneously more that one binding site on the tetrameric DC-SIGN CRD, knowing that each 
extended monomer within a ROMP-derived polymer spans approximately 5 Å and that the width of 
the DC-SIGN CRD is about 40 Å. Each polymer displays about 7 glycomimetic units and should be 
able also to cluster multiple copies of DC-SIGN on the cell surface. 
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Scheme 1.12 A) Shikimic acid derivative 1.10; B) its multivalent polymeric presentation 1.11. The ratio R2/R1 is about 
1:3. IC50 values were obtained through inhibition assays, using Man-BSA as competitor.56  
 
Several research groups, with the aim of synthesising powerful multivalent DC-SIGN ligands, used 
directly mannose or the Manα1-2Man disaccharide as monovalent substrates.  
The mannose containing glyco-polymer 1.12, with a degree of polymerization of ca. 58, was a 
potent DC-SIGN ligand, showing IC50 = 37 nM (SPR inhibition assay performed using gp120 
immobilized on the chip, as competitor, Scheme 1.13). It was obtained by coupling a suitable azide-
functionalised mannose on a polymer backbone synthesized by copper-mediated living radical 
polymerization of trimethylsilyl propargyl methacrylate. The azide-alkyne Huisgen cycloaddition 
was performed after removal of the trimethylsilyl groups on the polymer.58 
 
 
Scheme 1.13 Structure of the mannose containing glycopolymer 1.12. IC50 values were obtained through SPR 
inhibition assays, using gp120 as competitor.58  
 
A library of mannosylated gold-glyconanoparticles (GNPs) was obtained by decorating a 2 nm gold 
core with mannose or oligomannoses functionalised with linkers ending in a thiol group, thus 
suitable to be attached on the gold surface.59 The nature of the glyco-moieties as well of the linkers 
was varied in order to find the most active sugar and to modulate the solubility and the flexibility of 
the NP, respectively. Linker lengths modulate also the accessibility of the sugar epitope to the 
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receptor. Among all synthesised compounds, GNPs 1.13 and 1.14 presenting different densities of 
the Manα1-2Manα residue were the most active species, with IC50 values in the low nM range 
(obtained thorugh SPR assays, evaluating the ability of compounds to inhibit the binding of DC-
SIGN on gp120, Scheme 1.14). Given the similarity of their binding levels towards DC-SIGN (SPR 
inhibition assays), the authors concluded that, above a certain threshold, higher density of 
glycoconjugates does not improve the efficacy of the GNPs. 
 
 
 
Scheme 1.14 Mannosylated gold-nanoparticles 1.13 and 1.14. IC50 values were obtained through SPR inhibition assays, 
using gp120 as competitor.59 
 
The group of Wagner synthesised a small library of ampiphilic manno-lipids made by a 
polar mannose residue (the epitope), a hydrophilic linker (to improve solubility in water) and a 
hydrophobic saturated lipid chain of variable length.60 Among these compounds, 1.15 and 1.16 
displayed the highest KD towards DC-SIGN (Scheme 1.15). KD values were obtained through SPR 
direct assays, by evaluating the ability of compounds to bind to a surface were DC-SIGN is 
immobilized. Due to their amphiphilic structure, these compounds are able to form micelles in 
water, thus assuming a self-organized multivalent presentation without the need to synthetically 
create it. Interestingly, HIV-1 trans-infection inhibition assays revealed that 1.16 is active already 
under its Critical Micelle Concentration (IC50 = 500 nM, CMC = 109 µM), meaning that it is a good 
DC-SIGN binder also in its monovalent presentation. This can be explained by the formation of 
strong additional interactions of the lipid chain in DC-SIGN binding site or by the formation of 
other self-assembled multivalent structures that are not micelles.  
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Scheme 1.15 Glycolipids 1.15 and 1.16. KD values were obtained through SPR direct assays, immobilizing DC-SIGN 
on the chip; IC50 were calculated on the ability of compounds to inhibit the DC-SIGN mediated infection from DCs to T 
lymphocytes.60  
 
1.4.1.3 Non-carbohydrate based 
Trying to obtain monovalent compounds with a low-micromolar affinity towards DC-SIGN, 
in 2007 the group of Kiessling developed a high-throughput assay to screen a library of 36000 small 
molecules and find potential DC-SIGN ligands.61 Compounds were tested in a competition assay 
with Mannosylated BSA, bearing 20-25 copies of Man/BSA. In Scheme 1.16 the structures of 
identified DC-SIGN ligands are reported, together with the obtained IC50; compounds 1.17 and 1.19 
belong to the quinaxolinone derivatives, whereas compounds 1.18 and 1.20 contain a pyrazolone 
scaffold. They all revealed to have an affinity towards DC-SIGN higher than the one displayed by 
sugar-derived monovalent ligands. Remarkably, they don’t bear any hydroxyl group, meaning that 
either they coordinate Ca2+ in DC-SIGN binding sites with other functional groups (i.e. amides) or 
they can even bind the receptor at a site which is different from the one used by oligosaccharides, 
leading to an allosteric effect.  
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Scheme 1.16 Structure and activities of non-carbohydrate DC-SIGN ligands. IC50 values were obtained through 
inhibition assays, using Man-BSA as competitor.61 
 
Given the electrophilic behaviour of pyrazolone-containing compounds, they are not suitable for 
cell-based assays.62 On the contrary, the drawback of quinoxalinone-bearing molecules is the 
liability of the thioether group; indeed, they are not stable in air at room temperature and they 
undergo degradation and inactivation within few weeks. For this reason, the selected compound 
1.17 was modified by firstly substituting the thioether group with a methylene one, and then by 
varying three other positions (Scheme 1.17 left).63 The activity of synthesised compounds was 
assessed again in a competition experiment with the fluorescein mannosylated BSA. Compound 
1.24 (Scheme 1.17 right) revealed to be the most active one, with IC50 = 0.3 µM. This result 
underlines the importance of having aromatic groups to increase the affinity of artificial ligands by 
increasing lyophilic (hydrophobic) interactions with the lectin surface. 
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Scheme 1.17 1.24 is the lead compound obtained by varying R1, R2 and R3 positions depicted in the general structure 
(left). IC50 values were obtained through inhibition assays, using Man-BSA as competitor.63  
 
1.5 Multivalency 
The strength of the interaction between two materials can be dramatically increased by 
exploiting multivalency, meaning that multiple interactions occurring at the same time often lead to 
stronger binding. Nature has taken deep advantage of this concept and made the weak interactions 
between proteins and carbohydrates biological relevant by using multivalent binding partners.  
The valency of a material is defined as the number of separate, identical connections that it can 
make with its binding counterpart.64 There are several mechanisms, often occurring synergistically, 
that can lead to multiple connections.65 In this thesis, multivalency will always be referred to 
multivalent carbohydrate-based ligands interacting with a multivalent protein.66  
One mechanism that can enhance binding affinity is chelation, occurring when a ligand is able to 
bind simultaneously more than one binding site on the same multivalent receptor (Figure 1.7A). 
Also a ligand with two non-identical subunits can chelate two non-identical binding sites on the 
protein.  
When the linker separating ligand subunits is not long enough to allow chelation, or when the 
receptor has only one binding site, the presence of proximal additional sub-ligands that can easily 
replace the first one after it is released enhances the overall binding potency. This mechanism is 
called statistical rebinding (Figure 1.7B) and it has been interpreted as resulting from increased 
local concentration in the proximity of the binding site (see Ceff i.e. effective concentration in 
Paragraph 1.5.1).  
Finally, multivalent ligands can bind more than one receptor, resulting in protein aggregation 
(Figure 1.7C). This can occur with soluble receptors, but also receptors embedded in membranes 
can undergo a similar effect, due to membrane plasticity. In this case the effect is often referred to 
as “clustering” rather than aggregation. 
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Figure 1.7 Schematic representation of the main polyvalent binding mechanisms that can occur between a divalent 
ligand (red) and one ore more divalent protein (grey). 
 
Besides these binding mechanisms, simple statistical considerations can explain the multivalence 
effect, given that a multivalent material (ligand or receptor) provides higher density of the binding 
partner.  
 
1.5.1 On the thermodynamic principles of multivalency 
The thermodynamic parameters describing a multivalent binding can’t always be calculated 
from the ones of the corresponding monovalent interaction simply multiplying by the valency.67,64 
Indeed, when a multivalent ligand interacts with a receptor, sub-ligands don’t operate individually, 
but they influence the following binding events in a way that depends on the nature of their 
presentation.  
The enthalpic contribution ΔHmultivalent depends on the ΔH associated to the single interactions 
(Equation 1.1, term 1) but also on the enthalpy variation associated to the linker and the 
environment. Indeed, if the linker has not the ideal length to chelate at least two binding sites, 
enthalpic penalties have to be paid by the linker (if it is too long) or by the receptor (if the linker is 
too short) in order to fit the one with the other (Equation 1.1, term 2). In this case, a multiple 
interaction of the ligand with several separated receptor molecules instead of a chelating binding 
mode can be more beneficial for the system. Moreover, the breaking of old non-covalent 
interactions and the formation of new ones (e.g. ligand + receptor, linker + binding pocket, linker + 
water molecules) may affect the overall enthalpy (Equation 1.1, term 3).  
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Equation 1.1 Contributions to the multivalent enthalpy change. n is the ligand valency. 
 
Also the multivalent entropy change (ΔSmultivalent) is related to the entropy change experienced by 
each ligand after immobilization, but it has to be considered that the binding of one n-valent ligand 
to multivalent receptor is less entropically disfavoured than the binding of n monovalent ligands to 
the same receptor. This happens because, in a multivalent ligand, only the first subunit-receptor 
interaction pays the full entropic cost, whereas the other intramolecular interactions do not. The 
linker and water molecules play an important role also in entropic calculations. Indeed, the overall 
entropy will be affected by the reduction of linker degrees of freedom after binding, as well as by 
the disruption of water molecules organization around the binding pocket, the ligand and the linker 
(Equation 1.2). 
 ∆!!"# = !∆!!"#"′+ ∆!!"#$%&  !"#$ + ∆!!"#$%&,!"#$%&"' 
Equation 1.2 Contributions to the multivalent entropy change. ΔSmono’ takes account of the lower energy penalty paid 
by the nth ligand in a multivalent system with respect to a single monovalent one.  
 
These two parameters both contribute to the determination of the free energy released upon the 
formation of multiple interactions, as described by the well-known Equation 1.3. 
 ∆!!"# = ∆!!"# − !∆!!"# 
Equation 1.3 Enthalpic and entropic components of the multivalent free energy ΔGmul. 
 
From this brief thermodynamic overview, the importance of the linker clearly emerges. Indeed, the 
multivalent interaction will be more favoured if the linker has the ideal length not to pay enthalpic 
conformational penalties and is rigid enough to reduce also the entropic disfavouring components. 
 The effective concentration Ceff is another key parameter to model a multivalent 
interaction.68,69 When the first sub-unit of a multivalent ligand interacts with a multiple receptor, the 
other available binding sites experiment a higher density of the free sub-ligands, which have 
approached. When the local concentration density of the ligand is higher than its bulk 
concentration, intramolecular multivalent bindings are favoured. Also according to this model, an 
	   	   	  1 2 3 
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ideal linker length is required, since linkers that are too long separate the binding moiety from the 
receptor and make the effective concentration approaching to the bulk one. 
It is common and useful to evaluate the potency of a multivalent ligand with respect to the 
corresponding monovalent one. The potency enhancement, indicated as β factor, can therefore be 
calculated according to Equation 1.4, where !!!"#$is the association constant of the fully associated 
ligand-receptor complex, and !!"#" is the association constant of the corresponding monovalent 
ligand-receptor complex. Since the concept of avidity refers to the association constant of a 
polyvalent interaction, !!!"#$ ≡ !!"#$#%&  (Figure 1.8B), whereas !!"#" ≡ !!""#$#%& , being the 
affinity a qualitatively term that indicates a monovalent interaction (Figure 1.8A).  
 ! = !!!"#$!!"#" = !!"#$#%&!!""#$#%& 
Equation 1.4 β factor represents the benefit of having several ligands linked together and it is a measure of potency 
enhancement. 
 
 
Figure 1.8 Thermodynamic equilibriums used for the definitions of affinity, avidity and enhancement. 
 
When the β factor is divided by the valency of the ligand, the potency enhancement is corrected and 
evaluated per single ligand, obtaining the so called Relative Inhibitory Potency (R.I.P). R.I.P > 1 
means that the whole multivalent interaction is stronger than the sum of its parts, and indicates a 
real multivalent effect. During this thesis, potency enhancements of multivalent compounds relative 
to the monovalent ones will be calculated as R.I.P. values. 
 
1.5.2 Artificial ligands exploiting the chelation binding mode 
Epitopes tethered to long flexible scaffolds have relatively high degrees of freedom and can 
adapt their conformation to match lectin binding sites. However, ligands separated by a linker that 
has the correct geometry to fit the distance between contiguous binding sites on the same receptor 
have less enthalpic and entropic costs to pay (see Paragraph 1.5.1) and give rise to a very strong 
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multivalent effect.70 Moreover, exactly spanning the distance between the recognition sites on a 
protein leads to selective ligands that, in principle, can bridge only that specific distance. In this 
paragraph, some examples of carbohydrate-based ligands exploiting the chelation mechanism effect 
to bind lectins are presented.71 
One of the first examples of artificial ligands that chelate a lectin is the so-called Starfish compound 
1.25 (Scheme 1.18A) designed by Bundle and co-workers to bind the Shiga-like toxin I (SLT-1).72 
SLT-1 belongs to the category of bacterial AB5 toxins, which generally have a single toxic A-
subunit associated with five nontoxic B-subunits (CTB). In SLT-1, each B subunit contains three 
binding sites, which are separated by 9 Å; however, distances up to 50 have to be taken into account 
when considering not contiguous binding sites. Starfish consists of a pentavalent glucose-based core 
decorated with five divalent arms bearing two globotriose units each. A crystal structure of the 
ligand-toxin complex demonstrated not only that the compound is able to bind simultaneously the 
five B-subunits (Scheme 1.18B), but that if formed a sandwich like complex 2:1 in which two 
toxins bind one ligand; interestingly, each divalent arm of 1.25 shared the two globotriose units 
with the two toxins. This chelating binding mode led to an outstanding multivalency enhancement 
of 875500 (competitive ELISA assays vs BSA-glycoconjugate) with respect to globotriose. 
 
 
 
 
Scheme 1.18 A Structure of the SLT-I ligand 1.25; B Diagram of half of the Starfish:SLT-1 B5 sandwich obtained from 
crystallographic data; dashed magenta lines show a possible conformation for the central component of the linker, 
which could not be seen clearly in the electron density. Activity was measured through ELISA inhibitor assays, using 
glycosylated-BSA as competitor.72  
 
After this initial example, many other multivalent constructs were designed as antagonists of 
various different lectins and they have extensively reviewed.73,66 In this paragraph, I’m going to 
focus my attention on compounds that specifically exploit the chelating binding mode.  
B
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A
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Very recently, Turnbull and co-workers published the most potent inhibitor of the bacterial AB5 
Cholera Toxin (CT), designed with the similar concept of binding simultaneously each toxin B-
subunit.74 In this case, the spacing between two binding sites is about 31 Å. Inhibitor 1.26 is a 
neoglycoprotein based on an inactive mutant CTB protein modified with GM1 oligosaccharides 
(GM1os) ligands, known to be CT ligands (Scheme 1.19). In this way, the multivalent construct 
perfectly matches the size and the valency of the target CTB. This chelation-based interaction led to 
IC50 = 104 pM (competitive ELLA assays vs GM1 immobilized on a surface), corresponding to a 
potency enhancement of 5100 fold with respect to the monovalent GM1os. Dynamic Light 
Scattering and Analytical Ultracentrifugation assessed the formation of the 1:1 homodimer; on the 
contrary, Isothermal Titration Calorimetry showed a non-consistent KD, probably because the high 
concentration of 1.26 needed for the assay (43 µM) led to the formation of random aggregates. 
 
 
Scheme 1.19 1.26 binds CT forming a 1:1 homodimer. Activity was measured through ELLA inhibition assays, using 
GM1 as competitor.74 
 
Lectin A is the adhesion protein and virulence factor of the pathogen P. aeruginosa; it is specific 
for galactose and it is a tetramer where two contiguous binding sites are separated by a distance of 
26 Å. Pertici et al. modulated the length of a rigid linker to separate two galactose residues and 
chelate two binding sites on LecA.75 Linker consists of glucose units connected via triazoles; 
variations in linker length led to very strong variations in the affinity towards LecA, thus 
demonstrating the need of the suitable length to chelate the receptor and to deeply increase ligands’ 
potency. Among the small library of synthesised compounds, the most interesting were ligands 1.27 
and 1.28 (Scheme 1.20). Indeed, the first one didn’t show any affinity improvement compared to 
1.26Cholera Toxin
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the reference compound Ref(1.27), revealing to be too short, as confirmed by modeling. On the 
contrary, matching the distance between the two binding sites, compound 1.28 led to an activity 
improvement of 545-fold respect to the reference compound Ref(1.28) (IC50 = 220 nM, obtained 
through inhibition ELLA assays, using a galactoside functionalized surface as competitor). 
Remarkably, compound 1.28 presents a flexible C3 aliphatic chain between the galactose epitope 
and the linker that can allow the ligand to adjust its spatial disposition respect to the binding site, 
thus overcoming possible design imperfections.   
 
 
Scheme 1.20 Rigid Lec A ligands 1.27 and 1.28 and their corresponding monovalent units Ref(1.27) and Ref(1.28). 
Activity was measured through ELLA inhibition assays vs a galactoside functionalized surface.75 
 
A further improvement was obtained with compound 1.29, which showed IC50 = 2.7 nM, thus 
representing a gain of 7555-fold (values were calculated through the ELLA inhibition assay vs 
galactosylated surface) with respect to the monovalent compound Ref(1.29) (Scheme 1.21).76 
Molecular modeling confirmed that compound 1.29 had the “perfect length” (i.e. 26 Å) to chelate 
LecA. 
 
 Scheme 1.21 Ligands 1.28 and its corresponding monovalent unit Ref(1.28).76 
 
Divalent ligands using a rigid core constituted by phenylene-ethynylene units were synthesised in 
the groups of Pieters and Bernardi (Scheme 1.22).77 1.30 is a divalent galactose-based compound 
and was tested as LecA ligand, revealing IC50 = 900 nM (inhibition ELISA assay with respect to a 
galactosylated surface). Compound 1.31 was synthesised as potential DC-SIGN ligand, bearing one 
mannose unit at each scaffold end, but its activity was not evaluated. The interesting feature of this 
OHHO
OH
HO
1.27
1.28Ref (1.28)
Ref (1.27)
1.29Ref(1.29)
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family of scaffolds –also named rods- is their fluorescent behaviour and the possibility to easily 
tune their length by varying the number of phenylene units.  
 
 
Scheme 1.22 Divalent rods derivatives 1.30 and 1.31.77 
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2.1 Introduction 
2.1.1 Designing DC-SIGN ligands 
As seen in detail in Chapter 1.4, DC-SIGN is a tetrameric lectin (i.e. a carbohydrate-recognizing 
receptor) expressed at the surface of Dendritic Cells. Since the DC-SIGN-mediated anchoring of 
HIV virus on human cells represents the early stage of the infection,1 DC-SIGN is a valid target to 
develop compounds with viral anti-adhesive properties. Active DC-SIGN ligands can be 
synthesised by mimicking HIV epitopes. The disaccharide Manα1-2Man and the trisaccharide 
Manα1-2Manα1-6Man (Figure 2.1) are found in multiple copies of the HIV glycoprotein gp120 
(through which the virus interacts with the receptor)2 and they are known to bind to DC-SIGN.3  
 
 
Figure 2.1 Structures of the disaccharide Manα1-2Man (left) and the trisaccharide Manα1-2Manα1-6Man (right). 
 
These natural ligands can therefore be used as starting points to design artificial compounds, that 
would be more active and selective towards DC-SIGN with respect to other lectins (e.g. Langerin 
and the Mannose Receptor) once derivatized with functional groups able to participate in additional 
positive contacts with the target receptor. Activity can be improved also exploiting multivalency. 
Powerful DC-SIGN ligands could be used also against the plethora of other pathogens that infect 
humans through the mucosal entry pathway and that recognize DC-SIGN as their primary target.4 
 
2.1.2 Multivalency 
As stated in Chapter 1.5, multivalent interactions among binding partners lead to stronger binding.5 
Possible interactions between one divalent ligand (red) and one divalent receptor (blue) are reported 
as an example in Figure 2.2. The presence of two proximal active ligands at one binding site 
increases their effective concentration Ceff. The possibility that one active ligand easily replaces the 
first one after it is released increases the overall potency of the interaction and it is referred to as 
statistical rebinding effect5 (Figure 2.2 A). It is also possible that the two active ligands are separate 
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by a distance which fits the one between two binding sites on the receptor. When a ligand is able to 
chelate (i.e. to bind simultaneously more than one subunit on) its binding partner (Figure 2.2B), the 
resulting multivalent interaction is more probable and stronger. Indeed, from a thermodynamic 
point of view, only the first sub-ligand pays the full entropic costs associated with the interaction, 
thus favoring the binding of the second one. Finally, one multivalent ligand can cluster more than 
one receptor (Scheme 2.2 C). This is possible when receptors are soluble, but also when they are 
embedded in membranes, since membranes are flexible and receptors can diffuse in them.    
 
 
Figure 2.2 A) a multivalent ligand (red) binds to a protein (blue) exploiting the statistical rebinding (proximity) effect; 
B) a multivalent ligand chelates a divalent protein; C) a multivalent ligand clusters a soluble protein. 
 
The efficiency of one multivalent compound with respect to its monovalent unit can be expressed in 
terms of β factor,6 defined as in Equation 2.1, or in terms of Relative Inhibitory Potency R.I.P., 
which corresponds to the β factor corrected by valency (Equation 2.2). 
 
 = 	
	 
Equation 2.1 β factor represents the improvement obtained by using a multivalent presentation of a ligand with respect 
to the monovalent ligand itself.  
 
. . .= 	 	
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Equation 2.2 Relative Inhibitory Petency R.I.P. is the β factor corrected by valency. 
 
Nature has taken deep advantage of these concepts to increase the strength of the interactions that 
would be too weak if involving only monovalent partners. Carbohydrates, that have a low affinity 
for proteins, bind tighter to their partners when they are presented in a multivalent way. Pathogens 
attack human body through multivalent interactions between multivalent presentations of epitopes 
and multiple receptor units.   
In order to efficiently interfere with biological interactions, artificial ligands able to interact with a 
biological receptor in a multivalent fashion are suitable.7 
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2.2 State of the art 
With the aim of mimicking the disaccharide Manα1-2Man, our laboratory has developed a series of 
mannosylated DC-SIGN ligands (see Chapter 1.4.1.2 for a broader overview). Among them, the 
pseudo-dimannosylated compounds 1.78 and 1.99 are the most promising ones (Figure 2.3). They 
consist of one mannose residue, whose hydroxyl groups in position 3- and 4- are responsible for 
chelation of the calcium ion in the DC-SIGN binding pocket, and one conformationally locked 
cyclohexyl moiety, which is involved in additional Van der Waals contacts with the binding site.10 
Compound  1.7 bears methylesters on the cyclohexane moiety; their replacement with aromatic 
benzylamides in 1.9 provided more efficient interactions, thus leading to an affinity improvement.  
 
 
Figure 2.3 Structures of the lead compounds 1.7 (A) and 1.9 (B). 
 
Through SPR inhibition assays, performed by evaluating the ability of artificial compounds to 
inhibit DC-SIGN binding to a mannosylated surface (Man-BSA), activity performances were 
calculated in terms of IC50 values, finding a value of 1 mM for 1.7 and 300 µM for 1.9.11 
Compound 1.9 was the most active, thus identified as the lead for further modifications. Compound 
1.7 was still worth an interest, since it has a high solubility in water and it is active despite its 
simplicity.   
Multivalent presentations of 1.7 and 1.9 were prepared by coupling monovalent ligands to 
polyalkynes dendrimeric cores, obtaining dendrimers among which the most relevant are shown in 
Figure 2.4.12 These tetravalent, hexavalent and nonavalent compounds obtained from scaffolds IV, 
VI and IX, respectively (Figure 2.4) were more chemically stable than previously synthesised 
Boltorn-type dendrons and dendrimers derived from 2,2-bis(hydroxymethyl) propionic acid.13  
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Figure 2.4 Structure of tetravalent (IV), hexavalent (VI) and nonavalent (IX) presentations of 1.7 and 1.9. 
 
Biological performances (SPR and inhibition studies) obtained for multivalent derivatives of 1.7 
confirmed that multivalency helps in overcoming the low affinities associated to monovalent 
compounds. Moreover, multivalent compounds based on 1.7 had the advantage of having a rather 
high solubility in water (≥ 5 mM).  Still, the use of a more powerful monovalent ligand was 
demonstrated to be convenient, as shown by the best activities associated with the multivalent 
presentations of 1.9. The drawback of these compounds was having a mediocre water solubility (≤ 1 
mM), which became limiting for the nonavalent derivative IX.1.9.  
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Their IC50 obtained again through SPR competition assays and associated R.I.P. values are reported 
in Table 2.1. Among the complete series of compounds based on 1.7, it was possible to observe 
how the IC50 values decrease and the R.I.P. values increase by increasing the valency of the system. 
Similar results were obtained for the 1.9 series, which found the hexavalent derivative VI.1.9 to 
have the best R.I.P. values. No results were obtained for the nonavalent compound IX.1.9, because 
of solubility problems.  
 
IC50 (µM) (R.I.P.) 
Scaffold Ligand 1.7 Ligand 1.9 
Mono 1018 (1) 308 (1) 
Tetra (IV) 136 (1.9) 12 (6.4) 
Hexa (VI) 39 (4) 5.7 (9) 
Nona (IX) 14 (8) not soluble 
Table 2.1 IC50 values of tetravalent, hexavalent and nonavalent compounds 1.7- or 1.9-based. R.I.P. values with respect 
to corresponding monovalent ligands are in round brackets.12  
 
The most active DC-SIGN ligands were tested also as inhibitors of the DC-SIGN-mediated HIV 
infection, using a cellular in vitro model. Compound VI.1.9 was found to totally inhibit the 
infection already at a concentration of 10 µM (Figure 2.5). This assay also confirms the powerful 
effect of a more powerful monovalent ligand (compare IV.1.7 and IV.1.9) and of increased valency 
(compare IV.1.9 and VI.1.9) 
 
 
Figure 2.5 Percentage of DC-SIGN-mediated transmitted HIV infection, evaluated in a cellular in vitro infection 
model.12 
 
Chapter 2 
45 
 
In order to interpret the nature of the multivalent effect obtained with these multivalent compounds 
and to understand whether it derived from a statistical rebinding, chelating or clustering mechanism 
(or a combination of them), molecular dynamics simulations were used to estimate their average 
dimension. This was compared with the distance between two contiguous binding sites within one 
tetrameric DC-SIGN extracellular domain (ECD), which are separated by a distance ranging from 
35.3 to 37.8 Å (Figure 2.6).14 Distances were calculated between calcium atoms, which are 
anchoring sites for DC-SIGN ligands.  
Conformational analyses were conducted by Dr. G. Vettoretti and the undergraduate student A. 
Bertaglia under the supervision of Dr. L. Belvisi.  
 
 
Figure 2.6 Structure of a tetrameric DC-SIGN extracellular domain. The four binding sites are here colored in red, 
green, grey and blue. Distances were evaluated between calcium ions (orange spheres) in two contiguous binding sites.  
 
Compound VI.1.7 was used as a model; in principle, it should have the same size and behavior of 
the corresponding VI.1.9 derivative. The distance between oxygen atoms in 3- position of two 
different mannose residues was monitored, since mannose is known to chelate Calcium ions in DC-
SIGN using O3 and O4. Results showed that the maximum extension of the compound (i.e. the 
maximum distance between two O3 atoms -Max dO3-O3-), was 35.4 Å, which is not enough to bind 
simultaneously two DC-SIGN binding sites. In a similar way, also IV.1.7 was demonstrated not to 
be able to reach across, as expected, given its smaller structure with respect to the hexavalent 
derivative. The nonavalent derivatives were not investigated, because IX.1.9 is not soluble in water.  
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These assays revealed that the affinity improvement observed for the hexavalent and tetravalent 
dendrimers with respect to the monovalent ligand could be only due to the statistical rebinding 
effect or to protein clustering. The induction of DC-SIGN aggregation in the SPR assay can be 
easily understood, since DC-SIGN and the ligands flow free in solution; the induction of DC-SIGN 
clustering in the cellular inhibition assay could also be possible given DC-SIGN mobility on the 
membrane.15  
 
2.3 Goal of the project 
As stated in the previous paragraph, multivalent dendrimeric compounds based on tetravalent and 
hexavalent dendrimeric scaffolds are able to implement the multivalent mechanisms of statistical 
rebinding and/or protein clustering, leading to a gain in activity towards DC-SIGN receptor with 
respect to the corresponding monovalent compounds. We wanted to further improve the affinity of 
artificial ligands for DC-SIGN, with the aim to prepare potent inhibitors of DC-SIGN-mediated 
infections, especially the HIV one.  
Starting from the results obtained with multivalent dendrimeric-based compounds, only 
derivatizations of the hexavalent compounds were investigated. Indeed, the low solubility of IX.1.9 
suggested a limit to an approach based only on increased valency for ligand 1.9. Rather, we strived 
to find ways to efficiently exploit chelation mechanism and we therefore decided to separate two 
couples of trivalent materials with a rigid central spacer, obtaining compounds with the general 
structure shown in Scheme 2.1.  
 
 
Scheme 2.1 Schematic representation of an hexavalent compound where two trivalent dendrons are separated by one 
central spacer. White circles represent monovalent ligands. 
 
As monovalent ligand, the lead compound 1.9 was obviously employed. Compound 1.7 was used to 
build control molecules that were expected to be easier to synthesise and soluble in water and that 
would help in investigating the role of the monovalent ligand in determining the overall activity of 
the construct. 
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When designing a compound able to chelate a receptor, its rigidity is an important issue. When a 
ligand is equipped with a rigid linker, it has to pay less entropic costs to be fixed within the binding 
site, thus favoring the multivalent interaction. But ligands that do not fit the distance between 
contiguous binding sites demand for their bending or the receptor’s to match their reciprocal shape; 
enthalpic costs increase when the ligand is too rigid. For these reasons, searching for a balance 
between rigidity and flexibility, we decided to use flexible dendrons connected to rigid spacers. 
This design should be able to add chelation mechanism while preserving a relatively high local 
concentration of the monovalent ligand in the vicinity of each binding site. Trivalent dendrons were 
designed by our group for the synthesis of IX.1.912 and they are characterized by flexible, PEG-
based cores (Scheme 2.2).  
 
 
Scheme 2.2 Trivalent dendrimers presenting ligand 1.7 or 1.9 on a flexible scaffold. 
 
As spacers, molecular rods made by aromatic rings connected via triple bonds (named Rods, 
Scheme 2.3) were used. Three different Rods were generated by varying the number of phenylene-
ethynylene units, thus producing compounds 2.3 (Rod1, one unit, 8 Å), 2.4 (Rod2, two units, 12 Å) 
or 2.5 (Rod3, three units, 24 Å). They were functionalized with PEG chains to improve their 
solubility in water. Their synthesis was published by the groups of Bernardi and Pieters, and 
divalent Rod-based galactose derivatives were investigated as ligands for Pseudomonas aeruginosa 
lectin LecA.16  
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Remarkably, derivatives 2.4 and 2.5 have an intrinsic fluorescence, which confers to their 
derivatives the important feature of being directly detectable through fluorescent microscopy, for 
instance within a cell, without the need of extra fluorescent tags.   
 
 
Scheme 2.3 Structure of phenylene-ethynylene Rods 1-3. 
 
Since the fully extended conformation of VI.1.7 (Figure 2.3) was found to be only slightly shorter 
than the distance between two contiguous binding sites within the receptor, just adding the short 
Rod1 should result in a construct able to bridge two binding sites on the DC-SIGN tetramer. The 
synthesis of two series of compounds, characterized by three different lengths of the Rod (2.35-2.37 
and 2.43-2.45, Table 2.2), would allow to empirically assess which is the best ligand dimension to 
span the required distance for chelation. In order to investigate the effective role of valency in 
increasing compounds activity through the statistical rebinding effect, divalent compounds were 
also produced (2.38-2.40 and 2.46-2.48, Table 2.2), by combining two monomeric ligands based on 
1.7 or 1.9 to the Rods. To maintain the overall length of the molecules, 1.7 and 1.9 were first 
derivatized with an appropriate linker that matched the length of the dendrimeric core (Scheme 2.4). 
Two other divalent molecules (2.41 and 2.49, Table 2.2) were produced by directly linking 1.7 and 
1.9 to the longest rod, Rod3.  
 
 
Scheme 2.4 Structure of the elongated monovalent derivatives of 1.7 and 1.9. 
Chapter 2 
49 
 
 
All synthesised compounds are listed in Table 2.2. They are characterized by a progressive number, 
together with a conventional lab name made by PM (which stands for Polyman) followed by a 
number.  
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Structure 
 
Ligand 
1.7 
Ligand 
1.9 
 
2.35 
PM30 
2.43 
PM25 
 
2.36 
PM32 
2.44 
PM33 
 
2.37 
PM31 
2.45 
PM26 
 
2.38 
PM34 
2.46 
PM37 
 
2.39 
PM35 
2.47 
PM38 
 
2.40 
PM36 
2.48 
PM39 
 
2.41 
PM41 
2.49 
PM40 
 
2.42 
PM09 
2.50 
PM19 
Table 2.2 General structure of synthesised compounds, together with identification numbers and conventional names. 
Grey spheres represent monovalent ligands 1.7 or 1.9. 
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2.4 Synthesis 
2.4.1 Synthesis of monovalent disaccharides 1.7 and 1.9 
The synthesis of compounds 1.7 and 1.9 had already been accomplished by N. Varga during its PhD 
thesis (Scheme 2.5).17 Both compounds resulted from glycosylation of a cyclohexane derivative 
conveniently substituted (2.9 or 2.10) with a mannose donor activated as trichloroacetimidate at the 
anomeric position (2.8), yielding 2.11 and 2.12. The para-nitrophenyl (PNP) ester in 2.12 was 
replaced with a benzylamine to achieve the desired functionalization to give 1.9. Final products 1.7 
and 1.9 were obtained after removal of benzoyl protecting groups (Scheme 2.5).  
 
Scheme 2.5 A glycosylation reaction connects a trichloroacetimidate mannose derivative 2.8 and a cyclohexane 
conveniently substituted 2.9 or 2.10, yielding 2.11 or 2.12 precursors, respectively, of disaccharides 1.7 and 1.9. 
  
Compounds were obtained with an overall yield of 64 % for 1.7 and 22 % for 1.9, calculated based 
on 2.9 and 2.10. Respectively, 2 g and 1 g of the two final products were obtained.  
During my PhD thesis, I synthesised one batch of 100 mg of 1.9 (with 35 % yield, calculated based 
on 2.10). 
 
2.4.2 Synthesis of the Rods 
The synthesis of the phenylene-ethynylene units made extensive use of the Pd-Cu catalysed reaction 
known as Sonogashira coupling. 18 
 
2.4.2.1 Sonogashira couplings  
The catalytic cycle of Pd–Cu catalyzed cross-couplings of terminal acetylenes with sp2-carbon 
halides is depicted in Scheme 2.6. In this reaction, the active species Pd(0) undergoes first an 
oxidative addition with the aryl halide ArX. The resulting Pd(II) complex undergoes a ligand 
exchange reaction with the Cu acetylide formed in situ, to give the aryl-acetylide Pd species. A final 
reductive elimination leads to the formation of the new C-C bond.   
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As Pd(0) catalyst source (≈ 0.04 eq.) we directly used Pd0(PPh3)4 or, more conveniently because its 
higher air-stability, we reduced PdII(PPh3)2Cl2 in situ with PPh3 or NR3. The amine, NEt3 (TEA) or 
N,N’-diisopropylethylamine (DIPEA), was used as reducing agent and also as a base to deprotonate 
the terminal alkyne. Toluene or THF were used as solvents, conducting the reactions, respectively, 
at 50 °C or at room temperature. CuI (≈ 0.04 eq.) was the source of Cu(I). 
 
 
Scheme 2.6 Sonogashira coupling catalytic cycle. 
 
Remarkably, Copper in the presence of an oxidant species catalyzes also the acetylene 
homocoupling, known as Glaser reaction.19 A possible mechanism pathway is shown in Scheme 
2.7, where the Copper-acetylide dimerizes through a radical mechanism.  
Even if Sonogashira reactions were performed in the complete absence of oxygen, the oxidant 
environment was unavoidably created by the I-/I2 equilibrium generated by activation of the aryl 
iodide (ArX, X = I) and by the presence of CuI.  
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Scheme 2.7 Glaser homocoupling catalytic cycle. 
 
For this reason, one should know that terminal alkynes can’t be isolated as final products of 
Sonogashira couplings, since they would subsequently react with one another, at least in a certain 
amount. Moreover, given that the Glaser homocoupling competes with the Sonogashira one also for 
the terminal acetylene used as reagent, this last should be added in slight excess with respect to the 
halide. 
 
2.4.2.2 Synthesis of the Rods 
The synthesis of the three Rods started from the commercially available 1,4-dimethoxybenzene 
2.13, which was first transformed in the diiodide 2.15 by refluxing in methanol with iodine, in the 
presence of the periodic acid. The methyl ethers of 2.15 were first cleaved by treatment with BBr3 
at low temperature, yielding the bis-phenol 2.15, and then replaced with short polyethyleneglycol 
chains (n = 2) by reacting with 2-(2-Chloroethoxy)ethanol in the presence of K2CO3 as the base, 
obtaining the diiodide 2.16 (Scheme 2.8). 
 
 
Scheme 2.8 Synthesis of the bis-PEGylated diiodide benzene 2.16. 
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Compound 2.16 underwent a Sonogashira coupling with tri-isopropylsilylacetylene 2.17, which was 
added in the proper amount (1.5 eq.) to allow the formation of both the mono-substituted product 
2.18 and the di-substituted one TIPS-2.3 (TIPS-Rod1) (Scheme 2.9). Both products were obtained 
in similar yields (≈ 40 %) and 20 % of the starting material was recovered; compounds were easily 
separated through flash chromatography on silica. Remarkably, the synthesis of only mono-
substituted 2.18 was disfavoured; indeed, by adding 0.5 eq. of  tri-isopropylsilylacetylene, both 
compounds 2.18 and TIPS-2.23 were formed, thus increasing the amount of non-reacted 2.16 and 
decreasing the overall yield.  
 
 
Scheme 2.9 Synthesis of mono-substituted 2.18 and di-substituted TIPS-2.3 compounds.  
 
Deprotection of compound TIPS-2.3 with tetra-n-butylammonium fluoride (TBAF) gave 2.3 
(Rod1) in high yields (Scheme 2.10). 
 
 
Scheme 2.10 Synthesis of compound 2.3 (i.e. Rod1). 
 
We thought that another Sonogashira coupling reaction between compound 2.18 and 2.3 would 
provide the formation of both mono-protected Rod2 (2.19, Scheme 2.11) and TIPS-Rod3 (TIPS-
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2.5 Scheme 2.11), if using an excess of 2.3 (3:1). On the contrary, compound 2.19, which should 
derive from a single coupling between 2.18 and 2.3, couldn’t be formed, due to several side 
reactions -mainly oligomerization ones- in which it was involved. The main one, a Glaser reaction 
(see Paragraph 2.4.1), gave the dimeric compound 2.20 (Scheme 2.11).  
 
Scheme 2.11 A Sonogashira coupling between 2.18 and 2.3 (Rod1) afforded compound TIPS-2.3 but not compound 
2.19, which underwent oligomerization reactions leading, for instance, to the dimer 2.20. 
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In order to obtain 2.19, solvent and reaction temperatures were varied. Also a Copper free 
Sonogashira reaction was tried, using [1,1′-Bis(diphenylphosphino)ferrocene]dichloropalladium as 
catalyst, but the desired product was never obtained. Apparently, the homocoupling reaction can be 
catalysed also by the Palladium species.20 Tested reaction conditions are reported in Table 2.3.  
 
Table 2.3 Reaction condition tested to avoid Glaser homocoupling. Dppf = 1,1'-Bis(diphenylphosphino)ferrocene. a vs 
ArX, Reactions were performed in NEt3 10 eq. vs alkyne), at a concentration of 0.1-0.3 mM in the solvent.  
Pd source Cu source Phosphine Solvent T (°C) Time (h) 
Pd(PPh3)4  
0.1 eq.a 
CuI  
0.1 eq.a 
PPh3  
0.2 eq.a 
Toluene 50 24 
Pd(PPh3)4  
0.1 eq.a 
CuI  
0.1 eq.a 
PPh3  
0.2 eq.a  
DMF 20 44 
Pd(dppf)2Cl2 
0.05 eq.a 
Copper free 
Dppf  
0.1 eq.a 
Toluene 50, then 20 3 
 
We therefore realised that Rod2 could be stably obtained only if protected on each terminal side. 
This double protection can be achieved through a Sonogashira reaction between the already known 
compound 2.18 and a monoprotected di-alkynyl substrate 2.21 (Scheme 2.12).  
 
 
Scheme 2.12 Retrosynthetic route to di-protected Rod2. 
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Initial efforts to obtain 2.21 by selective monodeprotection of TIPS-2.3 (Scheme 2.13) with TBAF 
were unsuccessful, thus we envisaged to obtain 2.21 from the differentially protected analogue 2.22 
(Scheme 2.13).  
 
 
Scheme 2.13 Compound 2.22 is characterized by two orthogonal alkyne protecting groups. 
 
As orthogonal alkyne protecting groups, TIPS and 2-propanol were used. Compound 2.21 was 
synthesised by a slight modification of a known procedure (Scheme 2.14).21 Coupling of 2.18 with 
2-Methyl-3-butyn-2-ol (MEBYNOL, 2.23) under Sonogashira conditions afforded 2.22 in good 
yields. Removal of 2-propanol was achieved with NaOH under heterogeneous conditions. This 
reaction was rather critical because it didn’t reach full conversion even in 18 h, but longer reaction 
times led to desilylation and decomposition of 2.21 to 2.3 (Rod1). Under optimized conditions, the 
reaction was stopped after 5 hours, once the formation of the side-product 2.3 (Rod1) was observed 
by TLC (Toluene:acetone 6:4). The reaction mixture was diluted with MeOH in order to protonate 
the acetylide intermediate species; the use of a drop of CH3COOH for this purpose, led on the 
contrary to product degradation. 2.21 was isolated in 35% yields and 36% of 2.22 was recovered by 
silica chromatography (55% yield b.r.s.m.) (Scheme 2.14).  
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Scheme 2.14 Synthesis of the monoprotected di-alkynil benzene 2.21. 
 
A Sonogashira coupling reaction between compounds 2.18 and 2.21 conducted in the dark provided 
TIPS-2.4 (TIPS-Rod2) in excellent yields (Scheme 2.15).  
 
 
Scheme 2.15 Synthesis of TIPS-2.4 (TIPS-Rod2). 
 
Finally, compound TIPS-2.5 (TIPS-Rod3) was synthesised in moderate yields with a Sonogashira 
coupling between 2.18 (2.2 eq.) and 2.3 (Rod1, 1 eq.), conducted again under dark (Scheme 2.16). 
In the previously not optimized reaction, reported in Ref.16, a ratio 2.25:2.26 = 1:3 had been used. 
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Scheme 2.16 Synthesis of TIPS-2.5 (TIPS-Rod3). 
 
2.4.3 Copper(I)-catalyzed Azide-Alkyne Cycloaddition 
Copper(I)-catalyzed Azide-Alkyne Cycloaddition (CuAAC)22 is the catalysed variation of a 
Huisgen cycloaddition between a terminal triple bond and an azide. It is referred to also as click 
reaction, and it regioselectively yields a 1,4-substituted triazole (Scheme 2.17).  
 
n
= multivalent scaf fold
= ligand
N3
nN N
N
Cu(I)
 
Scheme 2.17 General scheme of a Copper(I) catalyzed 1,3-dipolar cycloaddition (click reaction) between a terminal 
alkyne (red) and an alkyl azide (blue). Multivalent scaffolds can be decorated with multiple ligands. 
 
A proposed mechanism of its catalytic cycle is depicted in Scheme 2.18.23 In the first step, the 
alkyne reacts with the cationic Cu(I) compound to give a Copper acetylide species, which then 
coordinates the nitrogen of the azide. The azido group and the Copper acetylide give a 
cycloaddition reaction that leads to an intermediate (I), which undergoes a rearrangement to give 
the triazole ring in a regioselective fashion. Finally, protonolysis of the Cu-C bond completes 
formation of the triazole. 
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Scheme 2.18 CuAAC catalytic cycle. 
 
In the optimized procedure followed by N. Varga17 and developed in the group of Dr. J. Rojo 
(Seville, SP), Copper(II) Sulphate and the reducing agent Sodium Ascorbate were used as a 
combined source of Cu(I). The possible re-oxidation of Copper(I) was prevented by stabilizing it 
with Tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine (TBTA) and by using an excess of 
NaAscorbate (4 times with respect to Cu). Moreover, reactions were conducted in the dark, under 
nitrogen atmosphere and using degased and/or freshly distilled solvents.  
A 1:1 mixture THF/H2O was found suitable to dissolve all the reagents. The reagents were added to 
the reaction vessel in the following order: alkyne, TBTA, CuSO4·5H2O, Sodium Ascorbate and 
finally the azide monovalent ligand (1.1 eq. per each triple bond).  
The final concentration of alkynes was 3-15 mM, depending on the solubility of the components 
and of the products in the solvent. When a concentration > 10 mM in 1:1 THF:H2O could be 
obtained, the reaction was stirred at room temperature for 12 -24 hours. For less soluble mixtures, 
the reaction was performed at lower concentrations (typically 3 mM) under microwave assisted 
conditions for 1-2 h at 60 °C. Yield varied from acceptable (50 %) to high (90 %). 
The reaction was monitored by TLC and/or MALDI mass spectrometry (DHB or sinapinic acid 
matrix) until completion. In general, the formation of divalent and trivalent compounds could be 
monitored by TLC, while most complex hexavalent compounds were best analysed by MALDI 
mass. When intermediates were observed but the azide monovalent ligand was totally consumed, 
the latter was added together with additional 0.4 eq. of Sodium Ascorbate.  
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The crude was purified by size exclusion chromatography on a Sephadex LH20 column and by 
reverse phase chromatography, when required. The metal scavenger Quadrasil™-MP was used to 
remove copper salts either from the reaction mixtures before purification, or from a solution of the 
isolated final compound. This was required because copper, in a certain amount, is toxic for cells.24 
Avoiding cytotoxicity is crucial both for biological cellular tests and, of course, for in vivo 
applications.  
 
2.4.4 Synthesis of the polyalkyne scaffolds 
The hexavalent scaffold 2.24 was available in the laboratory. It was prepared according to Ref.12 
starting from bis(pentaerythritol) 2.23, which underwent a Williamson etherification reaction with 
propargyl bromide using NaH as a base (Scheme 2.19). 
 
 
Scheme 2.19 Synthesis of the hexavalent scaffold 2.32. 
 
The trivalent scaffold 2.27 was synthesised as shown in Scheme 2.20, starting from pentaerythritol 
2.25, which underwent a Williamson reaction with propargyl bromide to give compound 2.26. 
2.26.1 was formed as a co-product (20%) and was separated by flash chromatography. A second 
reaction with bis-(2-Chloroethyl) ether gave 2.27 (Scheme 2.20). 
 
Scheme 2.20 Synthesis of the trivalent scaffold 2.31. 
 
2.4.5 Synthesis of the trivalent dendrons 
The trivalent dendrons 2.1 and 2.2 (Scheme 2.2) were produced by performing click reactions (see 
Paragraph 2.4) between the monovalent ligands 1.7 or 1.9 and the trivalent alkyne 2.27. The 
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chloride-substituted dendrons 2.28 and 2.29 were converted in the corresponding azide-derivatives 
2.1 and 2.2 through a chloride-azide reaction exchange catalysed by I- (Scheme 2.21).   
 
 
Scheme 2.21 General procedure to synthesize trivalent dendrimers 2.1 and 2.2. 
 
Remarkably, the purity of scaffold 2.27 was always assessed through TLC analysis prior each 
reaction, since it was demonstrated that it can degrade loosing propargyl functionalities to give 
alcohol 2.27.1 (Scheme 2.22). The reaction between degraded scaffold and monovalent ligands 
would result in intermediate species that can’t be separated from the desired final compound.      
 
 
Scheme 2.22 2.27.1 results from the degradation of 2.27. 
 
2.4.6 Synthesis of elongated monovalent ligands 
Linker 2.32 (Scheme 2.23) was used to functionalize monovalent compounds 1.7 and 1.9. It was 
obtained from the commercially available 3,7-Dioxa-1,9-nonanediol 2.30 that reacted with 
propargyl bromide in presence of NaH as the base, to give compound 2.31 (also the bis-
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propargylated co-product 2.31.1 was obtained in 13 % yield and separated through flash 
chromatography on silica). The free hydroxyl group was then transformed into a tosylate to give 
compound 2.32. This compound underwent a “click” reaction with 1.7 or 1.9, obtaining respectively 
compounds 2.33 and 2.34. A tosylate-azide exchange catalyzed by I- gave 2.6 and 2.7 (Scheme 
2.23). Remarkably, final compounds were obtained not completely pure, still containing 1-3 % w/w 
of the tosilate salt; nevertheless, they were used without further purifications in the subsequent click 
reactions, where the salt didn’t interfere.  
 
 
Scheme 2.23 Synthesis of elongated compounds 2.6 and 2.7. 
 
2.4.7 Synthesis of final molecules 
The final molecules were synthesised coupling trivalent dendrons (2.1, 2.2) or elongated 
monovalent ligands (2.6, 2.7) or monovalent ligands (1.7, 1.9), all bearing azide groups, on the 
terminal alkynes of the central scaffolds 2.3, 2.4, 2.5, 2.28. The general principle and reaction 
conditions of the CuAAC were explained in Paragraph 2.4.4. As previously reported, the 
cycloaddition was performed using copper(II) sulfate, in situ reduced by sodium ascorbate and 
stabilized by tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine (TBTA); azide-bearing compounds 
were used in slight excess (1.1 eq. per each triple bond).  
Final obtained molecules are listed in Table 2.4, together with their constituent moieties. 
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Structure 
 
Fragment 
Ligand
1.7 
Ligand
1.9 
 
 
2.35 
PM30 
2.43 
PM25 
 
 
2.36 
PM32 
2.44 
PM33 
 
 
2.37 
PM31 
2.45 
PM26 
 
 
2.38 
PM34 
2.46 
PM37 
 
 
2.39 
PM35 
2.47 
PM38 
 
 
2.40 
PM36 
2.48 
PM39 
 
 
2.41 
PM41 
2.49 
PM40 
 
 
2.42 
PM09 
2.50 
PM19 
Table 2.4 General structure of synthesised compounds, together with identification numbers and conventional names. 
Grey spheres represent monovalent ligands 1.7 or 1.9. Derivatives of compound 1.7 are shown in blue, derivatives of 
compound 1.9 are shown in red. 
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All reactions were performed at room temperature, overnight and in the dark, except for derivatives 
of the trivalent dendrimers 2.2. Its low solubility in water demanded for 4 final concentrations of the 
alkynes lower than 10 mM; therefore, reactions were accelerated under microwave irradiation at 60 
°C; reaction times decreased to less than 2 h.  
Compounds 2.35, 2.38, 2.43 and 2.46, which are based on Rod1 2.3, were synthesised by directly 
performing a CuAAC between 2.3 and the required trivalent dendrimer or elongated monovalent 
ligand (Scheme 2.24). 
 
 
Scheme 2.24 Synthesis of compounds based on Rod1/2.3. 
 
Rod2 (2.4) and Rod3 (2.5) were prepared immediately before performing the azide-alkyne 
cycloaddition by in situ desilylation of the corresponding tri-isopropyl-alkynylsilane TIPS-2.4 
(Scheme 2.25) and TIPS-2.5 (Scheme 2.26). Coupling with the trivalent dendrons (2.1, 2.2) or the 
elongated monovalent ligands (2.6, 2.7) or with monovalent ligands 1.7 and 1.9 directly gave the 
final Rod2- and Rod3-based dendrimers. 
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Scheme 2.25 Synthesis of compounds based on Rod2/2.4. 
 
 
Scheme 2.26 Synthesis of compounds based on Rod3/2.5. 
 
Hexavalent dendrimer-based compounds 2.42 and 2.50 were synthesised by coupling monovalent 
ligands on scaffold 2.24 (Scheme 2.27). Also the purity of scaffold 2.28 was assessed through TLC 
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analysis before performing the reaction, thus avoiding the presence of degraded compounds missing 
propargly units.  
 
 
Scheme 2.27 General procedure to synthesize hexavalent derivatives 2.42 and 2.50. 
 
2.5 Computational Analysis 
In order to predict the structural behavior of these compounds when interacting with DC-SIGN, the 
shape and size of the ligands were simulated by molecular dynamics (125-150 ns); analysis were 
performed by A. Bertaglia, Dr. G. Vettoretti and Dr. L. Belvisi. Compounds belonging to the 1.7-
series was used as model; for sake of simplicity, the PEG chains on the rods were replaced with 
methyl ethers.  
To gauge the average dimension of the glycodendrimers and evaluate if they are potentially able to 
chelate DC-SIGN. The distance between Man-O3 atoms of two distal sugar residues in a 
multivalent structure was chosen as representative for its maximum extension in terms of binding 
capacities.  
The simulations showed that, as previously described (see Ref.12 and Paragraph 2.2), the hexavalent 
dendrimer 2.42 is structurally not long enough to bridge between two DC-SIGN binding sites. On 
the contrary, the presence of one rod, even the short one (scaffold 2.3 in compound 2.38, Table 2.4), 
gives rise to structures that in their most extended conformation could comfortably reach across. 
Indeed, all compounds 2.37, 2.38, 2.40 and 2.41 had maximum O3-O3 distance (Max  dO3-O3) values 
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longer than 40 Å. However, the flexibility associated to the long linker of 2.37, 2.38, and 2.40 
induced sugars to fold over aromatic cores, so that the percentage of structures with an average O3-
O3 distance (<dO3-O3>) higher than 35 Å was < 5 %. Representative folded conformations of 
compounds 2.40 and 2.37 are shown in Figure 2.7. A Type I conformation shows a compact 
structure where sugar residues fold over the aromatic core from the two opposite sides. On the 
contrary, Type II conformations are obtained when sugar moieties are found on the same side of the 
central scaffold. For divalent compound 2.40 both conformation types were observed. On the 
contrary, Type II conformations were preferentially assumed by hexavalent compound 2.37, 
probably stabilized by Man-Man interactions (Figure 2.7).  
 
 
 
Figure 2.7 A) Structures of the most represented conformations sampled during the dynamic simulations of 2.40. Two 
types of folds (Type I and Type II ) were observed. B) Representative structures from the simulation of 2.37: Type II 
folds are favored. 
 
Remarkably, the most extended average structure was calculated for the dimeric compound 2.41, 
having the short linker. This dimer features Max dO3-O3 and  < dO3-O3 >  of 43.3 Å  and 31.7 Å, 
respectively. Most importantly, 30 % of the structures sampled during the simulations displayed 
dO3-O3 > 35 Å. This result highlighted that, among the structures synthesised, compound 2.41 has an 
optimal preorganization to act as DC-SIGN chelating agent. 
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Dynamics simulations of the binding complexes formed by 2.41, 2.40 and 2.38 and two DC-SIGN 
CRDs showed that they all are stable over the course of 25 ns. The structures of obtained complexes 
are reported in Figure 2.8. 
 
 
Figure 2.8 Docked complexes of divalent ligands A) 2.41, B) 2.40 and C) 2.38 on two adjacent DC-SIGN CRDs. 
 
2.6 Biological Characterization  
With the aim to assess the biological relevance of synthesised compounds, we performed two types 
of assays. SPR inhibition assays were used to evaluate binding efficiency of the DC-SIGN ligands 
(see Paragraph 2.6.1). I performed these experiments in the laboratories of Prof. F. Fieschi, where I 
also expressed and purified DC-SIGN. The ability of compounds to inhibit the DC-SIGN-mediated 
HIV infection was investigated in a trans-infection model with DC-SIGN expressing cells and CD4+ 
T-lymphocytes. These latter experiments were performed by Dr. A. Berzi in the group of Prof. M. 
Clerici (see Paragraph 2.6.2). Finally, the cytotoxicity of compounds was also excluded (see 
Paragraph 2.6.3), a feature that makes them suitable for topical applications.  
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2.6.1 Surface Plasmon Resonance (SPR) Inhibition Assays 
Surface Plamon Resonance (SPR) is a physical process that can occur when a beam of light hits a 
metallic surface and is reflected at the surface-solution interface. This resonance is possible only 
when the beam of light hits the surface at a certain angle Θ, the resonance angle, and it excites an 
electromagnetic field, named “evanescent” wave. By varying the mass of the surface, the suitable 
Θ that produces the evanescent wave changes as well. SPR technique is able to detect changes in 
terms of mass by monitoring in real time the changes in Θ. It gives back resonance signals (i.e. 
resonance units RU), proportional to mass change, versus time (Figure 2.9). 
An SPR assay allows to evaluate the interaction between one material immobilized over the surface, 
which is usually a gold layer, and another one flushing free in solution over the surface (Figure 
1.7).25 When the binding occurs, the weight of the surface changes, in a way related to the mutual 
affinity of biding partners.  
 
 
Figure 2.9 Surface plasmon resonance (SPR) detects the angle needed for the polarized light to excite the evanescent 
wave. The angle depends on the mass of the surface and can shift from I to II (bottom, left) when biomolecules bind to 
the surface, thus changing the mass of the surface layer. This angle change can be monitored in real time as a plot of 
resonance signal (proportional to mass change) versus time (bottom, right). 
 
This technique was used to evaluate the ability of multivalent synthesised compounds to inhibit the 
binding of soluble tetrameric DC-SIGN extracellular domain (ECD) to mannosylated Bovine Serum 
Albumin (Man-BSA, carrying 15 tri-mannose residues per unit), immobilized over the gold surface. 
Man-BSA competes with the ligand in the binding to DC-SIGN, being itself a DC-SIGN ligand, 
and it was used as a mimic of gp120 glycoprotein. The efficiency of inhibition as a function of a 
compound’s concentration is directly related to the ligand affinity toward DC-SIGN ECD. Since 
Immobilized 
binding partner
Free binding partner
in solution
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what is measured is the residual protein able to bind to the surface where the competitor is 
immobilized, this experiment is referred to as inhibition or competition assay.  
Preliminary SPR direct assays were also performed by the Fieschi group, evaluating the interaction 
between the ligands flushing over the gold surface where DC-SIGN ECD was immobilized. The 
interpretation of the obtained results is still on going.  
 
2.6.1 Tested compounds 
Tested compounds are listed in Table 2.2. During the course of my thesis, these molecules were 
assigned a conventional name PolymanXY, and an abbreviation PMXY, for communication 
between the different groups involved. These abbreviations are shown in Table 2.2, together with 
the structures and the numbering used so far. Their conventional abbreviated name PMXY will be 
used in the following paragraph. 
The non-chelating dendrimers 2.42 (PM09) and 2.50 (PM19) were used as references.12 
 
2.6.1.2 Experimental 
2.6.1.2.1 DC-SIGN ECD production, expression and purification 
2.6.1.2.1.1  Transformation of Ca2+-competent E.coli strain 
On ice, 5 µL of DC-SIGN ECD pET30 plasmid (produced by Dr. M. Thépaut, Institut de Biologie 
Structurale, Grenoble) were added to 200 µL of the Ca2+-competent E.coli strain BL21(DE3). After 
being incubated for 30 minutes on ice, the resulted solution underwent a heat shock for 45 seconds 
in 42 °C water. Then it was put back on ice, before adding 1 ml of SOC broth (sterile procedure) 
and incubating at 37 °C for 1 hour. After solution centrifugation (5000 rpm, 5 minutes), the 
majority of the supernatant was discarded, leaving a small residual amount in the tube, in which the 
obtained pellet was resuspended (sterile procedure).  
Resuspended cells were plated on a Petri dish with LB-Agar containing kanamycin antibiotic and 
incubated at 37 °C overnight (sterile procedure). 
2.6.1.2.1.2 Preculture and culture of DC-SIGN ECD 
Two clones selected from the Petri dish were inoculated to 100 mL of LB broth containing 50 
µg/mL of kanamycin antibiotic (sterile procedure). The obtained solution was cultivated at 37°C 
overnight to produce the preculture. 
The culture was started by inoculation of 50 mL of overnight preculture to 1 L of LB broth with 50 
µg/mL kanamycin (sterile procedure). The cells were grown at 37 °C for 3 h. 
Cell growth was controlled by measuring solution absorbance at 600 nm each (A = 1.86 at time of 
IPTG induction). 
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2.6.1.2.1.3 Overexpression of DC-SIGN ECD 
DC-SIGN ECD over-expression was induced by addition of IPTG to final concentration of 1 mM 
and the culture was continued at 37 °C for 3 hours.  
Cell growth was controlled by measuring solution absorbance at 600 nm each 20 minutes (Figure 
2.10), and expression was confirmed by a 12 % polyacrylamide gel electrophoresis (PAGE) before 
and after induction (Figure 2.11). 
 
 
Figure 2.10 UV-Vis time-control of induction at λ = 600 nm. 
 
 
Figure 2.11 12 % polyacrylamide gel electrophoresis. Cell culture was controlled before and after the IPTG induction. 
Page ruler uns protein ladder is a pre-stained marker containing 11 proteins with known molecular weight. The DC-
SIGN related spot corresponds to one monomeric extracellular domain.  
 
The cells were harvested by centrifugation at 5000 rpm for 20 min at 4 °C and resuspended in the 
buffer consisting of 25 mM Tris-HCl (pH 8), 150 mM NaCl, 4 mM CaCl2 (1 L pellet was 
resuspended in 30 mL of buffer) and stored at -20 °C. 
2.6.1.2.1.4 Inclusion body extraction 
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To the pellet of 1 L culture already suspended in 30 mL of buffer (25 mM Tris-HCl pH 8, 150 mM 
NaCl, 4 mM CaCl2), 1 tablet of “complete EDTA-free” protease inhibitor cocktail was added. The 
cells were disrupted by sonication in ice for a 2 minutes round at 90 % amplitude, using 2 s long 
sonications and 10 s long pauses in-between. The inclusion bodies together with cell debris were 
collected by centrifugation at 36800 rpm for 30 min at 4 °C. 
The resulting pellets was resuspended using Potter- Elvehjem homogenizer in 20 mL of buffer 
containing 25 mM Tris-HCl (pH 8), 150 mM NaCl, 2 M urea and 1% Triton-X100, and centrifuged 
at 36800 rpm for 30 minutes at 4 °C. It was then rinsed by resuspending in 40 mL of 25 mM Tris-
HCl (pH 8) and 150 mM NaCl buffer with Potter-Elvehjem homogenizer and centrifuging at 36800 
for 30 min at 4 °C. 
Inclusion bodies were solubilised with Potter-Elvehjem homogenizer in 60 mL of buffer containing 
6 M Gdn-HCl, 150 mM NaCl, 25 mM Tris-HCl pH 8 and 0.01 % β-mercaptoethanol, and 
centrifuged at 36800 for 40 minutes at 4 °C to eliminate insoluble part. The presence of DC-SIGN 
ECD in the resulting supernatant was assessed by a 12 % polyacrylamide gel electrophoresis 
(PAGE). Protein was subsequently refolded (see following paragraph) without being freeze nor 
stored, otherwise losing its ability to renaturate.  
2.6.1.2.1.5 Refolding 
Solubilised DC-SIGN ECD was diluted with the same buffer (6 M Gdn-HCl, 150 mM NaCl, 25 
mM Tris-HCl (pH 8) and 0.01 % β-mercaptoethanol) till the concentration (respect to the monomer) 
of 2 mg/mL was reached (211 mL). It was refolded by flash dilution (drop by drop) to 844 mL 
(final dilution 5X) of buffer consisting of 25 mM Tris-HCl (pH 8), 1.25 M NaCl, and 25 mM 
CaCl2, at 4 °C. The resulting protein solution was dialyzed overnight against 6189 mL of 25 mM 
Tris-HCl (pH 8) buffer, at 4 °C. Two more dialyses (3 hours + 2 hours, at 4 °C), against 7000 mL of 
25 mM Tris-HCl (pH 8), 150mM NaCl, and 4 mM CaCl2 buffer, continued and finished the 
refolding. The precipitates were eliminated by centrifugation at 36800 rpm for 1 h at 4 °C.  
For both the refolding and the dialysis, solubilised DC-SIGN ECD was divided in two batches. 
Each batch was refolded in 422 mL of buffer and dialyzed against 3095 mL and 3500 mL of buffer. 
2.6.1.2.1.6 Purification 
The purification of refolded DC-SIGN ECD was performed using automated purification protocol 
on an Akta Xpress FPLC system (MP3 platform, IBS Grenoble) at 4°C. Column used are a 20 mL 
Mannan-Agarose column (Sigma Aldrich Ref.: M9917) and a 125 mL Superose 12 column (GE 
Healthcare); gel filtration (GF) was cycled to fractionate the sample resulting from the Mannan-
Agarose column in 2 mL injections. 
• First step: Mannan-Agarose column 20 mL. 
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Equilibration buffer: 25 mM Tris (pH 8), 150 mM NaCl, 4 mM CaCl2. 
Elution buffer: 25 mM Tris (pH 8), 150 mM NaCl, 1 mM EDTA. 
- Column equilibration with 50 mL of equilibration buffer at 2.5 mL/min. 
- Loading of the whole sample at 2.5 mL/min. 
- Column washing with 150 mL of equilibration buffer at 2.5 mL/min. 
- Column elution with 100 mL of elution buffer at 2.5 mL/min and recovering of 
elution peak in a superloop (~20 mL of sample). 
• Second step: Superose 12 125 mL (11 cycles). 
GF buffer: 25 mM Tris (pH 8), 150 mM NaCl, 4 mM CaCl2. 
- Column equilibration with 150 mL of equilibration buffer at 1 mL/min. 
- Loading of the sample from SuperLoop by fractions of 2 mL. 
- Column elution with 150 mL of GF buffer at 1 mL/min, 1 mL fractions where 
collected when automatic peak detection occurred during elution in a 96-well deep 
well plate. 
The best yield obtained was 30 mg of DC-SIGN ECD for 2 L culture. 
 
2.6.1.2.2 SPR Assays set up 
SPR inhibition assays were conducted using the Biacore 3000 instrument from Biacore-GE 
Healthcare. Sensor Chip CM4, amine coupling kit (including EDC, NHS and ethanolamine), HBS-
P buffer (0.01 M HEPES (pH 7.4), 0.15 M NaCl, 0.005 % Surfactant P20) and 10 % P20 were from 
Biacore-GE Healthcare. Mannosylated bovine serum albumin Man α1-3[Man α1-6]Man BSA 
(Man-BSA, carrying 15 tri-mannose residues per unit) was from Dextra Laboratories Ltd. 
Flow cells (Fc) 1 and 2 on a CM4 sensor chip were functionalized through the amine coupling 
procedure, using HBS-P buffer at a flow rate of 5 µL/min as the running buffer. The carboxymethyl 
dextran matrixe of the sensor chip was activated by injection of a 1:1 mixture of 0.2 M EDC and 
0.05 M NHS (50 µL). One cell (Fc1) was functionalized with Man α1-3[Man α1-6]Man BSA 
(Man-BSA) (10 µg/mL solution of Man-BSA in 10 mM sodium acetate buffer pH 4), whereas the 
second one -Fc2- was used as reference and functionalized with BSA (100 µg/mL solution of BSA 
in 10 mM sodium acetate buffer pH4). The remaining activated but unbound carboxylic groups 
were blocked by the injection of 1 M ethanolamine pH 8 (30 µL). Finally, all surfaces were rinsed 
with 10 mM HCl (10 µL) and conditioned with 50 mM EDTA pH 8 (20 µL). On Fc1, the final 
response of immobilized level of Man-BSA was 1500 RU. 
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Glycodendrimers were solubilized in the running buffer consisting of 25 mM Tris-HCl (pH 8), 150 
mM NaCl, 4 mM CaCl2 and 0.005 % v/v P20, supplemented with 4 % DMSO for 1.9 derivatives, 
because of solubility problems.  
13 µL of a mixture consisting of compounds plus 20 µM DC-SIGN ECD (concentration of the 
monomeric subunit) were injected over the surfaces. The concentration of DC-SIGN ECD was 
chosen according to its affinity for immobilized Man-BSA, resulting in a maximum response of 
about 3000 RU. Compounds were tested at increasing concentrations, up to 2 mM for divalent 
compounds and 0.9 mM for hexavalent derivatives. Lectin alone at the concentration of 20 µM was 
injected in order to determine its full activity. Bound lectin was removed with 5 µL of 50 mM 
EDTA (pH 8) to regenerate the surface.  
 
2.6.1.2.3 Data analysis 
Obtained sensograms show the binding responses expressed in terms of response unit (RU), and 
represent the amount of lectin bound to the surface in the function of time. Equilibrium binding 
responses are the maxima RU values reached and were obtained 150 s after the start of the injection. 
DC-SIGN ECD binding responses (Req) were corrected for the references RU arising from the 
interaction between DC-SIGN ECD and BSA (reference Fc2), thus avoiding the possible 
contribution of unspecific interactions with the BSA surface. In Figure 2.12 the series of 
sensograms obtained for several concentrations of compound 2.35/PM30 is shown as an example.  
 
 
Figure 2.12 A mixture of 2.35/PM30 DC-SIGN ECD (20 µM) was injected over a CM4 sensor chip functionalized 
with Man-BSA (15 tri-mannoses on average). Obtained sensograms show the Relative Response Units (RU) in the 
function of time, indicating the amount of bound lectin corrected for the reference surface. DC-SIGN ECD binding 
responses (Req) were obtained 150 s after injection. The different sensograms correspond to different compound 
concentrations. 
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Req values were then converted to residual DC-SIGN ECD activity values by normalizing them with 
respect to the Req of the lectin alone (which was considered as a 100 % activity value), as shown in 
Figure 2.13 (again the behaviour of 2.35/PM30 is taken as an example). 
 
 
Figure 2.13 Residual DC-SIGN ECD activities in the presence of different concentration of compound PM30 were 
obtained from the binding responses Req normalized with respect to the Req values of DC-SIGN ECD alone.  
 
The plot of the residual DC-SIGN ECD activity (y, %) versus the corresponding compound 
concentration (Figure 2.13) was fit using the 4-parametre logistic model (Equation 2.3) 
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Equation 2.3 4-parameter logistic model used to fit the plots of the residual DC-SIGN ECD activity (y, %) with respect 
to the corresponding compound concentration (Conc). Rhi and Rlo are maximum and minimum asymptotes, A1 is the 
inflection point and A2 is a slope of the curve. 
 
Finally, IC50 values for each compound (i.e. the concentration needed to inhibit the binding of half 
of the injected protein to the BSA-Man surface) were calculated using Equation 2.4.  
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Equation 2.4 Equation used to calculate IC50 values of each compound, i.e. the concentration needed to inhibit binding 
of 50 % of the DC-SIGN ECD on the BSA-Man surface. 
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2.6.1.3 Results and discussion 
Sensograms relative to all tested compounds are reported in Figure 2.14A (1.9 derivatives) and 
Figure 2.14B (1.9 derivatives), whilst inhibition curves are shown in Figure 2.15A, 2.15B (1.7 
derivatives) and Figure 2.15C, 2.15D (1.7 derivatives). Calculated IC50 values of tested compounds 
are reported in Figure 2.16A (1.9 derivatives) and Figure 2.16B (1.7 derivatives) and in Table 2.5 
and 2.6. Results obtained for compound 2.42/PM09 derive from another campaign previously 
conducted by Dr. Ieva Sutkeviciute.26 
 
 
Figure 2.14A Inhibition of DC-SIGN interaction with BSA-Mannotriose surface. Compounds based on 1.9 at different 
concentrations were co-injected with DC-SIGN ECD (20 µM).  
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Figure 2.14B Inhibition of DC-SIGN interaction with BSA-Mannotriose surface. Compounds based on 1.7 at different 
concentrations were co-injected with DC-SIGN ECD (20 µM).  
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Figure 2.15 Inhibition curves of A) divalent and B) hexavalent 1.9-based ligands and C) divalent and D) hexavalent 
1.7-based ligands. The ability of ligands to inhibit DC-SIGN-ECD binding to a CM4 Sensor Chip where Man-BSA 
(Man α1-3[Manα1-6]Man-BSA, 15 trimannose residues, on average) was immobilized was evaluated. The residual DC-
SIGN-ECD activity (%) is plotted against ligand concentrations.  
 
 
 
Chapter 2 
80 
 
 
Figure 2.16 Activities of glycodendrimers bearing 1.9 (A, red bars) or 1.7 (B, blue bars) in inhibiting binding of DC-
SIGN ECD (20 µM) to Man-BSA (Man α1-3[Manα1-6]Man-BSA, 15 trimannose residues, on average) immobilized on 
a CM4 Sensor Chip. IC50 are expressed as dendrimer concentration (µM).  
 
The affinity improvements of multivalent ligands for DC-SIGN ECD with respect to the 
corresponding monovalent ones is expressed in terms of Relative Inhibitory Potency (R.I.P.), 
calculated according to Equation 2.5 and listed in Table 2.5 and 2.6. 
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Equation 2.5 Relative Inhibitory Potency (R.I.P.) represents the improvement of a multivalent compound with respect 
to the corresponding monovalent ligands and it is corrected for its valency. 
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Structure IC50 (µM) R.I.P. 
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34 4 
 
24 6 
 
9 17 
 
295 2 
 
175 3 
 
67 7 
 
36 13 
 
39 4 
Table 2.5 IC50 values (µM, dendrimer concentration) of multivalent derivatives of 1.7 inhibiting binding of DC-SIGN 
ECD to immobilized Man-BSA-Mannotriose. R.I.P. (Equation 2.5) of compounds are reported in round brackets. 
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Structure IC50 (µM) R.I.P. 
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5a 10 
 
6a 8 
 
7 7 
 
5a 9 
 
61 2 
 
34 4 
 
19 7 
 
5 10 
Table 2.6 IC50 values (µM, dendrimer concentration) of multivalent derivatives of 1.9 inhibiting binding of DC-SIGN 
ECD to immobilized BSA-Mannotriose. R.I.P. (Equation 2.5) of compounds are reported in round brackets. aLower 
limit of the assay was reached. 
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Clear trends were shown by the compounds bearing 1.7 as ligand (Figure 2.16B, Table 2.5). Both in 
the divalent and in the hexavalent series, activity and relative inhibitory potency increased by 
increasing the length of the Rod. For divalent compounds, IC50 decreased from 295 µM 
(2.38/PM34, Rod1 derivative) to 67 µM (2.40/PM36, Rod3 derivative), corresponding to an 
increase of the Reletive Inhibitory Potency, respectively, from 2 to 7. A similar trend was observed 
for hexavalent compounds, showing IC50 values varying from 34 µM (2.35/PM30, Rod1 derivative, 
R.I.P. = 4) to 7 µM (2.37/PM31, Rod3 derivative, R.I.P. = 17). Remarkably, already the presence of 
the shortest Rod1 contributed to slightly increase compound activity, which was 39 µM (IC50) for 
the hexavalent dendrimeric compound 2.42/PM09. Also valency revealed to influence 
glycodendrimers potency; indeed, keeping the Rod equal, hexavalent molecules were more active 
than the corresponding divalent ones (R.I.P. values at least doubled, compare 2.35/PM30 with 
2.38/PM34, 2.36/PM32 with 3.39/PM35 or 2.37/PM31 with 2.40/PM36). This is a clear 
demonstration of the involvement of the effective concentration Ceff in the multivalent effect (see 
Chapter 1.5). Indeed, simply by increasing the local concentration of one ligand at the binding site, 
activities were improved. Among divalent compounds, an improvement was obtained by reducing 
the length of the linker between the sugar moiety and Rod3, leading to an almost doubled activity of 
compound 2.41/PM41 (IC50 = 36 µM, R.I.P. = 13) with respect to 2.40/PM36 (IC50 = 67 µM, R.I.P. 
= 7). This can be explained by the tendency of the divalent compounds with the long linker to fold 
up, thus reducing the probability to expose the hydroxyl groups responsible for binding to DC-
SIGN. According to computational results, this tendency characterizes much less the short linker 
derivative (see Paragraph 2.5). From a thermodynamic point of view, 2.40/PM36 has to pay high 
energetic costs for reducing its degrees of freedom and assuming the optimal conformation to bind 
the lectin, thus decreasing its activity (see Chapter 1.5). 
A similar trend was observed for divalent 1.9 derivatives, which showed IC50 values decreasing by 
increasing the length of the Rod (series 2.46/PM37, 2.47/PM38, 2.48/PM39, Figure 2.16A, Table 
2.6). Again, optimal activities characterized the divalent compound with the short linker, 
2.49/PM40, with IC50 = 8 µM and R.I.P. = 17. This confirmed that a good preorganization of a 
ligand, with flexibility and spatial distribution matching the target binding site, leads to powerful 
antagonists. On the contrary, activities of 1.9 hexavalent derivatives (2.50/PM19, 2.43/PM25, 
2.44/PM33 and 2.45/PM26) didn’t follow any apparent trend and showed similar IC50 values in the 
low µM range (5-7 µM, Figure 2.16A). This occurred because the lower limit of the assay has been 
reached.  
Indeed, considering that the IC50 is defined as the inhibitor concentration required for inhibiting -i.e. 
binding- the 50 % of the protein, in the case of 1:1 inhibitor-protein interactions, half of the protein 
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concentration would always be the lower limit value. In the case of our experimental setup with 20 
µM DC-SIGN ECD (with respect to the monomer), assuming that every compound molecule binds 
one monomeric protein, IC50 values below 10 µM can no more be measured accurately. This can be 
observed also from inhibition curves of 2.44/PM33, 2.45/PM26, 2.49/PM40 (Figure 2.15A,B), that 
do not have a sigmoidal shape. 
 
2.6.2 Trans-infection Inhibition Assays 
Selected Rod derivatives PM25, PM26, PM39 and PM40 and, for comparison, the hexavalent 
derivative PM1912 (Table 2.2) were tested as inhibitors of DC-SIGN-mediated HIV trans-infection 
of CD4+ T-Lymphocytes. They all bear compound 1.9 as monovalent ligand. B-THP-1 cells that 
overexpress DC-SIGN were used as a model of Dendritic Cells. This assay is referred to as a trans-
infection assay because the virus is transmitted from B-THP to T-cells without having infected (i.e. 
being replicated in) B-THP-cells themselves (see Chapter 1.2).27  
The tests were performed by Dr. A. Berzi in the group of Prof. M. Clerici (Università degli Studi di 
Milano).  
B-THP-1/DC-SIGN cells were obtained by transfecting the B-THP-1 human B cell line with DC-
SIGN expression vector. They were first incubated with artificial DC-SIGN ligands for 30 min at 37 
°C and, subsequently, with HIV (the R5 tropic laboratory-adapted strain HIV-1) for 3 h at 37 °C, 
without removing the ligand. After an extensive washing step, B-THP-1/DC-SIGN cells were co-
cultured with activated CD4+ lymphocytes for three days (37 °C). Viral infection of lymphocytes 
was assessed by measuring the p24 concentration in the culture supernatants through ELISA assays. 
p24 is a structural component of HIV-1 virus and it is therefore commonly used to evaluate the 
level of infection by HIV. In this assay B-THP-1 cells are model of Dendritic Cells, easier to be 
obtained and cultured. They only express DC-SIGN as lectin that can be recognized both by 
artificial ligands and HIV-1; therefore, they represent a cellular model of HIV anchoring on 
Dendritic Cells that take into consideration only the role of DC-SIGN.  
In Figure 2.17, obtained results are reported. Each point is the average of three different assays 
performed using CD4+ T-lymphocytes deriving from three different healthy donors. This explains 
the observed variability, since every donor may be naturally more or less prone to be infected. 
Every compound was tested in the range of concentration 1 – 50 µM.  Cells not treated with DC-
SIGN ligands and incubated with the medium (MED, Figure 2.17) are the positive control. The 
level of trans-infection obtained in T-lymphocytes without inhibiting DC-SIGN can be considered 
as the maximum infection level (100 %). Also in this case it is possible to evaluate the IC50 value of 
one compound, defined as the concentration needed to decrease the infection level by half. It was 
Chapter 2 
85 
 
already assessed that B-THP-1 cells not transfected with DC-SIGN did not transmit the infection 
and can be used as negative control.28    
 
 
Figure 2.17 PM19, PM25, PM26, PM39 and PM40 were tested at the concentrations indicated as inhibitors of the T-
lymphocytes HIV-infection. Virus was transmitted by B-THP-1/DC-SIGN cells, and p24 measured in the T-
lymphocytes-culture supernatant reflected the level of infection. MED (blue bar) was the positive control, obtained 
without inhibiting DC-SIGN.  
 
The activity trend observed for the hexavalent series (PM19, PM25 and PM26) showed that 
already the presence of the small Rod1 in PM25 allows for activity increase by at least one order of 
magnitude over PM19. Indeed, the IC50 value of PM19 was confirmed to be about 1 µM (as 
previously reported),12 whereas the one of PM25 was lower than 0.1 µM. Compound PM26, 
bearing Rod3, was found to be even more active. The divalent series showed an IC50 of almost 1 
µM for PM39, underlying that a divalent compound with Rod3 can have a similar activity than an 
hexavalent dendrimeric derivative (PM19). Compound PM40, with an IC50 around 0.1 µM, was 
one order of magnitude more active that PM39, demonstrating again that structural preorganization 
of one molecule leads to a strong antagonist when it matches the protein structure. 
PM25, PM26 and PM40 were tested in a broader concentration range, from 0.01 to 50 µM (Figure 
2.18), and obtained points were fitted to 1:1 hyperbolic decay, in order to extrapolate IC50 values. 
Obtained values are 67 nM for PM25, 24 nM for PM26 and 161 nM for PM40. These results 
confirmed again the importance of the Rod, showing that PM25 and PM26 are 15 and 40 times 
more active than PM19 (IC50 ≈ 1 µM) respectively. The presence of Rod3 that, according to 
computational prediction (see Paragraph 2.5), should allow the compound to chelate easily two 
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binding sites in the tetrameric DC-SIGN is reflected in an almost triple activity of PM26 relative to 
PM25. Being the Rod equal, the increase in local ligand concentration generated by increasing the 
valency of the compounds (see PM26 vs PM40) resulted again in higher antagonism activity.  
 
 
Figure 2.18 PM25, PM26 and PM40 were tested at the concentrations indicated as inhibitors of the T-lymphocytes 
HIV-infection. Virus was transmitted by B-THP-1/DC-SIGN cells, and p24 measured in the T-lymphocytes-culture 
supernatant reflected the level of infection. MED (blue bar) was the negative control, obtained without inhibiting DC-
SIGN.  
 
Remarkably, tested compounds PM19, PM25, PM26 and PM40 were the ones that didn’t show 
any apparent trend in the SPR inhibition assay (see Paragraph 2.6.1). Results obtained here 
highlight that the presence and the length of the Rod do play an important role in compound’s 
activity. This may confirm that the strange results coming from SPR assays were affected by an 
experimental limit.   
 
2.6.3 Cytotoxicity 
Cytotoxicity assays were performed by Dr. A. Berzi in the group of Prof. M. Clerici (Università 
degli Studi di Milano) on the selected compounds PM25, PM26, PM39 and PM40. 
Tests were performed using B-THP-1 cells overexpressing DC-SIGN, i.e. to the same cell line used 
for trans-infection inhibition assays (see Paragraph 2.6.2). Cells were incubated together with 
compounds at different concentrations and for different times; the amount of dead cells was 
measured using 7-Aminoactinomycin D (7-AAD) (Scheme 2.28) after 3 hours and half and 24 
hours of incubation. 7-AAD is a fluorescent chemical compound with a strong affinity for DNA. It 
is able to reach DNA only if cellular membranes are compromised, which happens in dead cells. 
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The percentage of cells positive to 7-AAD, evaluated through flow citometry (FACS), is a measure 
of the percentage of dead cells.  
 
 
Scheme 2.28 The fluorescent dye 7-AAD used for evaluating the amount of dead cells. 
 
Results indicated that Rod derivatives are not cytotoxic. Indeed, even after 24 hours of incubation, 
the amount of dead cells was below 2 %.   
 
2.7 Conclusions 
Monovalent ligands 1.79 and 1.98 and corresponding tetravalent, hexavalent and nonavalent 
compounds12 (Figure 2.4) had already been synthesised in our laboratories as DC-SIGN 
antagonists, using dendrimers based on a pentaerythritol core.  
In principle, these dendrimers could be used to inhibit the binding of external pathogens that infect 
humans through the mucosal entry pathway recognizing DC-SIGN as their primary target.4 Their 
affinity for DC-SIGN was assessed through SPR competition assays, reveling that the series derived 
from 1.9 was more active than the corresponding 1.7 one. Compounds affinity for the receptor 
increased also with the valency, as a result of multivalent effect. Interestingly, computational 
modelling revealed that the multivalent effect associated with these compounds can only be due to 
the so called statistical rebinding effect, or to mechanisms of protein clustering. Indeed, these 
dendrimers have a dimension that doesn’t allow them to bridge two binding sites on the DC-SIGN 
tetramer. The distance between two contiguous DC-SIGN binding sites is about 4 Å, and the 
production of constructs able to bridge DC-SIGN could improve compounds activity exploiting also 
the chelation-binding mode. 
For this reason, with the aim to improve the activity of artificial DC-SIGN ligands, rather that 
increasing the valency of the constructs, we’ve tried to rationally control the spacing of the ligands.  
A library of multivalent compounds characterized by rigid rods of controlled length as the central 
scaffold units was designed and synthesised. Compounds are listed in Table 2.2. 
In order to dissect their relative contribution, the following elements were varied: 
- Ligand: both ligand 1.7 and 1.9 were used. 
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- Valency: hexavalent and divalent compounds were synthesized. 
- Length of the Rod:  Rod1 (8 Å), Rod2 (12 Å) or Rod3 (24 Å) were used. 
- Length of the linker separating monovalent ligands and the central scaffolds.  
The possibility of these compounds to adopt conformations where two mannose residues are 
separated by more than 4 Å was assessed by computational modelling, thus confirming their ability 
to be potential chelating agents for DC-SIGN. 
All compounds were tested as DC-SIGN ligands through an SPR inhibition assay, revealing first of 
all the importance of the monovalent ligands, since multivalent compounds based on 1.9 were 
always more active than those based on 1.7. Investigating the 1.7 series, both the length of the rod 
and the valency of the materials were found to influence the biological activity. The increase of the 
rod length increased compounds β factor, and activities of hexavalent molecules were always higher 
than the ones of corresponding divalent constructs. Once the rod becomes long enough to allow 
simultaneous interaction of two ligands with two DC-SIGN binding sites, the loss of entropy 
associated with a long flexible linker becomes apparent, and a divalent compound with the short 
linker had a lower IC50 value than the corresponding divalent compound with the long linker.  
Hexavalent compounds of the 1.9 series were too active to be tested through the SPR competition 
assay, since they reached its intrinsic lower limit. Nonetheless, the ability of 1.9-mutlivalent 
derivatives to inhibit the trans-infection of HIV virus from B-THP/DC-SIGN to CD4+ T 
lymphocytes was evaluated. Also in this case, inclusion of a rigid spacer in the dendrimer core 
improved the activity of the material with results that depend on the length of the spacer and on the 
overall valency of the system. Best results were obtained with compound 2.45/PM26, displaying an 
IC50 value in the low nM range. This result compares well with DC-SIGN inhibition activities 
described in the literature for constructs (polymers, dendrimers or gold nanoparticles) of much 
higher valency.29 Remarkably, the two tests (SPR and infection studies) differ radically in the way 
DC-SIGN is presented to the antagonists: as a soluble tetramer in the SPR assay, embedded in 
cellular membranes in the infection assay. Therefore, the SPR assay will also include protein 
aggregation effects that are much less likely to occur in the infection studies. Moreover, the results 
of cellular assays may depend also on other mechanisms, such as receptor internalization after 
ligand binding. 
These results demonstrate how a rational design can lead to molecules with high antagonism 
potency even at relatively low valency. The possibility of controlling their size and their shape can 
lead to fully characterized compounds that can also be tuned to match sterical and molecular 
features of their targets, thus being selective.  
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In conclusion, the combination of three elements in the design of 2.45/PM26, i.e. an effective (and 
selective) monovalent ligand, a rigid core of appropriate length and two trivalent dendrons, allowed 
to maximize the DC-SIGN antagonist activity of the construct taking advantage of both chelation 
and local ligand density effects.  
 
2.8 Experimental 
General procedures 
Chemicals were purchased by commercial sources and used without further purification, unless 
otherwise indicated. When anhydrous conditions were required, the reactions were performed under 
nitrogen atmosphere. Anhydrous solvents were purchased from Sigma-Aldrich® with a content of 
water ≤0.005 %. THF was dried over Na/benzophenone and freshly distilled prior to use. Thin-layer 
chromatography (TLC) was performed on Silica Gel 60 F254 plates (Merck) with UV detection 
(254 nm and 365 nm) or using appropriate developing solutions. Flash column chromatography was 
performed on silica gel 230-400 mesh (Merck), according with the procedure described in 
literature.30 Automated flash chromatography was performed on a Biotage® Isolera™ Prime 
system. Final compounds were purified by size-exclusion chromatography using Sephadex LH-20 
from GE Helthcare Life Science® and through reverse phase automated flash chromatography 
(C18) when required. NMR experiments were recorded on a Bruker AVANCE 400 MHz instrument 
at 298 K. Chemical shifts (δ) are reported in ppm downfield from TMS as internal standard, 
coupling constants (J) in Hz. The 1H and 13C-NMR resonances of compounds were assigned with 
the assistance of COSY and HSQC experiments. HSQC experiments were also used to assign the 
chemical shift of protons overlapping with the solvent signals. The numbering for protons and 
carbons in the NMR characterization are shown on the molecules. Mass spectra were recorded on 
ThermoFischer LCQ apparatus (ESI ionization), Apex II ICR FTMS (ESI ionization-HRMS), 
Waters Micromass Q-Tof (ESI ionization-HRMS), or Bruker Daltonics Microflex MALDI-TOF 
apparatus. Specific optical rotation values were measured using a Perkin-Elmer 241, at 589 nm in a 
1 mL cell. 
 
General procedure for the CuAAC reaction. In the optimized Copper(I)-catalyzed Azide-Alkyne 
Cycloaddition (CuAAC) procedure, starting materials and reagents were added to the reaction 
mixture as solids or as solutions in water or THF. Water was degassed by bubbling with nitrogen 
and THF was freshly distilled. The reagents were added to the reaction vessel in the following 
order: alkyne (1 eq., solid or THF), TBTA (0.2 eq., THF), CuSO4·5H2O (0.1 eq., H2O), Sodium 
Ascorbate (0.4 eq., H2O) and finally the azide monovalent ligand (1.1 eq. per each triple bond, solid 
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or water solution). The final concentration of multivalent scaffold was 3-15 mM in a 1:1 THF:H2O 
mixture, depending on the solubility of the components and the products in water. When a 
concentration > 10 mM in 1:1 THF:H2O could be obtained, the reaction was stirred at room 
temperature for 12 -24 hours, under nitrogen atmosphere and protected from light. For less soluble 
mixtures, the reaction was performed at lower concentrations (tipically 3 mM) under microwave 
assisted conditions for 1-2 h at 60 °C. In both cases, the reaction was monitored by TLC and/or 
MALDI mass spectrometry (DHB or sinapinic acid matrix) until completion. In general, the 
formation of divalent compounds could be monitored by TLC (eluent: CH2Cl2:MeOH:H2O in a 
ratio that depended on molecules polarity) while hexavalent compounds were best analysed by 
MALDI mass (DHB or sinapinic acid matrix). When intermediates were observed but the azide 
monovalent ligand was totally consumed, the latter was added together with additional 0.4 eq. of 
sodium ascorbate. The crude was purified by size exclusion chromatography on a Sephadex LH20 
column (Ø 3 cm, H 55 cm; eluent: MeOH) as MeOH solution and by reverse phase chromatography 
(C18; eluent: water with a gradient of MeOH from 0 % to 100 %), when required. The metal 
scavenger Quadrasil™-MP31 was used to remove copper salts either from the reaction mixtures 
before purification, or from a solution of the isolated final compound. In either case, the suspension 
was stirred for 10 min and the resin filtered off. 
 
Synthesis of 1,4-diiodo-2,5-dimethoxybenzene, 2.14 
 
 
To a solution of H5IO6 (10 g, 42 mmol, 0.6 eq.) in 7 mL of MeOH, stirred for 10 min at room 
temperature, I2 (11.5 g, 90.0 mmol, 1.25 eq.) was added; the resulting brownish solution was stirred 
for other 10 min. Finally, p-dimethoxybenzene (10 g, 72 mmol, 1 eq.) was slowly added. The 
reaction mixture was first stirred at room temperature for 40 min, then refluxed for 3 hours and 
finally stirred at room temperature overnight. The formation of a yellow precipitate was observed 
during time. TLS analysis (Hex:AcOEt 9:1) revealed that the reaction was complete. The crude was 
slowly dissolved in a Na2S2O5 water solution (20g in 200 mL H2O) and stirred at room temperature 
for 15 min. The precipitate was isolated using through Buckner funnel, washed with H2O (50 mL) 
and MeOH (20 mL). The resulting 28 g of a not pure solid (2.14) were crystallized in i-propanol 
(200 mL), obtaining a not complete dissolution. The yellowish solid was recovered through 
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filtration (Buckner funnel) from the yellow solution, obtaining 20.9 g of pure product 2.14 (yield 
74 %), with spectral data identical to those reported.17,16. 
 
1H NMR (400 MHz, CDCl3): δ 7.18 (s, 2H, Ar-H); 3.81 (s, 6H, OCH3). 
 
Synthesis of 2,5-diiodobenzene-1,4-diol, 2.15. 
 
 
To a solution of 2.14 (10 g, 25.6 mmol, 1 eq.) in 250 mL of dry CH2Cl2 cooled at -78 °C, BBr3 (1 M 
solution in MeOH, 77 mL, 3 eq.) was added dropwise under nitrogen atmosphere. The resulting 
brownish suspension was allowed to recover at room temperature; the reaction proceeded at RT and 
under nitrogen, overnight. TLS analysis (Hex:AcOEt 8:2) revealed that the reaction was complete. 
The reaction mixture was cooled to 0 °C and quenched with cold water (0 °C, 50 mL), leading to 
the formation of a white precipitated. The resulting mixture was diluted with AcOEt (500 mL) and 
washed with water (2 x 200 mL) and brine (2 x 200 mL); the organic phase was then dried over 
anhydrous sodium sulfate and concentrated, obtaining 10 g of not pure 2.15. After a crystallization 
in CH2Cl2 (60 mL), the yellowish solid was isolated through bukner funnel from a brown solution, 
obtaining 7.8 g of pure product 2.15 (yield 84 %), with spectral data identical to those reported.17,16. 
 
1H NMR (400 MHz, CDCl3): δ 7.27 (s, 2H, Ar-H); 4.81 (bs, 2H, OH). 
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Synthesis of 2,2'-((((2,5-diiodo-1,4-phenylene)bis(oxy))bis(ethane-2,1-diyl))bis(oxy))diethanol, 
2.16 
 
To a suspension of 2.15 (7.3 g, 20.2 mmol, 1 eq.) in 20 mL of dry DMF, 7.0 g of K2CO3 (7.0 g, 
50.4 mmol, 2.5 eq.) were added, without obtaining complete dissolution; the resulting reddish 
suspension was stirred for 10 min at room temperature. Finally, 2-(2-Chloroethoxy)ethanol (8.5 mL, 
70.7 mmol, 4 eq.) was added. The reaction mixture was stirred at RT for 20 min, than at 70 °C for 
18 h, under nitrogen atmosphere. TLC analysis (Hex:AcOEt 3:7) revealed that the reaction was 
complete. The solvent was evaporated under reduced pressure, then the crude redissolved in AcOEt 
(500 mL) and washed with a water solution of Na2S2O5 (10 g in 100 mL), water (3 x 100 mL) and 
brine (2 x 100 mL). A black solid remained insolubilized. The organic phase was dried over 
anhydrous sodium sulfate, then concentrated. The resulting brownish oil was purified through 
automated flash chromatography (silica, Hex with a gradient of AcOEt from 50 % to 90 %). 4.6 g 
of pure 2.16 were obtained (yield 44 %), with spectral data identical to those reported.17,16. 
 
1H NMR (400 MHz, CDCl3): δ 7.22 (s, 2H, H3), 4.11 – 4.07 (m, 4H, H4), 3.88 – 3.84 (m, 4H, H5), 
3.76 – 3.72 (m, 4H, H7), 3.71 – 3.76 (m, 4H, H6), 1.67 (s, 2H, H8). 
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Synthesis of 1,4-bis[2-(2-hydroxyethoxy)ethoxy]-2-[tris(1-methylethyl)silyl]ethynyl)-5-
Iodobenzene, 2.18 and 1,4-bis[2-(2-hydroxyethoxy)ethoxy]-2,5-bis[tris(1-methylethyl)silyl]-
ethynyl)benzene, TIPS-2.3. 
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2.16 (2.5 g, 4.63 mmol, 1 eq.), Pd(PPh3)2Cl2 (130.0 mg, 0.185 mmol, 0.04 eq.), CuI (88.2 mg, 0.463 
mmol, 0.1 equiv), and PPh3 (121.3 mg, 0.463 mmol, 0.1 eq.) were placed into the reaction flask and 
dried under vacuum. Then reagents were dissolved in toluene (32 mL) and finally 
ethynyltriisopropylsilane (TIPS-acetylene, 1.56 mL, 6.94 mmol, 1.5 eq.) and Et3N (6.5 mL) were 
added under nitrogen. The reaction was heated at 50 °C, under nitrogen atmosphere, overnight. 
TLC analysis (Hex:AcOEt 3:7) revealed that the reaction was complete (a trace of 2.16 was still 
observed). The reaction was then diluted with AcOEt and finally dried. The crude was purified 
through automated flash chromatography (Hex with a gradient of AcOEt from 5 % to 100 %), 
obtaining 905 mg of 2.18 (yield 33 %) and 1.26 g of TIPS-2.3, (yield 42 %). 470 mg of 2.16 were 
recovered, both with spectral data identical to those reported.17,16. 
 
Compound 2.18 
1H NMR (400 MHz, CDCl3): δ 7.27 (s, 1H, H6), 6.87 (s, 1H, H3), 4.15 – 4.05 (m, 4H, H7, H11), 
3.93 – 3.78 (m, 4H, H8, H12), 3.77 – 3.58 (m, 8H, H9, H10, H13, H14), 1.16 – 0.86 (m, 3H, H17), 1.10 - 
1.12 (m, 18H, H18). 
Compound TIPS-2.3 
1H NMR (400 MHz, CDCl3): δ 6.89 (s, 2H, H3), 4.15 – 4.09 (m, 4H, H4), 3.85 – 3.80 (m, 4H, H5), 
3.74 – 3.67 (m, 4H, H7), 3.66 – 3.59 (m, 4H, H6), 1.29 – 0.91 (m, 6H, H10), 1.10 – 1.12 (m, 38H, 
H11). 
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Synthesis 1,4-bis[2-(2-hydroxyethoxy)ethoxy]-2,5-diethynylbenzene, 2.3 
 
 
To a solution of TIPS-2.3 (633 mg, 0.98 mmol, 1 eq.) in dry THF (3.3 mL), TBAF (1 M in THF, 
2.0 mL, 1.96 mmol, 2 eq.) was added dropwise. The resulting solution was stirred for 45 min at 
room temperature, under nitrogen atmosphere. TLC analysis (CHCl3:MeOH 95:5) revealed that the 
reaction was complete. The solvent was removed under reduced pressure and the crude was purified 
by automated flash chromatography (silica, CHCl3 with gradient of MeOH from 0 to 5%) to afford 
297 mg of pure product 2.3 (yield 91 %), with spectral data identical to those reported.17,16. 
 
Compound’s characterization was identical to the one presented in Ref.17,16. 
1H NMR (400 MHz, CDCl3): δ 6.98 (2H, s, H3), 4.16–4.10 (4H, m, H4), 3.90–3.82 (4H, m, H5), 
3.76–3.70 (4H, m, H7), 3.68–3.62 (4H, m, H6), 3.34 (2H,s, H9). 
 
Synthesis of 2,2'-((((2-(3-hydroxy-3-methylbut-1-yn-1-yl)-5-((triisopropylsilyl)ethynyl)-1,4-
phenylene)bis(oxy))bis(ethane-2,1-diyl))bis(oxy))diethanol, 2.22 
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2.18 (50 mg, 84.4 µmol, 1 eq.), Pd(PPh3)2Cl2 (3.0 mg, 4.22 µmol, 0.05 eq.) and CuI (1.0 mg, 4.22 
µmol, 0.05 eq.) were dissolved in 260 µL of dry THF, under nitrogen atmosphere. DIPEA (34 µL) 
and finally 2-methylbut-3-yn-2-ol (10 µL, 0.1055 mmol, 1.25 eq.) were added. The reaction was 
stirred at room temperature and under nitrogen atmosphere overnight. TLC analysis (Hex:AcOEt 
3:7) revealed that the reaction was complete. The reaction mixture was directly purified through 
flash chromatography (silica, Hex with a gradient of AcOEt from 50 % to 70 %), obtaining 39.3 mg 
of 2.22 as a yellowish oil (yield 85 %). 
 
1H NMR (400 MHz, CDCl3): δ 6.90 (2s, 2H, H2 and H5 ), 4.15–3.95 (m, 4H, H7, H11), 3.95–3.88 
(m, 2H, H8) 3.86-3.82 (m, 2H, H12), 3.78–3.75 (m, 2H, H9), 3.70-3.74 (m, 4H, H10, H14), 3.62–3.67 
(m, 2H, H13) 2.55 (bs, 2H, OH), 1.59 (s, 6H, H22), 1.18-1.10 (m, 21H, H17, H18). 
13C NMR (100 MHz, CDCl3): 13C NMR (100 MHz, CD3OD) δ 154.3, 154.2 (C4, C1); 117.8, 
117.5 (C2, C5); 114.4, 113.9 (C3, C6); 102.8 (C15); 100.71 (C16); 97.08 (C20); 77.80 (C19); 72.8, 72.3 
(C9, C13); 69.87, 69.86 (C8, C12); 69.3 (C7, C11); 65.1 (C21); 62.1, 61.6 (C10, C14); 31.5 (C22); 18.9 
(C18); 11.6 (C17). 
 
MS (ESI): calculated for [C30H48NaO7Si]+: 571.32; found: 571.5. 
 
Synthesis of 2,2'-((((2-ethynyl-5-((triisopropylsilyl)ethynyl)-1,4-phenylene)bis(oxy))bis(ethane-
2,1-diyl))bis(oxy))diethanol, 2.21 
 
 
2.22 (27 mg, 0.05 mmol, 1 eq.) was dissolved in dry toluene (500 µL) and solid NaOH (7 mg, 0.18 
mmol, 3.6 eq.) was added. The reaction was stirred for 6 h at 45 °C under nitrogen atmosphere and 
in the dark. TLC analysis (toluene:acetone 6:4) revealed that the reaction was not complete, but the 
side product 2.3 was starting forming. Therefore the mixture was diluted with CHCl3:MeOH (97:3, 
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2 mL) and purified by flash chromatography (silica, Hex:AcOEt 4:6), obtaining 8.5 of pure product 
2.21 (yield 35 %). 10 mg of 2.22 was also recovered. 
 
1H NMR (400 MHz, CDCl3) δ 6.96, 6.95 (2s, 2H, H2 and H5), 4.25–4.10 (m, 4H, H7, H11), 3.90–
3.80 (m, 4H, H8, H12), 3.75–3.60 (m, 8H, H9, H10, H13, H14), 3.35 (s, 1H, H20), 2.05 (bs, 2H, OH) 
1.45–1.00 (m, 21H, H17, H18). 
13C NMR (100 MHz, CDCl3): δ 154.3, 154.2 (C4, C1); 118.5, 118.3 (C2, C5); 115.4, 113.3 (C3, C6); 
102.6 (C15); 97.7 (C16); 83.1, 80.0 (C19, C20); 72.9 (C9, C13); 69.9, 69.8, 69.7, 69.4 (C7, C8, C11, C12); 
62.2 (C10, C14); 19.4 (C18); 11.6 (C17). 
 
MS (ESI) calculated for [C27H42NaO6Si]+: 513.7; found: 513.4. 
 
Synthesis of TIPS-2.4/TIPS-Rod2 
 
 
Compound 2.21 (24.2 mg, 0.05 mmol, 1 eq.), PdCl2(PPh3)2 (2 mg, 0.003 mmol, 0.05 equiv) and CuI 
(1 mg, 0.005 mmol, 0.1 equiv) were dissolved in dry THF (245 µL) under nitrogen atmosphere. 
DIPEA (20 µL 0.11 mmol, 2 eq.) was added; finally 2.18 (36.7 mg, 0.061 mmol, 1.25 eq.) dissolved 
in THF (145 µL) and washed with remaining THF (100 µL) was added. The reaction mixture was 
stirred for 3 h at room temperature under nitrogen and in the dark. TLC analysis (CHCl3:MeOH 
10:0.5) revealed that the coupling was complete. The solvent was removed under reduced pressure 
and the resulting crude was purified by automated flash chromatography (silica, Hex with a gradient 
of AcOEt from 0 % to 10 %), to afford 38 mg of pure TIPS-2.4 as a yellowish solid (yield 81 %). 
12 mg of 2.21 were recovered. 
Chapter 2 
97 
 
 
1H NMR (400 MHz, CD3OD): δ 7.11 (2H, s, H2), 7.05 (2H, s, H5), 4.31–4.12 (8H, m, H7, H11), 
3.95–3.80 (8H, m, H8, H12), 3.74–3.60 (16H, m, H9, H10, H13, H14), 1.45-1.00 (42H, m, H17, H18). 
13C NMR (100 MHz, CD3OD, HSQC): δ 119.1, 118.0 (C5, C2); 73.79, 73.76 (C9, C13); 70.59, 
70.54 (C7, C8, C11, C12); 62.01, 61.96 (C10, C14); 18.83 (C18); 12.20 (C17). 
 
MS (ESI): calculated for [C52H82NaO12Si2]+: 977.53; found: 978.0. 
 
Synthesis of TIPS-2.5/TIPS-Rod3 
 
 
2.3 (26 mg, 0.077 mmol, 1 eq.), Pd(PPh2)2Cl2, (2.7 mg, 0.004 mmol, 0.05 eq.) and CuI (2.8 mg, 
0.008 mmol, 0.1 equiv) were dissolved in dry THF (350 µL) under nitrogen atmosphere. DIPEA 
(30.8 µL 0.177 mmol, 2.3 eq.) was added; finally 2.18 (100.4 mg, 0.169 mmol, 2.2 eq.) dissolved in 
THF (300 µL) and washed with remaining THF (120 µL) was added. The reaction was stirred at 
room temperature for 3 h, under nitrogen atmosphere and in the dark. TLC analysis (CH2Cl2:MeOH 
9:1) revealed that the coupling was complete. The reaction mixture was concentrated under reduce 
pressure and purified through automated flash chromatography (silica, CHCl3 with gradient of 
MeOH from 1 % to 20 %), affording 47.7 mg of pure product TIPS-2.5 as yellow solid (yield 
50 %), with spectral data identical to those reported.17,16. 
 
1H NMR (400 MHz, CD3OD): δ 7.16 (s, 2H, H2), 7.12 (s, 2H, H5), 7.05 (s, 2H, H23), 4.31–4.12 
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(m, 12H, H7, H11, H24), 3.97–3.80 (m, 12H, H8, H12, H25), 3.76–3.56 (m, 24H, H9, H10, H13, H14, 
H26, H27), 1.35–0.98 (6H, m, H17), 1.16–1.18 (m, 36H, H18).  
 
Synthesis of 3-(prop-2-yn-1-yloxy)-2,2-bis((prop-2-yn-1-yloxy)methyl)propan-1-ol, 2.26 
 
 
To a solution of pentaeritritol (0.5 g, 3.67 mmol, 1 eq.) in dry DMF (15 mL), sodium hydride (60 
%, 0.48 g, 12.12 mmol, 3.3 eq.) was slowly added under nitrogen atmosphere at 0 ºC; not complete 
dissolution was obtained. The mixture was stirred at 0 ºC for 30 min, under flushing nitrogen. Then 
propargyl bromide (80% in toluene, 1.3 mL, 12.12 mmol effective, 3.3 eq.) was added. The reaction 
mixture was recovered at room temperature, then stirred under nitrogen overnight. TLC analysis 
(Hex:AcOEt 8:2) revealed that the reaction was complete. Reaction mixture was cooled at 0 °C and 
cold water (20 mL, 0 °C) was added. The product was extracted using Et2O (3 x 50 mL). The 
resulting organic phase was dried over anhydrous sodium sulfate and concentrated. The crude was 
purified through flash chromatography (Hex with a gradient of AcOEt from 10 % to 30 %), 
obtaining 436 mg of pure product 2.26 (yield 47 %), with spectral data identical to those reported. 
17,12
  
 
1H NMR (400 MHz, CDCl3): δ = 4.14 (d, 6H, H2, J3-1 = 2.3 Hz), 3.69 (s, 2H, H4), 3.57 (s, 6H, H3), 
2.24 (t, 3H, H1, J3-1 = 2.3 Hz). 
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Synthesis of 3-(3-(2-(2-chloroethoxy)ethoxy)-2,2-bis((prop-2-yn-1-yloxy)methyl)propoxy)prop-
1-yne, 2.27 
 
 
 
To a solution of 2.26 (434 mg, 1.73 mmol, 1 eq.) in bis(2-cloroethyl)eter (2.1 mL), (nBu)4NHSO4 
(1.2 mg, 3.46 mmol, 2.1 eq.) and NaOH (aq. 50%, 2.6 mL) were slowly added at room temperature. 
Complete dissolution was not obtained. The reaction mixture was vigorously stirred at 45 ºC for 18 
h, under nitrogen atmosphere. TLC analysis (Hex:AcOEt 6:4) revealed that the reaction was 
complete. CH2Cl2 (50 mL) and water (80 mL) were added; the resulting organic phase was 
separated and washed with distilled water (2 x 50 mL) and brine (50 mL), dried over anhydrous 
sodium sulphate and finally concentrated under reduced pressure. The crude was purified by flash 
chromatography (silica, Hex with a gradient of AcOEt from 5 % to 30 %), affording 170 mg of pure 
product 2.27 as a colorless oil (yield 30 %), , with spectral data identical to those reported. 17,12  
 
1H NMR (300 MHz, CDCl3): δ = 4.05 (d, 6H, H2, J3-1 = 2.4 Hz), 3.70 (t, 2H, H8, J7-8 = 5.9 Hz), 
3.61 – 3.50 (m, 6H, H5, H6, H7), 3.46 (s, 6H, H3), 3.40 (s, 2H, H4), 2.33 (t, 3H, H1, J3-1 = 2.4 Hz). 
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Synthesis of trivalent glycodendron, 2.28 
 
 
To scaffold (2.27) (40.4 mg, 113 µmol, 1 eq.) dissolved in THF (2.55 mL) under inert atmosphere 
at room temperature, reagents were added as solutions in the following order: TBTA in THF (12.0 
mg, 22.6 µmol, 0.2 eq., in 0.95 mL), CuSO4·5H2O in water (2.8 mg, 11.3 µmol, 0.1 eq., in 0.56 mL) 
and Sodium Ascorbate in water (9.0 mg, 45.2 µmol, 0.4 eq., in 0.83 mL). The reaction mixture was 
stirred under inert atmosphere, at RT and in the dark for 10 min, then 1.7 in water was added (189.1 
mg, 408 µmol, 3.6 eq., 2.5 mL). The THF and water volumes were adjusted to 4.4 mL each and the 
mixture was stirred for 18 h. TLC analysis (CHCl3:MeOH:H2O 8:2:0.5) revealed that the reaction 
was complete. Quadrasil™-MP (S/Cu 2:1, 15 mg) was added to the reaction mixture, which was 
stirred for 10 min, and then filtered off. The crude was dried, then redissolved in MeOH and 
purified by size exclusion chromatography on a Sephadex LH-20 (MeOH) column to give 186 mg 
of 2.28 as a white solid (yield 94 %), , with spectral data identical to those reported.17,12. 
 
1H NMR (400 MHz, CD3OD): δ 7.98 (s, 3H, HT5), 4.90 (bs, 3H, H1), 4.60 (t, 6H, H8, J8-7 = 5 Hz), 
4.55 (s, 6H, HL1), 4.00 - 3.79 (m, 15H, H2, H6a, HD2, H7), 3.75 - 3.45 (m, 37H, H6b, HD1, H3, HOMe, 
H4, H5, HL5, HL6, HL7, HL8), 3.48 (s, 6H, HL2), 3.43 (s, 2H, HL4), 2.83 – 2.63 (m, 6H, HD4, HD5), 
2.04-1.92 (m, 6H, HD3eq, HD6eq), 1.78 - 1.51 (m, 6H, HD3ax, HD6ax). 
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Synthesis of trivalent glycodendron, 2.21 
 
 
 
To a solution of 2.28 (123.6 mg, 0.07 mmol, 1 eq.) in DMF (1 mL), sodium azide (37 mg, 0.57 
mmol, 8 eq.) was added. The reaction was stirred at 60 ºC for 3 days. A MALDI mass analysis 
(DHB matrix) revealed that the reaction was complete. The solvent was removed under reduced 
pressure and the resulting crude was purified by size exclusion chromatography (Sephadex LH20, 
MeOH) to afford 93.2 mg of pure product 2.1 as a white solid (yield 76 %), with spectral data 
identical to those reported.17,12. 
 
1H NMR (400 MHz, CD3OD): δ 7.97 (s, 3H, HT5), 4.90 (bs, 3H, H1), 4.60 (t, 6H, H8, J8-7 = 5 Hz), 
4.55 (s, 6H, HL1), 4.01 - 3.80 (m, 15H, H2, H6a, HD2, H7), 3.72 - 3.49 (m, 35H, H6b, HD1, H3, HOMe, 
H4, H5, HL5, HL6, HL7), 3.48 (s, 6H, HL2), 3.44 (s, 2H, HL4), 3.40 – 3.32 (m, 2H, HL8), 2.84-2.61 (m, 
6H, D4, HD5), 2.05 – 1.95 (m, 6H, HD3eq, HD6eq), 1.77 - 1.46 (m, 6H, HD3ax, HD6ax). 
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Synthesis of trivalent glycodendron, 2.29 
 
 
To scaffold (2.27) (32.1 mg, 89.9 µmol, 1 eq.) dissolved in THF (2.55 mL) under inert atmosphere 
at RT, reagents were added as solutions in the following order: TBTA in THF (9.5 mg, 18.0 µmol, 
0.2 eq., in 0.96 mL), CuSO4·5H2O in water (2.2 mg, 9.0 µmol, 0.1 eq., in 0.24 mL) and Sodium 
Ascorbate in water (7.1 mg, 36.0 µmol, 0.4 eq., in 0.35 mL). The reaction mixture was stirred under 
inert atmosphere, at room temperature and in the dark for 10 min, then 1.9 in water was added (218 
mg, 323.6 µmol, 3.6 eq., 1 mL). The THF and water volumes were adjusted to 2 mL each and the 
mixture was stirred for 18 h. MALDI mass (DHB matrix) revealed that the reaction was complete. 
Quadrasil™-MP (S/Cu 2:5, 15 mg) was added to the reaction mixture, which was stirred for 10 
min, and then filtered off. The crude was dried, then redissolved in MeOH and purified by size 
exclusion chromatography on a Sephadex LH-20 (MeOH) column to give 110 mg of 2.29 as a 
white solid (yield 50 %), , with spectral data identical to those reported.17,12. 
 
1H NMR (400 MHz, CD3OD): δ = 7.98 (s, 3H, HT5); 7.28 – 7.16 (m, 24H, HAr2, HAr3); 4.89 (br s, 
3H, H1); 4.58 – 4.50 (m, 6H, H8); 4.55 (s, 12H, CH2OH); 4.48 (s, 6H, HL1); 4.28 (s, 6H, CH2NH); 
4.26 (s, 6H, CH2NH); 3.99 - 3.80 (m, 15H, H2, H6a, HD2, H7); 3.73 - 3.61 (m, 11H, H6b, HD1, H3, 
HL8); 3.61-3.44 (m, 12H, H4, H5, HL5, HL6, HL7), 3.42 (bs, 6H, HL2), 3.39 (bs, 2H, HL4), 2.90 – 2.76 
(m, 6H, HD4, HD5), 1.96 – 1.68 (m, 12H, HD3, HD6). 
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Synthesis of trivalent glycodendron, 2.2 
 
 
 
To a solution of 2.29 (140.4 mg, 0.06 mmol, 1 eq.) in DMF (0.8 mL), sodium azide (30.7 mg, 0.47 
mmol, 8 eq.) was added. The reaction was stirred at 60 ºC for 3 days. A MALDI mass analysis 
(DHB matrix) revealed that the reaction was complete. The solvent was removed under reduced 
pressure and the resulting crude was purified by size exclusion chromatography (Sephadex LH20, 
MeOH) to afford 130.4 mg of pure product 2.2 as a white solid (yield 93 %), with spectral data 
identical to those reported.17,12. 
 
1H NMR (300 MHz, CDCl3): δ = 7.98 (s, 3H, HT5), 7.30 – 7.13 (m, 24H, HAr2, HAr3), 4.89 (bs, 3H, 
H1), 4.60 – 4.50 (m, 6H, H8), 4.55 (s, 12H, CH2OH), 4.48 (s, 6H, HL1), 4.28 (s, 6H, CH2NH), 4.26 
(s, 6H, CH2NH), 3.97 - 3.80 (m, 15H, H2, H6a, HD2, H7), 3.73 - 3.62 (m, 9H, H6b, HD1, H3), 3.62 - 
3.46 (m, 14H, H4, H5, HL5, HL6, HL7, HL8), 3.43 (bs, 6H, HL2), 3.40 (bs, 2H, HL4), 2.90 – 2.76 (m, 
6H, HD4, HD5), 1.96 – 1.69 (m, 12H, HD3, HD6). 
 
 
 
 
 
 
 
 
Chapter 2 
104 
 
Synthesis of 2-(3-(2-(prop-2-yn-1-yloxy)ethoxy)propoxy)ethanol, 2.31 
 
 
A stirred solution of 3,7-dioxa-1,9-nonanediol (130.9 mg, 0.8 mmol, 1 eq.) in dry DMF (3.5 mL) 
was slowly treated with NaH (60% in oil, 35.0 mg, 0.9 mmol, 1.1 eq.) at 0 °C under nitrogen 
atmosphere. After 30 min, propargyl bromide (80% in toluene, 94.5 µL, 0.9 mmol, 1.1 eq.) was 
added. The reaction mixture was left to warm to RT and stirred under nitrogen overnight. The 
reaction was quenched by slow addition of iced water and then concentrated under reduced 
pressure. The crude was purified by flash chromatography (Hex:AcOEt 3:7) affording 81 mg of 
pure 2.31 as a yellow oil (yield 50 %). Also 26 mg of the bis-propargyl ether byproduct was isolated 
as yellow oil (yield 13 %). 
 
1H NMR (400 MHz, CD3OD): δ 4.19 (d, J = 2.4 Hz, 2H, H8); 3.68 – 3.63 (m, 4H, H7, H1); 3.61 – 
3.60 (m, 2H, H6); 3.59 – 3.54 (m, 4H, H3, H5); 3.52 – 3.50 (m, 2H, H2); 2.85 (t, J = 2.4 Hz, 1H, 
H10); 1.84 (tt, J = 6.4 Hz, 1H, H4).  
13C NMR (100 MHz, CD3OD): δ 75.97 (C10, C9); 73.31 (C2); 71.02 (C6); 70.06 (C7); 69.11 (C5, 
C3); 62.22 (C1); 59.08 (C8); 31.05 (C4).  
 
MS (ESI-HRMS): calculated for [C10H18O4Na]+: 225.10973; found = 225.10959.  
 
Synthesis of 2-(3-(2-(prop-2-yn-1-yloxy)ethoxy)propoxy)ethyl 4-methylbenzenesulfonate, 2.32 
 
 
To a stirred solution of 2.31 (72.4 mg, 0.4 mmol, 1 eq.) in dry CH2Cl2 (500 µL), TsCl was added 
(102.4 mg, 0.5 mmol, 1.5 eq.), then pyridine (57.7 µL, 0.7 mmol, 2 eq.) was added at 0 °C under 
nitrogen atmosphere. The reaction mixture was left to warm to RT and stirred under nitrogen 
overnight. TLC analysis (Hex:AcOEt 3:7) revealed that the reaction was complete. CH2Cl2 (10 mL) 
was added and the mixture was washed with water (10 mL), HCl 1 M (10 mL), water (10 mL), 
NaHCO3 sat. sol. (10 mL) and water again (10 mL). The organic phase was finally dried over 
anhydrous sodium sulfate and concentrated under reduced pressure. The crude was purified by flash 
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chromatography (Hex:AcOEt 65:35), affording 88 mg of pure compound 2.32 as a yellow oil (yield 
69 %).  
 
1H NMR (400 MHz, CD3OD): δ 7.80 (d, J = 8.3 Hz, 2H, H12); 7.45 (d, J = 8.3 Hz, 2H, H13); 4.18 
(d, J = 2.4 Hz, 2H, H8); 4.15 – 4.13 (m, 2H, H1); 3.66 – 3.64 (m, 2H, H7); 3.60 – 3.56 (m, 4H, H2, 
H6); 3.51 – 3.43 (m, 4H, H3, H5); 2.85 (t, J = 2.4 Hz, 1H, H10); 2.46 (s, 3H, H15); 1.74 (tt, J = 6.3 
Hz, 1H, H4). 
13C NMR (100 MHz, CD3OD): δ 146.4 (C11); 134.4 (C14); 131.0 (C13); 129.0 (C12); 80.3 (C10); 
75.7 (C9); 71.0 (C2); 70.0 (C1); 68.9 (C7); 68.7 (C6); 59.1 (C3, C6); 30.6 (C4); 21.5 (C15).  
 
MS (ESI-HRMS): calculated for [C17H24O6S1Na]+: 379.11858; found: 379.11815. 
 
Synthesis of compound 2.33 
 
 
Reagents were added in the reaction vessel as solids or solutions in the following order: linker 2.32 
as a solid (60.7 mg, 170 µmol, 1 eq.), TBTA in THF (18.0 mg, 34 µmol, 0.2 eq., 960 µL of THF), 
CuSO4·5H2O in H2O (4.2 mg, 17 µmol, 0.1 eq., 226 µL of H2O) and Sodium Ascorbate in H2O 
(13.5 mg, 68 µmol, 0.4 eq., 530 µL of H2O). The reaction mixture was stirred at room temperature, 
under nitrogen atmosphere and in the dark for 10 minutes. Then 1.7 (87.1 mg, 190 µmol, 1.1 eq.) 
was added as a solid. THF and H2O volumes were adjusted to 4 mL each. The reaction was stirred 
at room temperature, under nitrogen atmosphere and in the dark. TLC analysis (Hex:AcOEt 7:3) 
showed total conversion of linker 2.32; TLC (AcOEt:MeOH:H2O 85:15:2.5) showed the formation 
of a single new product. Quadrasil™-MP (S/Cu 2:1, 20 mg) was added to the reaction mixture, 
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which was stirred for 10 minutes, and then filtered off. The solvent was removed under reduced 
pressure and the resulting mixture redissolved in MeOH and purified by size exclusion 
chromatography (Sephadex LH-20, MeOH), obtaining 126 mg of pure 2.33 as a colourless oil 
(yield 91 %). 
 
1H NMR (400 MHz, CD3OD): δ 8.00 (s, 1H, HT5); 7.79 (d, 2H, HOTs, J = 8.3 Hz); 7.44 (d, 2H, 
HOTs, J = 8.3 Hz); 4.89 (bs, 1H, H1); 4.65 (s, 2H, HL1); 4.60 (t, 2H, H8, J = 5.0 Hz); 4.16 – 4.11 (m, 
2H, HL8); 3.98 – 3.85 (m, 4H, H6a, HD2, H7); 3.82 – 3.80 (m, 1H, H2); 3.70 – 3.61 (m, 11H, H3, H6b, 
HD1, HL7, HCOOMe); 3.61 – 3.44 (m, 10H, H4, HL2, HL3, HL4, HL6, H5); 2.82 – 2.62 (m, 1H, HD4, HD5); 
2.45 (s, 3H, CH3Ts), 2.02 – 1.94 (m, 2H, HD3eq, HD6eq); 1.79 – 1.66 (m, 3H, HL5, HD3ax or HD6ax); 
1.61 – 1.49 (m, 1H, HD3ax or HD6ax). 
13C NMR (100 MHz, CD3OD): δ 176.7 (COOMe); 146.5 (CquatOTs); 145.9 (CT4); 134.5 (CquatOTs); 
131.1 (COTs); 128.8 (COTs); 126. 1 (CT5); 100.5 (C1); 75.7 (C5); 75.6 (C3); 72.5 (CD1); 72.4 (C2); 72.1 
(CD2); 71.2 (CL2, CL3); 71. 0 (CL8); 70.7 (CL7); 69.4, 68.94, 68.91 (CL4, CL6); 68.6 (C4); 68.4 (C7); 
65.0 (CL1); 63.1 (C6); 52.5 (COOMe); 51.7 (C8); 40.1 (CD4, CD5); 31.0 (CL5); 28.8 (CD3 or CD6); 28.4 
(CD3 or CD6); 21.6 (CH3Ts). 
 
MS (ESI-HRMS): calculated for [C35H53N3O17Na]+: 842.29879; found: 842.29713. 
[α]D 25: 26.5 (c = 0.34, MeOH). 
 
Synthesis of elongated monovalent ligand, 2.6 
 
 
To a solution of 2.33 (117 mg, 140 µmol, 1 eq.) in DMF dry (1.5 mL), NaN3 (37 mg, 570 µmol, 4 
eq.) and Bu4NI (6.0 mg, 16 µmol, 0.1 eq.) were added. The reaction mixture was stirred at 65 °C 
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under nitrogen for 20 h. ESI-MS analysis showed total conversion of the starting material. The 
solvent was removed under reduced pressure and the resulting crude was redissolved in MeOH and 
purified by size exclusion chromatography (Sephadex LH-20, MeOH), obtaining 89 mg of 2.6 as a 
white foam (yield 88 %), still containing 3 % (w/w, as measured by NMR integration) of a tosylate 
salt. Compound 2.6 was used for conjugation to the rods without further purifications. 
 
1H NMR (400 MHz, CD3OD): δ 8.00 (s, 1H, HT5); 4.89 (bs, 1H, H1); 4.65 (s, 2H, HL1); 4.60 (t, 2H, 
H8, J = 5.1 Hz); 3.99 – 3.82 (m, 4H, H6a, HD2, H7); 3.81 (dd, 1.7 Hz, 1H, H2, J = 3.2); 3.70 – 3.60 
(m, 15H, H3, H6b, COOMe, HD1, HL2, HL3, HL7); 3.60 – 3.54 (m, 5H, H4, HL4, HL6); 3.54 – 3.45 (m, 
1H, H5); 3.37 – 3.32 (m, 2H, HL8); 2.82 – 2.64 (m, 2H, HD4, HD5); 2.02 – 1.95 (m, 2H, HD3eq, HD6eq); 
1.84 (tt, 2H, HL5, J = 6.3 Hz,); 1.77 – 1.49 (m, 2H, HD3ax, HD6ax). 
13C NMR (100 MHz, CD3OD): δ 176.8; 176.7 (COOMe); 146.0 (CT5); 100.5 (C1); 75.7 (C5); 75.6 
(C3); 72.5 (CD1); 72.4 (C2); 72.1 (CD2); 71.2, 70.9, 70.7 (CL2, CL3, CL7); 68.96, 68.90 (CL4, CL6); 
68.6 (C4); 68.4 (C7); 65.0 (CL1); 63.1 (C6); 52.4 (COOMe); 51.8 (C8); 51.6 (CL8); 40.2, 40.1 (CD4, 
CD5); 31.1 (CL5); 28.9 (CD3, or CD6); 28.2 (CD3, or CD6). 
 
MS (ESI): calculated for [C28H46N6O4Na]+: 713.7; found: 713.4.  
 
Synthesis of compound 2.34 
 
Reagents were added in the reaction vessel as solids or solutions in the following order: linker 2.32 
as solid (55.8 mg, 160 µmol, 1 eq.), TBTA in THF (16.7 mg, 31 µmol, 0.2 eq., 960 µL of THF), 
CuSO4·5H2O in H2O (3.9 mg, 16 µmol, 0.1 eq., 710 µL of H2O) and Sodium Ascorbate in H2O 
(12.4 mg, 63 µmol, 0.4 eq, 880 µL of H2O). The reaction mixture was stirred at room temperature, 
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under nitrogen atmosphere and in dark for 10 minutes. Then 1.9 (115.9 mg, 170 µmol, 1.1 eq.) was 
added as solid. THF and H2O volumes were adjusted to 4 mL each. The reaction continued 
overnight, stirred at room temperature, under nitrogen atmosphere and in dark. TLC analysis 
(Hex:AcOEt 7:3) showed total conversion of linker 2.32; TLC (CHCl3:MeOH:H2O 85:25:2.5) 
showed the formation of a single new product. Quadrasil™-MP (S/Cu 2:1, 20 mg) was added to the 
reaction mixture, which was stirred for 10 minutes, and then filtered off. The solvent was removed 
under reduced pressure and the resulting mixture redissolved in MeOH and purified by size 
exclusion chromatography (Sephadex LH-20, MeOH), obtaining 155 mg of pure 2.34 as a 
colourless oil (yield 96 %). 
 
1H NMR (400 MHz, MeOD): δ 8.04 (s, 1H, HT5); 7.78 (d, 2H, HOTs, J = 8.3 Hz); 7.42 (d, 2H, HOTs, 
J = 8.3 Hz); 7.28 – 7.19 (m, 8H, HAr2, HAr3); 4.90 (bs, 1H, H1); 4.64 – 4.52 (m, 8H, HL1, CH2OH, 
H8); 4.30 – 4.28 (m, 4H, CH2NH); 4.14 – 4.07 (m, 2H, HL8); 4.02 – 3.81 (m, 5H, H2, HD2, H6a, H7); 
3.72 – 3.65 (m, 3H, HD1, H3, H6b); 3.62 – 3.59 (m, 2H, HL7); 3.58 – 3.49 (m, 6H, H5, H4, HL2, HL3); 
3.46 – 3.41 (m, 4H, HL4, HL6); 2.89 – 2.74 (m, 2H, HD4, HD5); 2.44 (s, 3H, CH3Ts); 1.97 – 1.74 (m, 
4H, HD3, HD6); 1.70 (tt, J = 6.3 Hz, 2H, HL5). 
13C NMR (100 MHz, MeOD): δ 176.9, 176.7 (CONH); 146.5 (CquatOTs); 146.0 (CT4); 141.5 
(CquatOTs); 139.1 (CAr1, CAr4); 134.4 (COTs); 131.1 (COTs); 128.4, 128.3, 128.2, 128.1 (CAr2, CAr3); 
126.1 (CT5); 100.3 (C1); 76.2 (C3); 75.54 (C5); 72.53 (CD1); 72.3 (C2); 72.1 (CD2); 71.1,  71.0, 70.7 
(CL2, CL3, CL8); 69.3, 68.9 (CL4, CL6, CL7); 68.8 (C4); 68.4 (C7); 64.9 (CH2OH, CL1); 63.1 (C6); 51.6 
(C8); 43.6 (CH2NH); 41.8 (C4, C5); 30.8 (CL5); 29.7 (CD3 or CD6); 28.9 (CD3 or CD6); 21.6 (CH3Ts). 
 
MS (ESI): calculated for [C49H67N5O17SNa]+: 1053.0; found: 1052.6. 
 
[α]D 25: 3.9 (c = 0.42, MeOH). 
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Synthesis of elongated monovalent ligand 2.7 
 
 
To a solution of 2.34 (147.8 mg, 140 µmol, 1 eq.) in DMF dry (1.5 mL), NaN3 (37.3 mg, 570 µmol, 
4 eq.) and NaI (3.5 mg, 23 µmol, 0.16 eq.) were added. The reaction mixture was stirred at 65 °C 
under nitrogen for 20 h. ESI-MS analysis showed total conversion of the starting material. The 
solvent was evaporated under reduced pressure and the resulting crude was redissolved in MeOH 
and purified by size exclusion chromatography (Sephadex LH-20, MeOH), obtaining 121 mg of 2.7 
as a white foam (yield 93 %), still containing the 0.4 % (w/w, as measured by NMR integration) of 
a tosylate salt. Compound 2.7 was used for conjugation with the rods without further purifications. 
 
1H NMR (400 MHz): δ 8.05 (s, 1H, HT5); 7.29 – 7.21 (m, 8H, HAr2, HAr3); 4.90 (bs, 1H, H1); 4.63 – 
4.53 (m, 8H, HL1, CH2OH, H8); 4.29 (d, 4H, H10, J = 5.5 Hz); 4.01 – 3.82 (m, 5H, H7, HD2, H6a, 
H2); 3.71 – 3.64 (m, 3H, HD1, H3, H6b); 3.63 – 3.55 (m, 6H, HL2, HL3, HL7); 3.55 – 3.52 (m, 6H, H4, 
H5, HL4, HL6); 3.35 – 3.32 (m, 2H, HL8); 2.92 – 2.71 (m, 2H, HD4, HD5); 1.99 – 1.69 (m, 6H, HD3, 
HD6, HL5).  
13C NMR (100 MHz): δ 176.9, 176.7 (CONH); 146.0 (CT4); 141.5, 139.1 (CAr1, CAr4); 128.36, 
128.34, 128.15, 128.13 (CAr2, CAr3); 126.1 (CT5); 100.2 (C1); 76.1 (C3); 75.6 (C5); 72.5 (CD1); 72.3, 
72.2, (C2, CD2); 71.1, 70.9, 70.7 (CL2, CL3, CL7); 68.94, 68.87 (CL4, CL6); 68.78 (C4); 68.4 (C7); 64.9 
(CH2OH, CL1); 63.1 (C6a,b); 50.35 (C25); 50.25 (C8); 42.27 (CH2NH); 40.36, 40.32 (CD4, CD5); 29.63 
(C22); 28.34 (CD3 or CD6); 27.54 (CD3 or CD6). 
 
MS (ESI): calculated for [C42H60N8O14]+: 923.9; found: 923.4. 
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Synthesis of hexavalent glycodendrimer 2.35 
 
 
To a reaction vessel containing 2.3 (3.7 mg, 11.06 µmol, 1 eq.), reagents were added as solutions in 
the following order: TBTA in THF (1.17 mg, 2.21 µmol, 0.2 eq., 245 µL of THF), CuSO4·5H2O in 
H2O (0.277 mg, 1.10 µmol, 0.1 eq., 44 µL of H2O) and Sodium Ascorbate in H2O (0.877 mg, 4.24 
µmol, 0.4 eq., 82 µL of H2O). The reaction mixture was stirred at room temperature, under nitrogen 
atmosphere and in the dark for 10 min. Then 2.1 (42.7 mg, 24.3 µmol, 2.2 eq.) in 1:1 THF:H2O 
(200 µL) was added. THF and H2O volumes were adjusted to 325 µL each. The reaction was stirred 
overnight, at RT, under nitrogen atmosphere and in the dark. TLC analysis (CH2Cl2:MeOH 9:1) 
revealed total consumption of 2.3; mass analysis (MALDI, DHB or sinapinic acid matrix) 
confirmed that the reaction was complete. The crude mixture was directly loaded onto a Sephadex 
LH-20 column (MeOH) and purified by size exclusion chromatography, obtaining 38 mg of pure 
2.35 as a white solid (yield 90 %). Copper salts were removed by adding Quadrasil™-MP (S/Cu 
6.8:1, 5 mg) to a solution of the product in MeOH; the mixture was stirred for 10 min, then the resin 
was filtered off and the solvent evaporated. 
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1H NMR (400 MHz, CD3OD): δ 8.59 (s, 2H, HTC4); 7.92 (s, 6H, HT4); 7.86 (s, 2H, HR2); 4.89 (br s, 
6H, H1); 4.70 – 4.61 (m, 4H, HL8); 4.57 (t, 12H, H8, J = 4.8 Hz); 4.47 (s, 12H, HL1); 4.31 (s, 4H, 
HG1); 4.02 – 3.80 (m, 38H, H7, H6a, H2, HD2, HL7, HG2); 3.79 – 3.73 (m, 4H, HG3); 3.72 – 3.63 (m, 
22H, H6b, HD1, H3, HG4); 3.62 (s, 36H, COOMe); 3.60 – 3.54 (m, 10H, H4, HL5); 3.53 – 3.45 (m, 
10H, H5, HL6); 3.38 (s, 12H, HL2); 3.35 (s, 4H, HL4); 2.77 (td, 6H, HD4, J = 12.5, 3.5 Hz); 2.66 (td, 
6H, HD5, J = 12.2, 3.4 Hz); 2.05 – 1.88 (m, 12H, HD3eq, HD6eq); 1.70 (t, 6H, HD6ax or HD3ax, J = 13.3 
Hz); 1.54 (t, J = 12.7 Hz, 6H, HD6ax or HD3ax).   
13C NMR (100 MHz, CD3OD): δ 176.8, 176.6 (COOMe); 150.9 (CR3); 146.2 (CT4); 143.7 (CTC4); 
127.6 (CTC5); 125.7 (CT5); 121.0 (CR1); 112.26 (CR2); 100.5 (C1); 75.7 (C5); 75.6 (C3); 73.7 (CG3); 
72.5 (CD1); 72.4 (C2); 72.2 (CD2); 72.0 (CL6); 71.5 (CL5); 70.8 (CL7); 70.6 (CG2); 69.9 (CL2, CL4); 
68.6 (C4); 68.4 (C7); 65.4 (CL1); 63.1 (C6); 62.3 (CG4); 52.5, 52.5 (COOMe); 51.5 (C8, CL8); 46.55 
(CL3); 40.21 (CD4); 40.08 (CD5); 28.86 (CD3 or CD6); 28.32 (CD3 or CD6).  
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MS (ESI-HRMS): m/z calculated for [C162H247N24O82]+: 3841.5929; found: 3841.5871 (after 
deconvolution).  
[α]D25: +29.5 (c = 0.65, MeOH). 
 
Synthesis of hexavalent glycodendrimer 2.36 
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To a stirred solution of TIPS-2.4 (5 mg, 5.2 µmol, 1 eq.) in THF (120 µL), TBAF (1 M in THF, 
10.5 µL, 2 eq.) was added under nitrogen. After 1 h, TLC analysis (CH2Cl2:MeOH 9:1) showed that 
the desilylation reaction was complete. The CuAAC reagents were added as solutions in the 
following order: TBTA in THF (0.53 mg, 1.00 µmol, 0.2 eq., 21 µL of THF), CuSO4·5H2O in H2O 
(0.13 mg, 0.52 µmol, 0.1 eq., 39 µL of H2O) and Sodium Ascorbate in H2O (0.40 mg, 2.08 µmol, 
0.4 eq., 32 µL of H2O). The reaction mixture was stirred at room temperature, under nitrogen 
atmosphere and in dark for 10 minutes. Then 2.1 (20 mg, 11.4 µmol, 2.2 eq.) was added as a solid. 
THF and H2O volumes were adjusted to 150 µL each. The reaction was stirred overnight, at room 
temperature, under nitrogen atmosphere and in the dark. TLC analysis (CH2Cl2:MeOH 9:1) 
revealed total consumption of deprotected 2.4; mass analysis (MALDI, DHB or sinapinic acid 
matrix) confirmed that the reaction was complete. Quadrasil™-MP (S/Cu 14.4:1, 5 mg) was added 
to the reaction mixture, which was stirred for 10 min, and then filtered off. The solvent was 
removed under reduced pressure and the resulting mixture was redissolved in MeOH and purified 
by size exclusion chromatography (Sephadex LH-20, MeOH), obtaining 13 mg of pure 2.36 as a 
yellow solid (yield 62 %). 
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1H NMR (400 MHz, CD3OD): δ 8.60 (s, 2H, HTC5); 7.92 (s, 6H, HT5); 7.85 (s, 2H, HR2); 7.22 (s, 
2H, HR5); 4.87 (br s, 6H, H1); 4.69 – 4.63 (m, 4H, HL8); 4.59 (t, 12H, H8, J = 4.7 Hz); 4.46 (s, 12H, 
HL1); 4.34 – 4.24 (m, 8H, HG1, HG5); 4.00 – 3.90 (m, 24H, HG2, HG6, H7, HL7); 3.90 – 3.79 (m, 18H, 
HD2, H2, H6a); 3.79 – 3.71 (m, 8H, HG4, HG8); 3.71 – 3.63 (m, 26H, HG3, HG7, H3, H6b, HD1); 3.62 (s, 
36H, COOMe); 3.60 – 3.53 (m, 10H, H4, HL5 or HL6); 3.53 – 3.46 (m, 10H, H5, HL5 or HL6); 3.35 (s, 
16H, HL2, HL4); 2.77 (td, 6H, HD4, J = 12.6, 3.4 Hz); 2.66 (td, 3.5 Hz, 6H, HD5, J = 12.3); 2.03 – 
1.91 (m, 12H, HD3eq, HD6eq); 1.75 – 1.49 (m, 12H, HD3ax, HD6ax).  
13C NMR (100 MHz, CD3OD): δ 176.8, 176.6 (COOMe); 155.3 (CR6); 150.5 (CR3); 146.2 (CTC4); 
143.5 (CT4); 125.7 (CTC5); 125.6 (CT5); 122.3 (CR1); 118.4 (CR5); 114.5 (CR2); 100.6 (C1); 75.70 
(C5); 75.6 (C3); 74.1, 73.8 (CG3, CG7); 72.5 (CD1); 72.4 (C2); 72.2 (CD2); 72.0, 71.5 (CL5, CL6); 70.9, 
70.7, 70.5 (CG2, CG6, CG1); 69.9 (CL2, CL4); 69.5 (CG5); 68.6 (C4); 68.4 (C7, CL7); 65.4 (C13); 63.1 
(C6); 62.4, 62.3 (CG4, CG8); 52.5, 52.5 (COOMe); 51.6 (C8, CL8); 40.2, 40.1 (CD4, CD5); 28.9 (CD3 or 
CD6); 28.3 (CD3 or CD6).  
 
MS (MALDI, matrix: sinapinic acid, solvent: MeOH): m/z calculated for [C178H267N24O88]+: 
4151.22; found: 4150.0.  
MS (ESI-HRMS): calculated for [C178H266N24O88]: 4147.70772; found: 4147.71526 (after 
deconvolution).  
 
[α]D25: +24.1 (c = 0.24, MeOH). 
 
Synthesis of hexavalent glycodendrimer 2.37 
 
 
To a stirred solution of TIPS-2.5 (12.4 mg, 9.82 µmol, 1 eq.) in THF (400 µL), TBAF (1 M in 
THF, 22 µL, 2 eq.) was added at room temperature under nitrogen. After 1 h, TLC analysis 
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(CH2Cl2:MeOH 9:1) showed that the desilylation reaction was complete. The CuAAC reagents 
were added as solutions in the following order: TBTA in THF (1.17 mg, 2.21 µmol, 0.2 eq., 160µL 
of THF), CuSO4·5H2O in H2O (0.277 mg, 1.10 µmol, 0.1 eq., 56 µL of H2O) and Sodium Ascorbate 
in H2O (0.877 mg, 4.24 µmol, 0.4 eq., 74 µL of H2O). The reaction mixture was stirred at room 
temperature, under nitrogen atmosphere and in the dark for 10 min. Then 2.1 (42.7 mg, 24.3 µmol, 
2.2 eq.) was added as a solid. THF and H2O volumes were adjusted to 500 µL each. The reaction 
was stirred overnight, at room temperature, under nitrogen atmosphere and in the dark. TLC 
analysis (CH2Cl2:MeOH 9:1) revealed total consumption of 2.5; mass analysis (MALDI, DHB or 
sinapinic acid matrix) confirmed that the reaction was complete. The crude mixture was directly 
loaded onto a Sephadex LH-20 column (MeOH) and purified by size exclusion chromatography, 
obtaining 37 mg of pure 2.37 as yellow solid (yield 85%). Copper salts were removed by adding 
Quadrasil™-MP (S/Cu 6.8:1, 5 mg) to a 2.37 solution in MeOH; the mixture was stirred for 10 min, 
then the resin was filtered off and the solvent evaporated. 
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1H NMR (400 MHz, CD3OD): δ 8.58 (s, 2H, HTC5); 7.92 (s, 6H, HT5); 7.84 (s, 2H, HR10); 7.20 (s, 
4H, HR2, HR5); 4.89 (br s, 6H, H1,); 4.65 (s, 4H, HL8); 4.58 (t, 12H, H8, J = 4.7 Hz); 4.46 (s, 12H, 
H13); 4.35 – 4.21 (m, 12H, HG1, HG5, HG9); 4.00 – 3.89 (m, 28H, H7, HL1, HG2, HG6, HG10); 3.89 – 
3.83 (m, 12H, HD2, H6a); 3.82 (dd, 1.6 Hz, 6H, H2, J = 3.1); 3.78 – 3.71 (m, 12H, HG3, HG7, HG11); 
3.71 – 3.64 (m, 30H, H3, H6b, HD1, HG4, HG8, HG12); 3.62 (s, 36H, COOMe); 3.60 – 3.53 (m, 10H, 
H4, HL5); 3.53 – 3.45 (m, 10H, H5, HL6); 3.35 (s, 12H, HL2); 3.33 (s, 4H, HL4); 2.77 (td, 6H, HD4, J = 
12.4, 3.5 Hz); 2.66 (td, 6H, HD5, J = 12.4, 3.5 Hz); 2.06 – 1.86 (m, 12H, HD6eq, HD3eq); 1.70 (t, J = 
13.4 Hz, 6H, HD6ax or HD3ax); 1.54 (t, J = 12.6 Hz, 6H, HD6ax or HD3ax).  
13C NMR (100 MHz, CD3OD): δ 176.8, 176.6 (COOMe); 155.3, 155.0, 150.5, 146.2 (CT4); 143.5 
(CTC4); 127.06 (CTC5); 125.7 (CT5); 122.4, 119.1 (CR2); 118.3 (CR5); 115.9, 114.3, 112.9 (CR10); 
103.2, 101.4, 100.5 (C1); 92.8, 91.7, 91.1, 75.7 (C5); 75.6 (C3); 74.1, 73.7, 72.5 (CD1); 72.4 (C2); 
72.2 (CD2); 72.0 (CL6); 71.5 (CL5); 71.0, 70.9, 70.8, 70.7, 70.5, 69.8 (CL2, CL4); 69.5 (CG9); 68.6 
(C4); 68.4 (C7); 65.4 (CL1); 63.1 (C6); 62.4, 62.4, 62.3, 52.54, 52.53 (COOMe); 51.5 (C8, CL8); 46.6 
(CL3); 40.2 (CD4); 40.1 (CD5); 28.9 (CD3 or CD6); 28.3 (CD3 or CD6).  
0102030405060708090100110120130140150160170180
f1 (ppm)
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MS (ESI-HRMS): m/z calculated for [C194H287N24O94]+: 4458.8404; found: 4457.8511 (after 
deconvolution).  
 
[α]D25: +24.1 (c = 0.65, MeOH). 
  
Synthesis of divalent glycodendrimer 2.38  
 
 
In a reaction vessel containing 2.3 (4 mg, 12 µmol, 1 eq.), reagents were added as solutions in the 
following order: TBTA in THF (1.3 mg, 2.4 µmol, 0.2 eq., 80 µL of THF), CuSO4·5H2O in H2O 
(0.3 mg, 1.2 µmol, 0.1 eq., 30 µL of H2O) and Sodium Ascorbate in H2O (1.0 mg, 4.8 µmol, 0.4 eq. 
32 µL of H2O). The reaction mixture was stirred at room temperature, under nitrogen atmosphere 
and in the dark for 10 min. Finally 2.6 (19.1 mg 97 % w/w, 26.8 µmol effective, 2.2 eq.) was added 
as solid. THF and H2O volumes were adjusted to 270 µL each. The reaction was stirred at room 
temperature under nitrogen in the dark overnight. TLC analysis (CH2Cl2:MeOH 9:1) revealed total 
consumption of 2.3; TLC (CHCl3:MeOH:H2O 75:25:2.5) revealed the presence of a single new 
species, together with a small amount of starting material 2.6; mass analysis (MALDI, DHB or 
sinapinic acid matrix) confirmed that the reaction was complete. Quadrasil™-MP (S/Cu 6.3:1, 5 
mg) was added to the reaction mixture, which was stirred for 10 min, and then filtered off. The 
solvent was removed under reduced pressure and the resulting mixture was redissolved in MeOH 
and purified by size exclusion chromatography (Sephadex LH-20, MeOH), obtaining 15 mg of pure 
2.38 as a white solid (yield 73 %). 
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1H NMR (400 MHz, CD3OD): δ 8.60 (s, 2H, HTC5); 7.93 (s, 2H, HT5); 7.90 (s, 2H, HR2); 4.88 (bs, 
2H, H1); 4.65 (t, 4H, HL8, J = 4.9 Hz); 4.57 – 4.53 (m, 8H, H8, HL1); 4.36 – 4.31 (m, 4H, HG1); 3.98 
– 3.94 (m, 4H, HG2); 3.94 – 3.84 (m, 10H, HL7, H7, HD2); 3.83 – 3.80 (m, 4H, H6a, H2); 3.78 – 3.73 
(m, 4H, HG4); 3.71 – 3.68 (m, 4H, HG3); 3.65 – 3.61 (m, 18H, H3, H6b, HD1, COOMe); 3.59 – 3.50 
(m, 10H, H5, HL2 or HL3, HL4 or HL6); 3.50 – 3.39 (m, 10H, H4, HL2 or HL3, HL4 or HL6); 2.76 (td, 
2H, HD4 or HD5, J = 12.6, 3.5 Hz); 2.64 (td, 2H, HD4 or HD5, J = 12.6, 3.5 Hz); 2.04 – 1.88 (m, 4H, 
HD3eq, HD6eq); 1.78 (tt, 4H, HL5, J = 6.2 Hz); 1.74 – 1.64 (m, 2H, HD3ax or HD6ax); 1.59 – 1.47 (m, 
2H, HD3ax or HD6ax).  
13C NMR (100 MHz, CD3OD): δ 176.8, 176.6 (COOMe); 150.9 (CR3); 145.9 (CTC4); 143.7 (CT4); 
126.9 (CTC5); 125.8 (CT5); 121.0 (CR1); 112.2 (CR2); 100.5 (C1); 75.7 (C5); 75.6 (C3); 73.8 (CG3); 
72.5 (CD1); 72.4 (C2); 72.1 (CD2); 71.2 (CL2 or CL3); 70.8 (CG2); 70.6 (CL2 or CL3); 70.2 (C7 or CL7); 
69.4 (CG1); 68.89, 68.86 (CL4, CL6); 68.6 (C4); 68.4 (C7 or CL7); 64.9 (CL1); 63.1 (C6); 62.3 (CG4); 
52.4 (COOMe); 51.6 (C8); 51.5 (CL8); 40.2, 40.1 (CD4, CD5); 30.9 (CL5); 28.8 (CD3 or CD6); 28.3 
(CD3 or CD6).  
 
MS (MALDI, matrix: sinapinic acid, solvent: MeOH): m/z calculated for [C74H114N12O34Na]+: 
1738.4; found: 1738.0.  
MS (ESI-HRMS): m/z calculated for [C74H114N12O34Na1]+: 1737.74526; found:1737.74278.   
 
[α]D 25: +30.2 (c = 0.35, MeOH). 
 
Synthesis of divalent glycodendrimer 2.39 
 
 
To a stirred solution of TIPS2.4 (13.4 mg, 14 µmol, 1 eq.) in THF (300 µL), TBAF (1 M in THF, 
28.0 µL, 2 eq.) was added under nitrogen. After 1 h, TLC analysis (CH2Cl2:MeOH 9:1) showed that 
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the desilylation reaction was complete. The CuAAC reagents were added as solutions in the 
following order: TBTA in THF (1.49 mg, 2.8 µmol, 0.2 eq., 120 µL of THF), CuSO4·5H2O in H2O 
(0.35 mg, 1.4 µmol, 0.1 eq., 50 µL of H2O) and Sodium Ascorbate in H2O (1.06 mg, 5.6 µmol, 0.4 
eq., 140 µL of H2O). The reaction mixture was stirred at room temperature, under nitrogen 
atmosphere and in dark for 10 min. Finally 2.6 (22.3 mg 97 % w/w, 31.3 µmol effective, 2.2 eq.) 
was added as a solid. THF and H2O volumes were adjusted to 450 µL each. The reaction was stirred 
at room temperature under nitrogen in the dark overnight. TLC analysis (CH2Cl2:MeOH 9:1) 
revealed total consumption of 2.4; TLC (CHCl3:MeOH:H2O 75:25:2.5) revealed the presence of a 
single new species, together with a small amount of starting material 2.6. Quadrasil™-MP (S/Cu 
5.4:1, 5 mg) was added to the reaction mixture, which was stirred for 10 min, and then filtered. The 
solvent was removed under reduced pressure and the resulting mixture was redissolved in MeOH 
and purified by size exclusion chromatography (Sephadex LH-20, MeOH), obtaining 23 mg of 2.39 
not pure. The remaining tetrabutylammonium salt was removed by automated reverse phase flash 
chromatography (C18, water with gradient of MeOH from 0 % to 100 %), obtaining 17 mg of pure 
2.39 as a yellow solid (yield 60 %). 
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1H NMR (400 MHz, CD3OD): δ 8.58 (s, 2H, HTC5); 7.94 (s, 2H, HT5); 7.87 (s, 2H, HR2); 7.22 (s, 
2H, HR5); 4.87 (br s, 2H, H1); 4.64 (t, 4H, HL8, J = 4.8 Hz); 4.62 – 4.52 (m, 8H, H8, HL1); 4.37 – 
4.30 (m, 4H, HG1); 4.30 – 4.22 (m, 4H, HG5); 3.98 – 3.92 (m, 8H, HG2, HG6); 3.92 – 3.88 (m, 4H, H7 
or HL7); 3.88 – 3.83 (m, 6H, H7 or HL7, HD2); 3.83 – 3.78 (m, 4H, H6a, H2); 3.78 – 3.70 (m, 8H, HG3, 
HG4); 3.70 – 3.59 (m, 26H, HG7, HG8, H6b, HD1, H3, COOMe); 3.59 – 3.47 (m, 12H, HL4 or HL6, HL2 
or HL3, H4, H5); 3.47 – 3.37 (m, 8H, HL4 or HL6, HL2 or HL3); 2.76 (td, 2H, HD4 or HD5, J = 12.6, 3.6 
Hz); 2.64 (td, 2H, HD4 or HD5, J = 12.6, 3.6 Hz); 1.95 (t, 4H, HD3eq, HD6eq, J = 14.2 Hz); 1.77 (tt, 4H, 
HL5, J = 6.4 Hz); 1.72 – 1.64 (m, 2H, HD3ax or HD6ax); 1.56 – 1.48 (m, 2H, HD3ax or HD6ax).  
13C NMR (100 MHz, CD3OD): δ 176.8, 176.6 (COOMe); 155.3 (CR6); 150.5 (CR3); 145.84 (CTC4); 
143.5 (CT4); 127.1 (CTC5); 125.9 (CT5); 122.2 (CR1); 118.8, 118.3 (CR5); 114.6 (CR4); 112.9 (CR2); 
100.5 (C1); 91.8 (CR7); 75.7 (C5); 75.6 (C3); 74.1, 73.7 (CG3, CG7); 72.5, 72.4 (C2, CD1); 72.1 (CD2); 
71.1 (CL2 or CL3); 71.0, 70.9 (CG2, CG6); 70.7 (CG1); 70.6 (CL2 or CL3); 70.2 (C7 or CL7); 69.5 (CG5); 
68.9 (CL4, CL6); 68.6 (C4); 68.4 (C7 or CL7); 64.9 (CL1); 63.1 (C6); 62.4, 62.3 (CG4, CG8); 52.4 
(COOMe); 51.6 (C8, CL8); 40.2, 40.1 (CD4, CD5); 30.9 (CL5); 28.8 (CD3 or CD6); 28.3 (CD3 or CD6).  
 
MS (MALDI, matrix: sinapinic acid, solvent: MeOH): m/z calculated for [C90H134N12O40Na]+: 
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2047.0; found: 2046.4.  
MS (ESI-HRMS): calculated for [C90H134N12O40]: 2022.88203; found: 2022.88641 (after 
deconvolution).   
 
[α]D 25: +16.1 (c = 0.50 MeOH). 
 
Synthesis of divalent glycodendrimer 2.40 
 
To a stirred solution of TIPS-2.5 (13 mg, 10.5 µmol, 1 eq.) in THF (280 µL), TBAF (1 M in THF, 
21.0 µL, 2 eq.) was added under nitrogen. After 1 h, TLC analysis (CH2Cl2:MeOH 9:1) showed that 
the desilylation reaction was complete. Then reagents were added as solutions in the following 
order: TBTA in THF (1.2 mg, 2.2 µmol, 0.2 eq., 50 µL of THF), CuSO4·5H2O in H2O (0.3 mg, 1.1 
µmol, 0.1 eq., 16 µL of H2O) and sodium ascorbate in H2O (0.9 mg, 4.4 µmol, 0.4 eq., 46 µL of 
H2O). The reaction mixture was stirred at room temperature, under nitrogen atmosphere and in dark 
for 10 min. Finally 2.6 (16.8 mg 97 % w/w, 23.6 µmol effective, 2.2 eq.) was added as a solid. THF 
and H2O volumes were adjusted to 350 µL each. The reaction was stirred at RT under nitrogen and 
in the dark overnight. TLC analysis (CH2Cl2:MeOH 9:1) revealed total consumption of 2.5; TLC 
(CHCl3:MeOH:H2O 80:20:2.5) revealed the presence of a single new species, together with a small 
amount of starting material 2.6; mass analysis (MALDI, DHB or sinapinic acid matrix) confirmed 
that the reaction was complete. Quadrasil™-MP (S/Cu 6.8:1, 5 mg) was added to the reaction 
mixture, which was stirred for 10 min, and then filtered off. The solvent was removed under 
reduced pressure and the resulting mixture was redissolved in MeOH and purified by size exclusion 
chromatography (Sephadex LH-20, MeOH), obtaining 23 mg of pure 2.40 as a yellow solid (yield 
92 %). 
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1H NMR (400 MHz, CD3OD): δ 8.56 (s, 2H, HTC5); 7.93 (s, 2H, HT5); 7.86 (s, 2H, HR2); 7.20 (s, 
2H, HR5); 7.17 (s, 2H, HR10); 4.87 (br s, 2H, H1); 4.64 (t, 4H, HL8, J = 4.7 Hz); 4.61 – 4.52 (m, 8H, 
H8, HL1); 4.34 – 4.24 (m, 12H, HG1, HG5, HG9); 3.98 – 3.88 (m, 16H, HG2, HG6, HG10, H7 or HL7); 
3.88 – 3.84 (m, 8H, H7 or HL7, HD2, H6a); 3.84 – 3.78 (m, 4H, H2, H6b); 3.77 – 3.74 (m, 4H, HG4); 
3.74 – 3.70 (m, 8H, HG3, HG7); 3.70 – 3.66 (m, 12H, HG8, HG12, HG11); 3.65 – 3.63 (m, 4H, H3, HD1); 
3.62 (s, 12H, COOMe); 3.59 – 3.47 (m, 12H, HL4 or HL6, HL2 or HL3, H4, H5); 3.46 – 3.39 (m, 8H, 
HL2 or HL3, HL4 or HL6); 2.76 (td, 2H, HD4 or HD5, J = 12.7, 3.6 Hz); 2.65 (td, 2H, HD4 or HD5, J = 
12.7, 3.6 Hz); 2.01 – 1.90 (m, 4H, HD3eq, HD6eq); 1.83 – 1.73 (m, 4H, HL5); 1.73 – 1.64 (m, 2H, 
HD3ax or HD6ax); 1.57 – 1.47 (m, 2H, HD3ax or HD6ax).   
13C NMR (100 MHz, CD3OD): δ 176.77, 176.62 (COOMe); 155.32, 154.92 (CR6, CR11); 150.46 
(CR3); 145.81 (CTC4); 143.43 (CT4); 127.09 (CTC5); 125.87 (CT5); 122.30 (CR1); 119.00 (CR10); 
118.20 (CR5); 115.86 (CR4); 114.34 (CR9); 112.79 (CR2); 100.48 (C1); 92.81, 91.70 (CR7, CR8); 75.68 
(C5); 75.57 (C3); 74.12, 73.74 (CG3, CG7, CG11); 72.47, 72.39 (CD1, C2); 72.09 (CD2); 71.12 (CL2 or 
CL3); 70.93, 70.83 (CG1, CG5); 70.67 (CG2, CG6, CG10); 70.55 (CL2 or CL3); 70.19 (C7 or CL7); 69.40 
(CG9); 68.84 (CL4, CL6); 68.61 (C4); 68.34 (C7 or CL7); 64.86 (CL1); 63.08 (C6); 62.38, 62.36, 62.27 
(CG4, CG8, CG12); 54.83, 52.45 (COOMe); 51.58, 51.53 (CL8, C8); 40.19, 40.05 (CD4, CD5); 30.85 
(C17); 28.81 (CD3 or CD6); 28.26 (CD3 or CD6).  
 
MS (ESI-HRMS): calculated for [C106H154N12O46]: 2331.00802; found: 2331.00805 (after 
deconvolution).  
 
[α]D 25: +8.5 (c 0.29, MeOH). 
 
Synthesis of divalent glycodendrimer 2.41 
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To a stirred solution of TIPS-2.5 (16.2 mg, 12.8 µmol, 1 eq.) in THF (300 µL), TBAF (1 M in 
THF, 26.0 µL, 2 eq.) was added under nitrogen. After 1 h, TLC analysis (CH2Cl2:MeOH 9:1) 
showed that the desilylation reaction was complete. Then reagents were added as solutions in the 
following order: TBTA in THF (1.4 mg, 2.6 µmol, 0.2 eq., 100 µL of THF), CuSO4·5H2O in H2O 
(0.32 mg, 1.28 µmol, 0.1 eq., 50 µL of H2O) and sodium ascorbate in H2O (1.01 mg, 5.1 µmol, 0.4 
eq., 50 µL of H2O). The reaction mixture was stirred at room temperature, under nitrogen 
atmosphere and in dark for 10 min. Finally 1.7 (13.1 mg, 28.2 µmol, 2.2 eq.) was added. THF and 
H2O volumes were adjusted to 400 µL each. The reaction was stirred at RT, under nitrogen and in 
the dark overnight. TLC analysis (CH2Cl2:MeOH 9:1) revealed total consumption of 2.5; TLC 
(CH2Cl2:MeOH:H2O 80:20:2.5) showed the formation of a single new product and the remaining of 
a small amount of 1.7. Quadrasil™-MP (S/Pd 5.9:1, 5 mg) was added to the reaction mixture, 
which was stirred for 10 min, and then filtered off. The solvent was removed under reduced 
pressure and the resulting mixture was redissolved in MeOH and purified by size exclusion 
chromatography (Sephadex LH-20, MeOH), obtaining 22 mg of 2.41 not pure. The remaining 
tetrabutylammonium salt was removed through automated reverse phase flash chromatography 
(C18, water with gradient of MeOH from 0 % to 100 %), obtaining 18 mg of pure 2.41 as a yellow 
solid (yield 71 %). 
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1H NMR (400 MHz, CD3OD): δ 8.61 (s, 2H, HTC5); 7.88 (s, 2H, HR2); 7.22 (s, 2H, HR5); 7.17 (s, 
2H, HR10); 4.88 (br s, 2H, H1); 4.67 (t, J = 4.6 Hz, 4H, H8); 4.39 – 4.31 (m, 4H, HG9); 4.30 – 4.21 
(m, 8H, HG1, HG5); 4.00 – 3.91 (m, 16H, H7, HG2, HG6, HG10); 3.90 – 3.81 (m, 4H, HD2, H6a); 3.80 – 
3.74 (m, 6H, H2, HG12); 3.74 – 3.63 (m, 26H, HD1, H3, H6b, HG4, HG8, HG3, HG11, HG7); 3.62 – 3.45 
(m, 16H, COOMe, H4, H5); 2.81 – 2.57 (m, 4H, HD4, HD5); 2.04 – 1.85 (m, 4H, HD3eq, HD6eq); 1.73 – 
1.62 (m, 2H, HD3ax or HD6ax); 1.52 – 1.44 (m, 2H, HD3ax or HD6ax).  
13C NMR (100 MHz, CD3OD): δ 176.9, 176.4 (COOMe); 155.4, 154.9 (CR6, CR11); 150.6 (CR3); 
143.5 (CTC4); 127.3 (CT4); 122.5 (CR1); 119.1 (CR10); 118.4 (CR5); 116.0, 114.3 (CR4, CR9); 113.0 
(CR2); 100.4 (C1); 92.7, 91.7 (CR7, CR8); 75.6 (C5); 75.5 (C3); 74.1, 73.7 (CG3, CG7, CG11); 72.5 
(CD1); 72.4 (C2); 71.9 (CD2); 70.9 (CG1 or CG5); 70.9 (CG9); 70.6 (CG2, CG6, CG10); 69.4 (CG1 or CG5); 
68.6 (C4); 68.5 (C7), 63.1 (C6); 62.4, 62.3 (CG4, CG8, CG12); 52.4 (COOMe); 51.6 (C8); 40.1 (CD4, 
CD5); 29.1 (CD3 or CD6); 28.1 (CD3 or CD6).  
 
MS (ESI): m/z calculated for [C86H120N6O40Na2]2+: 961.8; found: 961.9.  
MS (ESI-HRMS): m/z calculated for [C86H120N6O40]+: 1876.75403; found: 1876.76014.  
 
[α]D 25: +27.5 (c 0.59, MeOH). 
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Synthesis of hexavalent glycodendrimer 2.43 
 
 
To a reaction vessel containing 2.3 (1.15 mg, .4 µmol, 1 eq.), reagents were added as solutions in 
the following order: TBTA in THF (0.36 mg, 0.69 µmol, 0.2 eq., 100 µL of THF), CuSO4·5H2O in 
H2O (0.09 mg, 0.34 µmol, 0.1 eq., 50 µL of H2O) and Sodium Ascorbate in H2O (0.27 mg, 1.37 
µmol, 0.4 eq, 50 µL of H2O). The reaction mixture was stirred at room temperature, under nitrogen 
atmosphere and in dark for 10 min, then 2.2 (18 mg, 7.55 µmol, 2.2 eq.) was added as a solid. THF 
and H2O volumes were adjusted to 500 µL each and The reaction mixture was heated at 60 °C 
under microwave irradiation for 90 min. TLC analysis (CH2Cl2:MeOH 9:1) revealed total 
consumption of 2.3; mass analysis (MALDI, DHB or sinapinic acid matrix) confirmed that the 
reaction was complete. Quadrasil™-MP (S/Cu 22:1, 5 mg) was added to the reaction mixture, 
which was stirred for 10 min, and then filtered off. The solvent was removed under reduced 
pressure and the resulting mixture was redissolved in MeOH and purified by size exclusion 
chromatography (Sephadex LH-20, MeOH), obtaining 9 mg of pure 2.43 as a yellowish solid (yield 
50 %).  
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1H NMR (400 MHz, CD3OD): δ 8.55 (s, 2H, HTC5); 7.90 (s, 6H, HT5); 7.82 (s, 2H, HR2); 7.27 – 
7.12 (m, 48H, HAr2, HAr3); 4.88 (br s, 6H, H1); 4.61 – 4.56 (m, 4H, HL8); 4.53 (s, 24H, CH2OH); 
4.50 – 4.44 (m, 12H, H8); 4.40 (s, 12H, HL1); 4.26 – 4.24 (m, 28H, CH2NH, HG1); 3.93 - 3.85 (m, 
32H, H2, HD2, H7, HL7, HG2); 3.82 (bs, 6H, H6a); 3.72 - 3.67 (m, 14H, H6b, HG3, HG4); 3.65 – 3.62 
(m, 12H, H3, HD1); 3.60 - 3.52 (m, 16H, H4, H5, HL5); 3.45 – 3.44 (m, 4H, HL6); 3.33 – 3.27 (m, 
16H, HL2, HL4); 2.91 – 2.74 (m, 12H, HD4, HD5); 1.96 – 1.66 (m, 24H, HD3, HD6).  
13C NMR (100 MHz, CD3OD): δ 177.1, 176.8 (CONH); 146.3 (CT4); 141.7, 141.7; 139.2, 139.2 
(CAr1, C Ar4); 128.6, 128.5, 128.3, 128.3 (C Ar2, C Ar3); 126.4 (CTC5); 126.1 (CT5); 112.6 (CR2); 100.6 
(C1); 76.3 (C3); 75.7 (C5); 73.9 (CG3); 72.6, 72.4, 72.3 (CD1, CD2, C2); 71.9, 71.2 (CL5, CL6); 70.50 
(CG2); 69.83 (CL2, CL4); 68.7 (C4); 69.0 (CG1); 68.5 (C7, CL7); 65.5 (CL1); 65.1 (CH2OH); 63.3 (C6); 
62.5 (CG4); 51.7 (CL8, C8); 43.9 (CH2NH); 41.9 (CD4, CD5); 29.7 (CD3 or CD6); 29.1 (CD3 or CD6).  
 
MS (MALDI, matrix: sinapinic acid, solvent: MeOH): m/z calculated for [C246H330N36O82]+: 
5103.4; found: 5102.6.  
MS (ESI-HRMS): m/z calculated for [C246H330N36O82]+: 5100.27592; found: 5100.29384 (after 
deconvolution).  
 
[α]D 25: -18.9 (c = 0.1, MeOH). 
 
Synthesis of hexavalent glycodendrimer 2.44 
 
 
To a stirring solution of TIPS-2.4 (4.1 mg, 4.38 µmol, 1 eq.) in THF (200 µL), TBAF (1 M in THF, 
8.8 µL) was added under nitrogen. After 1 h, TLC analysis (CH2Cl2:MeOH 9:1) showed that the 
desilylation reaction was complete. The CuAAC reagents were added as solutions in the following 
order: TBTA in THF (0.47 mg, 0.9 µmol, 0.2 eq., 200 µL of THF), CuSO4·5H2O in H2O (0.11 mg, 
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0.44 µmol, 0.1 eq., 150 µL of H2O) and Sodium Ascorbate in H2O (0.33 mg, 1.8 µmol, 0.4 eq., 150 
µL of H2O). The reaction mixture was stirred at room temperature, under nitrogen atmosphere and 
in the dark for 10 min. Then 2.2 (23 mg, 9.6 µmol, 2.2 eq.) was added as a solid. THF and H2O 
volumes were adjusted to 600 µL each. The reaction mixture was heated at 60 °C under microwave 
irradiation for 60 min and then left stirring at room temperature overnight in the dark. TLC analysis 
(CH2Cl2:MeOH 9:1) revealed total consumption of 2.4; mass analysis (MALDI, DHB or sinapinic 
acid matrix) confirmed that the reaction was complete. Quadrasil™-MP (S/Pd 17:1, 5 mg) was 
added to the reaction mixture, which was stirred for 10 minutes, and then filtered off. The solvent 
was removed under reduced pressure and the resulting mixture was redissolved in MeOH and 
purified by size exclusion chromatography (Sephadex LH-20, MeOH), obtaining 12 mg of pure 
2.44 as a yellow solid (yield 52%). 
 
 
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0
ppm
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1H NMR (400 MHz, CD3OD): δ 8.56 (s, 2H, HTC5); 7.93 (s, 6H, HT5); 7.80 (s, 2H, HR2); 7.25 – 
7.16 (m, 50H, HAr2, HAr3, HR5); 4.88 (br s, 6H, H1); 4.65 – 4.60 (m, 4H, HL8); 4.55 – 4.48 (m, 36H, 
CH2OH, H8); 4.40 (s, 12H, HL1); 4.29 – 4.16 (m, 32H, CH2NH, HG1, HG5); 3.95 - 3.80 (m, 42H, H2, 
H6a, HD2, H7, HL7, HG2, HG6); 3.71 - 3.62 (m, 34H, H6b, HD1, H3, HG3, HG7, HG4, HG8); 3.59 - 3.50 
(m, 16H, H4, H5, HL5); 3.45 - 3.42 (m, 4H, HL6); 3.33 – 3.27 (m, 16H, HL4, HL2); 2.85 – 2.80 (m, 
12H, HD4, HD5); 1.92 – 1.65 (m, 24H, HD3, HD6).  
13C NMR (100 MHz, CD3OD): δ 179.0, 176.7 (CONH); 146.1 (CT4); 143.5 (CTC4); 141.6, 141.53; 
139.1, 139.0 (CAr1, CAr4); 128.4, 128.2 (CAr2, CAr3); 126.3 (CTC5); 125.7 (CT5); 118.3 (CR5); 112.7 
(CR2); 100.5 (C1); 76.1 (C3); 75.6 (C5); 74.0 (CG3, CG7); 72.6 (CD1); 72.3 (C2, CD2); 71.99, 71.49 
(CL5, CL6); 70.8 - 69.5 (CG1, CG5, CG2, CG6, CL2, CL4); 68.8 (C4); 68.3 (C7, CL7); 65.3 (CL1); 64.9 
(CH2OH); 63.0 (C6); 62.3 (CG4, CG8); 51.5 (CL8, C8); 43.6 (CH2NH); 41.7 (CD4, CD5); 29.7 (CD3 or 
CD6), 29.0 (CD3 or CD6).  
 
MS (MALDI, matrix: sinapinic acid, solvent: MeOH): m/z calculated for [C262H351N36O88]+: 
5412.3; found: 5413.2.  
 
MS (ESI-HRMS): calculated for [C262H350N36O88]:5411.41100; found: 5411.42469 (after 
102030405060708090100110120130140150160170180
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deconvolution).  
 
[α]D 25: -1.7 (c = 0.51, MeOH). 
 
Synthesis of hexavalent glycodendrimer 2.45 
 
To a stirred solution of TIPS-2.5 (3.2 mg, 2.5 µmol, 1 eq.) in THF (200 µL), TBAF (1 M in THF, 
5.1 µL) was added under nitrogen atmosphere. After 1 h, TLC analysis (CH2Cl2:MeOH 9:1) 
showed that the desilylation reaction was complete. Then reagents were added as solutions in the 
following order: TBTA in THF (0.27 mg, 0.5 µmol, 0.2 eq., 100 µL of THF), CuSO4·5H2O in H2O 
(0.06 mg, 0.25 µmol, 0.1 eq., 100 µL of H2O), and sodium ascorbate in H2O (0.20 mg, 1.0 µmol, 
0.4 eq., 100 µL of H2O). The reaction mixture was stirred at RT, under nitrogen atmosphere and in 
dark for 10 min. Then 2.2 (13.3 mg, 5.6 µmol, 2.2 eq.) was added as solid. THF and H2O volumes 
were adjusted to 400 µL each. The reaction mixture was heated at 60 °C under microwave 
irradiation for 90 min. TLC analysis (CH2Cl2:MeOH 9:1) revealed total consumption of 2.5; mass 
analysis (MALDI, DHB or sinapinic acid matrix) confirmed that the reaction was complete. 
Quadrasil™-MP (S/Cu 30:1, 5 mg) was added to the reaction mixture, which was stirred for 10 
min, and then filtered off. The solvent was removed under reduced pressure and the resulting 
mixture was redissolved in MeOH and purified by size exclusion chromatography (Sephadex LH-
20, MeOH), obtaining 12 mg of pure 2.45 as a yellowish solid (yield 85 %).  
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1H NMR (400 MHz, CD3OD): δ 8.56 (s, 2H, HTC5); 7.92 (s, 6H, HT5); 7.82 (s, 2H, HR2); 7.28 – 
7.13 (m, 52H, HAr2, HAr3, HR5, HR10); 4.88 (br s, 6H, H1); 4.62 – 4.57 (m, 4H, HL8); 4.56 – 4.48 (m, 
36H, CH2OH, H8); 4.39 (s, 12H, HL1); 4.32 – 4.17 (m, 36H, CH2NH, HG1, HG5, HG9); 3.95 - 3.79 
(m, 46H, H2, H6a, HD2, H7, HL7, HG2, HG6, HG10); 3.75 - 3.61 (m, 42H, H6b, HD1, H3, HG3, HG7, HG11, 
HG4, HG8, HG12); 3.60 - 3.39 (m, 16H, H4, H5, HL5); 3.45 – 3.44 (m, 4H, HL6); 3.33 – 3.27 (m, 16H, 
HL2, HL4); 2.89 – 2.75 (m, 12H, HD4, HD5); 1.96 – 1.66 (m, 24H, HD3, HD6).  
13C NMR (100 MHz, CD3OD): δ 177.1, 176.8 (CONH); 146.3 (CT4); 143.7 (CTC4); 141.7, 139.2, 
139.2 (CAr1, CAr4); 128.6, 128.5, 128.3, 128.3 (CAr2, CAr3); 126.3 (CTC5); 126.0 (CT5); 119.3 (CR10, 
CR5); 113.5 (CR2); 100.6 (C1); 76.3 (C3); 75.7 (C5); 74.3, 74.3, 73.9 (CG3, CG7, CG11); 72.6, 72.4, 
72.3 (CD1, C2, CD2); 72.3 – 69.0 (CL5, CL6, CL2, CL4, CG2, CG6, CG10, CG1, CG5, CG9,); 69.0 (C4); 68.5 
(C7, CL7); 65.5 (CL1); 65.1 (CH2OH); 63.3 (C6); 62.6, 62.5, 62.5 (CG4, CG8, CG12); 51.7 (CL8, C8); 
43.9 (CH2NH); 42.0, 41.9 (CD4, CD5); 29.9 (CD3 or CD6); 29.2 (CD3 or CD6).  
 
MS (MALDI, matrix: sinapinic acid, solvent: MeOH): m/z calculated for [C278H370N36O94Na]+: 
5743.1; found = 5744.6; calculated for [C278H370N36O94]+: 5720.1; found = 5719.9.  
MS (ESI-HRMS): m/z calculated for [C278H370N36O94]+: 5716.52790; found = 5719.52543 (after 
deconvolution).  
 
[α]D 25: -8.1 (c = 0.22, MeOH). 
 
Synthesis of divalent glycodendrimer 2.46 
 
 
In a reaction vessel containing 2.3 (4 mg, 12 µmol, 1 eq.), reagents were added as solutions in the 
following order: TBTA in THF (1.3 mg, 2.4 µmol, 0.2 eq., in 68 µL of THF), CuSO4·5H2O in H2O 
(0.3 mg, 1.2 µmol, 0.1 eq., 22 µL of H2O) and Sodium Ascorbate in H2O (0.95 mg, 4.8 µmol, 0.4 
eq., 26 µL of H2O). The reaction mixture was stirred at room temperature, under nitrogen 
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atmosphere and in dark for 10 min. Finally 2.7 (19.1 mg 99.6 % w/w, 26.6 µmol effective, 2.2 eq.) 
was added as solid. THF and H2O volumes were adjusted to 250 µL each. The reaction was stirred 
at RT, under nitrogen and in the dark overnight. TLC analysis (CH2Cl2:MeOH 9:1) revealed total 
consumption of 2.3; TLC (CH2Cl2:MeOH:H2O 70:30:2.5) monitored the formation of a new polar 
species and the disappearance of another one having a slightly higher polarity relative to 2.7 
(probably corresponding to the monosubstituted intermediate). Quadrasil™-MP (S/Cu 6.3:1, 5 mg) 
was added to the reaction mixture, which was stirred for 10 min, and then filtered off. The solvent 
was removed under reduced pressure and the resulting mixture was redissolved in MeOH and 
purified by size exclusion chromatography (Sephadex LH-20, MeOH), obtaining 20 mg of 2.46 not 
pure. The remaining tetrabutylammonium salt was removed through automated reverse phase flash 
chromatography (C18, H2O with gradient of MeOH from 0 % to 100 %), obtaining 17 mg of pure 
2.46 as a white solid (yield 65 %). 
 
 
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0
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1H NMR (400 MHz, CD3OD): δ 8.58 (s, 2H, HTC5); 7.96 (s, 2H, HT5); 7.88 (s, 2H, HR2); 7.30 – 
7.15 (m, 16H, HAr2, HAr3); 4.89 (br s, 2H, H1); 4.62 (t, 4H, HL8, J = 4.9 Hz); 4.58 – 4.47 (m, 16H, 
H8, CH2OH, HL1); 4.29 (dd, 4.8 Hz, 12H, CH2NH, HG1, J = 13.2); 3.96 – 3.85 (m, 16H, HG2, H7, 
HL7, H2, HD2); 3.83 (d, 2H, H6a, J = 5.0 Hz); 3.74 (t, J = 3.6 Hz, 4H, HG4); 3.72 – 3.60 (m, 10H, HG3, 
H3, H6b, HD1); 3.58 – 3.48 (m, 12H, H5, HL1, HL2, H4); 3.45 – 3.36 (m, 8H, HL6, HL3); 2.89 – 2.71 
(m, 4H, HD4, HD5); 1.97 – 1.78 (m, 8H, HD3, HD6); 1.78 – 1.71 (m, 4H, HL5). 
13C NMR (100 MHz, CD3OD): δ 176.9, 176.7 (CONH); 150.9 (CR3); 145.8 (CTC4); 143.7 (CT4); 
141.6, 141.5, 139.1, 139.0 (CAr1, CAr4); 128.3, 128.2 (CAr2, CA3); 126.9 (CTC5); 126.1 (CT5); 121.0 
(CR1); 112.2 (CR2); 100.4 (C1); 76.2 (C3); 75.6 (C5); 73.7 (CG3); 72.6, 72.3, 72.1 (CD1, C2, CD2); 71.1 
– 70.2 (CL2, CL3, CG1, CG2); 69.3 (CG1); 68.88, 68.86 (CL4, CL6); 68.81(C4); 68.4 (C7, CL7); 64.9, 
64.9 (CH2OH, CL1); 63.1 (C6); 62.3 (CG4); 51.6, 51.5 (C8, CL8); 43.7, 43.6 (CH2NH); 41.8, 41.7 
(CD4, CD5); 30.9 (CL5); 29.7 (CD3 or CD6); 29.0 (CD3 or CD6).  
 
MS (ESI-HRMS): m/z calculated for [C102H142N16O34Na]+: 2157.97666; found: 2157.98424.  
 
[α]D 25: -3.2 (c 0.39, MeOH). 
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Synthesis of divalent glycodendrimer 2.47 
 
 
To a stirred solution of TIPS-2.4 (12 mg, 12.6 µmol, 1 eq.) in THF (300 µL), TBAF (1 M in THF, 
25.1 µL, 2 eq.) was added under nitrogen. After 1 h, TLC analysis (CH2Cl2:MeOH 9:1) showed that 
the desilylation reaction was complete. The CuAAC reagents were added as solutions in the 
following order: TBTA in THF (1.34 mg, 2.5 µmol, 0.2 eq., 75 µL of THF), CuSO4·5H2O in H2O 
(0.31 mg, 1.3 µmol, 0.1 eq., 25 µL of H2O) and Sodium Ascorbate in H2O (0.96 mg, 5.0 µmol, 0.4 
eq., 36 µL of H2O). The reaction mixture was stirred at room temperature, under nitrogen 
atmosphere and in dark for 10 min. Finally 2.7 (25.3 mg 99.6 % w/w, 28 µmol effective, 2.2 eq.) 
was added as a solid. THF and H2O volumes were adjusted to 400 µL each. The reaction was stirred 
at RT under nitrogen and in the dark overnight. TLC analysis (CH2Cl2:MeOH 9:1) revealed total 
consumption of 2.4; TLC (CHCl3:MeOH:H2O 70:30:2.5) revealed the presence of a single new 
species, together with a small amount of starting material 2.7. Quadrasil™-MP (S/Cu 5.8:1, 5 mg) 
was added to the reaction mixture, which was stirred for 10 min, and then filtered off. The solvent 
was removed under reduced pressure and the resulting mixture was redissolved in MeOH and 
purified by size exclusion chromatography (Sephadex LH-20, MeOH), obtaining 19 mg of 2.47 not 
pure. The remaining tetrabutylammonium salt was removed through automated reverse phase flash 
chromatography (C18, water with gradient of MeOH from 0 % to 100 %), obtaining 17 mg of pure 
2.47 as a yellow solid (yield 57 %). 
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1H NMR (400 MHz, CD3OD): δ 8.57 (s, 2H, HTC5); 7.98 (s, 2H, HTC); 7.86 (s, 2H, HR2); 7.26 – 
7.17 (m, 18H, HAr2, HAr3, HR5); 4.87 (br s, 2H, H1); 4.66 – 4.59 (m, 4H, HL8); 4.59 – 4.52 (m, 16H, 
H8, CH2OH, HL1); 4.35 – 4.29 (m, 4H, HG1); 4.29-4.25 (m, 8H, CH2NH); 4.26 – 4.21 (m, 4H, HG5); 
3.95 – 3.82 (m, 24H, HG2, HG6, H7, HL7, HD2, H2, H6); 3.78 – 3.73 (m, 4H, HG4); 3.73 – 3.69 (m, 4H, 
HG3 or HG7); 3.67 – 3.63 (m, 12H, HG8, HG3 or HG7, HD1, H3); 3.57 – 3.51 (m, 4H, H4, H5); 3.50 – 
3.48 (m, 4H, HL2 or HL3, HL4 or HL6); 3.44 – 3.34 (m, 4H, HL2 or HL3, HL4 or HL6); 2.86 – 2.71 (m, 
4H, HD4, HD5); 1.95 – 1.78 (m, 8H, HD3, HD6); 1.77 – 1.73 (m, 4H, HL5).  
13C NMR (100 MHz, CD3OD): δ 176.9, 176.7 (CONH); 155.4 (CR6); 150.5 (CR3); 145.8 (CTC4); 
143.5 (CT4); 141.6, 141.5, 139.1, 139.0 (CAr1, CAr4); 128.4, 128.2 (CAr2, CAr3); 127.1 (CTC5); 126.1 
(CT5); 122.2 (CR1); 118.3 (CR5); 114.6 (CR4); 112.9 (CR2); 100.3 (C1); 91.8 (CR7); 76.2 (C3); 75.6 
(C5); 74.1, 73.7 (CG3, CG7); 72.6, 72.3, 72.11 (CD1, C2, CD2); 71.1 – 70.2 (CL2, CL3, CG1, CG2, CG6); 
69.5 (CG5); 68.9 (CL4, CL3), 68.8 (C4); 68.4 (C7, CL7); 64.92, 64.87 (CH2OH, CL1); 63.1 (C6); 62.4, 
62.3 (CG8, CG4); 51.7, 51.5 (CL8, C8); 43.7, 43.6 (CH2NH); 41.8 (CD4, CD5); 30.9 (CL5); 29.7 (CD3 or 
CD6); 29.0 (CD3 or CD6). 
 
MS (ESI-HRMS): calculated for [C118H162N16O40]: 2443.11342; found: 2443.11450 (after 
deconvolution).  
 
[α]D 25: +3.9 (c 0.95, MeOH). 
 
Synthesis of divalent glycodendrimer 2.48 
 
 
To a stirred solution of TIPS-2.5 (12.4 mg, 10 µmol, 1 eq.) in THF (250 µL), TBAF (1 M in THF, 
20.0 µL, 2 eq.) was added under nitrogen atmosphere. After 1 h, TLC analysis (CH2Cl2:MeOH 9:1) 
showed that the reaction was complete. Then reagents were added as solutions in the following 
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order: TBTA in THF (1.06 mg, 2.0 µmol, 0.2 eq., 34 µL of THF), CuSO4·5H2O in H2O (0.25 mg, 
1.0 µmol, 0.1 eq., 17 µL of H2O) and Sodium Ascorbate in H2O (0.79 mg, 4.0 µmol, 0.4 eq., 30 µL 
of H2O). The reaction mixture was stirred at room temperature, under nitrogen atmosphere and in 
the dark for 10 min. Finally 2.7 (20.2 mg 99.6 % w/w, 22.3 µmol effective, 2.2 eq.) was added. 
THF and H2O volumes were adjusted to 300 µL each. The reaction was stirred at room temperature 
under nitrogen and in the dark overnight. TLC analysis (CH2Cl2:MeOH 9:1) revealed total 
consumption of 2.5; TLC (CH2Cl2:MeOH:H2O 70:30:2.5) monitored the formation of a new polar 
species and the disappearance of another one having a slightly higher polarity relative to 2.7 
(probably corresponding to the monosubstituted intermediate); mass analysis (MALDI, DHB 
matrix) confirmed that the reaction was complete. Quadrasil™-MP (S/Cu 7.5:1, 5 mg) was added to 
the reaction mixture, which was stirred for 10 min, and then filtered off. The solvent was removed 
under reduced pressure and the resulting mixture was redissolved in MeOH and purified by size 
exclusion chromatography (Sephadex LH-20, MeOH), obtaining 20 mg of 2.48 not pure. The 
remaining tetrabutylammonium salt was removed through automated reverse phase flash 
chromatography (C18, H2O with gradient of MeOH from 0 % to 100 %), obtaining 17 mg of pure 
2.48 as a yellow solid (yield 60 %). 
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1H NMR (400 MHz, CD3OD): δ 8.56 (s, 2H, HTC5); 7.98 (s, 2H, HT5); 7.85 (s, 2H, HR2); 7.28 – 
7.15 (m, 20H, HAr2, HAr3, HR5, HR10); 4.87 (br s, 2H, H1); 4.62 (t, 4H, HL8, J = 4.8 Hz); 4.57 – 4.51 
(m, 16H, H8, CH2OH, HL1); 4.34 – 4.29 (m, 4H, HG1); 4.29 – 4.20 (m, 16H, HG5, HG9, CH2NH); 
3.98 – 3.88 (m, 16H, H7 or HL7, HG2, HG6, HG10); 3.88 – 3.80 (m, 10H, H7 or HL7, HD2, H2, H6a); 
3.77 – 3.61 (m, 30H, HG4, HG3, HG7, HG11, HG8, HG12, HD1, H3, H6b); 3.59 – 3.51 (m, 4H, H4, H5); 
3.50 – 3.47 (m, 8H, HL2 or HL3, HL4 or HL6); 3.43 – 3.33 (m, 8H, HL2 or HL3, HL4 or HL6); 2.89 – 
2.70 (m, 4H, HD4, HD5); 1.93 – 1.80 (m, 8H, HD3, HD6); 1.78 – 1.69 (m, 4H, HL5).  
13C NMR (100 MHz, CD3OD): δ 176.9, 176.7 (CONH); 155.4, 154.9 (CR6, CR11); 150.5 (CR3); 
145.8 (CTC4); 143.5 (CT4); 141.6, 141.5, 139.1, 139.0 (CAr1, CAr4); 128.4, 128.4, 128.15 (CAr2, CAr3); 
127.1 (CTC5); 126.1 (CT5); 122.3 (CR1); 119.0 (CR5 or CR10); 118.2 (CR5 or CR10); 115.9 (CR4); 114.4 
(CR9); 112.8 (CR2); 100.3 (C1); 92.8, 91.7 (CR7, CR8); 76.2 (C3); 75.6 (C5); 74.1, 73.7 (CG3, CG7, 
CG11); 72.5, 72.3, 72.1 (CD1, C2, CD2); 71.1 (C19 or C20); 71.1 – 70.6 (CG2, CG6, CG10, CG5, CG1, CL2 
or CL3); 70.2 (CD2); 69.4 (CG9); 68.9 (CL4, CL6); 68.8 (C4); 68.4 (C7, CL7); 64.9, 64.9 (CH2OH, CL1); 
63.1 (C6); 62.4, 62.4, 62.3 (CG4, CG8, CG12); 51.7, 51.5 (CL8, C8); 43.7, 43.6 (CH2NH); 41.8 (CD4 or 
CD5); 41.7 (CD4 or CD5); 30.9 (CL5); 29.7 (CD3 or CD6); 29.0 (CD3 or CD6).  
 
0102030405060708090100110120130140150160170180
ppm
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MS (MALDI, matrix: sinapinic acid, solvent: MeOH): m/z calculated for [C134H183N16O46]+: 
2754.0; found: 2752.3.  
MS (ESI-HRMS): calculated for [C134H182N16O46]: 2751.23941; found: 2751.23567 (after 
deconvolution).  
 
[α]D 25: -4.6 (c = 0.33, MeOH). 
 
Synthesis of divalent glycodendrimer 2.49 
 
To a stirred solution of TIPS-2.5 (11.5 mg, 9.1 µmol, 1 eq.) in THF (200 µL), TBAF (1 M in THF, 
18.0 µL, 2 eq.) was added under nitrogen. After 1 h, TLC analysis (CH2Cl2:MeOH 9:1) showed that 
the desilylation reaction was complete. The CuAAC reagents were added as solutions in the 
following order: TBTA in THF (0.97 mg, 1.7 µmol, 0.2 eq., 50 µL of THF), CuSO4·5H2O in H2O 
(0.22 mg, 0.9 µmol, 0.1 eq., 50 µL of H2O) and Sodium Ascorbate in H2O (0.72 mg, 3.6 µmol, 0.4 
eq., 50 µL of H2O). The reaction mixture was stirred at room temperature, under nitrogen 
atmosphere and in dark for 10 minutes. Finally 1.9 (13.5 mg, 20.0 µmol, 2.2 eq.) was added. THF 
and H2O volumes were adjusted to 300 µL each. The reaction was stirred at RT, under nitrogen and 
in dark overnight. TLC analysis (CH2Cl2:MeOH 9:1) revealed total consumption of 2.5; TLC 
(CH2Cl2:MeOH:H2O 75:25:2.5) monitored the formation of a new polar species and the 
disappearance of another one having a slight higher polarity relative to 1.9 (probably corresponding 
to the monosubstituted intermediate). Quadrasil™-MP (S/Cu 8.3:1, 5 mg) was added to the reaction 
mixture, which was stirred for 10 minutes, and then filtered off. The solvent was removed under 
reduced pressure and the resulting mixture was redissolved in MeOH and purified by size exclusion 
chromatography (Sephadex LH-20, MeOH), obtaining 15 mg of 2.49 not pure. The remaining 
tetrabutylammonium salt was removed through automated reverse phase flash chromatography 
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(C18, H2O with gradient of MeOH from 0 % to 100 %), obtaining 11 mg of pure 2.49 as a yellow 
solid (yield 54 %). 
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1H NMR (400 MHz, CD3OD): δ 8.61 (s, 2H, HTC5); 7.84 (s, 2H, HR2); 7.28 – 7.13 (m, 20H, HAr2, 
HAr3, HR5, HR10); 4.90 (br s, 2H, H1); 4.68 – 4.61 (m, 4H, H8); 4.56 (d, J = 6.2 Hz, 8H, CH2OH); 
4.32 – 4.13 (m, 20H, CH2NH, HG1, HG5, HG9); 4.01 (t, 4H, H7, J = 4.8 Hz); 3.96 – 3.80 (m, 20H, 
HG2, HG6, HG10, H2, HD2, HG12); 3.78 – 3.61 (m, 28H, H6, HG3, HG4, HG8, HG7, HG11, HD1, H3); 3.60 – 
3.48 (m, 4H, H4, H5); 2.88 – 2.75 (m, 4H, HD4, HD5); 1.94 – 1.60 (m, 8H, HD3, HD6).   
13C NMR (100 MHz, CD3OD): δ 177.0, 176.7 (CONH); 155.4, 155.0 (CR6, CR11); 150.4 (CR3); 
143.5 (CTC4); 141.6, 139.1, 139.0 (CAr1, CAr4); 128.4, 128.3, 128.19, 128.15 (CAr2, CAr3); 127.0 
(CTC5); 122.4 (CR1); 119.1, 118.5 (CR5, CR10); 116.0, 114.4 (CR4, CR9); 112.8 (CR2); 100.3 (C1); 92.8, 
91.7 (CR7, CR8); 76.5 (C3); 75.5 (C5); 74.1 (CG3, CG7, CG11); 72.5, 72.4, 72.2 (C2, CD1, CD2); 71.0 - 
70.7 (CG2, CG6, CG10); 69.5, 68.9 (CG1, CG5, CG9, C7); 68.7 (C4); 65.0 (CH2OH); 63.0 (CG12); 62.4, 
62.4 (CG4, CG8); 62.3 (C6); 51.7 (C8); 43.6 (CH2NH); 41.8 (CD4, CD5); 30.0 (CD3 or CD6); 29.0 (CD3 
or CD6).  
 
MS (ESI-HRMS): m/z calculated for [C144H148N10O40Na2]2+: 1171.48194; found: 1171.47672.  
 
[α]D 25 : 1.7 (c = 0.75, MeOH). 
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Synthesis of hexavalent glycodendrimer 2.50 
 
O O O
O
O
O
O
N
N
N
NN
N
N
N
N
N
N
N
N
N
N
N N
N
D1
D5
D2D3
D4 D6
13
4
2
6
5
7
8
Ar4
Ar3
Ar1
Ar2
OHO
HO
OH
OH
O
H
N
O
O
HN
O
HO
HO
N
O
O
N
N
L1
L2
L3 L4
TC4
TC5
2.50
 
To a stirred solution of 2.24 (3.0 mg, 6.0 µmol, 1 eq.) in THF (50 µL), the CuAAC reagents were 
added as solutions in the following order: TBTA in THF (0.64 mg, 1.2 µmol, 0.2 eq., 50 µL of 
THF), CuSO4·5H2O in H2O (0.15 mg, 0.6 µmol, 0.1 eq., 24 µL of H2O) and sodium ascorbate in 
H2O (0.48 mg, 2.4 µmol, 0.4 eq., 50 µL of H2O). The reaction mixture was stirred at RT, under 
nitrogen atmosphere and in the dark for 10 minutes. Finally 1.9 (26.9 mg, 40.0 µmol, 6.6 eq.) was 
added. THF and H2O volumes were adjusted to 550 µL each. The reaction was stirred at RT, under 
nitrogen and in dark overnight. TLC analysis (CHCl3:MeOH:H2O 55:45:7.5) revealed the presence 
of a single new species. Quadrasil™-MP (S/Pd 11.4:1, 5 mg) was added to the reaction mixture, 
which was stirred for 10 minutes, and then filtered off. The solvent was removed under reduced 
pressure and the resulting mixture was redissolved in MeOH purified by size exclusion 
chromatography (Sephadex LH-20, MeOH), obtaining 21 mg of pure 2.50 as a white solid (yield 77 
%), with characterization data identical to those reported in Ref.12,17. 
 
1H NMR (400 MHz, CDCl3): δ = 7.95 (s, 6H, HTC5), 7.28 – 7.07 (m, 48H, HAr2, HAr3), 4.89 ( br s, 
6H, H1), 4.54 (s, 24H, CH2OH), 4.51 - 4.45 (m, 12H, H8), 4.44 (s, 12H, HL1), 4.28 - 4.20 (m, 24H, 
CH2NH), 3.95 - 3.80 (m, 30H, H2, H6a, HD2, H7), 3.73 - 3.61 (m, 18H, H6b, HD1, H3), 3.60 - 3.47 (m, 
12H, H4, H5), 3.38 (br s, 12H, HL2), 3.26 (br s, 4H, HL4), 2.89 – 2.78 (m, 12H, HD4, HD5), 1.93 –1.69 
(m, 24H, HD3, HD6). 
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Synthesis of monovalent control of glycodendrimer 2.49 
 
NO
NN
TC5
TC4
7
8
O
O
O
O
HO
OH
R1
R2
R3
R4
R5
R6
G1
G2
G3
G4
G5
G6
G7
G8
R7
O
O
O
HO
R8
G9
G10
G11
G12
R9
R10
R11
D1
D2
D3
D5
D6
D4
O
O
HO
OH
HO
HO
N
H
OHO
HN
O
HO
Ar1
Ar2Ar3
Ar4
O
OH
G13
G14
G15
G16
O
O
OH
G21
G22
G23
G24
O
O
HO
G17
G18
G19
G20
R18
R19
R20
R21
R22
R17R15
R16
R23
R12
R13
R14
 
To a stirred solution of TIPS-2.5 (6.4 mg, 5.0 µmol, 1 eq.) in THF (200 µL), TBAF (1 M in THF, 
10.0 µL, 2 eq.) was added under nitrogen. After 1 h, TLC analysis (CH2Cl2:MeOH 9:1) showed that 
the desilylation reaction was complete. The CuAAC reagents were added as solutions in the 
following order: TBTA in THF (0.53 mg, 1.0 µmol, 0.2 eq., 100 µL of THF), CuSO4·5H2O in H2O 
(0.12 mg, 0.5 µmol, 0.1 eq., 80 µL of H2O) and Sodium Ascorbate in H2O (0.40 mg, 2.0 µmol, 0.4 
eq., 80 µL of H2O). The reaction mixture was stirred at room temperature, under nitrogen 
atmosphere and in dark for 10 minutes. Finally 1.9 (2.7 mg, 4.0 µmol, 0.8 eq.) was added as solid. 
THF and H2O volumes were adjusted to 250 µL each. The reaction was stirred at RT, under 
nitrogen and in dark overnight. TLC analysis (CH2Cl2:MeOH 9:1) revealed total consumption of 
2.5; TLC (CH2Cl2:MeOH:H2O 75:25:2.5) monitored the formation of a new polar species (that 
MALDI MS analysis –DHB matrix- confirmed to be the expected product), together also with small 
amounts of divalent 2.49 and residual starting material. Quadrasil™-MP (S/Cu 15:1, 5 mg) was 
added to the reaction mixture, which was stirred for 10 minutes, and then filtered off. The solvent 
was removed under reduced pressure and the resulting mixture was redissolved in MeOH and 
purified by size exclusion chromatography (Sephadex LH-20, MeOH, 1 drop in 4 seconds), 
obtaining 2.3 mg of final compound (yield 28 %). 
 
Chapter 2 
148 
 
 
 
 
4
.7
0
2
.3
9
2
.8
1
2
3
.1
3
2
.8
6
1
3
.3
2
2
.2
1
1
4
.8
9
3
.8
5
2
.2
6
1
.9
0
6
.4
3
3
.8
9
1
.0
3
1
.0
0
1
.8
3
2
.8
1
3
.6
7
3
.7
0
3
.7
7
3
.9
2
4
.2
0
4
.2
4
4
.5
5
4
.5
7
4
.6
7
7
.1
2
7
.1
9
7
.2
4
7
.8
5
8
.6
3
1.01.52.02.53.03.54.04.55.05.56.06.57.07.5
ppm
0
10
20
30
40
50
60
70
80
90
100
110
120
130
140
150
f1
 (
p
p
m
)
Chapter 2 
149 
 
NO
NN
TC5
TC4
7
8
O
O
O
O
HO
OH
R1
R2
R3
R4
R5
R6
G1
G2
G3
G4
G5
G6
G7
G8
R7
O
O
O
HO
R8
G9
G10
G11
G12
R9
R10
R11
D1
D2
D3
D5
D6
D4
O
O
HO
OH
HO
HO
N
H
OHO
HN
O
HO
Ar1
Ar2Ar3
Ar4
O
OH
G13
G14
G15
G16
O
O
OH
G21
G22
G23
G24
O
O
HO
G17
G18
G19
G20
R18
R19
R20
R21
R22
R17R15
R16
R23
R12
R13
R14
 
 
1H NMR (400 MHz, CD3OD): δ 8.63 (s, 1H, HTC5), 7.85 (s, 1H, HR2), 7.31 – 7.09 (m, 12H, HAr2, 
HAr3, HR5, HR10, HR13, HR18, HR21), 4.71 – 4.64 (m, H8), 4.59 – 4.53 (m, 4H, CH2OH), 4.35 – 4.13 
(m, 16H, CH2NH, HG1, HG5, HG9, HG13, HG17, HG21), 4.07 – 3.98 (m, 2H, H7), 3.97 – 3.80 (m, 16H, 
HD2, H2, HG2, HG6, HG10, HG12, HG14, HG18, HG22), 3.79 – 3.60 (m, 26H, H6a, H6b, H3, HD1, HG3, HG7, 
HG11, HG15, HG19, HG23, HG4, HG8, HG16, HG20, HG24), 3.60 – 3.46 (m, 2H, H5, H4), 3.59 – 3.45 (m, 
3H), 2.90 – 2.73 (m, 2H, HD4, HD5), 1.96 – 1.72 (m, 6H, HD3, HD6). 
 
13C NMR (100 MHz, CD3OD): δ 177.01, 176.60 (CONH), 155.65, 155.45, 155.08, 154.97, 154.81 
(CR6, CR11 CR14, CR19, CR22), 150.72 (CR3), 143.74 (CTC4), 141.59, 141.53, 139.14, 138.92 (CAr1, 
CAr4), 128.38, 128.31, 128.19, 128.15 (CAr2, CAr3), 127.26 (CTC5), 122.43 (CR1), 119.86, 119.22, 
119.04, 118.64 (CR5, CR10, CR13, CR18, CR21), 116.23, 116.16, 115.67, 114.90, 114.44 (CR4, CR9, 
CR12, CR17, CR20), 112.31 (CR2), 100.31 (C1), 76.01 (C5), 75.55 (C3), 74.10 (CG3, CG7, CG11, CG15, 
CG19, CG23), 72.54 (C2), 72.36 (CD2), 72.15 (CD1), 71.26 – 70.55 (CG2, CG6, CG10, CG14, CG18, CG22, 
CG1, CG5, CG9, CG13, CG17, CG21), 69.22 (C7), 69.03 (C4), 64.88 (CH2OH), 63.01 (CG12), 62.55 – 
62.16 (C6, CG4, CG8, CG12, CG16, CG20, CG24), 51.45 (CG8), 43.67 (CH2NH), 41.95 (CD4, CD5), 25.56 
(CD3, CD6). 
 
MS (ESI-HRMS): m/z calculated for [C82H105N5O29Na2]2+: 834.83398; found: 834.83574.  
 
[α]D 25 : -16.4 (c = 0.1, MeOH). 
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3.1 Receptor-mediated internalization of antigens 
As stated in Chapter 1.1, antigen-presenting cells (APCs) recognize and capture antigens through 
their surface receptors. The recognition of antigens presented on APCs surface as Major 
Histocompatibility Complexes (MHC) by T lymphocytes activates the antigen-specific immune 
responses. When antigens are internalized by APCs and routed to acidic endosomes and lysosomes, 
they are presented to CD4+ T helper cells as MHC type II complexes. On the contrary, when they 
are internalized into early endosomes, they are then presented as MHC type I complex to CD8+ 
cytotoxic T cells.1  
Dendritic Cells are antigen-presenting cells recognizing a plethora of pathogens through their 
Pathogen Recognition Receptors, amongst which surface receptor DC-SIGN.2,3 Targeting DC-
SIGN with artificial selective ligands is a strategy to prevent pathogens binding to human cells, thus 
running so-called anti-adhesive therapies. Remarkably, also artificial compounds can induce DC-
SIGN internalization and can be routed to specific cellular organelles. Internalization of this kind of 
ligands can in principle stimulate an antigen-specific immune response. Knowing the fate of 
artificial compounds once internalized via DC-SIGN, it is possible to predict, evaluate and also 
modulate the type of activated immune response. 
 
3.1.1 DC-SIGN-mediated internalization of antagonists: examples in the literature 
In the literature, only a few examples of artificial ligands designed as DC-SIGN antagonists to 
prevent HIV infection were demonstrated to be internalized by cells expressing the DC-SIGN 
receptor. An explanation of the so small number of examples is that it is not possible to detect 
ligands inside cells if they are not fluorescent. Moreover, the label of ligands with fluorescent dyes 
can in principle affect their properties, at least in terms of toxicity and binding. 
In 2012, the group of Rojo reported mannose- and fucose- based nonavalent dendrimers labelled 
with the fluorescent dye BODIPY (Scheme 3.1) that are internalized by Dendritic Cells and routed 
to lysosomes.4 The fate of internalized glycodendrimers was investigated using flow citometry, 
labelling early endosomes and late endosomes/lysosomes with appropriate markers. 
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Scheme 3.1 Nonavalent glycodendrimers bearing mannose of fucose as sugar moieties and labelled with the fluorescent 
dye BODIPY (circled in black).4 
 
In the same year, the group of Penades evaluated the internalization of mannosylated gold 
nanoparticles labelled with FITC -fluorescein isothyocyanate- (Scheme 3.2) in immature Dendritic 
Cells.5 FITC-nanoparticles were found to be internalized into early endosomes. Internalization 
experiments were carried out using confocal microscopy, analysing the colocalization between the 
fluorescence signals of the gold nanoparticles and those of markers of cellular organelles.  
 
Chapter 3 
	   156 
 
Scheme 3.2 Mannosylated-gold nanoparticles labelled with the FITC (coloured as green).5 
 
Finally, the group of Kiessling showed that a non-carbohydrate glycomimetic compound based on 
Shikimic acid conjugated with BSA -bovine serum albumin- (Scheme 3.3) and then coupled with a 
fluorescent dye was internalized by Raji Cells expressing DC-SIGN.6  Authors also assessed the 
production of phosphor-JNK, a specific kinase involved in the dendritic cell maturation and the 
response to “danger” signals,7, when Raji/DC-SIGN cells were treated with the glycoprotein 
surrogate. This observation demonstrated the possibility of initiating immune signalling events by 
using DC-SIGN artificial binders. 
 
 
Scheme 3.3 Glycoprotein surrogate constituted by a Shikimic acid derivative connected to BSA and labelled with a 
fluorescent dye (not shown).6 
 
3.2 Goal of the assays 
Rod2, Rod3 and their derivatives are fluorescent molecules. We therefore decided to exploit their 
natural fluorescence to analyse their interaction with DC-SIGN and immature Dendritic Cells 
through fluorescence microscopy. PM26 (Scheme 3.4) was selected as target compound because of 
its higher biological activity in SPR and trans-infection competition assays (see Chapter 2.6). I 
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conducted all these experiments with the collaboration of B. Joosten visiting the group of Prof. A. 
Cambi at the Radboud University Medical Centre (Nijmegen, NL).   
 
	  
Scheme 3.4 Structure of compound PM26. Red sheres represent 1.9 ligand. 
 
3.3 Intrinsic fluorescence properties of PM26 compound 
Using a Perkin Elmer Fluorescence Spectrometer, the fluorescence properties of PM26 in Hank's 
Balanced Salt Solution (HBSS) were investigated. As shown in Figure 3.1, compound PM26 was 
found to have an excitation maximum of 372 nm and emission maximum of 425 nm in HBSS. Also 
a shoulder, probably corresponding to a second fluorophore, was observed. 
 
 
Figure 3.1 Excitation and emission spectra of 2.4 nM PM26 in HBSS. Also a shoulder of the main peak can be 
observed. 
 
PM26 emission in HBSS was found to decrease by decreasing the solution pH (Figure 3.2). This is 
probably due to protonation of the triazole moieties (pKa = 9.3) directly linked to the central rod. 
Remarkably, the decrease of fluorescence involved more the shoulder (450-460 nm) than the main 
peack (425 nm). Indeed, the ratio between the fluorescent intensity observed in the range 420-430 
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nm and the fluorescent intensity observed in the range 450-460 nm increased by decreasing the pH 
(i.e. 1.81 when pH = 7.8; 1.88 when pH = 5.4; 2.12 when pH = 3.1; 2.49 when pH = 1.2). This 
suggests that the second emission (450-460 nm) is more pH dependant than the first one (425 nm). 
 
 
Figure 3.2 Emission spectra of 13 nM PM26 in HBSS at different pH values. PM26 was excited at 372 nm. 
 
The observation of two emission bands is consistent with the detection of two fluorophores for 
compound PM31 in HBSS (Figure 3.3A). In that case, a first species absorbing at 376 nm and 
emitting at 426 nm (Figure 3.3B) and a second species absorbing at 392 nm and emitting at 450 nm 
were observed (Figure 3.3C). 
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Figure 3.3 A) Structure of PM31; blue spheres represent ligand 1.7. B) and C) Excitation and emission spectra of 4 nM 
PM31 in HBSS. 
 
The fluorescence of PM26 was investigated also in the presence of 4 % paraformaldehyde (PFA), 
which is the reagent of choice used for fixing cells for microscopy analysis. In these conditions, a 
completely altered emission spectrum was observed (Figure 3.4). 
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Figure 3.4 Emission spectra of 10 nM PM26 in HBSS alone and in the presence of 4 % PFA. PM26 was excited at 376 
nm. 
 
Finally, since microscopy analyses were conducted in the presence of specific fluorescent dyes, we 
recorded fluorescence spectra of PM26 in the presence of selected Ovalbumin absorbing at 647 nm 
(i.e. OVA 647). At least in this wavelength region, we excluded that PM26 emission is reduced by 
the presence of the dye (Figure 3.5). 
 
 
Figure 3.5 Emission spectra of 10 nM PM26 in HBSS alone and in the presence of 5 µg/mL or 20 µg/mL of OVA647. 
PM26 was excited at 376 nm. 
 
3.4 Evaluation of DC-SIGN subdomain targeted by PM26 
With the aim to investigate which is the preferential DC-SIGN region bound by PM compounds, 
the interaction between PM26 and two different DC-SIGN mutants was evaluated. Together with 
DC-SIGN wild type (DC-SIGN-wt), also DC-SIGN lacking the CRD domain (DC-SIGN-ΔCRD) 
and DC-SIGN lacking the tandem repeats in the extracellular neck region (DC-SIGN-ΔRep) were 
investigated. The amount of PM26 binding to the cell lines harbouring the wild type or the mutated 
DC-SIGN was then assessed by fluorescence microscopy.  
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3.4.1 Experimental 
CHO cells stably expressing DC-SIGN-wt, ΔCRD and ΔRep were established by LipofectamineTM 
2000 transfection. Cells plated on a 96-well plate were incubated with 100 µM PM26 in HBSS for 
30 min at room temperature. After thorough washing with HBSS, images were obtained using a 
commercial Leica DMI6000 epi fluorescence microscope with AFC equipped with a 63× oil 
immersion objective (HC PL APO 63x/1.40-0.60 OIL, Leica Microsystems) and filter system DAPI 
ET, GFP ET, DsRed ET and Y5 ET. PM26 was excited at 340-380 nm; emission was recorded at 
450-490 nm. 
Images were analyzed using Fiji software. 
 
3.4.2 Results and discussion 
Cell pictures are shown in Figure 3.6 and the calculated mean fluorescence values are listed in 
Table 3.1. Untransfected CHO cells were used as a negative control, both incubated with HBSS 
(obtaining no fluorescence signal) and with PM26 (Figure 3.6A). It was possible to observe that 
DC-SIGN-wt (Figure 3.6B) and ΔRep (Figure 3.6D) bound to fluorescent PM26, while the ΔCRD 
mutant did not show binding (Figure 3.6C).  
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Figure 3.6 Specificity control of DC-SIGN binding to PM26. Cells incubated with PM26 for 30 min at RT A) 
Negative control: untransfected CHO; B) CHO cells expressing DC-SIGN-wt; C) CHO cells expressing DC-SIGN-
ΔCRD; D) CHO cells expressing DC-SIGN-ΔRep.  
 
Entry Imaged cells Mean Fluorescence 
1 CHO + HBSS (negative control) 112.6 ± 16.7 
2 CHO + PM26 (negative control) 127.6 ± 14.2 
3 CHO-DC-SIGN-wt + PM26 134.5 ± 10.2 
4 CHO-DC-SIGN-ΔCRD + PM26 117.2 ± 5.2 
5 CHO-DC-SIGN-ΔRep + PM26 162.9 ± 12.9 
Table 3.1 Mean fluorescence of imaged cells calculated with ImageJ software. 
 
The weak fluorescence intensity variation among all tested cell lines depends on the weak intrinsic 
fluorescence of PM26, which is not optimal for this fluorescence assay. Moreover, PM26 
excitation, with an incident beam set to wavelengths proper of the UV light (340-380 nm) couldn’t 
be too strong, otherwise inducing both cellular autofluorescence and death.  
CHO + PM26 DC-SIGN-wt + PM26 
!CRD + PM26 !Rep + PM26 
A B 
C D 
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Fluorescence values increased from CHO cells treated with HBSS and the same cell line treated 
with PM26 (Table 3.1 Entries 1 and 2); nevertheless, they decreased again for cells carrying DC-
SIGN-ΔCRD incubated with PM26 (Table 3.1, Entry 4). The interaction between the compound 
and DC-SIGN-ΔRep was the strongest observed (Table 3.1, Entry 5), even higher than that detected 
between PM26 and DC-SIGN-wt (Table 3.1, Entry 3). All these results could also be indicative of a 
different level of DC-SIGN expression on CHO cells. Nonetheless, the large difference in binding 
between PM26 and DC-SIGN-ΔCRD (Figure 3.5C, Table 3.1, Entry 4) or DC-SIGN-ΔRep (Figure 
3.5D, Table 3.1, Entry 5) assessed the selective binding of PM26 with the CRD domain and not the 
neck domain on DC-SIGN. 
 
3.5 PM26 internalization 
3.5.1 PM26 internalization as a function of temperature 
PM26 internalization in immature dendritic cells (iDCs) was assessed through confocal microscopy 
using DiD oil (1,1’-Dioctadecyl-3,3,3’,3’-Tetramethylindodicarbocyanine Perchlorate) as a marker 
for the cellular membrane. The benefit of using confocal microscopy is the possibility to optically 
slice cellular samples (referred to z-sections), therefore observing both dorsal (top) and ventral 
(bottom) membranes and cross sections in the middle of the cells body.    
 
3.5.1.1 Experimental 
Human immature DCs were generated from peripheral blood monocytes of healthy donors8 and 
they were allowed attaching to a Labtek 8-chamber slides in serum free RPMI medium. Cells were 
incubated with 50 µM PM26 in HBSS both at 37 °C for 60 min and 4 °C for 20 min and washed 
with HBSS. Also cells incubated at 37 °C were stored at 4 °C for 20 min; indeed, at 4 °C cells were 
found to assume a round shape more suitable to perform z-sections. Cells were incubated with Did 
for 2 min at RT. After a washing step (HBSS), cells were fixed with 1 % paraformaldehyde for 20 
min at RT, washed and blocked with 100 mM glycine in TBS (Tris-buffered saline) for 10 min at 
RT. Confocal images were obtained in a sequential manner using a commercial Leica SP8 SMD-
WLL (Leica Microsystems) confocal microscope equipped with PMT and Hybrid detectors 
(HyD) and a 63× water immersion objective (HC PL APO 63×/1.2 W motCORR CS2, Leica 
Microsystems). PM26 was excited at 405 nm. Images were analyzed using Fiji software.	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3.5.1.2 Results and discussion 
In Figure 3.7, iDCs with labelled membrane (rendered as green) and treated with PM26 (rendered 
as red) are presented. For each sample, optical slices were recorded, imaging both external 
membrane and cross sections. Negative controls were included. 
 
 
Figure 3.7 Optical slices of immature Dendritic Cells incubated with 50 µM PM26 in HBSS and stained with Did as 
membrane marker Left: dorsal membrane; centre: middle of the cell body; right: ventral membrane. A) Negative 
control; B) iDCs were incubated with 50 µM of PM26 at 37 °C for 60 min; C) iDCs were incubated with 50 µM of 
PM26 at 4 °C for 20 min. Membrane is rendered as green; PM26 is rendered as red. 
 
PM26 incubated with DCs at 37 °C was internalized, reaching fluorescence levels 18 times above 
background levels, as shown in the cross section (Figure 3.7B, centre); dorsal and ventral labelled 
membrane clearly show the absence of compound PM26 on cells surface (Figure 3.7B left and 3.7B 
 Ventral Membrane 
A) Negative Control 
B) PM26        incubated at 37 °C for         60 min 
C) PM26         incubated at 4 °C for        20 min 
Dorsal Membrane! Cross section!
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right). Remarkably, no internalization occurred when compounds were incubated with iDCs at 4 °C. 
Since incubation of cells at 4 °C has been described as a method to inhibit energy-dependent 
internalization, 9,10 this result shows that PM26 internalization is mediated by active mechanisms, as 
receptor-mediated internalization is.  
Remarkably, also images recorded on live cells after 10 (Figure 3.8A) and 20 min (Figure 3.8B) of 
incubation at 37 °C showed internalization of PM26 in the middle of cell body. 
 
 
Figure 3.8 Optical slices of immature Dendritic Cells incubated with 50 µM PM26 in HBSS (rendered as red) and 
stained with Did as membrane marker (rendered as green). A) Incubation for 10 min at RT, live cells; B) Incubation for 
10 min at RT, live cells; C) Incubation for 60 min at 37 °C, fixed cells with 1 % PFA. 
 
3.5.2 PMs compounds localization within immature Dendritic Cells 
To study the internalization route of PM26 in iDCs and its localization in intracellular 
compartments, fluorescent ovalbumin (OVA 488), Cholera Toxin Subunit B (CTB 647), 
Transferrin (633) and Lysotracker Red (577) were used. OVA,11 Cholera Toxin12 and Transferrin13 
are internalized by cells and routed to early endosomes compartments; therefore, once labelled with 
fluorescent dyes, they can be used to visualize these specific organelles. LysoTracker Red is a red-
fluorescent dye for labelling and tracking acidic organelles in live cells, therefore it is selective for 
late endosomes and lysosomes. Also immature Dendritic Cells transfected with Rab5-GFP were 
used; Rab5 is a protein marker for early endosomes.  
To understand also whether PM26 follows DC-SIGN in the internalization route, a fluorescent 
antibody specific for DC-SIGN neck (DCN46 labelled first with biotin and then, as second step, 
with fluorescent streptavidin) was used. 
Remarkably, the common procedure in which cells, after first being incubated with the fluorescent 
compound, are fixed and permeabilized to let antibodies specifically label cellular organelles could 
not be used. Indeed, after fixation with paraformaldehyde (4 %) followed by membrane 
permeabilization and many washing steps, PM26 could not be detect any longer. The alteration of 
fluorescence in the presence of PFA (Figure 3.4) was probably combined also with physical 
A)! B)! C)!
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removal of the compound that, once internalized, can in principle dissociate from DC-SIGN and 
exit the cell from the permeabilized membrane. 
 
3.5.2.1 Experimental 
Human immature DCs were generated from peripheral blood monocytes of healthy donors8 and 
they were allowed to attach to a labtek 8 well chamber slides in serum free medium. Incubation 
with dyes was always followed by extensive washing steps with HBSS, unless otherwise stated. 
Cells were incubated with HBSS solution of 50 µM PM26 plus fluorescent OVA, CTB or 
transferrin for 10 min at room temperature. In the case of transfected cells with labelled Rab5, 
incubation lasted for 2 min at room temperature. Lysotracker was added and not removed, after 
incubating cells with PM26 for 20 min at room temperature or 2 hours at 37 °C. The colocalization 
experiments with labelled DC-SIGN were performed by incubating cells with DCN46 for 5 min at 
room temperature and, after washing steps, incubating cells with HBSS solution of 50 µM PM26 
plus Streptavidine-TxRed. Images were recorded through confocal microscopy (the apparatus was 
described in Paragraph 3.5.1) on live cells with at time chase dependent on experimental needs for 
setting the instrument up. The intracellular localization of PM26 and dyes was assessed over time 
by confocal microscopy. PM26 was excited at 405 nm, while dyes at the specific and required 
wavelength. In the case of experiment performed with OVA, CTB, transferrin, labelled Rab5 and 
labelled DC-SIGN, sequential images in time were recorded on the same cells. Unfortunately, the 
low staining intensity of CTB prevented us to draw conclusions. 
Images were analyzed using Fiji software. 
The degree of colocalization, expressed as PM26 fraction overlapping with the dye, was calculated 
with Manders’ coefficients with the JACoP plugin, using the automatic threshold.14 
 
3.5.2.2 Results and discussion 
Figure 3.9 shows selected immature dendritic cells presenting PM26 stain (rendered as red) 
superimposed to the dye (rendered as green), for each dye at different time points. Colocalized 
stains result in yellow spots. In each figure, colocalization coefficients are plotted as histograms 
(Figure 3.10).   
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Figure 3.9 Pictures were obtained through confocal microscope; PM26 is rendered as red and the dye is rendered as 
green. A) iDCs were incubated with PM26 (50 µM) plus OVA 488 in HBSS, for 10 min at RT and analysed at 
indicated time chase. B) iDCs were incubated with PM26 (50 µM) plus Transferrin in HBSS, for 10 min at RT and 
analysed at indicated time chase. C) iDCs were incubated with 100 µM PM26 for 20 min at RT or 120 min at 37 °C; 
after a washing step, LysoTracker was added and cells were analysed at indicated time chase. D) Cells transfected with 
anti Rab5 were incubated with 50 µM PM26 for 2 min at RT and analysed at indicated time chase. E) iDCs were 
incubated with DCN46 anti DC-SIGN-neck for 5 min at RT; after a washing step, PM26 (50 mM) plus Streptavdine in 
HBSS were added for 10 min at RT. Cells were analysed at indicated time chase.  
A) PM26 + OVA 488 
t = 8’ chase t = 10’ chase t = 15’ chase t = 20’ chase t = 30’ chase t = 40’ chase 
B) PM26 + Transferrin 633 
t = 8’ chase t = 10’ chase t = 15’ chase t = 20’ chase t = 30’ chase t = 40’ chase 
D) PM26 + Rab5 
t = 5’ chase t = 6’ chase t = 8’ chase t = 10’ chase t = 15’ chase t = 20’ chase 
C) PM26 + LysoTracker 577 
Incubation 30’ @ RT + 20’ chase Incubation 120’ @ 37 °C + 20’ chase 
E) PM26 + DC-SIGN (DCN46 vs neck) 
t = 6’ chase t = 8’ chase t = 10’ chase t = 15’ chase t = 20’ chase t = 30’ chase 
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Figure 3.10 Manders’ colocalization coefficients plot representing the fraction of PM26 overlapping with A) OVA 488, 
B) Transferrin 633, C) LysoTracker 577, D) Rap5, E) stained DC-SIGN. 
 
The colocalization of PM26 and OVA (Figure 3.9A, 3.10A) gradually increased in time, reaching 
higher values after 20 min of chase; subsequent decrease of colocalization could indicate that PM26 
and the dye follow different endocytic routs. On the contrary, PM26 colocalization with Transferrin 
(Figure 3.9B, 3.10B) remained almost constant over the time. The highest degree of colocalization 
was obtained between PM26 and LysoTracker, reaching coefficient values higher that 0.8 (Figure 
3.9C, 3.10C). Remarkably, Manders’ coefficients indicating the overlapping of PM26 with 
Lysosomes remained constant by increasing incubation times. Colocalization coefficients between 
PM26 and Rab5 (Figure 3.9D, 3.10D) gradually increased from 5 min to 6 min of chase, reaching 
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the highest value < 0.4, but then started decreasing; this low colocalization level could derive also 
from a not perfect stain of Rab5 obtained in transfected cells. 
The colocalization between PM26 and DCN46 was surprisingly low, reaching medium values only 
after 15 min chase (Figure 3.9E, 3.10E). Assuming that PM26 and DCN46 bind to different DC-
SIGN tetramers, even if the were both added to cells in saturation concentrations, it is possible that 
they have different internalization kinetics and/or they follow different endocytosis routes. Indeed, 
PM26 was demonstrated to bind DC-SIGN CRD (see Paragraph 4.4), and Tacken et al. 
demonstrated that DC-SIGN follows alternative endocytic pathways with prolonged residence in 
early endosomes when targeted via its neck region.15 It is therefore possible that PM26 and stained 
DCN46 are routed to the same organelles only after times chase > 15 min. It is also possible that a 
portion of DC-SIGN tetramers targeted by the antibody started to be internalized before the 
incubation with the compounds. Or, it is also possible that PM26 has others binding receptors 
expressed on Dendritic Cells, not being totally selective for DC-SIGN. Further experiments would 
be needed to clarify this point. 
 
3.6 Conclusions 
Analysing PM26 behaviour through fluorescence microscopy was rather challenging, since the 
compound doesn’t have the optimal fluorescence properties required for this kind of analysis. First 
of all, it has to be excited at a high energy wavelength (i.e. around 400 nm, Figure 3.1), which is 
detrimental for cells. Fixing cells with PFA was also not viable, since this alters Rod fluorescence 
(Figure 3.4); therefore, more difficult experiments on live cells were mainly conducted. Moreover, 
PM26 fluorescence decreases by increasing the acidity of the medium (Figure 3.3). Therefore, once 
internalised in acidic compartments (early endosomes pH = 6.5-6.0; late endosomes and lysosomes 
pH = 5.5-4.5), it is less probable to detect the compound. Nevertheless, it was possible to draw 
relevant conclusions. 
It was demonstrated that PM26 binds DC-SIGN selectively via the CRD, since it was not able to 
interact with CHO ΔCRD cells, whereas it did bind CHO cells lacking the neck domain (Figure 3.6). 
PM26 appeared to be internalized inside immature Dendritic Cells. Internalization seemed to be 
receptor dependant, since it didn’t occur at 4 °C (Figure 3.7). Internalization happened already after 
10 min of incubation at room temperature (Figure 3.8). The specific internalization route of PM26 
was also investigated, finding that this dendrimer ends up in lysosomes (Figure 3.10C). When an 
antigen is routed to lysosomes, it must do so through endosomes. Colocalization with Rab5 positive 
organelles, even if low (Figure 3.10D), demonstrated that PM26 transit via the early endosomes en 
route to the lysosomal compartments (Figure 3.8 and 3.9). These results suggest that PM26 could in 
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principle stimulate an immune response, and could therefore be used as adjuvant for vaccines. The 
immune response of iDCs associated to PM26 internalization will be further investigated by Dr. A. 
Berzi (Università degli Studi di Milano). 
The observed not very high colocalization level between PM26 and DC-SIGN (Figure 3.10E) 
demands for further investigation to evaluate both the kinetics associated to the internalization of 
DC-SIGN targeted with an anti-neck antiboby or with PM26 and the selectivity of PM26 for DC-
SIGN itself. SPR and trans-inhibition assays (Chapter 2.6) clearly demonstrated the affinity of 
PM26 to DC-SIGN, but it is also probable that other mannose-recognizing receptors expressed at 
the surface of DCs are able to bind it and to drive it inside cells.  
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Morphological behaviour of ROD-based 
glycodendrimers in aqueous solution 
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4.1 Introduction 
With the aim of interpreting the biological performances of synthesised compounds and to 
assess whether their biological activity depends on single molecules or aggregates, we studied their 
morphological behaviour in water and aqueous solutions. The hypothesis that they could form 
aggregates in water was related to their amphiphilic structure (Scheme 4.1A) and to their rather low 
solubility in water (Table 4.1). Derivatives based on the disaccharide 1.9 (Scheme 4.1B), bearing 
aromatic amide moieties, have a lower solubility with respect to those based on 1.7 (Scheme 4.1C).  
 
 
Scheme 4.1 A) Schematic representation of Rod derivatives, highlighting their amphiphilic structure; B) Structure of 
the disaccharide 1.7; C) Structure of the disaccharide 1.9. 
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Compound   
Name Ligand Valency 
Schematic 
structure 
Max 
Solubility 
Solvent 
PM25 1.9 6 
 
0.5 mM H2O 
1 mM SPR buffera + 4% DMSO 
PM26 1.9 6 
 
0.15 mM SPR buffera + 4% DMSO 
PM30 1.7 6 
 
≥ 5 mM SPR buffera 
PM31 1.7 6 
 
≥ 5 mM SPR buffera 
PM34 1.7 2  ≥ 5mM SPR buffer
a 
PM36 1.7 2  ≥ 5 mM SPR buffer
a 
Table 4.1 Solubility ranges of compounds PM25, PM26, PM30, PM31, PM34 and PM36. 
aSPR buffer consists of 25 mM Tris-HCl (pH 8), 150 mM NaCl, 4 mM CaCl2, 0.005 % P20. The full structure of the 
compounds is shown in Chapter 2. 
 
Water and/or buffer solutions of selected compounds were analysed through: 
- Surface Tension determination, to evaluate if micelles are formed 
- Diffusion-Ordered NMR Spectroscopy (DOSY), to determine particle size 
- Transmission Electron Microscopy (TEM), to determine particle size 
- Sedimentation Velocity Analytical Ultracentrifugation (SV-AUC), to determine particle size 
and homogeneity 
- Dynamic Light Scattering (DLS), to determine particle size and polydispersity 
Experimental sets up and results will be described in the following paragraphs. 
 
4.2 Background 
In the literature, a number of amphiphilic compounds that self-assemble in water has been 
described.  
The group of Percec reported the preparation of several libraries of amphiphilic Janus dendrimers 
that self-assemble into stable bilayer vesicles, referred to as dendrimersomes, as well as in other 
complex architectures.1 Janus dendrimers are non-symmetric dendrimers constituted by linking two 
chemically distinct dendritic building blocks, thus they terminate with two different functionalities. 
Amphiphilic Janus dendrimers bear a hydrophobic end and a hydrophilic one. Self-assembly was 
induced by injecting Janus dendrimers solutions (10-20 mg/mL in ethanol, tetrahydrofurane, 
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acetone or dimethylsulfoxide) in water or buffer. The nature of the spontaneous aggregates was 
evaluated through Cryogenic TEM (cryo-TEM), revealing that some Janus dendrimers form 
spherical dendrimersomes (Figure 4.1A) and that others, on the contrary, form polygonal (4.1B) or 
tubolar (4.1C) dendrimersomes and spherical (4.1D) or rod-like, tubular and helical micelles (4.1E).  
 
 
Figure 4.1 A) Spherical dendrimersomes B) Polygonal dendrimersomes C) Tubular dendrimersomes D) Spherical 
Micelles E) Rod-like, tubular and helical micelles.1 
 
Compound 4.1 (Figure 4.2A) was one of the dendrimers that aggregate as spherical 
dendrimersomes shown in Figure 4.1A. The size and the polydispersity of the aggregates were 
evaluated through Dynamic Light Scattering of their aqueous dispersion. With a final concentration 
of 0.1 mg/mL in water, 4.1 produces dendrimersomes with an average size of 233 nm and a 
Polydispersity Index (PDI) of 0.08 (0 corresponds to a perfectly uniform size distribution, Figure 
4.2B). The ability of its simpler derivative 4.2 (Figure 4.3A) to form dendrimersomes was 
confirmed also by modeling, showing that a vesicle is completely formed after 80 ns of simulation. 
Figure 4.3B and 4.3C represent the modelled dendrimersome and its cut-away view, respectively.  
 
A
D
B C
E
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Figure 4.2 A) Janus dendrimer 4.1; B) DLS evaluation of the size and the polydispersity of dendrimersomes formed by 
dispersing an ethanol solution of 4.1 in water (0.1 mg/mL final concentration in water).1 
 
 
Figure 4.3 A) Janus dendrimer 4.2; B) Computational simulation of a vesicle formed by compound 4.2; C) Cut-away 
view of the vesicle. Hydroxyls groups are represented in red, alkane chains in green.1  
 
The group of Prasad reported the formation of µm-sized aggregates by a pyrene-modified 
polyamidoamine dendrimer (PAMAM) 4.3 (Scheme 4.2) in dichloromethane solution.2 Aggregates 
were analysed by Scanning Electron Microscopy (SEM), revealing their doughnut-type shape 
(Figure 4.4). This morphological behaviour is probably driven by hydrophobic interactions between 
pyrene units and hydrogen bonds between dendrimeric regions.  
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Scheme 4.2 Pyrene-modified polyamidoamine dendrimer 4.3 (left) and its schematic representation where grey ovals 
represent pyrene units (right).2 
 
 
Figure 4.4 Schematic representation of a doughnut-shape aggregate in dichloromethane (left) and SEM images of 
aggregates (right).2 
 
Also carbohydrates can be the polar head of the amphiphilic compounds.  
Byung-Sun et al. reported that rod-coil amphiphiles bearing mannose at one end of the coil self-
assemble in water in a way that depends on the conformational behaviour of the monomer.3 
Compounds 4.4, 4.5 and 4.6 (Scheme 4.3) were synthesised and their morphological behaviour in 
water was assessed through TEM and DLS.  
 
 
Scheme 4.3 Amphiphilic rod-coil molecules 4.4, 4.5 and 4.6, together with their schematic representations were the rod 
is yellow and the coil is green.3 
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Compound 4.4 self-assembled into bilayer vesicular structures with a diameter of 40 nm, where 
mannose moieties cover external surfaces (Figure 4.5A, 4.5D, 4.6A). On the contrary, compound 
4.5 spontaneously aggregated as micelles with a diameter of 20 nm, which corresponds 
approximately twice the extended molecular length of 10 nm -calculated through modeling- (Figure 
4.5B, 4.5E, 4.6B). Probably this behaviour depends on a more cone-shaped -conformation of its 
coil moiety that would not be able to fill all of the internal volume of a bilayer. Finally, compound 
4.6 self-assembled into cylindrical micelles with, again, a diameter 20 nm long (Figure 4.5C, 4.5F). 
Probably, the strong π-π interaction among the aromatic moieties drives their preferential stacking.  
 
 
Figure 4.5 Up: schematic representation of the aggregates; down: TEM images of the aggregates. A,D) compound 4.4; 
B,E) compound 4.5; C,F) compound 4.6.3 
 
 
Figure 4.6 A vesicle (A) is formed when a bilayer sheet (down) turns and closes. B) In a typical micelle formed in 
aqueous solution, the hydrophilic external structure protects hydrophobic moieties from water. 
 
Amphiphilic Janus dendrimers can bear carbohydrates in their hydrophilic part; in this case, they 
can be referred to as Janus glycodendrimers. The group of Percec reported also the self-assembling 
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of 51 Janus glycodendrimers when their THF or ethanol solutions are injected into water or buffer.4 
Besides the formation of aggregates with rigid membranes (Figure 4.7A, 4.7B), denoted as solid or 
hard, fluid or soft glycodendrimersomes were formed (Figure 4.7C, 4.7D).  
 
 
Figure 4.7 Cryo-TEM images of A) solid lamellae; B) solid glycodendrimersomes; C) and D) soft 
glycodendrimersomes.4 
 
Authors remarked that Janus glycodendrimers with carbohydrate moieties attached via a 
tri(ethylene glycol) or tetra(ethylene glycol) spacer and with a 3,5-disubstituted linear or branched 
hydrophobic pattern (like compounds 4.7 and 4.8, Scheme 4.4) are more prone to form soft 
glycodendrimersomes with narrow molar mass and mass distribution (Scheme 4.4A, 4.4B). 
 
 
Scheme 4.4 Janus glycodendrimers 4.7 and 4.8 and cryo-TEM images of the soft glycodendrimersomes that they form 
when their THF or ethanol solutions are injected in water.4  
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Discotic amphiphilic molecules, such as 4.9 depicted in Scheme 4.5, can form self-assembled 
columnar polymers in water.5 4.10 bears hydrophobic cores and oligo(ethylene oxide) side chains to 
increase its water solubility. Disks’ stacking is driven by π-π hydrophobic interactions among 
aromatic cores; inter- and intramolecular hydrogen bonds fix the disks in a peculiar conformation. 
Aggregation was demonstrated by broad signals in the 1H-NMR spectra, a red shift of the UV-Vis 
spectra and a strong fluorescence intensity. Compound 4.10 (Scheme 4.5) was obtained decorating 
4.9 with mannose moieties; from a mixture of compounds 4.9 and 4.10 in water, a multivalent self-
assembled columnar glycol-polymers was obtained (Figure 4.8).6 Aggregation was confirmed by 
the high fluorescence of molecules. 
 
 
Scheme 4.5 Discotic compound 4.9 and its mannose derivative 4.10.5 
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Figure 4.8 Self-assembled columnar glycopolymer from compounds 4.9 and 4.10 in water.6 
 
4.3 Analysed molecules 
In Scheme 4.6 the structure of all tested compounds are reported. For every N-valent compound, 
only one sugar is depicted: the others are replaced with a sphere for a matter of simplicity. Red 
sphere represent ligand 1.9, blue sphere represent ligand 1.7. Along the following paragraphs, the 
reader should refer to this scheme for molecular structures.  
 
4.10
4.9
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Scheme 4.6 Structures of tested compounds. Blue spheres represent ligand 1.7, red spheres represent ligand 1.9 
 
4.4 UV-Visible absorption spectra 
UV-Vis spectra of selected compounds in water were recorded as a matter of characterization. Rod1 
derivatives (as PM25, PM30 and PM34) showed absorption peaks at 331 and 283 nm, whereas 
Rod3 derivatives (as PM26, PM31 and PM36) at 392 and 311 nm. The UV-Vis absorption 
spectrum of compound PM34 is shown as an example (Figure 4.9). Absorption bands are not sharp, 
but they are in agreement with those obtained from rods alone.7  
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Figure 9 UV-Vis spectra of PM34 2.010-4 M in water. 
 
Remarkably, no absorption peak shift was observed by varying sample concentration in the range 
10-3-10-5 M. In principle, this could have been characteristic of different aggregative process 
existing at different concentrations. 
 
4.5 Surface Tension determination 
Within a liquid, bulk molecules experience a zero-value net force, being attracted at the same level 
by other molecules in every direction (Figure 4.10B). On the contrary, molecules located at the 
surface of a liquid experiment a net inward force (Figure 4.10S), thus they tend to move inwardly. 
When molecules leave the surface, this shrinks. Surface tension is the work done by the system in 
such a reduction of the area.  
 
Figure 4.10 Non-equilibrate forces acting of a surface molecule (S) result in its inward movement; a bulk molecule (B) 
experiments a zero-value net force. 
 
From a thermodynamic point of view, surface tension γ can be defined as in Equation 4.1 and 
represents the surface excess free energy.8  
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Equation 4.1 Surface tension γ can be expressed as the increment in Gibbs free energy per unit increment in area. 
 
Surfactants, i.e. materials that bear a hydrophilic head and a hydrophobic tail, are able to reduce the 
surface tension of water by adsorbing at the interphase liquid-gas. Indeed tails, which are not 
soluble in water, prevent the surfactants movement towards the bulk, which would result from 
attractive forces exerted on the hydrophilic heads (Figure 4.11). 
 
Figure 4.11 A surfactant reduces the surface tension of a liquid by adsorbing at the interphase liquid-gas. 
 
By increasing surfactant concentration, amphiphilic molecules tend to accumulate at the surface of 
the liquid, thus gradually decrease surface tension. The Critical Micelle Concentration (CMC) is 
defined as the concentration at which surfactant molecules self-assemble in micelles. Micelles are 
spherical aggregates where the hydrophilic heads are in contact with the surrounding and the 
hydrophobic tails are protected in the micelle centre (Figure 4.6, see Paragraph 4.2). After the 
CMC, surface tension doesn’t decrease anymore because additional surfactant molecules go to 
micelles. 
It is possible to evaluate the critical micelle concentration of a species by measuring surface tension 
as a function of concentration. The De Noüy method and the pendant drop one are the ones used in 
this PhD thesis.  
With the De Noüy method, the surface tension of a liquid is determined in relation to the force 
needed for detaching a ring of wire from the surface (Figure 4.12A). Besides surface tension value 
γ, this force depends also on the ring weight W and its perimeter, which corresponds to the 
periphery of the surface detached (Equation 4.2, Figure 4.12B).  
 
Gas
Liquid
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Figure 4.12 A) Ring method; B) The upward force Ftot needed to detach the ring from the liquid surface depends on the 
weight Wring and the perimeter of the ring and on the surface tension γ of the liquid. R is ring’s radius. 
  
The pendant drop method relates the surface tension of a liquid to the shape of its drop hanging 
from a tip. As stated in Equation 4.3 (Figure 4.13), surface tension γ depends on the drop equatorial 
diameter de, on a factor H also depending on drop’s shape and on the difference in density Δρ 
between the liquid and the gas at the interphase; g is the gravitational constant.  
 
 
Figure 4.13 A) Pendant drop method; B) The surface tension γ is related on drop’s equatorial diameter de; H value also 
depend on drop’s shape; Δρ is the difference in density between the liquid and the gas at the interphase; g is the 
gravitational constant. 
 
4.5.1 Experimental 
Surface Tension analyses of selected compounds PM34, PM36, PM30, PM31 (Scheme 4.6, see 
Paragraph 4.2) solubilized in water at different concentrations were performed with the aim to 
evaluate the nature of the monomers and of possible the aggregates. These experiments were 
performed in collaboration with Dr. D. Meroni and Prof. S. Ardizzone, with the pendant drop 
method, which has the benefit of using only small quantities of the sample (≈ 100-200 µL). Using a 
Krüss EasyDrop instrument equipped with DSA1 software, the shape of the pendent drop was fitted 
using Equation 4.3 (Figure 4.13), which relates surface tension to the shape of the drop. A 
calibrated syringe was used.  
Force 
Liquid 
Ring 
Ftot =Wring + 4!R"
A B 
Equation 4.2 
A B 
Equation 4.3 
! =
!"gde2
H
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One selected sample was analyzed with both the pendant drop and the more common De Noüy 
methods, obtaining comparable results, thus demonstrating the good accuracy of the pendant drop 
one (γPendantDrop = 61.7 mN/m; γDe-Nouy = 58.0 mN/m). An analogous result was obtained also with 
milliQ water (γPendantDrop = 71.8 mN/m; γDe-Nouy = 72.8 mN/m). 
 
4.5.2 Results and discussion 
Analogous trends were found for all analysed compounds; as shown in Figure 4.14, surface tension 
decreases by increasing sample concentration. Remarkably, the classical behaviour of a surfactant 
that, after reaching the CMC, shows an almost invariant plateau was not observed. Nevertheless, the 
decrease of surface tension reflects the behaviour of molecules positively adsorbed at the interphase 
air-water, which is typical of molecules having two different functionalities. This corroborates the 
hypothesis that monomers have two explicit hydrophobic and hydrophilic functionalities. Surface 
tension tendency doesn’t unequivocally indicate the presence of aggregates. On the contrary it 
suggests that, increasing sample concentration, the amount of free monomer that adsorbs at the 
interphase increases as well. In principle, it could also happen that aggregates are formed and they 
are able to adsorb at the interphase and participate to the γ decrease; this behavior is not possible for 
a micelle-like material, but it can’t be excluded for more complex aggregates that can display 
hydrophobic moieties on their surface.  
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Figure 4.14 Surface tension trends of tested compounds PM30, PM31, PM34, PM36 and PM25 in water at 
concentrations indicated in the legends. Cartoons accompany compounds’ name; blue spheres correspond to 1.7, red 
spheres to 1.9.  
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Comparing the curves displayed by all compounds, it is possible to observe a general more rapid 
decay at low concentrations; then, surface tension still decreases, but slighter. The comparison 
between PM30 and PM31 or PM34 and PM36 shows the relevance of the rod in the surface 
tension trend: being the valency equal, at mM concentrations, Rod3 derivatives (PM31 and PM36) 
display lower γ values relative to corresponding Rod1 derivatives (PM30 and PM34). But 
remarkably, compounds bearing Rod1 are the ones that show a faster γ decrease at low 
concentrations. If this behaviour is slight for PM34 and PM36, PM31 starts having lower γ values 
than PM30 only at a concentration of ≈ 0.7 mM. Also the influence of the valency was assessed: 
being rod-length equal, hexavalent compounds (PM30 and PM31) have lower surface tension 
values than the corresponding divalent ones (PM34 and PM36). Thus, the presence of sugar 
moieties increases the ability of compounds to adsorb at the interphase. Interestingly, for 
compounds PM30 and PM34, bearing Rod1, the valency effect is more marked at lower 
concentrations. All together, these results corroborate also the hypothesis that the less soluble 
compounds are, the lower is their surface tension (PM31 less soluble than PM30; PM36 less 
soluble than PM34, PM31 less soluble than PM36, PM30 less soluble than PM34, Table 4.1, see 
Paragraph 4.1). The small concentration range in which PM25 was tested is due to its low solubility 
in water (Table 4.1, see Paragraph 4.1). This can explain also a trend that is difficult to compare 
with other ones.  
 
4.6 Diffusion-Ordered NMR Spectroscopy (DOSY)  
In the absence of a net force acting on them, molecular particles self-diffuse in solution (i.e. 
they randomly translate) as a consequence of their thermal energy; people refer to this motion as the 
Brownian one. The Stokes-Einstein equation (Equation 4.4) relates the self-diffusion coefficient (D) 
to the temperature T, the viscosity of the medium η and the species’ hydrodynamic radius RH 
(which is the radius of an hypothetical hard sphere that diffuses at the same rate as the species 
itself).  
 ! = !!!6!!!! 
Equation 4.4 Stokes-Einstein equation to calculate self-diffusion coefficients D; kb is the Boltzmann constant. 
 
Diffusion-Ordered NMR Spectroscopy (DOSY) is a technique able to evaluate the diffusion 
coefficients D of species in solution, and therefore their effective size.9  By the use of an NMR 
gradient, molecules can be spatially labelled, i.e. marked depending on their position in the sample 
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tube. If they move after this encoding during the subsequent diffusion time Δ, their new position 
can be decoded by a second gradient. The measured signal is the integral over the whole sample 
volume, and the NMR signal intensity is attenuated depending on the diffusion time Δ and the 
gradient parameters. A DOSY experiment provides a two-dimensional matrix where chemical shifts 
are plotted along one axis and diffusion coefficients are plotted along the perpendicular one. The 
diffusion information is obtained by an inverse Laplace transformation of the signal decay data.  
 
4.6.1 Experimental 
In collaboration with Dr. I. Guzzetti and Dr. D. Potenza of the University of Milano, DOSY 
experiments were performed on compounds PM34, PM36 and PM31 in water (Scheme 4.6, see 
Paragraph 4.3). 1.7 derivatives were chosen because of their higher solubility in water, that allows 
achieving millimolar concentrations suitable for NMR experiments. A range of concentrations from 
4 mM to about 1 mM was tested. NMR spectra were recorded on a Bruker AVANCE 400 MHz 
instrument, in D2O at 298 K. Diffusion coefficients were calculated with the module T1/T2 
relaxation of the software Topspin, using the diffusion coefficient of D2O (= 10-8 m2/s) as internal 
standard. For each species and each concentration, reported D values are an average of diffusion 
coefficients obtained for four different protonic regions. The Stockes-Einstein equation (Equation 
4.4) allowed the calculation of hydrodynamic radii.  
 
4.6.2 Results and discussion 
Representative DOSY NMR 2D spectra are reported in Figure 4.15, whereas diffusion coefficients 
D and corresponding hydrodynamic radii are listed in Table 4.2. 
 
 
Figure 4.15 DOSY NMR spectra of compounds (D2O, 298 K); diffusion coefficients are plotted along the vertical axis. 
A) PM34 3.9 mM; B) PM36 3.7 mM; C) PM31 4.0 mM. In the cartoons of tested molecules, blue spheres represent 
1.7. 
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Table 4.2 Concentrations of tested compounds, together with determined D and RH values; A) PM34, B) PM36, C) 
PM31. 
 
Obtained D and RH values can be associated with the dimension of monomeric species, as predicted 
by Molecular Dynamics simulations described in Chapter 2.5. Maxima and averaged gyration radii 
calculated for the three compounds are listed in Table 4.3. The gyration radius Gyradius, defined as 
the mass weighted average distance from the core of a molecule to each mass element in the 
molecule, can be compared with the hydrodynamic one in a first approximation. MD simulations 
were run for 25 ns in implicit solvent.   
  
 
Table 4.3 Maxima and averaged gyration radii of PM34, PM36 and PM31. MD simulations were run for 25 ns in 
implicit solvent.   
 
PM34 
Concentration (mM) D (m2/s) RH (nm) 
3.89 1.66E-10 1.05 
2.02 1.74E-10 1.00 
1.33 //// too diluted  
PM36 
Concentration (mM) D (m2/s) RH (nm) 
4.00 1.09E-10 1.60 
2.57 1.05E-10 1.66 
1.89 1.1E-10 1.59 
1.50 1.16E-10 1.51 
1.24 1.15E-10 1.52 
1.06 1.17E-10 1.49 
0.5 1.25E-10 1.40 
PM31 
Concentration (mM) D (m2/s) RH (nm) 
3.70 8.84E-11 1.98 
2.45 8.92E-11 1.96 
1.84 8.70E-11 2.01 
1.47 9.58E-11 1.82 
1.23 9.56E-11 1.83 
1.02 /// too diluted 
A B 
C 
!
Compound Rod length (nm) Max Gyradius (nm) <Gyradius> (nm) 
PM34 0.8 1.81 0.78 
PM36 2.2 2.32 0.97 
PM31 2.2 2.20 1.09 
!
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Being concentrations equal (3.85 ± 0.15 mM, Table 4.2), the smallest compound PM34 displayed 
the lowest RH value. By increasing the length of the rod from 1 to 3 units, as in PM36, RH value 
increased. This derives of course from bigger dimensions of PM36 relative to PM34. In PM31, the 
presence of trivalent dendrons at the two ends of the longest rod resulted in a further increase of the 
averaged hydrodynamic radius. It is apparent that the size of RH varies mostly with the length of the 
rod (50 % increase from PM34 to PM36) and less with the valency of the molecule (25 % increase 
from PM36 to PM31). This is also consistent with the results from MS simulations (Table 4.3), 
which suggests how these molecules fold over. In the range of concentrations studied, little or no 
variation of RH was observed.  
The trend of the RH values was reflected also in the shape of diffusion coefficients D. Indeed, the 
peak representing the diffusion coefficient of PM34 was sharp (Figure 4.15A), whilst it become 
broader by shifting to PM36 and PM31. Less compact peaks associated to PM36 and PM31 could 
also indicate the presence of several subpopulations in dynamic equilibrium. 
 
4.7 Transmission Electron Microscopy Imaging 
Transmission Electron Microscopy is able to image soft matter that is hit by a focused beam of 
accelerated electrons. Since the sample has a thickness < 200 nm, it doesn’t absorb electrons, 
whereas it transmits or scatters them. The number of transmitted electrons depends on the solid 
materials that they encounter; they finally hit a fluorescent screen that gives a brighter or darker 
image back. When electrons are transmitted, the image is bright, whereas in the regions where 
electrons have been diffracted by the sample, the image is dark. There is also a range of greys in 
between depending on how electrons have interacted with and scattered by the sample. From this, it 
is possible to obtain information with regard to the sample morphology.  
In a conventional TEM instrument, sample is dried over a grid, while, performing a Cryo-TEM 
analysis, sample molecules are frozen in thin ice.  
High-resolution transmission electron microscopy (HR-TEM) uses not only the transmitted, but 
also the scattered beams to create images; in that way, resolution can be improved. 
Generally, being the resolution of a microscope defined as the distance between two details just 
separable from one another and directly proportional to the wavelength of the incident beam, the 
use of accelerated electron allows for a higher resolution relative to using photons. TEM resolution 
can be lower that 1 nm. 
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4.7.1 Experimental 
Conventional TEM images were collected using a Zeiss LEO 912ab Energy Filtering TEM 
operating at an acceleration voltage of 120 kV, equipped with a CCD-BM/1K system. The sample 
preparation was carried out according to the following procedure. Aliquots of 5 µL of the PM 
solution were deposited onto Formvar-coated 300 mesh copper grids. The excess of water was then 
gently blotted using filter paper. When solvent evaporated at room temperature under atmospheric 
pressure for 24 h, the grids were negatively stained by 1.5 wt % phosphertungstic acid. The 
aggregates diameters were measured by the EsiVision software (Olympus,Germany). 
CryoTEM imaging was executed at -178 °C using a Zeiss LIBRA 200FE-HR TEM, operating at 
200 kV. Images were processed by means of the iTEM TEM Imaging Platform software 
(Olympus). The mean diameter and size distribution of the observed aggregates were obtained from 
a statistical analysis of over 270 aggregates. 
 
4.7.2 Results and discussion 
TEM images of compounds PM31 and PM26 were acquired. Images obtained with HR-TEM are 
displayed in Figure 4.16. Compound PM31 at a millimolar concentration resulted in a solid layer 
that couldn’t be analysed (Figure 4.16A). On the contrary, lower concentrations of both PM31 
(Figure 4.16A-C) and PM26 (Figure 4.16D-F) revealed the presence of big aggregates, 
characterized by radii of hundreds of nanometres, together with a plethora of other smaller 
materials. In Figure 4.16, big aggregates are circled in red, whereas smaller observable objects are 
circled in green. Stained samples (i.e. Figure 4.16C and 4.16F) allowed for better evaluation of the 
shape of aggregates, which displayed less dense and softer cores. In principle, they could be 
vesicles or doughnut-like materials. 
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Figure 4.16 TEM images of A) PM31 2.2 mM; B) PM31 0.22 mM; C) PM31 0.22 mM stained; 
D) PM26 mM 0.11 mM; E) PM26 0.11 mM stained; F) PM26 0.011 mM stained.  
Big aggregates are circled in red, small meterials are circled in greed. In the cartoons of tested molecules, blue spheres 
represent monovalent ligand 1.7 and red spheres represent monovalent ligand 1.9. 
 
In order to assess if the drying step of sample preparation for the HR-TEM analyses induced the 
formation of aggregates, cryo-TEM images were also acquired on selected PM26 (0.11 mM, Figure 
4.17). Again, hundreds-nanometre-sized aggregates were detected and still smaller objects can be 
observed in the background. Also this assays suggests that aggregates have a vesicle or doughnut-
like shape (Figure 4.17). In Table 4.4, the diameter distribution calculated over 271 observed 
species is reported. 
 
500 nm 
A B 
200 nm 
C 
200 nm 
D E 
200 nm 500 nm 
F 
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Chapter 4 
	   195 
 
Figure 4.17 Cryo-TEM images of PM26 0.11 mM. Big aggregates are circled in red, small meterials are circled in 
green. In the cartoons of the tested molecule, red spheres represent 1.9. 
 
Mean 30 nm 
Median 22 nm 
Standard deviation 25 nm 
Minimum 8 nm 
Maximum 164 nm 
Mode 15 nm 
Table 4.4 Diameter distributions calculated over 271 aggregates, from Cryo-TEM images of PM26 0.11 mM. 
 
Remarkably, the presence of aggregates was detected at a concentration in which the presence of 
micelles was excluded by surface tension determination analyses (see Paragraph 4.5).  
 
4.8 Sedimentation Velocity Analytical Ultracentrifugation Analysis 
Sedimentation velocity (SV-AUC) is an analytical ultracentrifugation method that measures at 
which rate molecules move in response to a high centrifugal force generated in a centrifuge. In a 
classical SV-AUC experiment, an initially uniform solution is placed in a cell; when the cell rotates, 
the solute sediments towards the bottom of the cell. By measuring the sample absorbance as a 
function of radial position and at different times, it is possible to evaluate how it changes within the 
cell. A sharp boundary between the depleted region (top) and the region that contains molecules is 
formed and, during time, it moves away from the meniscus (Figure 4.18). For molecules obeying to 
the Lambert-Beer Law, concentrations at given times can be evaluated measuring absorbance. 
Normally, the absorbance of every sample is corrected by the absorbance of the solvent alone, 
which is placed as reference in a second sector of the cell. The rate of movement of the boundary, 
200 nm 100 nm 
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which is referred to as sedimentation rate, can be measured and it provides values of the 
sedimentation coefficients of the species in solution. Sedimentation coefficient (s) can be expressed 
as in Equation 4.5; it depends on the molar mass of the solute M, its partial specific volume ! and 
its frictional coefficient f, which is linked to the shape and size of the particle.  
 ! = !(1− !!)!"  
Equation 4.5 Sedimentation coefficient s. The buoyant effective molar mass !(1 − !!) of a particle corrects the 
effects of buoyancy, i.e. the upward force exerted by the fluid that is displaced by the particle itself. ! is the partial 
specific volume of the solute, i.e. the volume that each of its grams occupies in solution. ρ is the density of the solvent. f 
is proportional to the resistance exerted by the fluid to the solute motion, calculated according to Equation 4.6. N is the 
Avogadro’s number. 
 
f =6πηRH 
Equation 4.6 Frictional coefficient f. It is related to solvent viscosity η and the particle hydrodynamic radius RH. RH can 
be expressed as a function of the radius of the anhydrous volume, Rmin, which can be derived from M and !. 
The frictional ratio f/fmin = RH/Rmin, and it is related to the particle anisotropy and hydration. 
 
Therefore, SV-AUC can provide information about both the molecular mass and the shape of 
particles.10  
 
 
Figure 4.18 Principle of SV-AUC measurement.11 
 
4.8.1 Experimental 
In collaboration with V. Porkolab, A. Le Roy, Prof. F. Fieschi and Prof. C. Ebel, I performed SV-
AUC analyses on selected glycodendrimer solutions at the Institut de Biologie Structurale of 
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Grenoble (FR). Compounds PM25, PM26, PM30 and PM31 (Scheme 4.6, see Paragraph 4.2) were 
chosen to evaluate the effect of both the rod length and the sugar moiety on the eventual formation 
of aggregates. All compounds were solubilised in the same buffer used for the SPR inhibition 
studies (see Chapter 2.6.1), which consists of 25 mM Tris-HCl (pH 8), 150 mM NaCl, 4 mM CaCl2, 
0.005 % P20 ± 4 % DMSO. It should be noted that P20 is a surfactant, used in the SPR experiment 
to reduce non-specific interactions between the analytes and the surface; therefore, in principle, it 
could decrease also the non-specific aggregating interactions among glycodendrimers. In order to 
evaluate the role of the solvent, the behaviour of PM25 and PM30 was investigated also in water. 
Several concentrations were tested, trying to approach also compounds’ solubility limits (see 
Paragraph 4.1). All tested samples are listed in Table 4.5. 
Sedimentation velocity experiments were performed in a Beckman XL-1 analytical ultracentrifuge 
using an AN-50 Ti rotor (Beckman instruments), at 20 °C. The experiments were carried out at 
42000 rpm, using 50 µL, 100 µL or 430 µL samples in, respectively, two-channels 0.15 cm, 0.3 cm 
or 1.2 cm path length centerpieces equipped with sapphire windows (Nanolytics GmbH).  
The absorption was monitored at several wavelengths, depending on the absorption behaviour and 
concentration of solutions, as indicated in Table 4.5, with, typically, radial steps of 0.003 cm and 
time between profiles on a given sample of 20 min.  
 
Compound Solvent Conc [mM] λ  monitored [nm] Optical Path Length [mm] 
PM25 Buffer 0.5 295 12 
PM25 Buffer 0.1 295 12 
PM25 H2O 0.15 295 12 
PM26 Buffer 0.15 391 1.5 
PM26 Buffer 0.05 391 3 
PM26 Buffer 0.015 391 12 
PM30 Buffer 3.5 295 1.5 
PM30 Buffer 1.0 295 1.5 
PM30 H2O 3.5 295 1.5 
PM30 H2O 1.0 295 1.5 
PM31 Buffer 1.0 280 1.5 
PM31 Buffer 0.5 280 1.5 
PM31 Buffer 0.01 391 12 
Table 4.5 Experimental conditions of tested compounds in SV-AUC assays. 
Buffer = 25 mM Tris-HCl (pH 8), 150 mM NaCl, 4 mM CaCl2, 0.005 % P20 ± 4 % DMSO. 
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The distribution of sedimentesion coefficients, c(s), were obtained from sedimentation velocity 
profiles, fitting with the SEDFIT software12 the following parameters: meniscus, bottom and 
frictional ratio f/fmin. The partial specific volume (ῡ) of tested glycodendrimers was considered to be 
0.7 cm3g-1, as a mean between values for hexose sugars and glycerol (about 0.6 and 0.77 cm3g-1).13 
Using SEDNTERP software, the viscosity and the density of the buffers were estimated to be, 
respectively, 0.01023 poise and 1.005 gcm-3. Water viscosity (0.01002 poise) and density (0.998 
gcm-3) are tabulated. For a regularization procedure, a confidence level of 0.68 was used. In Figure 
4.19A, sedimentation velocity profiles of an illustrative sample are reported; in Figure 4.19B, the 
table of fixed and fitted parameters to obtain the c(s) values are reported. The c(s) curve in Figure 
4.19C represents the distribution of sedimentation coefficients, s, expressed in Svedberg (S) units; 
the area under each peak is directly related to the absorption, and, therefore, quantifies the 
sedimenting species. 
 
 
Figure 4.19 A) sedimentation velocity profiles; B) fixed and fitted parameters by Sedfit software; C) sedimentation 
coefficients distribution. 
 
4.8.2 Results and discussion 
Obtained sedimentation coefficients were compared with theoretical values expected if the 
molecules moved as globular compact particles in solution (therefore, having a frictional ratio f/fmin 
of 1.25), having RH predicted values as reported in Table 4.6.  
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Compound 
Predicted RH values (nm) 
Monomer Dimer Trimer Tetramer 
PM30 1.28 1.61 1.84 2.03 
PM31 1.34 1.69 1.94 2.13 
PM25 1.40 1.77 2.02 2.23 
PM26 1.46 1.84 2.10 2.31 
Table 4.6 Predicted RH values of compounds PM30, PM31, PM25 and PM26 both in water and in buffer. Values were 
calculated using f/fmin = 1.25 and ῡ = 0.7 cm3g-1. 
Buffer = 25 mM Tris-HCl (pH 8), 150 mM NaCl, 4 mM CaCl2, 0.005 % P20 ± 4 % DMSO. 
 
For all of the tested compounds in both buffer and water, prevalent species had sedimentation 
coefficients (s) very close to that of the corresponding monomers, revealing that they are mainly in 
the monomeric state (Figure 4.20.1, 4.20.2, 4.20.3, 4.20.4,). In a few cases, also sedimentation 
coefficients corresponding to dimeric, trimeric or tetrameric species were observed, but their 
amounts were always less than the 10 % on the total moles. 
 
Figure 4.20.1: c(s) distributions in sedimentation profiles of PM30 solutions rotating at 42000 rpm at 298 K. In the 
table, experimental sedimentation coefficients, sexp, are compared to expected theoretical ones, stheo, for globular 
particles. 
aExpected for a globular particle of RH = 1.28 nm; bExpected for a globular particle of RH = 1.84 nm; cExpected for a 
globular particle of RH = 2.03 nm. Buffer = 25 mM Tris-HCl (pH 8), 150 mM NaCl, 4 mM CaCl2, 0.005 % P20. In the 
cartoon of tested molecule, blue spheres represent 1.7. 
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PM30 Slow Boundary Fast Boundary 
Conc. [mM] sexp stheo,monoa sexp stheo,trimerb  stheo,tetramer
c 
3.5 in Buffer 0.75 (100 %) 0.77 /// 1.60 1.94 
1.0 in Buffer 0.78 (100 %) 0.77 /// 1.60 1.94 
3.5 in H2O 0.81 (82 %) 0.80 1.91 (10 %) 1.66 2.01 
1.0 in H2O 0.81 (100 %) 0.80 /// 1.66 2.01 
PM30 
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Figure 4.20.2: c(s) distributions in sedimentation profiles of PM31 solutions rotating at 42000 rpm at 298 K. In the 
table, experimental sedimentation coefficients, sexp, are compared to expected theoretical ones, stheo, for globular 
particles. aExpected for a globular particle of RH = 1.34 nm; bExpected for a globular particle of RH = 1.94 nm. 
cExpected for a globula particle of RH = 2.13 nm. Buffer = 25 mM Tris-HCl (pH 8), 150 mM NaCl, 4 mM CaCl2, 0.005 
% P20. In the cartoon of tested molecule, blue spheres represent 1.7. 
 
 
Figure 20.3: c(s) distributions in sedimentation profiles of PM25 solutions rotating at 42000 rpm at 298 K. In the table, 
experimental sedimentation coefficients, sexp, are compared to expected theoretical ones, stheo, for globular particles. 
aExpected for a globular particle of RH = 1.40 nm; bExpected for a globular particle of RH = 1.77 nm; cExpected for a 
globular particle of RH = 2.02 nm. Buffer = 25 mM Tris-HCl (pH 8), 150 mM NaCl, 4 mM CaCl2, 0.005 % P20 + 4 % 
DMSO. 
In the cartoon of tested molecule, red spheres represent 1.9. 
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PM31 Slow Boundary Fast Boundary 
Conc. [mM] sexp stheo,monoa stheo,dimerb sexp stheo,trimerc 
1.0 in Buffer 1.2 (100 %) 0.85 1.25 /// 1.76 
0.5 in Buffer 1.2 (100 %) 0.85 1.25 /// 1.76 
0.01 in Buffer 0.94 (98 %) 0.85 1.25 1.70 (2 %) 1.76 
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PM25 Slow Boundary Fast Boundary 
Conc. [mM] sexp stheo,monoa sexp stheo,dimerb stheo,trimerc 
0.5 in Buffer 0.81 (96 %) 0.93 1.66 (4 %) 1.47 1.93 
0.1 in Buffer 0.74 (100 %) 0.93 /// 1.47 1.93 
0.08 in H2O 0.95 (100 %) 0.96 /// 1.53 2.00 
PM25 
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Figure 20.4: c(s) distributions in sedimentation profiles of PM26 solutions rotating at 42000 rpm at 298 K. In the table, 
experimental sedimentation coefficients, sexp, are compared to expected theoretical ones, stheo, for globular particles. 
aExpected for a globular particle of RH = 1.46 nm; bExpected for a globular particle of RH = 1.84 nm; cExpected for a 
globular particle of RH = 2.10 nm. Buffer = 25 mM Tris-HCl (pH 8), 150 mM NaCl, 4 mM CaCl2, 0.005 % P20 + 4 % 
DMSO. In the cartoon of tested molecule, red spheres represent 1.9. 
 
These results highlight that PM26 is the species more prone to form dimers, which exist in 
increasing amount (6 % - 11 %) at all tested concentrations (15 µM to 150 µM). This is in 
agreement with the fact that PM26 is the compound less soluble in aqueous solutions. 
In Table 4.7, frictional ratios f/fmin obtained after the fitting process are listed; practically no 
differences were obtained by varying the solvent. It is possible to observe that 1.7 derivatives, with 
an averaged f/fmin=1.31 for PM30 and 1.32 for PM31, behave similarly to globular compact 
particles in solution. On the contrary, 1.9 derivatives PM25 (averaged f/fmin =1.54) and PM26 
(averaged f/fmin=1.60) have less compact shapes. However, the interpretation of these results is 
limited because they depend on the input on the partial specific volume of the compounds, for 
which we’ve considered only a default constant value.  
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PM26 Slow Boundary Fast Boundary 
Conc. [mM] sexp stheo,monoa sexp stheo,dimerb stheo,trimerc 
0.15 in Buffer 1.05 (88 %) 1.00 1.78 (11 %) 1.59 2.08 
0.05 in Buffer 1.02 (92 %) 1.00 1.78 (7 %) 1.59 2.08 
0.0,15 in Buffer 0.83 (94 %) 1.00 1.51 (6 %) 1.59 2.08 
PM26 
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Compound Solvent Conc [mM] Fitted f/fmin 
PM25 Buffer 0.5 1.55 
PM25 Buffer 0.1 1.50 
PM25 H2O 0.15 1.57 
PM26 Buffer 0.15 1.61 
PM26 Buffer 0.05 1.60 
PM26 Buffer 0.015 1.58 
PM30 Buffer 3.5 1.36 
PM30 Buffer 1.0 1.25 
PM30 H2O 3.5 1.33 
PM30 H2O 1.0 1.33 
PM31 Buffer 1.0 1.42 
PM31 Buffer 0.5 1.31 
PM31 Buffer 0.01 1.23 
Table 4.7 Frictional ratios obtained by fitting sedimentation velocity profiles; partial specific volume (ῡ) was fixed at 
0.7 cm3g-1. Buffer = 25 mM Tris-HCl (pH 8), 150 mM NaCl, 4 mM CaCl2, 0.005 % P20 ± 4 % DMSO. 
 
Interestingly, except in one case, a loss of absorption was observed when the ultracentrifuge was 
speeded up from 3000 to 42000 rpm, as shown in Table 4.8. This suggests that a portion of samples 
exists as large aggregates that are pelleted at high rotational speed. If this assumption is true, it is 
possible to say that, when large aggregates exist in solution, they can be removed by centrifugation. 
Remarkably, Rod1 derivatives (PM25 and PM30, Table 4.8) displayed a higher loss of absorption 
compared to Rod3 derivatives (PM26 and PM31, Table 4.8). Being the Rod equal, 1.9-derivatives 
seemed to have a higher amount of aggregates that precipitate (compare PM25 and PM26 with 
PM30 and PM31, Table 4.8); this can be related to their lower solubility in aqueous solutions. 
Solvent (water or buffer) didn’t seem to affect material precipitation.  
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Absorption Variation (%) 
PM30 
 
3.5 mM Buffer 
(λ = 295 nm) 
1.0 mM Buffer 
(λ = 295 nm) 
3.5 mM H2O 
(λ = 295nm) 
1.0 mM H2O 
(λ = 295 nm) 
- 17% - 23% + 8% - 22% 
PM31 
 
1.0 mM Buffer 
(λ = 280 nm) 
0.5 mM Buffer 
(λ = 280 nm) 
  
- 14% - 5%   
PM25 
 
0.5 mM Buffer 
(λ = 295 nm) 
0.1 mM Buffer 
(λ = 295 nm) 
0.08 mM H2O 
(λ = 295 nm) 
 
- 32% - 24% - 24%  
PM26 
 
0.15 mM Buffer 
(λ = 391 nm) 
0.05 mM Buffer 
(λ = 391 nm) 
0.015 mM Buffer 
(λ = 391 nm) 
 
- 17% - 19% - 11%  
Table 4.8 Absorption variation (%) of tested samples speeding the rotor up from 3000 to 42000 rpm. If variation is 
positive (+), absorption increases; if variation is negative (-), absorption decreases. In the cartoons of tested molecules, 
blue spheres represent 1.7 and red spheres represent 1.9. Buffer = 25 mM Tris-HCl (pH 8), 150 mM NaCl, 4 mM 
CaCl2, 0.005 % P20 ± 4 % DMSO. 
 
4.9 Dynamic Light Scattering Analysis 
The electric field associated to a beam of light that hits matter induces a polarization of electrons in 
the molecules. Molecules become therefore a new source of light and they scatter light, i.e. they re-
emit light in all directions. When molecules are experiencing a Brownian motion, the intensity I of 
the light scattered by an ensemble of particles varies in time, in a way related to their size.  
A Dynamic Light Scattering (DLS) device irradiates the sample with a laser beam and, through a 
detector and digital correlator, measures the intensity fluctuations of the scattered light during the 
time. The correlation function G(τ) of the signal I(t), which is expressed as in Equation 4.7, allows 
for the determination of diffusion coefficients D of particles in solution (Figure 4.21).14  
 ! ! =< ! ! ∙ !(! + !) > 
Equation 4.7 Correlation function of the signal I(t). 
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Figure 4.21 A) In a Dynamic Light Scattering assay, a digital correlator measures the variation of the intensity I of the 
scattered light in time; B) intensity variations are evaluated through the correlation function G(τ). 
 
Indeed, for a system of identical particles, G(τ) takes the simple form of a single exponential 
relaxation: G(τ) ≈ exp(-τ/τc) with τc = 1/(2Dq2), where q is the scattering vector, dependent on light 
wavelength and on the angle at which scattered light is collected; in practice, it corresponds to the 
inverse of the lengthscale at which particle rearrangement takes place producing dephasing of light 
and intensity fluctuations. It is possible to take polydispersity of the sample into account with slight 
modifications of the reported functional form (see below Equation 4.8). 
With the previously seen Stokes-Einstein equation (Equation 4.4, see Paragraph 4.6) it is thus 
possible to calculate the hydrodynamic radius of the scattering species.  
It should be noted that the intensity of the scattered light is proportional to the 6th power of RH. This 
makes DLS highly sensitive to detect minor amounts of aggregates and less sensitve to monomeric 
species. 
 
Preliminary DLS assays had been conducted at the Institut de Biologie Structurale (Grenoble, with 
Prof. C. Ebel) using a Dynapro Nanostar (Wyatt technology, Santa Barbara, CA, USA). Both 
monomers and aggregates had been detected (Figure 4.22). Because of the much higher intensity 
scattered by aggregates, they dominate the intensity distribution. However, it was possible to extract 
the corresponding mass distribution, which is dominated by monomers. Results are not very 
accurate, since we considered approximate inputs (Rg model = sphere and dn/dc = 0.15, i.e. 
differential index of refraction associated to carbohydrates). Nevertheless, aggregates clearly 
appeared to represent only a small percentage of the molecules in solution. In the following sections 
we focus on their characterization. 
 
Time !  
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Figure 4.22 Size distributions extracted from DLS experiment for PM26 on a Dynapro Nanostar. Tested concentration 
was 0.15 mM in buffer (25 mM Tris-HCl (pH 8), 150 mM NaCl, 4 mM CaCl2, 0.005 % P20 + 4 % DMSO). 
 
4.9.1 Experimental 
Dynamic light scattering measurements were performed in collaboration with Dr. G. Zanchetta 
(University of Milano) on a ST100 Scitech Instruments apparatus. Data reported here were 
collected at a scattering angle of 90 °, corresponding to scattering vector q ~ 0.022 nm-1. 
Obtained correlation functions were fitted with Equation 4.8 using OriginPro8.5 software. 
 ! = !! +   !!( !!!)! 
Equation 4.8 Equation used to fit the correlation functions. G(τ) is the correlation function. 
 
The fitting allowed extrapolating the τc and α parameters. From τc values, it was possible to 
calculate the diffusion coefficient D of the scattering species. The stretching exponent α can give an 
estimate of the polidispersity of the system (when α = 1, the single exponential decay is recovered, 
corresponding to a monodispersed system). 
Finally, using the Stoke-Einstein Equation 4.4, the RH of species in solution can be determined.  
PM26 0.15 mM in Buffer 
!
Density Distribution Radius (nm) % Intensity % Mass 
Peak 1 1.351 0.9 95.2 
Peak 2 510.905 99.1 4.8 
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Compounds were tested at different concentrations; before dissolution, compounds were filtered 
through a PTFE filter 0.45 µm, then lyophilized and re-solubilized in a filtered solvent (water or 
buffer, i.e. 25 mM Tris-HCl (pH 8), 150 mM NaCl, 4 mM CaCl2, ± 4 % DMSO). 
 
4.9.2 Results and discussion 
All the samples at all concentrations displayed a single (stretched) exponential decay of the 
correlation function, indicating a monomodal particle size distribution. No evidence was found for a 
fast decay of the correlation function associated to the presence of free monomers, probably 
because of their weak scattered intensity. On the contrary, for all tested compounds, hundreds 
nanometer-sized aggregates were detected. The width of Gaussian distribution reported in Figure 
4.23 corresponds to the largest value between the polydispersity estimated from the stretching 
exponent or from cumulant analysis of correlation functions and standard deviation are due to 
sample/measurement variability. Remarkably, no evidence was found for depolarized scattering 
signal, which would be expected from anisotropic assemblies. The polidispersity indication and the 
isotropic shape of the aggregates are in line with what we have observed in TEM images (see 
Paragraph 4.7). 
Characteristic distributions for the tested compounds at different concentrations are reported in 
Figure 4.23. 
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Figure 4.23 Size distributions extracted from DLS experiments for PM compounds at various concentrations	   
(indicated in the panels). In the cartoons of tested molecules, blue spheres represent 1.7 and red spheres represent 1.9. 
 
In the case of PM30, PM31, PM25 and PM26 tested at a concentration with the same order of 
magnitude of their limit of solubility (1710-4 M, 110-3 M, 4.710-4 M, 1.210-4 M, see Table 4.1 
for comparison), bigger species with RH = 250, 150, 500 and 250 nm respectively were observed, 
probably corresponding to incipient precipitating materials. Otherwise, RH didn’t remarkably 
change varying the concentration. Interestingly, Rod1 derivatives (PM30 and PM34) showed the 
presence of larger aggregates relative to molecules containing Rod3 (PM34 vs PM36 and PM30 vs 
PM31). This is consistent with the observation, made by the AUC assays, that Rod1 subset lost 
higher percentages of absorption by speeding the rotor up from 3000 to 42000 rpm respect to the 
corresponding Rod3 one (PM25 vs PM26 and PM30 vs PM31, see Paragraph 4.8).  
0 200 400 600
0.000
0.005
0.010
0.015
0.020
p 
(R
h)
R
h
 (nm)
 0.468E-4 M
 0.946E-4 M
 4.7E-4 M
PM25 
100 200 300 400
0.00
0.01
0.02
0.03
0.04
p(
R
h)
R
h
 (nm)
 1.7E-4 M
 3.4E-4 M
 17E-4 M
PM30 
0 200 400
0.000
0.002
0.004
0.006
0.008
0.010
0.012
0.014
p(
R
h
)
R
h
 (nm)
 3.2E-4 M
 26E-4 M
PM34 
0 20 40 60 80 100
0.00
0.02
0.04
0.06
0.08
p(
R
h)
R
h
 (nm)
 22E-4 M
PM36 
PM31 
PM26 
1.2E-4M 
Chapter 4 
	   208 
The morphological behaviour of PM31 at 0.62 mM was tested also at 40 °C, revealing that 
temperature doesn’t affects significantly the size of the aggregates. Testing PM31 at the same 
concentration both in water and in buffer also gave comparable results. 
With the aim of confirming the nature of the aggregates and that they can be eliminated through 
centrifugation, DLS analysis of PM31 1 mM in water was performed before and after 
centrifugation. Different aliquots of the solutions were centrifuged for 1 h, 13 h or 40 h at 4000 
rpm. Interestingly, already after 1 h, the intensity signal associated with aggregates decreased by 
about 50 %. Also the mean RH shrank, probably because the bigger components of the Gaussian 
curve were removed first. I(t) and RH kept decreasing by increasing the duration of the 
centrifugation reaching a plateau after a few hours. Remarkably, neither the intensity nor the 
hydrodynamic radius increased by stocking the 40 h-centrifuged sample for 4 weeks at 4 °C, 
indicating that, once removed, aggregates don’t form anymore in these conditions. Results are 
reported in Figure 4.24A and Figure 4.24B and Table 4.9.  
An analogous experiment was conducted also on PM26 0.12 mM, but it was not possible to 
interpret results due to very low intensity values associated also to the pre-centrifuge sample, which 
didn’t allow for a reliable fit of the correlation function. 
 
 
Figure 4.24 A) Intensity and B) RH variations as a consequence of the centrifugation (4000 rpm) of PM31 1 mM in 
H2O. 
 
Centrifugation time (h) Intensity (a.u.) RH (nm) 
0 4579.2 ± 1591.2 164.9 ± 10.2 
1 2230.1 ± 732.7 135.1 ± 11.1 
13 803.9 ± 233.0  109.0 ± 13.9 
A B 
RH (t) variations I (t) variations 
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40 1257.8 ± 317.8 102.6 ± 13.9 
40* 1210.5 ± 261.3 87.9 ± 2.6 
Table 4.9 Intensity and RH values vary as a consequence of the centrifugation (4000 rpm) of PM31 1 mM in H2O. 
Values were obtained as a mean of two different measurements of the scattered light both at Θ = 90 °C with respect to 
the incident laser beam. * Sample stored at 4 °C for 4 weeks after 40 h of centrifugation. 
 
The loss of signal was investigated also through UV-Visible analyses. After centrifugation, the 
supernatant (65 µL) of the sample was separated through a syringe from the supposed pelleted-
containing solution (30 µL). As reported in Tables 4.10 and 4.11, after centrifugation lower 
absorption values were associated to supernatant solutions; in the case of PM31, this was consistent 
with an increase of the absorption in the pellet solution. Through these analyses, pelleted samples 
were found to be only a small percentage (< 10 %) of the overall solution. These absorbance 
variations are in line with those recorded through the spectrophotometer of the Analytical 
Ultracentrifugation machine (Table 4.8). 
 
Table 4.10 PM31 1 mM was tested through UV-Vis spectroscopy before and after centrifugation (40 h). Equal aliquots 
of the sample before the centrifugation and after the centrifugation (both supernatant and pellet) were diluted 1:10 
before conducting the analysis.  
Initial concentration 1 mM 
Abs391 pre 3.124 
Abs391 post_supernatant 3.034 (-3 %) 
Abs391 post_pellet 3.162 (+ 12 %) 
Abs315 pre 2.437 
Abs315 post_supernatant 2.222 (- 9%) 
Abs315 post_pellet 2.561 (+ 5 %) 
 
Table 4.11 PM26 0.12 mM was tested through UV-Vis spectroscopy before and after centrifugation (13 h). After the 
centrifugation, only the supernatant was analysed, because the amount of the pellet (≈ 30 mM) was to low.  
Initial concentration 0.12 mM 
Abs391 pre 1.406 
Abs391 post_supernatant 1.291 (- 8%) 
Abs315 pre 0.716 
Abs315 post_supernatant 0.692 (- 3%) 
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4.10 Conclusions 
DOSY NMR and SV-AUC analyses allowed to observed that the prevailing species in solution is 
monomeric for all tested compounds. Similarly, preliminary DLS examination of PM26 confirmed 
that the mass distribution is dominated by monomers. Nevertheless, AUC revealed a loss in 
absorption by speeding the rotor up from 3000 to 42000 rpm, suggesting that there is a portion of 
the compounds that exists in an aggregate morphology and that pellets by centrifuging the sample. 
This aggregate material could be what was observed by TEM and Cryo-TEM and also by DLS 
analyses. In this last case, hundreds nanometer-size aggregates were clearly detected, their size not 
really being related to the concentration of sample, the temperature, the kind of ligand nor the 
length of the rod. DLS and UV-Vis analyses were used to validate the assumption that aggregates 
precipitate after centrifugation. DLS conducted on PM31 1 mM in water revealed a loss of intensity 
of the aggregate (- 50 %) already after 1 h of centrifugation. Recording samples absorptions of 
PM31 1 mM and PM26 0.12 mM in water before and after centrifugations revealed a 3-8 % 
reduction of absorption and therefore concentration, after centrifugation. These last results seem to 
confirm that a big portion (> 50 %) of aggregates can be removed through centrifugation and that 
aggregates represent only a small percentage (< 10 %) of the sample. Since the size of aggregates is 
not affected by temperature nor concentration, it is reasonable to assume that they are a portion of 
molecules that have failed to dissolve. Indeed, supernatant solutions removed after 40 h of 
centrifugation retain ≥ 90 % of the UV-Vis absorption intensity and do not show any new aggregate 
formation after 4 weeks at 4 °C. The tendency of the samples to pack together was shown also by 
the detection of dimers, trimers and tetramers through AUC, even if in very low amount. PM26, 
which is the less soluble compound among the synthesised ones (solubility limit ≈ 150 µM), formed 
the biggest aggregates (RH = 200 nm, detected through DLS) and the highest amount of dimers (≈ 
10 %, detected through AUC). 
Obtained results prompted us to conclude that all these compounds exert their biological activity as 
DC-SIGN binders and HIV-1 trans-infection inhibitors mainly as monomers. This hypothesis is 
supported by the fact that big aggregates should not be able to deeply affect the trend of obtained 
IC50 values. Indeed, even if the morphology of aggregates could in principle depend on the 
monomers, their resulting size and shape could not be related to the trend of IC50 variation, which 
was deeply size- and valency-dependant. Moreover, SPR experiments were always conducted 
centrifuging the sample before the analysis, thus removing at leas a considerable amount of 
aggregates. In parallel, trans-infection inhibition assays were conducted by dissolving the samples 
in DMSO, and then by diluting the resulting solution with the biological buffer; this way of 
solubilisation should be, in principle, more efficient.  
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Even if the formation of aggregates was found to be negligible for the biological activity of 
compounds, which still is their fundamental application, we wanted to evaluate their nature. TEM 
analyses suggest that they are similar to doughnut-shaped materials or to perforated vesicles. 
Surface tension analysis excluded the formation of micelles. Future computational analysis will be 
performed with the aim to evaluate which forces among monomers could drive the aggregation 
mechanism and predict possible structures.   
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DC-SIGN vs Langerin: synthesis of 6-amino-
pseudo-dimannosides 
 
  
Chapter 5 
	  
 
	  
215	  
5.1 Langerin 
As stated in Paragraph 1.3.1, Langerin is a C-type lectin expressed by a subset of Antigen 
Presenting Cells (APCs); it is specific for mannose or related sugars (e.g. glucose and fucose) that 
show two adjacent hydroxyl groups free to chelate Ca2+ ions in the carbohydrate recognition 
domain (CRD) of the protein.1 Langerin is involved in the recognition and degradation of HIV-1 
virus,2 which probably happens in subdomains of the endosomal compartments named Birbeck 
granules.3 Since Langerin has an efficient role against HIV virus, anti-adhesive therapeutic 
strategies, aimed to use artificial ligands to antagonize DC-SIGN or other receptors involved in HIV 
infection, must not target Langerin. In this Ph.D. project, DC-SIGN is the target of ad hoc 
synthesised ligands (see Chapter 2); the design and synthesis of ligands that bind DC-SIGN but not 
Langerin is mandatory. A rational approach for producing selective ligands takes into account the 
morphology of the receptors binding sites and aims to synthesise ligands that have higher affinity 
for the one targeted and lower or no affinity for the others. In previous studies, we have already 
shown that our current lead, ligand 1.9, is rather selective for DC-SIGN vs Langerin.4Errore. Il segnalibro 
non è definito. However, since multivalency can increase the affinity even of weak ligands, refinement 
of the monovalent antagonist seems to be the most practical way to control the selectivity issue. In 
order to do so, in the course of my thesis we have explored some structural modifications of 1.7 and 
1.9, based on diffractional analysis of the lectin structures.  
The extracellular domain of Langerin consists of a neck region and a CRD; coiled-coil structures in 
the neck regions lead to the formation of trimers where the three carbohydrate recognition domains 
are spaced by a distance of 41.5 Å (Figure 5.1A; in Figure 5.1B tetrameric DC-SIGN ECD is shown 
for comparison). Stabilizing interactions occur among neck regions, but also between the neck of 
one monomer and the CRD of another one and between two adjacent CRDs.5 
 
 
Figure 5.1 A) Trimer of Langerin (a truncated version); blue spheres represent Ca2+ ions.5 B) Tetramer of DC-SIGN (a 
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truncated version); orange spheres represent Ca2+ ions.6 
 
A unique feature of Langerin with respect to DC-SIGN is the presence of two positively charged 
lysine residues (Lys 299 and Lys313) in its binding site.7 
Screening the glycan array of the Consortium for Functional Glycomics, the group of Weis 
demonstrated that 50 µg/mL of fluorescently-labelled Langerin significantly binds only high 
mannose oligosaccharides, few structures with terminal 6-sulfated galactose residues and the blood 
group B epitope (Galα1-3(Fucα1-2)Gal) (Figure 5.2).  
 
 
Figure 5.2 Ability of fluorescent Langerin to bind oligosaccharides. Ligands that gave highest signals are identified and 
reported as coloured bars. 
 
The same group solved the crystal structure of monomeric Langerin CRD bound to various 
carbohydrate ligands. Manα1-2Man-containing compounds preferentially bind Langerin CRD with 
the 3-OH and 4-OH groups of the non-reducing end, leaving the 2-OH group free to form hydrogen 
bonds with Lys299. In that case, both chains extended either from the reducing end or from the 6- 
position of the nonreducing end can be accommodated. The reducing end can then form extra 
contacts with the protein (Figure 5.3A). The interaction between Langerin and 6-SO4-Gal is 
remarkable, since Langerin binds galactose more weakly than mannose and fucose.1 This 
interaction is driven by the SO42- group that forms salt bridges with Lys299 and Lys 313. These 
charge-charge interactions can therefore compensate the absence of hydroxyl groups properly 
oriented to chelate Ca2+ ions (Figure 5.3B). The blood group B epitope binds Langerin with the 
equatorial 2-OH and 3-OH groups of the fucose moiety; the 4-OH group forms hydrogen bonds 
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with the Lys299 (Figure 5.3C). The non-reducing galactose residue is involved in other interactions 
with the protein, while the central one is positioned away from the binding site (Figure 5.3D).  
 
 
Figure 5.3 Interactions between oligosaccharides and the monomeric Langerin CRD. Carbohydrate ligands are: A) 
Manα1-2Man, B) 6-SO4-Gal-GlcNAc, C) and D) blood group B epitope: Galα1-3(Fucα1-2)Gal. Orange spheres 
represent Ca2+ ions. 
 
5.2 Artificial monovalent mannose-based ligands not targeting Langerin 
Knowing the structure of the binding sites of DC-SIGN and Langerin, it is possible to design 
ligands with a high affinity towards the target DC-SIGN and with a lower ability to be recognized 
by Langerin.  
In previous works conducted by our and Prof. F. Fieschi’s group,8,9 1.9 (Scheme 5.1A, Figure 5.5) 
was found to be not only a good monovalent DC-SIGN inhibitor (see Chapter 2.2), but also to be 
more active towards DC-SIGN than Langerin, showing a gain in selectivity of 6 times over the 
monovalent ligand 1.7 (Scheme 5.1B, Figure 5.5). Further improvements were obtained by 
replacing the 6-OH group in the mannose residue of 1.7 with an -NH2 group. The final compound 
5.1 was tested as a receptor antagonist by SPR, displaying a doubled affinity towards DC-SIGN 
with respect to 1.7 and a 4 times higher selectivity against Langerin.  
 
A
C D
B
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Scheme 5.1 Structures of monovalent ligands A) 1.9, B) 1.7, C) 5.1. 
 
The better affinity for DC-SIGN may arise from positive interactions between the amino group and 
carboxylic side chains in the vicinity of the Ca2+ binding site, as predicted by docking studies (J. 
McGeagh, Anterio GmbH, unpublished results). NMR studies confirmed that 5.1 interacts with DC-
SIGN in solution as its lead compounds 1.7 (Figure 5.4, P. M. Nieto, unpublished results). Thus, it 
coordinates Ca2+ ions in the binding site with 3-OH and 4-OH of the mannose residue, and the 
cyclohexane ring participates in the interaction through van der Waals contacts (Figure 5.4).10  
 
 
Figure 5.4 A) Structure of 1.7 and B) X-ray structure of the DC-SIGN complex.10 The protein is shown in olive, 1.7 in 
yellow and the Ca2+ is a green sphere. Nitrogen and oxygen atoms are, respectively, blue and red. Hydrogen bonds are 
shown as dashed purple lines, Ca2+ coordination bonds are dashed black lines, and key van der Waals interactions are 
indicated by dashed blue lines. 
 
The primary amine group in 5.1 should be largely protonated at physiological pH thus, in principle, 
increasing the compound solubility in water. Furthermore, the presence of positively charged 
groups can lead to electrostatic repulsions with the Lysine residues in Langerin binding site, 
explaining the lower affinity of this compound for Langerin. Crystal structures resolved in the 
group of Weis showed the proximity of the 6- position of the non-reducing mannose moiety of the 
disaccharide Manα1-2Man to Lys299 (Figure 5.3A).5  
In the course of previous PhD program (Varga 2012, 8 Sutkeviciute 20129), interactions between 
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compounds and the two lectins were evaluated through SPR competition assays (described in 
Chapter 2.6.2), measuring IC50 values (Figure 5.5).  
 
 
Figure 5.5 IC50 values (µM) of compounds 1.7, 1.9 and 5.1 inhibiting the anchoring of DC-SIGN ECD (blue bars) or  
Langerin (red bars) on a highly mannosylated sensor chip.8 
 
Combining the positive effects of amide groups on the cyclohexyl moiety (1.9) and -NH2 groups on 
the mannose residue could result in a potent DC-SIGN ligand, selective with respect to Langerin. In 
the course of my thesis, ligand 5.2 (Scheme 5.2) was synthesised on this purpose.  
 
 
Scheme 5.2 Structure of 5.2. 
 
5.2.1 Synthesis  
As for compounds 1.7 and 1.9 (see Chapter 2.4), the synthesis of compounds 5.1 and 5.2 was 
accomplished by combining one mannose donor activated as trichloroacetimidate at the anomeric 
position (5.3, Scheme 5.3) with a cyclohexane derivative conveniently substituted (Scheme 5.3). 
Cyclohexane derivatives 5.4 and 5.5 are analogous of compounds 2.9 and 2.10 presented in Chapter 
2.4, but they bear a chloride atom rather than an azide on the ether tether. The glycosylation 
reaction led to 5.6 or 5.7 respectively (Scheme 5.3), precursors of the final compounds. Final 
molecules 5.8 and 5.9 were isolated as Trifluoroacetate salts of the 6-amine (Scheme 5.3).  
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Scheme 5.3 A glycosylation reaction connects a trichloroacetimidate mannose derivative 5.3 and a cyclohexane 
conveniently substituted 5.4 or 5.5 yielding a precursors 5.6 or 5.7 of desired 6-NH2 derivatives. Final compounds were 
isolated as TFA salts 5.8 and 5.9. 
  
Although 5.8 had already been synthesised within the group by Dr. Norbert Varga,8 the synthesis of 
the mannose derivative 5.3 was optimized in this PhD thesis using a new procedure depicted in 
Scheme 5.4, route B. The primary hydroxyl group of mannose was first activated as a tosylate, 
using tosyl chloride in the presence of pyridine, giving compound 5.10 (α anomer). When a 
tosylate-azide reaction exchange was performed at this stage, it yielded the desired compound 5.11, 
in a mixture with an undesired byproduct (Scheme 5.4, route A). ESI mass analysis revealed that 
the byproduct has the same molecular weight of compound 5.12. This bicyclic molecule, coming 
from an intramolecular cyclisation where the 2-hydroxyl function has displaced the tosylate group, 
can be the actual byproduct according to 1H-NMR data. No further investigation were performed to 
fully characterize its structure. The byproduct not only did reduce reaction yields (up to 0 % in one 
case), but it was also difficult to remove. Several reaction conditions listed in Table 5.1 were tried 
in vain to avoid the formation of 5.12. Changing the solvent (DMF, DMA, H2O, H2O:DMA 1:1, 
H2O:DMF 1:1), the reaction time (overnight or several days) and also using microwave irradiation, 
desired compound 5.11 was never obtained pure nor recovered pure after a chromatographic 
purification step.  
 
Catalyst Solvent [5.10] Temperature (°C) Time Byproduct 
Bu4NI DMF 0.5 M 60, batch 2 days Yes 
/// DMA 0.6 M 50, batch 3 days Yes 
/// DMA 0.6 M 50, batch Overnight Yes 
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/// H2O 0.15 M 50, batch Overnight Yes 
/// DMA:H2O 0.64 M 60, MW 6 h Yes 
/// DMF:H2O 0.6 M 65, MW 6 h Yes 
/// DMF 0.6 M 60 °C, MW 6 h Yes 
Table 5.1 Reaction conditions to synthesise compound 5.11. The formation of byproduct was investigated. MW = 
microwave irradiation. 
 
A more suitable reaction pathway involved first the protection of the residual free –OH groups in 
5.10 as benzoate derivatives, performed in the presence of benzoyl chloride and 4-
dimethylaminopyride (DMAP) as catalyst to give compound 5.13 (α−anomer). Reaction times and 
temperatures were optimized to minimize both the formation of a byproduct where the tosylate 
group is replaced by a chloride anion and the presence of an intermediate with a residual non-
protected hydroxyl group (probably the one in 2- position for a matter of steric hindrance). Highest 
yields were obtained by performing the reaction at room temperature overnight in pyridine.  
The subsequent tosylate-azide reaction exchange (60 °C, DMA) gave a mixture of α and β anomers 
of 5.14 in good yields. When Bu4NI was used as catalyst and reaction times were around 24 hours, 
the side-reaction involving the deprotection of the anomeric hydroxyl group was less favored, 
giving ≈ 15 % of the not-expected compound 5.15.  
Selective deprotection of the anomeric position using methylamine afforded 5.15 (α−anomer). 
Activation of the anomeric hydroxyl group, yielding the α-anomer of compound 5.3, was 
performed using freshly distilled trichloroacetonitrile in the presence of DBU as the catalytic base. 
After flash chromatography, protected compound 5.3 was obtained in 70 % yield, and almost 20 % 
of the starting material 5.15 was recovered. 
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Scheme 5.4 Reaction pathway to obtain the activated glycosyl donor 5.3. Route A was performed by Dr Norbert 
Varga;8 Route B was optimized one during this PhD thesis. 
 
The synthesis of 5.8 (Scheme 5.5) involved a trimethylsilyltriflate-catalized glycosylation reaction 
between 5.3 and the cyclohexyl donor 5.4. 1.5 g of compound 5.4 were available in the laboratory, 
synthesised by Dr. Norbert Varga in 92 % overall yield from diacid 5.19 (shown in Scheme 5.6) 
following a procedure described in Ref.11.  
After the glycosylation step, the benzoyl protecting groups in 5.6 were removed using 0.18 M 
sodium methoxide in methanol (Zemplen’s conditions, Scheme 5.5), obtaining compound 5.16. The 
azide group in the 6- position of the sugar moiety was reduced (H2/Pd-C) in the presence of a slight 
excess of Boc2O (1.5 eq.) and the amine was obtained directly protected as tbutylcarbamate 
derivative 5.17. A chloride-azide reaction exchange gave compound 5.18; 100 mg were produced. 
The Boc removal was performed using trifluoroacetic acid in CH2Cl2 (≈ 30 % v/v), at room 
temperature for 1 hour to afford 5.8 (Scheme 5.5).  
Reactions shown in Scheme 5.5 were performed by the undergraduate student M. Valletta under my 
supervision. 
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 Scheme 5.5 Synthesis of 5.8 derivative as a trifluoroacetate salt. 
 
An analogous reaction pathway was used to synthesise compound 5.9. In this case, glycosylation 
step (Scheme 5.8) involved 5.3 and the cyclohexyl donor 5.5 (Scheme 5.6). 5.5 was synthesised 
according to the procedure shown in Scheme 5.6 and described by our group in Ref.4. Only the first 
step, where the acid groups of the diacid 5.19 are activated as p-NO2-phenyl esters to give 5.20, was 
improved by performing the basic workup to remove the remaining not-reacted phenol with 
NaHCO3 sat.sol. at 0 °C. The following reaction steps involved the oxidation of the double bond to 
give the epoxyde 5.21 and the ring opening with chloroethanol assisted by Copper(II)triflate to give 
compound 5.5. 1.3 g of 5.5 were obtained in 35 % overall yield. 
 
Scheme 5.6 Synthesis of the acceptor cyclohexyl derivative 5.5. 
 
After the glycosylation reaction to afford compound 5.7 (Scheme 5.8), p-NO2-phenyl ester groups 
were displaced by the benzylic amine 5.24 to obtain compound 5.25. 800 mg of 5.24 were already 
available in the laboratory, obtained from the commercially available methyl(4-
aminomethyl)benzoate·HCl 5.22 in 79 % overall yield. As shown in Scheme 5.8, the free amine was 
first restored using a Na2CO3 solution, then the methylester was reduced to benzyl alcohol using 
LiAlH4. Treatment of 5.25 under Zemplen’s conditions (0.18 mM MeONa in MeOH) yielded 
compound 5.26 (Scheme 5.7). The azide group in the 6- position of the mannose derivative was 
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reduced under hydrogen atmosphere in the presence of Boc2O, obtaining 5.27. This time Lindlar 
Palladium was used as catalyst because Pd/C could reduce the -CH2-OH group on the amide moiety 
to -CH3. Finally, a chloride-azide reaction exchange led to compound 5.28 in high yield, even if 
long reaction times (2-3 days) were required; 200 mg of 5.28 were produced. Final compound 5.9 
was obtained again as trifluoroacetate salt, after Boc deprotection using trifluoroacetic acid in 
CH2Cl2 (100 or 50 % v/v (Scheme 5.7). A Boc deprotection reaction in the presence of HCl in 
MeOH didn’t afford the desired compound.  
Compound 5.9 was synthesised in collaboration with V. Porkolab (Institut de Biologie Structurale, 
Grenoble), who visited our laboratories. 
	  
Scheme 5.7 Synthesis of 6-NH2-Man030 derivative as a trifluoroacetate salt 5.9.	  
	  
	  
Scheme 5.8 Synthesis of amine 5.24. 
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5.2.2 Biological assays 
5.2.2.1 Surface Plasmon Resonance Inhibition Assays  
6-NH2- derivatives were analyzed as trifluoroacetate salts (5.8 and 5.9). The affinity of 5.8 for DC-
SIGN and its selectivity with respect to Langerin was investigated through SPR inhibition assays, as 
reported (Figure 5.5, Paragraph 5.2). Analogous assays were performed on 5.9. In contrast with the 
behavior shown by 5.8 vs 1.7, the replacement of the 6-OH group in 1.9 with a primary amine led to 
a only slight affinity improvement: 5.9 was found to be only 1.3 times more active towards DC-
SIGN than the corresponding compound 1.9. But, remarkably, 5.9 was totally selective for DC-
SIGN over Langerin. Indeed, it was not possible to detect any binding of 5.9 with Langerin even at 
high compound concentration (4.5 mM). Results are reported in Table 5.2.  
 
IC50 values (mM) towards the two lectins 
Compound DC-SIGN Langerin 
1.9 0.3 2.6 
5.9 0.25 No binding 
Table 5.2 IC50 (mΜ) values of compounds 1.9 and 5.9 inhibiting the anchoring of DC-SIGN ECD or Langerin to a 
highly mannosylated sensor chip. 5.9 did not inhibit Langerin anchoring at any concentration up to 4.5 mM, therefore it 
was not possible to determine an IC50 value. 
 
5.2.2.2 Isothermal Titration Calorimetry  
Isothermal Titration Calorimetry (ITC) was used to determine thermodynamic parameters 
associated with binding of 5.9 to DC-SIGN ECD. I performed this assays at the Institut de Biologie 
Structurale of Grenoble with the collaboration of V. Porkolab, Prof. F. Fieschi and M. Trovaslet.  
A 5 mM solution of 5.9 in a buffer consisting of 25 mM Tris (pH 8), 150 mM NaCl, 4 mM CaCl2 
was titrated into a solution of DC-SIGN ECD (566 µM with respect to the binding sites, i.e. 
concentration of one single CRD) in the same buffer at 25 °C.  
Fitting data allowed to obtained KD = 171.8 µM, ΔH = -9.54 kJ/mol and stoichiometric value n = 
1.07. The n value confirmed a mode of binding in which one single compound 5.9 binds only one 
CRD. In Table 5.3 thermodynamic fitted and calculated thermodynamic parameters are listed. 
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KA KD n ΔH ΔG ΔS 
5820 M-1 171.8 µM 1.07 -9.54 kJ/mol 21.48 kJ/mol 40.06 J/(mol K) 
Table 5.3 Thermodynamic parameters associated with the interaction between 5.9 and DC-SIGN ECD. KA, n and ΔH 
were obtained by fitting data. KD was obtained as 1/KA. ΔG was obtained from the equation ∆! = −!"#$!!; R = 8.314 
J mol-1 K-1; T is temperature expressed in Kelvin. ΔS was obtained from the equation ∆! = ∆! − !∆!. 
 
In a first approximation, KD and IC50 values can be compared. ITC experiments revealed a higher 
affinity of 5.9 towards DC-SIGN ECD with respect to data obtained with the SPR competition 
experiments (KD = 172 µM vs IC50 = 254 µM). Nevertheless, the two values have the same order of 
magnitude and differentiate less than a factor of 2, showing the reliability of the two methods.  
ITC experiments have been previously conducted by Dr. I. Sutkeviciute to evaluate the interaction 
between DC-SIGN ECD and compound 1.7.9 On the contrary, the thermodynamic behaviour of 
compound 1.9 was never investigated. She titrated 12.7 mM of 1.7 into lectin solution (71 µM with 
respect to binding sites). Fitting one binding site model on the data with an assumed stoichiometry 
value n fixed to 1 yielded a KD value of 990.10 ± 19.7 µM, in strong agreement with IC50 values 
(i.e. 900-1000 µM, depending on the campaign) found through SPR inhibition assays. 
Unfortunately, low affinity prevented the reliable interaction enthalpies and entropies to be 
obtained.  
 
5.2.2.3 Saturation Transfer Difference (STD) NMR assay 
To confirm that the binding mode of 5.2 to DC-SIGN is the same of 1.7 and 2.1, Saturation 
Transfer Difference (STD) NMR experiments will be performed in the group of Prof. P. Nieto. The 
trifluoroacetate-derivative 5.9 will be used for the investigation and, in particular, it will be 
converted to molecule 5.9.1 (Scheme 5.9). It was indeed already demonstrated that the presence of 
the triazole units allows the splitting of the axial and equatorial signals of the D3 and D6 
cyclohexane protons (Scheme 5.9), without affecting the binding mode.10 
 
	  
Scheme 5.9 5.9.1 maintain the same binding mode of 5.9, but its 1H NMR spectrum is more easy to interpreter because 
it is possible to discriminate between axial and equatorial D3 and D6 protons.  
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5.3 Artificial multivalent mannose-based ligands potentially not targeting Langerin 
5.1 and 5.2 were used to decorate multivalent scaffolds, in order to obtain multivalent compounds 
with higher affinity towards DC-SIGN and potentially improved selectivity over Langerin. The 
hexavalent scaffold 2.24 depicted in Scheme 5.10A was functionalised with both monovalent 
carbohydrates 5.1 and 5.2, as well as the scaffold 2.5/Rod3 (Scheme 5.10B). Nonavalent scaffold 
5.24 (Scheme 5.10C), on the contrary, was used to prepare only multivalent derivatives of 5.2.  
All these scaffolds are characterized by a chemically solid backbone and are decorated with 
terminal triple bonds to be coupled with the azide functions of the monovalent ligands.  
 
 
Scheme 5.10 Structure of multivalent ligands to be decorated with 5.1 and 5.2. A) hexavalent scaffold 2.24; B) divalent 
Rod3 2.5; C) nonavalent scaffold 5.29.  
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According to computational studies performed in these laboratories and described in Chapter 2.5, 
hexavalent derivatives based on 2.24 should exploit only the statistical rebinding effect or protein 
aggregation to improve their affinity for the target receptor.12 On the contrary, divalent Rod3 
derivatives should be able to assume extended conformations that allow for a simultaneous binding 
of two different subunits within one single DC-SIGN tetramer, thus exploiting the chelation 
effect.13 A stated in Paragraph 5.2, the primary amine group of 5.1 and 5.2 could in principle be 
protonated at physiological pH; we wanted to exploit this feature to synthesis a nonavalent 
compound based on 5.2 more soluble in aqueous solution. 
 
5.3.1 Synthesis 
5.3.1.1 Synthesis of the scaffolds 
Hexavalent and nonavalent scaffolds were available in the laboratory and prepared according to 
Ref.12 The synthetic pathway to achieve the hexavalent scaffold 2.24 was already described in 
Chapter 2.4. 
The synthesis of the nonavalent derivative was accomplished by coupling a trivalent sugar dendron 
5.45 (Scheme 5.16) on the aromatic-based trivalent core 5.31 (Scheme 5.11). The synthesis of 5.45 
involved the trivalent scaffold 2.27 (see Chapter 2.4) and it will be explained in the following 
Paragraph 5.3.1.2. The aromatic trivalent core 5.31 was synthesised with 1,3,5-trihydroxybenzene 
5.30 performing a Williamson etherification reaction with propargyl bromide in the presence of 
K2CO3 as the base (Scheme 5.11). 200 mg of 5.31 were obtained in 60 % yield. 	  
 
  
Scheme 5.11 Synthesis of the trivalent aromatic core 5.31.	  
 
Rod3 2.5 was synthesised as described in Chapter 2.4. 
 
5.3.1.2 Synthesis of final multivalent compounds 
Multivalent compounds were synthesised by combining monovalent ligands bearing an azide group 
and the central cores functionalized with terminal triple bonds. The copper(I)-catalyzed 1,3-dipolar 
cycloaddition between an alkyl azide and a terminal alkyne functional groups (CuAAC or click 
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reaction) is a regioselective and catalyzed variation of an Huisgens cycloaddition. Principles of the 
click chemistry were explained in Chapter 2.4. 
The goal of the investigation was to decorate hexavalent, Rod3 and novavalet scaffolds (bearing the 
terminal alkyne groups, Scheme 5.10) with 6-NH2-derivatives (Scheme 5.12), bearing the azide 
group. We initially wondered which was the best monovalent ligand to undergo a click reaction, 
among the –Boc protected (Scheme 5.12A), the trifluoroacetate salt (Sceme 5.12B) or the free 
amine derivatives (Scheme 5.12C).  
 
 
Scheme 5.12 Monovalent ligands bearing an azide group that, in principle, could react with terminal triple bonds in a 
Copper(I) catalyzed click reaction. A) –Boc derivative; B) trifluoroacetate salt; C) free amine. 
 
A first attempt was performed on compound 5.8, as a TFA salt, which reacted with the hexavalent 
core 2.24. Even after 24 h, the reaction did not go to completion and MALDI mass detected the 
presence of tetravalent and pentavalent intermediates. Several trials were done to achieve total 
conversion of the starting materials, such as adding other portions of monovalent ligand 5.8 and 
heating under microwave irradiation (60 °C). Nonetheless, the reaction did not go to completion. 
Size exclusion chromatography afforded a mixture of tetra and pentavalent species together with the 
hexavalent one (5.32), which couldn’t be isolated pure (Scheme 5.13).  
 
 
Scheme 5.14 The reaction between 5.8 and the hexavalent scaffold 2.24 afforded the desired hexacationic compound 
5.32, together with tetravalent and pentavalent intermediates. 
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A possible explanation of this behavior  is  the thermodynamic difficulty of forming an hexacationic 
species, probably due to electrostatic repulsion. Moreover, it is possible that  the amino functions on 
the sugar coordinate and deactivate Cu(I), thus blocking the catalytic cycle. This last assumption 
would be true also using the derivative with the free amine, (Scheme 5.12C). For these reasons, 
click chemistry was performed between multivalent scaffolds and monovalent ligands with the 
amine protected as Boc-derivative, i.e. compounds 5.18 and 5.28 (Scheme 5.12A). Final 
compounds were purified by size exclusion chromatography and automated reverse phase 
chromatography when needed. 
Compounds 5.18 and 5.28 reacted with the hexavalent scaffold 2.24 to afford hexavalent Boc-
protected species (5.33 and 5.38 respectively, Scheme 5.14). The general procedure already 
explained in Chaper 2.4 was followed: 1.1 eq. of azide derivative per each triple bond; 
CuSO4*5H2O (0.1 eq.), Sodium Ascorbate (0.4 eq.) and TBTA (0.2 eq.) were used in catalytic 
amount; reactions were performed in a 1:1 THF/H2O mixture, under nitrogen atmosphere and in the 
dark at room temperature; final concentration of the scaffold was between 5 and 10 mM. Also in 
this case, the purity of scaffold 2.24 was always checked through TLC analysis immediately befor 
the reaction. 
 
 
Scheme 5.14 General procedure to synthesise hexavalent derivatives 5.33 and 5.38. 
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Analogous click reactions were conducted between 5.18 or 5.28 and Rod3 (2.5, Scheme 5.16). 
Rod3 (2.5) was formed in situ, after removal of triisopropylsilyl protecting group from compound 
TIPS-Rod3 (TIPS-2.5) and subsequently underwent the CuAAC reaction to give, respectively, 
compounds 5.35 or 5.41 (Scheme 5.16). 
 
 
Scheme 5.15 General procedure to synthesise divalent Rod3 derivatives 5.35 and 5.41. 
 
As stated in Paragraph 5.3.1.1, the synthesis of the nonavalent derivative implies coupling between 
of three trivalent dendrons onto a central aromatic trivalent core. Only the nonavalent presentation 
of 5.2 was synthesised. The trivalent dendron 5.44 was produced by performing a click reaction 
between 5.28 and the trivalent core 2.27 (Scheme 5.16). The terminal chloride was then replaced by 
an azido group through a chloride-azide reaction exchange. Obtained compound 5.44 underwent 
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then a further click reaction on scaffold 5.31 to give the desired nonavalent construct 5.46 (Scheme 
5.16).   
 
 
Scheme 5.16 General procedure to synthesise nonavalent 5.46. 
 
Boc- protecting groups were removed from the multivalent derivatives using trifluoroacetic acid in 
CH2Cl2 as solvent (TFA was used from 20 to 50 % v/v) Multivalent cationic compounds were 
obtained always with almost quantitative yields without any purification. The excess of TFA was 
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eliminated through co-evaporation with toluene and Et2O (Scheme 5.17). A deprotection reaction 
with HCl in dioxane did not afford the desired compound. 
 
	  
Scheme 5.17 General procedure for the Boc- removal in the presence of TFA in CH2Cl2. 
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The formation of the TFA-salt derivatives in 5.32 and 5.36 bearing ligand 5.8 was assessed by TLC 
analyses (developed with ninhydrin) and NMR analysis in MeOH. On the contrary, TLC analysis of 
5.39, 5.42 and 5.47 bearing ligand 5.9 was difficult to interpret and extensive NMR characterization 
was avoided, in order not to expose the compounds to nucleophiles (MeOD; D2O). Therefore, only 
MALDI mass was used for characterization.  
Remarkably, 1H NMR spectra of cationic deprotected compounds sometimes showed signals 
splitting (Figure 5.6), probably due to the presence of equilibriums in solution between species with 
either the free amine or the salt and/or between species with either neutral or protonated triazoles. 
MS spectra (MALDI) were consistent with a fully deprotected compound; the NMR spectra were 
not analyzed further. 
 
 
Figure 5.6 1H NMR spectra of 5.33 (Boc-derivative, A) and 5.32 (TFA-derivative, B) in MeOH zoomed in the aromatic 
region between 8.7 and 7.7 ppm. Red circles highlight new signals probably deriving from equilibriums between 
different species. Integrals were obtained by fixing to 4H a multiplet at 2.7 ppm. 
 
The free amine functionalities were restored treating with an excess (> 10 eq. per each amine) of 
Amberlyst A21 (tertiary amine groups) 14 pre-washed with CH2Cl2, THF and finally MeOH. The 
reaction was shaken and not stirred, in order to avoid resin breaking; 3 h were arbitrarily chosen as 
reaction times (Scheme 5.18). Remarkably, final nonavalent construct 5.48 had a rather low 
solubility in MeOH (< 300 nM). 
A B 
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Scheme 5.18 General procedure for the TFA- removal in the presence of Amberlyst A-21 in MeOH. 
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For 5.34 and 5.37, bearing ligand 5.1, it was possible to compare 1H-NMR spectra (5.32 or 5.36 
before and 5.34 or 5.37 after the resin-based reaction exchange). The signals of the CH2 group in 
the 6-position of the sugar moiety were slightly shifted in the two species, and their shape changed 
from sharper in the salt (5.32 in Figure 5.6A), to broader in the free amine (5.34 in Figure 5.6B). 
Moreover, trazole C-H signals that were found splitted in the salt derivatives (5.32) reverted to 
sharp singlets in 5.34 (Figure 5.6C).  
 
 
  
 
 
Figure 5.6 1H NMR spectra of 5.32 (TFA-derivative, A) and 5.34 (free amine, B) in MeOH zoomed on the CH2 in the 
6- position of the sugar moiety. (C) 1H NMR spectrum of 5.34 in MeOH zoomed in the aromatic region between 8.7 
and 7.7 ppm, showing single peaks not splitted anymore. Integrals were obtained by fixing to 4H a multiplet at 2.7 ppm. 
 
5.3.2 Compounds nomenclature 
Also this library of compounds was assigned a conventional name Polyman43-47-PM43-47. 
Structures of obtained compounds together with conventional names are reported in Table 5.4 
 
A B 
C 
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Structure 
 
Ligand 5.1 Ligand 5.2 
 
5.34 
PM43 
5.40 
PM45 
 
5.37 
PM44 
5.46 
PM46 
 
/// 
5.48 
PM47 
Table 5.4 General structure of synthesised compounds, together with identification numbers and conventional names. 
Grey spheres represent monovalent ligands 5.1 or 5.2. 
 
5.3.3 Biological Assays 
Biological analysis to be performed on 6-NH2-derivatives are still on-going, with the aim to 
evaluate: 
• Compounds affinity for DC-SIGN, through SPR assays 
• Compounds affinity for Langherin (i.e. selectivity), through SPR assays 
• Compounds ability to inhibit DC-SIGN-mediated HIV infection, through trans-infection 
inhibition assays performed of BTHP/DC-SIGN cells as Dendritic Cells model. 
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5.3.3.1 Citotoxicity 
It is known that polycationic species can be cytotoxic.15,16 They are able to neutralize the 
negatively-charged cell surface, thus inducing membrane damage which is followed by a decrease 
of the metabolic activity and cellular death. Cellular metabolic activity can be measured through i.e. 
the Method of Transcriptional and Translational (MTT) assay, which assesses the proper 
functionality of mithocondria, the principal cellular energy source. Once internalized, polycations 
can disrupt also the plasma, nuclear, mitrocondrial, endosomial and lysosomial membranes and they 
can interact with cytoskeleton elements. Multivalent PMs compounds bearing free amine groups are 
cationic once solubilized at physiological pH. For these reason, 5.34/PM43 was chosen to conduct 
preliminary cytotoxicity assays, performed by Dr. A. Berzi and Prof. M. Clerici (Università degli 
Studi di Milano) using the protocol described in Chapter 2.6.3.  
The tests were performed by using B-THP-1 cells overexpressing DC-SIGN and belonging to the 
same cell line used for trans-infection inhibition assays (see Chapter 2.6.2). Cells were incubated 
together with 5.34 at different concentrations and after different times; the amount of dead cells was 
measured using the fluorescent dye 7-AAD. 3 hours and half and 72 hours were chosen because 
they are characteristic of the HIV-trans infection assays set up (see Chapter 2.6.2) 
Results (Figure 5.8) indicated that 5.34/PM43 is cytotoxic at concentrations ≥ 100 µM after 24 
hours of incubation. Increasing incubation times, also lower concentrations (50 µM) were found to 
be toxic. Nevertheless, with respect to the behavior of the analogous compound bearing 1.9 as 
ligand,12 we can assume that 5.34/PM43 would be active already at concentrations lower than 50 
µM. 
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Figure 5.8 Percentage of dead cells (i.e. positive to the 7AAD dye) with respect to 5.34/PM43 concentration. 
Cytotoxicity was measure after 3 h and 30’ (A), 24 h (B) and 72 h (C). MED represents the negative control, i.e. cells 
not treated with the compound. 
 
5.4 Experimental 
 
General procedures 
Chemicals were purchased by commercial sources and used without further purification, unless 
otherwise indicated. When anhydrous conditions were required, the reactions were performed under 
nitrogen atmosphere. Anhydrous solvents were purchased from Sigma-Aldrich® with a content of 
water ≤0.005 %. THF was dried over Na/benzophenone and freshly distilled prior to use. Thin-layer 
chromatography (TLC) was performed on Silica Gel 60 F254 plates (Merck) with UV detection 
(254 nm and 365 nm) or using appropriate developing solutions. Flash column chromatography was 
performed on silica gel 230-400 mesh (Merck), according with the procedure described in 
literature.17 Automated flash chromatography was performed on a Biotage® Isolera™ Prime 
system. Final compounds were purified by size-exclusion chromatography using Sephadex LH-20 
from GE Helthcare Life Science® and through reverse phase automated flash chromatography 
(C18) when required. NMR experiments were recorded on a Bruker AVANCE 400 MHz instrument 
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at 298 K. Chemical shifts (δ) are reported in ppm downfield from TMS as internal standard, 
coupling constants (J) in Hz. The 1H and 13C-NMR resonances of compounds were assigned with 
the assistance of COSY and HSQC experiments. HSQC experiments were also used to assign the 
chemical shift of protons overlapping with the solvent signals. The numbering for protons and 
carbons in the NMR characterization are shown on the molecules. Mass spectra were recorded on 
ThermoFischer LCQ apparatus (ESI ionization), Apex II ICR FTMS (ESI ionization-HRMS), 
Waters Micromass Q-Tof (ESI ionization-HRMS), or Bruker Daltonics Microflex MALDI-TOF 
apparatus. Specific optical rotation values were measured using a Perkin-Elmer 241, at 589 nm in a 
1 mL cell. 
 
General procedure for the CuAAC reaction. In the optimized Copper(I)-catalyzed Azide-Alkyne 
Cycloaddition (CuAAC) procedure, starting materials and reagents were added to the reaction 
mixture as solids or as solutions in water or THF. Water was degassed by bubbling with nitrogen 
and THF was freshly distilled. The reagents were added to the reaction vessel in the following 
order: alkyne (1 eq., solid or THF), TBTA (0.2 eq., THF), CuSO4·5H2O (0.1 eq., H2O), Sodium 
Ascorbate (0.4 eq., H2O) and finally the azide monovalent ligand (1.1 eq. per each triple bond, solid 
or water solution). The final concentration of multivalent scaffold was 3-15 mM in a 1:1 THF:H2O 
mixture, depending on the solubility of the components and the products in water. When a 
concentration > 10 mM in 1:1 THF:H2O could be obtained, the reaction was stirred at room 
temperature for 12 -24 hours, under nitrogen atmosphere and protected from light. For less soluble 
mixtures, the reaction was performed at lower concentrations (tipically 3 mM) under microwave 
assisted conditions for 1-2 h at 60 °C. In both cases, the reaction was monitored by TLC and/or 
MALDI mass spectrometry (DHB or sinapinic acid matrix) until completion. In general, the 
formation of divalent compounds could be monitored by TLC (eluent: CH2Cl2:MeOH:H2O in a 
ration that depended on the polarity of the molecule) while hexavalent compounds were best 
analysed by MALDI mass (DHB or sinapinic acid matrix). When intermediates were observed but 
the azide monovalent ligand was totally consumed, the latter was added together with additional 0.4 
eq. of sodium ascorbate. The crude was purified by size exclusion chromatography on a Sephadex 
LH20 column (Ø 3 cm, H 55 cm; eluent: MeOH) as MeOH solution and by reverse phase 
chromatography (C18; eluent: water with a gradient of MeOH from 0 % to 100 %), when required. 
The metal scavenger Quadrasil™-MP18	  was used to remove copper salts either from the reaction 
mixtures before purification, or from a solution of the isolated final compound. In either case, the 
suspension was stirred for 10 min and the resin filtered off. 
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Synthesis of 6-(p-toluensulfonyl)-D-mannopyranose, 5.10 
 
 
To a stirred suspension of D-mannose (4 g, 0.22 mol, 1 eq.) in 10 mL of dry pyridine, a solution of 
TsCl (6.35 g, 0.33 mol, 1.5 eq.) in 12 mL of dry pyridine was added drop by drop at 0°C under inert 
atmosphere, obtaining a light blue mixture. The reaction was stirred under nitrogen atmosphere for 
2.5 h; TLC analysis (CH2Cl2:MeOH 8:2) revealed that the tosylation was complete. Pyridine was 
evaporated under reduced pressure and a dark green mixture was obtained; the crude was 
redissolved in CH2Cl2:MeOH 9:1 and purified over a sodium carbonate pad (Ø = 4 cm, h = 4 cm). 
The resulting solution was evaporated and purified again by flash chromatography (CH2Cl2:MeOH 
9:1) to give 3.21 g of final product (5.10) as a white solid (yield 48 %). The α anomer was obtained, 
with spectral data identical to those reported.8	  
 
1H-NMR (400 MHz, CD3OD): δ 7.80 (d, 2H, H8, J8-9 =8.3 Hz), 7.43 (d, 2H, H9, J8-9 = 8.3 Hz), 5.00 
(d, 1H, H1, J1-2 = 1.4 Hz), 4.39 - 4.23 (m, 1H, H6a), 4.19 – 4.07 (m, 1H, H6b), 3.93 - 3.82 (m, 1H, 
H5), 3.75 (dd, 1H, H2, J1-2 = 1.4 Hz, J3-2 = 3.3 Hz), 3.70 (dd, 1H, H3, J3-4 = 9.3 Hz, J3-2 = 3.3 Hz), 
3.51 (t, 1H, H4, J3-4 = 9.3), 2.45 (s, 1H, H11). 
 
Synthesis of (1,2,3,4-O-tetrabenzoyl)-6-(p-toluensulfonyl)-D-mannopyranose, 5.13 
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To a stirred solution of 5.10 (3.21 g, 9.59 mmol, 1 eq.) in 32 mL of dry pyridine, BzCl (10.78 g, 
76.7 mmol, 8 eq.) and DMAP (0.117 g, 0.96 mmol, 0.1 eq.) were added under inert atmosphere at 0 
°C, obtaining a yellow mixture. The room temperature was restored and the reaction was stirred for 
18 h under nitrogen atmosphere; TLC analysis (Hex:AcOEt 8:2) revealed that the benzoylation was 
complete. The reaction was diluted with 90 mL of Et2O and washed with HCl 1M (2 x 100 mL), 
NaHCO3sol. sat. (2 x 100 mL) and water (3 x 100 mL); the organic phase was dried over Na2SO4 
anhydrous and the solvent was evaporated. The crude was purified by flash chromatography (silica, 
Hex:AcOEt 8:2) to give 5.31 g of final product (5.13) as a white solid (yield 74 %). The α anomer 
was obtained. 
 
1H-NMR (400 MHz, CDCl3): δ 8.17-7.20 (m, 24H; HBz, H9, H10), 6.48 (d, 1H, H1, J1-2 = 1.9 Hz), 
5.98-5.96 (m, 2H, H3, H4), 5.80 (dd, 1H, J2-3 = 2.7, J1-2 = 1.9 Hz), 4.45-4.40 (m, 1H, H5), 4.34 (dd, 
1H, H6a, J6a-6b = 11.3, J6a-5 = 2.5 Hz), 4.25 (dd, H6b, J6b-6a = 11.3, J6b-5 = 4.8 Hz). 
13C NMR (100 MHz, CDCl3): δ 165.75, 165.33, 165.32, 163.83 (COBz), 145.01 (C7), 134.29, 
133.96, 133.81, 133.63 (CHBz), 132.63 (C10), 130.33, 130.24, 129.99, 129.94, 129.87 (CHBz, C9), 
129.03 (CquatBz), 129.00, 128.92 (CHBz, C8), 128.86, 128.79, 128.76 (CquatBz), 128.66, 128.58, 
128.24 (CHBz), 91.14 (C1), 71.20 (C5), 69.89 (C3), 69.44 (C2), 67.79 (C6), 66.24 (C4), 21.78 (C11). 
 
MS (ESI): calculated for: [C41H34O12SNa]+ = 773.2, found: 773.5 
Calculated for dimer: [C82H68O24S2Na]+ = 1523.4, found: 1523.3 
 
Synthesis of (1,2,3,4-O-tetrabenzoyl)-6-(azido)-D-6-deoxymannopyranose, 5.14 
 
 
To a stirred solution of 5.13 (2.69 g, 3.46 mmol, 1 eq.) in 8 mL of dry DMA, NaN3 (680 mg, 10.4 
mmol, 3 eq.) and Bu4NI (128 mg, 0.35 mmol, 0.1 eq.) were added under inert atmosphere, obtaining 
a not completed dissolved reddish reaction mixture. The reaction was heated at 60 °C and stirred 
overnight; TLC analysis (Hex:AcOEt 7:3) revealed that the reaction was complete. The solvent was 
concentrated under reduced pressure to 4 mL. The crude was dissolved in 20 mL of Et2O and 
washed with water (3 x 20 mL); then the organic phase was dried over Na2SO4 anhydrous and the 
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solvent evaporated. The crude was purified by flash chromatography (silica, Hex:AcOEt 9:1) to 
give 1.57 g of final product (5.14) as a white solid (yield 72 %). Obtained ratio of two anomers: β/α 
= 0.58. 
 
1H-NMR (400 MHz, CDCl3): 
α anomer: δ 8.20 – 7.20 (m, 20H, HBz), 6.60 (d, 1H, H1, J1-2 = 2.0 Hz), 6.05 – 6.00 (m, 1H, H4), 5.88 
– 5.85 (m, 1H, H2), 5.74 – 5.63 (m, 1H, H3), 4.41 – 4.34 (m, 1H, H5), 3.55 – 3.41 (m, 2H, H6a, H6b).  
β anomer: δ = 8.20 – 7.20 (m, 20H, HBz), 6.36 (d, 1H, H1, J1-2 = 1.1 Hz), 6.07 (dd, 1H, H2, J1-2 =  
1.1 Hz, J3-2 = 3.2 Hz), 5.94 (pt, 1H, H4, J4-3 = J4-5= 9.8 Hz), 5.75 (dd, 1H, H3, J3-4 = 9.8 Hz, J3-2 = 
3.2), 4.20 – 4.13 (m, 1H, H5), 3.61 (dd, 1H, H6a, J5-6a = 2.8 Hz, J6a-6b = 13.5 Hz), 3.53 (dd, 1H, H6b, 
J5-6a = 5.5 Hz, J6a-6b = 13.5 Hz). 
 
13C NMR (100 MHz, CDCl3):  
α anomer: δ = 165.9, 165.6, 165.6, 164.3 (COBz); 134.3, 133.9, 133.8, (CHBz); 130.8, 130.4, 130.3, 
130.0 (CHBz); 129.5 (CquatBz); 129.1, 129.0 (CHBz); 128.8 (CquatBz); 128.8, 128.6 (CHBz); 91.4 
(C1); 74.9 (C5); 69.5 (C4); 68.6 (C3); 67.2 (C2); 51.1 (C6). 
β anomer: δ = 165.9, 165.6, 165.6, 164.3 (COBz); 134.0, 133.9, 133.8, 133.7 (CHBz); 130.4, 130.3, 
130.0 (CHBz); 129.5 (CquatBz); 128.9, 128.8 (CHBz); 128.8 (CquatBz); 128.7, 128.6 (CHBz); 91.3 
(C1); 74.9 (C5); 71.5 (C3); 69.5 (C2); 67.3 (C4); 51.1 (C6). 
 
MS (ESI) calculated for: [C34H27N3O9Na]+: 644.6, found: 644.3. 
 
Synthesis of (2,3,4-O-tribenzoyl)-6-(azido)-D-6-deoxymannopyranose, 5.15 
 
	  
To a stirred solution of 5.14 (1.01 g, 1.62 mmol, 1 eq.) in 4.6 mL of dry THF, MeNH2 (0.8 mL, 6.48 
mmol, 4 eq.) was added under inert atmosphere at 0 °C. After 1 h of stirring, a TLC analysis 
(Hex:AcOEt 7:3) revealed that the debenzoylation of the anomeric hydroxyl group was complete. 
The solvent and methyl amine were evaporated and the crude was purified by flash chromatography 
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(silica, Hex:AcOEt 8:2) to give 783 mg of final product (5.15) as a light yellow solid (yield 93 %). 
Only the α anomer was obtained; with spectral data identical to those reported.8 
 
1H-NMR (400 MHz, CDCl3): δ 8.13 – 8.04 (m, 2H, HBz), 8.00 – 7.90 (m, 2H, HBz), 7.87 – 7.75 (m, 
2H, HBz), 7.67– 7.56 (m, 1H, HBz), 7.55 – 7.45 (m, 3H, HBz), 7.43 – 7.32 (m, 3H, HBz), 7.29 – 7.18 
(m, 2H, HBz), 5.96 (dd, 1H, H3, J3-4 = 10.0 Hz, J3-2= 3.3), 5.87 (pt, 1H, H4, J4-3 = J4-5= 10.0 Hz), 5.71 
(dd, 1H, H2, J1-2 = 1.6 Hz, J3-2 = 3.3 Hz), 5.52 (d, 1H, H1, J1-2 = 1.6 Hz), 4.54 – 4.43 (m, 1H, H5), 3.51 
– 3.45 (m, 2H, H6a,b), 3.35 (bs, 1H, H7). 
 
Synthesis of (1S,2S,4S,5S) (2,3,4-O-tribenzoyl)-6-(azido)-D-6-deoxymannopyranosyl tri-
chloroacetoimidate, 5.3 
 
 
To a stirred solution of 5.15 (786 mg, 1.52 mmol, 1 eq.) in 5.1 mL of dry CH2Cl2, freshly distilled 
Cl3CCN (0.762 mL, 7.60 mmol, 5 eq.) and DBU (45 µL, 0.30 mmol, 0.2 eq.) were added under 
inert atmosphere. After 2 h of stirring at room temperature, a TLC analysis (Hex:AcOEt 7:3) 
revealed that the formation of the trichloroacetoimidate was completed. The solvent was evaporated 
and the crude was purified by flash chromatography (silica, Hex:AcOEt 8:2) to give 567 mg of final 
product (5.3) as a light yellow solid (yield 71 %). Only α anomer was obtained, with spectral data 
identical to those reported.8 
 
1H-NMR (400 MHz, CDCl3): δ 8.88 (s, 1H, H8), 8.13 – 8.08 (m, 2H, HBz), 7.97 – 7.93 (m, 2H, 
HBz), 7.83 – 7.78 (m, 2H, HBz), 7.65 – 7.59 (m, 1H, HBz), 7.55 – 7.46 (m, 3H, HBz), 7.45 – 7.33 (m, 
3H, HBz), 7.29-7.22 (m, 2H, HBz), 5.56 (d, 1H, H1, J1-2 = 1.8 Hz), 5.99 (pt, 1H, H4, J4-3 = J4-5 = 9.8 
Hz), 5.95-5.86 (m, 2H, H2, H3), 4.48 – 4.41 (m, 1H, H5), 3.54 (dd, 1H, H6a, J5-6a = 2.8 Hz, J6a-6b = 
13.6 Hz), 3.49 (dd, 1H, H6b, J5-6a = 5.4 Hz, J6a-6b= 13.6 Hz). 
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Synthesis of (1S,2S,4S,5S) 1,2-Cyclohexanedicarboxylic acid, 4-(2-chloroethoxy)-5-((2,3,4-O-
tribenzoyl)-6-azido-α-D-6-deoxymannopyranosyloxy)-1,2-dimethyl ester, 5.6 
 
 
5.4 (127 mg, 0.43 mmol, 1 eq.) and 5.3 (314 mg, 0.47 mmol, 1.1 eq.) were coevaporated with 
toluene 3 times. Under inert atmosphere, molecular sieves (4Å) were added and the mixture was 
kept under vacuum overnight. Then the mixture was dissolved under inert atmosphere in 4.3 mL of 
dry CH2Cl2 and cool down at -30°C. Finally, TMSOTf (16 µL, 0.09 mmol, 0.2 eq.) was added drop 
by drop, and the reaction was stirred for 1 h. A TLC analysis (Hex:AcOEt 7:3) revealed that the 
glycosylation reaction was complete. The reaction was quenched by the addition of dry Et3N (200 
µL) and stirred for other 15 min. Restored the room temperature, the mixture was filtered over 
celite pad and the solvent evaporated; the crude was purified by flash chromatography (silica, Hex 
with gradient of AcOEt from 0 % to 50 %) to give 291 mg of final product α-anomer (5.6) as a 
white solid (yield 85 %). Spectral data were identical to those reported.8 
 
1H-NMR (400 MHz, CDCl3): δ 8.1 – 8.05 (m, 2H, HBz), 7.99 – 7.89 (m, 2H, HBz), 7.83 – 7.74 (m, 
2H, HBz), 7.65 – 7.56 (m, 1H, HBz), 7.55 – 7.46 (m, 3H, HBz), 7.45 – 7.33 (m, 3H, HBz), 7.29 –7.17 
(m, 2H, HBz), 5.84 – 5.76 (m, 2H, H3, H4), 5.66 (dd, 1H, H2, J2-1 = 1.9 Hz, J2-3 = 2.7 Hz), 5.24 (d, 
1H, H1, J1-2 = 1.6 Hz), 4.29 (pt, 1H, H5, J6a-5 = J5-4 = 7.2 Hz), 4.06 (dd, 1H, HD2, JD1-D2 = 4.0 Hz, JD2-
3 or 6 = 7.8 Hz), 3.93 – 3.83 (m, 1H, H7a), 3.81 – 3.67 (m, 8H, H7b, H2, H10), 3.63 (t, 2H, H8, J8-7 = 
5.77 Hz), 3.57 (dd, 1H, H6a, J6b-5 = 7.2 Hz, J6a-6b = 13.3 Hz), 3.40 (dd, 1H, H6a, J6b-5 = 2.3 Hz, J6a-6b = 
13.3 Hz), 3.13 - 3.00 (m, 2H, HD4, HD5), 2.17 – 1.97 (m, 4H, HD3, HD6). 
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Synthesis of (1S,2S,4S,5S) 1,2-Cyclohexanedicarboxylic acid, 4-(2-chloroethoxy)-5-(6-azido-α-
D-deoxymannopyranosyloxy)-1,2-dimethyl ester, 5.16 
 
 
To a stirred suspension of 5.6 (269 mg, 0.34 mmol, 1 eq.) in 3.4 mL of dry MeOH, 1 M MeONa in 
MeOH (500 µL, 0.51 mmol, 1.5 eq.) was added under inert atmosphere. Only after the addition of 
the base, the starting material 5.6 fully dissolved. The reaction was stirred for 1.5 h under inert 
atmosphere. A TLC analysis (CHCl3:MeOH 95:5) revealed that the debenzoylation reaction was 
complete. The reaction was quenched by the addition of Amberlite IR120 H+ until pH 7 was 
reached and then filtered; ìthe filtrate was concentrated and the crude was purified by flash 
chromatography (silica, CHCl3:MeOH 95:5) to give 157 mg of final product (5.16) as a colourless 
oil (yield 96%). Spectral data were identical to those reported.8 
 
1H-NMR (400 MHz, CD3OD): δ 4.95 (d, 1H, H1, J1-2 = 1.6 Hz), 4.03 – 3.99 (m, 1H, HD2), 3.94– 
3.89 (m, 1H, H6a), 3.88 – 3.76 (m, 4H, H2, H3, H7), 3.75 – 3.71 (m, 1H, HD1), 3.71 - 3.64 (m, 9H, 
H8, H5, H10), 3.61 – 3.54 (m, 1H, H4), 3.51 (dd, 1H, H6a, J6a-6b = 13.0 Hz, J6a-5 = 2.1 Hz), 3.43 
(dd, 1H, H6a, J6a-6b = 13.0 Hz, J6a-5 = 8.1 Hz), 3.00 – 2.81 (m, 2H, HD4, HD5), 2.21 - 1.94 (m, 2H, 
HD3ax, HD6ax), 1.94 – 1.72 (m, 2H, HD3eq, HD6eq). 
 
Synthesis of  (1S,2S,4S,5S) 1,2-Cyclohexanedicarboxylic acid, 4-(2-chloroethoxy)-5-(6-N-
carbo-t-butoxy-α-D-6-deoxymannopyranosyloxy)-1,2-dimethyl ester, 5.17 
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To a stirred solution of 5.16 (155 mg, 0.32 mmol, 1 eq.) in 32 mL of dry MeOH, Boc2O (105 mg, 
0.48 mmol, 1.5 eq.) and Pd-C (catalytic) were added under inert atmosphere. The mixture was 
stirred for 3 h under hydrogen atmosphere. A TLC analysis (CHCl3:MeOH 95:5) revealed that the 
reaction was complete. The mixture was filtered over a celite pad and the solvent was evaporated; 
the crude was purified by flash chromatography (silica, CHCl3 with a gradient of MeOH from 2 % 
to 5 %) to give 142 mg of final product (5.17) as a colourless oil (yield 80 %). Spectral data were 
identical to those reported.8 
 
1H-NMR (400 MHz, CD3OD): δ 4.90 (d, 1H, H1, J1-2 = 1.6 Hz), 4.98 – 3.93 (m, 1H, HD2), 3.85– 
3.74 (m, 3H, H2, H7), 3.72 – 3.62 (m, 10H, H10, HD1, H8, H3), 3.62 – 3.45 (m, 3H, H4, H5, H6a), 3.19 
(dd, 1H, H6b, J6a-6b = 13.3 Hz, J6a-5 = 5.1 Hz), 2.97 – 2.78 (m, 2H, HD4, HD5), 2.14 - 1.98 (m, 2H, 
HD3ax, HD6ax), 1.86 – 1.71 (m, 2H, HD3eq, HD6eq) , 1.44 (s, 9H, tBu). 
 
Synthesis of (1S,2S,4S,5S) 1,2-Cyclohexanedicarboxylic acid, 4-(2-azidoethoxy)-5-(6-N-carbo-
t-butoxy-α-D-6-deoxymannopyranosyloxy)-1,2-dimethyl ester, 5.18 
 
 
To a stirred solution of 5.17 (132 mg, 0.24 mmol, 1 eq.) in 3 mL of dry DMF, NaI (3.6 mg, 0.024 
mmol, 0.1 eq.) and NaN3 (77 mg, 1.18 mmol, 5 eq.) were added under inert atmosphere at room 
temperature. The reaction was heated to 50 °C and stirred for 3 days. 1H-NMR analysis assessed the 
completion of the reaction. The solvent was evaporated and the crude was purified with flash 
chromatography (silica, CHCl3:MeOH 95:5) to give 117 mg of final product (5.18) as a colourless 
oil (yield 88 %). Spectral data were identical to those reported.8 
 
1H-NMR (400 MHz, CD3OD): δ 4.84 (d, 1H, H1, J1-2 = 1.6 Hz), 3.93 – 3.89 (m, 1H, HD2), 3.78 – 
3.77 (m, 1H, H2), 3.74 – 3.64 (m, 2H, H7), 3.65 – 3.55 (m, 8H, H10, HD1, H3), 3.51 – 3.36 (m, 3H, 
H4, H5, H6a), 3.31 (t, 2H, H8, J7-8 = 4.7 Hz), 3.12 (dd, 1H, H6b, J6a-6b = 13.5 Hz, J6a-5 = 5.4 Hz), 2.90 
Chapter 5 
	  
 
	  
248	  
– 2.72 (m, 2H, HD4, HD5), 2.08 - 1.92 (m, 2H, HD3ax, HD6ax), 1.80 – 1.63 (m, 2H, HD3eq, HD6eq), 1.46 
(s, 9H, tBu). 
 
Synthesis of (1S,2S,4S,5S) 1,2-Cyclohexanedicarboxylic acid, 4-(2-azidoethoxy)-5-(6-N-amino-
α-D-6-deoxymannopyranosyloxy)-1,2-dimethyl ester, 5.8 
 
 
Compound 5.18 (52.3 mg, 0.094 mmol, 1 eq.) was dissolved in CH2Cl2 (3.7 mL); TFA (1.2 mL, 
166 eq.) was added. The resulting solution was stirred at room temperature for 1h. TLC analysis 
(CHCl3:MeOH 85:15) revealed that the reaction was complete. The solvent was removed under 
reduce pressure; the crude was washed and dried twice with diethyl ether. 54.4 mg of 5.8 were 
obtained as a white solid (yield 100 %). Spectral data were identical to those reported.8 
 
1H-NMR (400 MHz, CD3OD): δ 4.98 (d, 1H, H1, J1-2 = 1.6 Hz), 4.04 – 3.89 (m, 1H, HD2), 3.87 
(dd, 1H, H2, J1-2 = 1.6 Hz, J3-2 = 3.0 Hz), 3.82 – 3.76 (m, 1H, H7a), 3.74 – 3.63 (m, 9H, H10, HD1, H3, 
H7b), 3.63 – 3.50 (m, 2H, H4, H5), 3.42 – 3.34 (m, 2H, H8), 3.19 (dd, 1H, H6a, J6a-6b = 13.2 Hz, J6a-5 = 
2.6 Hz), 3.04 – 2.79 (m, 3H, H6b, HD4, HD5), 2.20 – 2.00 (m, 2H, HD3ax, HD6ax), 1.88 – 1.70 (m, 2H, 
HD3eq, HD6eq). 
 
Synthesis of (1S,2S) 4-cyclohexene-1,2-dicarboxylic acid bis(p-nitro-phenylester), 5.20 
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To a solution of (1S,2S)-4-Cyclohexane-1,2-dicarboxylic acid,(+) 5.19 (1.27 g, 7.5 mmol, 1 eq.) in 
dry THF (75 mL) under nitrogen atmosphere, EDC-HCl (5.0 g, 26.1 mmol, 3.5 eq.) was added. 
After 10 minutes, p-nitrophenol (3.13 g, 22.5 mmol, 3 eq.) was added. The solution was stirred at 
room temperature for 2 h. TLC analysis (Hex:AcOEt 6:4) revealed that the reaction was complete. 
The solvent was removed under reduce pressure and the crude was taken up in AcOEt (240 mL). 
The organic phase was washed with 1M HCl (2 x 120 mL), NaHCO3 sat.sol. (0 °C, 2 x 100 mL) and 
H2O (2 x 120 mL) and the dried over Na2SO4 anhydrous. The crude was concentrated under 
reduced pressure to obtain 1.95 g 5.20 as a pale yellow solid (yield 62 %). 
 
1H NMR (400 MHz, CDCl3): δ = 8.26-8.24 (m, 4H, H10); 7.26-7.23 (m, 4H, H9); 5.83 (d, J = 3.0 
Hz, 2H, H4, H5); 3.24-3.21 (m, 2H, H1, H2); 2.78-2.68 (m, 2H, H3ps-eq, H6ps-eq); 2.47-2.36 (m, 2H, 
H3ps-ax, H6ps-ax). 
13C NMR (CDCl3): δ = 172,6, 171,5 (C7); 155.4 (C11); 145.7 (C8); 125.5 (C10); 124.9 (C5, C4); 
122.5 (C9); 41.5 (C1, C2); 28.0 (C3, C6). 
 
[α]D25: +129.6 (c = 1 in CHCl3) 
 
Synthesis of (3S,4S) 7-Oxabicyclo [4.1.0]heptane-3,4-dicarboxylic acid bis(p-nitro-phenyl-
ester), 5.21 
 
 
Compound 5.20 (1.9 g, 4.65 mmol, 1 eq.) was dissolved in dry CH2Cl2 (16 mL). 77 % mCPBA (1.3 
g, 5.8 mmol effective, 1.2 eq.) was added. The solution was stirred at room temperature under 
nitrogen atmosphere overnight. TLC analysis (Hex:AcOEt 6:4) revealed that the reaction was 
complete. The organic phase was washed with NaHCO3 sat. sol. (2 x 60 mL), H2O (60 mL) and brine 
(60 mL) and then dried over Na2SO4 anhydrous. The crude was concentrated under pressure, to 
obtain 2.05 g of 5.21 as a pale yellow solid (yield 100 %). 
 
1H NMR (400 MHz, CDCl3): δ = 8.28-8.23 (m, 4H, H10); 7.30-7.25 (m, 4H, H9); 3.46-3.44 (m, 1H, 
H4 or H5); 3.40-3.38 (m, 1H, H4 or H5); 3.37-3.27 (m, 1H, H1 or H2); 3.16-3.04 (m, 1H, H1 or H2); 
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2.85-2.75 (m, 1H, H3eq or H6eq); 2.64 (m, 1H, H3eq or H6eq); 2.46-2.37 (m, 1H, H3ax or H6ax); 2.26-
2.16 (m, 1H, H3ax or H6ax). 
13C NMR (100 MHz, CDCl3): δ = 172.6, 171.5 (C7); 155.4, 155.3 (C8); 149.9 (C11); 125.5 (C10); 
122.5, 122,6 (C9); 51.8, 50.3 (C4, C5); 40.1, 38.1 (C1, C2); 26.8, 26.3 (C3, C6). 
 
MS (ESI) calculated for [C20H16N2O9Na]+: 451.3, found: 452.0 
 
[α]D25: +82.2 (c = 1.1 in CHCl3). 
 
Synthesis of (1S,2S,4S,5S) 1,2-Cyclohexanedicarboxylic acid, 4-hydroxy-5-(2-chloroethoxy)- 
1,2-bis(4-nitro)phenyl ester, 5.5 
 
 
To a solution of 5.21 (2.0 g, 4.67 mmol, 1 eq.) in a minimum amount of dry CH2Cl2 (3.6 mL), 2-
chloroethanol (4.7 mL, 70.0 mmol, 15 eq.) and Cu(OTf) 2 (272.76 mg, 0.75 mmol, 0.2 eq) were 
added. The solution was stirred at room temperature overnight. After completion of the reaction 
(TLC Hex:AcOEt 1:1), the crude was concentrated under reduce pressure and purified by flash 
chromatography (silica, Hex:AcOEt 6:4). 1.3 g of final compound 5.5 were obtained as yellowish 
oil (yield 54 %). 5.5 contained the 3 % w/w of free p-NO2-phenol, but it was used without further 
purifications. 
 
1H NMR (400 MHz, CDCl3): δ = 8.29–8.25 (m, 4H, H12); 7.28-7.24 (m, 4H, H11); 4.19-4.16 (m, 
1H, H2); 3.95–3.90 (m, 1H, H7a); 3.81–3.76 (m, 1H, H7b); 3.69–3.66 (m, 3H, H8, H1); 2.50–2.36 (m, 
2H, H4, H5); 2.37–2.14 (m, 4H, H3, H6). 
13C NMR (100 MHz, CDCl3): δ = 172.9, 172.9 (C9); 155.6 (C10); 145.8, 145.7 (C13); 125.6 (C12); 
122.7, 122,7 (C11); 76.5 (C1); 69.5 (C7); 66.5 (C2); 43.6 (C8); 39.6, 39.1 (C4, C5); 30.7, 27.3 (C3, 
C6). 
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Synthesis of (1S,2S,4S,5S) 1,2-Cyclohexanedicarboxylic acid, 4-(2-chloroethoxy)-5-[(2,3,4,-tri-
O-benzoyl)-6-azido-α-D-6-deoxymannopyranosyloxy]-1,2-bis(p-nitrophenyl ester), 5.7 
 
 
The acceptor 5.5 (381 mg, 0.755 mmol, 1 eq.) and the donor 5.3 (450 mg, 0.68 mmol, 0.9 eq.) were 
coevaporated with toluene three times. Powdered and activated acid washed 4 Å molecular sieves 
were added; the mixture was kept under vacuum overnight and then dissolved in 7.6 mL of dry 
CH2Cl2. After cooling at -30°C, TMSOTf (27 µL, 0.15 mmol, 0.2 eq.) was added and the reaction 
was stirred under nitrogen flushing for 1 h. TLC analysis (Hex:AcOEt 7:3) revealed that the 
reaction was complete. The mixture was quenched with dry Et3N (300 µL) and the mixture warmed 
to room temperature and filtered over a celite pad. The filtrate was was evaporated at reduce 
pressure and the crude purified by flash chromatography (silica, Hex with gradient of AcOEt from 0 
% to 40 %), obtaining 484.7 mg of 5.7 as yellowish solid (yield 69 %). 5.7 contained the 2 % w/w 
of free p-NO2phenol, but it was used without further purifications. 
 
1H NMR (400 MHz, CDCl3): δ  = 8.36-8.24 (m, 4H, H12); 8.13-8.07 (m, 2H, HBz); 8.01-7.93 (m, 
2H, HBz); 7.84-7.76 (m, 2H, HBz); 7.73-7.61 (m, 1H, HBz); 7.59-7.48 (m, 4H, HBz); 7.48-7.38 (m, 
4H, HBz); 7.34-7.28 (m, 4H, H11); 5.90 (dd, 1H, H3, J3-2 = 3.1 Hz, J3-4 = 10.0 Hz); 5.84 (t, 1H, H4, 
J4-3 = 3.1 Hz, J4-5 = 10.0 Hz); 5.76-5.75 (m, 1H, H2); 5.35 (bs, 1H, H1); 4.35-4.19 (m, 2H, H5, HD2); 
4.06-3.93 (m, 2H, H7a, HD1); 3.93-3.80 (m, 1H, H7b); 3.71 (t, 1H, H8, J8-7 = 5.5 Hz); 3.63 (dd, 1H, 
H6a, J6a-5 = 7.8 Hz, J6a-6b = 13.3 Hz); 3.52-3.36 (m, 3H, H6b, HD5, HD4); 2.63-2.44 (m, 2H, HD3eq, 
HD6eq); 2.32-2.17 (m, 2H, HD3ax, HD6ax). 
13C NMR (100 MHz, CDCl3): δ = 171.9, 171.8 (C9); 165.6, 165.4, 165.3 (COBz); 155.1, 155.1 
(C10); 145.4, 145.3 (C13); 133.6, 133.7, 133.3 (CHBz); 129.7, 129.6, 129.5 (CHBz); 128.8, 128.5, 
128.3 (CquatBz); 128.5, 128.4, 128.3 (CHBz); 125.1, 125,0 (C12); 122.3, 122.2 (C11); 96.4 (C1); 74.1 
(CD1); 72.1 (CD2); 71.9 (C5) 71.1 (C2); 70.2 (C7); 69.7 (C3); 67.3 (C4); 51.2 (C6); 42.7 (C8); 38.7, 
38.6 (CD4, CD5); 27.3, 26.5 (CD3, CD6). 
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Synthesis of (1S,2S,4S,5S) N1,N2-bis(4-(hydroxymethylene)benzyl),1,2-Cyclohexanedi-
carboxamide,4-(2-chloroethoxy)-5-[2,3,4-tri-O-benzoyl-6-azido-α-D-6-deoxy-
mannopyranosyloxy], 5.25 
 
 
To a solution of compound 5.7 (464 mg, 0.47 mmol, 1 eq.) in dry MeCN (2 mL), a solution of (4-
(aminomethyl)phenyl)methanol 5.24 (193.4 mg, 1.41 mmol, 3 eq.) in MeCN (3.7 mL) was added 
drop by drop. The reaction was stirred under nitrogen atmosphere, at room temperature overnight. 
TLC analysis (CHCl3:(CH3)2O 65:35) revealed that the reaction was complete. The solvent was 
evaporated under reduce pressure and the crude purified by flash chromatography (silica, 
CHCl3:(CH3)2O 65:35) obtaining 413.4 mg of 5.25 as a white solid (yield 88 %). 
 
1H NMR (400 MHz, CDCl3): δ = 8.06-7.95 (m, 4H, HBz); 7,71-7, 69 (m, 2H, HBz); 7.64, 7.60 (m, 
1H, HBz); 7.56-7.365 (m, 6H, HBz, HAr3); 7.27-7.14 (m, 8H, HBz, HAr2); 5.88-5.86 (m, 2H, H3, H4); 
5.69-6.67 (m, 1H, H2); 5.27 (bs, 1H, H1); 4.68–4.53 (m, 4H, CH2OH); 4.45–4.27 (m, 5H, CH2NH, 
H5); 4.13-4.08 (m, 1H, HD2), 3.88–3.77 (m, 3H, H7, HD1); 3.71 (t, 2H, H8, J8-7 = 5.6 Hz); 3.53 (dd, 
1H, H6a, J6a-6b = 13.3 Hz, J6a-5 = 6.9 Hz); 3.45 (dd, 1H, H6b, J6b-6a = 13.3 Hz, J6b-5 = 2.0 Hz); 3.14–
2.97 (m, 2H, HD4, HD5); 2.34–2.18 (m, 2H, HD3eq, HD6eq); 2.09–1.98 (m, 2H, HD3ax, HD6ax). 
13C NMR (100 MHz, CDCl3): δ = 174.7, 174.6 (CONH); 166.3, 166.2,166.1 (COBz); 140.3, 140.2 
(CAr1); 137.9, 137.8 (CAr4); 133.8, 133.7, 133.4, 133.3 (CHBz); 130.4, 130.4, 130.2 (CHBz); 129.1, 
128.9, 128.8 (CAr2, CAr3); 128.1, 128.0, 127.7 (CHBz); 95.9 (C1); 73.9, 73.6 (CD1, CD2); 71.3 (C2, 
C5); 68.7 (C7); 69.5, 67.4 (C4, C3); 64.8 (CH2OH); 50.1 (C6); 43.2,  41,1 (CH2NH, C8); 40.8, 40.6 
(CD4, CD5); 27.8, 27.7 (CD3, CD6). 
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Synthesis of (1S,2S,4S,5S) N1,N2-bis(4-(hydroxymethylene)benzyl),1,2-Cyclohexane-
dicarboxamides-4-(2-chloroethoxy)-5-[6-azido-α-D-6-deoxy-mannopyranosyloxy], 5.26 
 
 
The compound 5.25 (413.3 mg, 0.41 mmol, 1 eq.) was dissolved in dry MeOH (4.1 mL), under 
nitrogen atmosphere at room temperature, and a solution of sodium methoxide in MeOH (1 M, 620 
µL, 0.620 mmol, 1.5 eq.) was added. The reaction was stirred under nitrogen atmosphere at room 
temperature for 2.5 h; TLC analysis (CH2Cl2:MeOH 85:15) revealed that the reaction was complete. 
The mixture was purified by flash chromatography (silica, CH2Cl2:MeOH 85:15) to afford 260 mg 
of 5.26 as a white solid (yield 91 %).  
  
1H NMR (400 MHz, CD3OD): δ = 7.27 (d, 4H, HAr3, J = 8.1 Hz); 7.22 (d, 4H, HAr2, J =8.1 Hz); 
4.95 (bs, 1H, H1); 4.56 (s, 4H, CH2OH); 4.29 (s, 4H, CH2NH); 4.03-4.02 (m, 1H, HD2); 3.93-3.81 
(m, 1H, H2); 3.86 (dd, 1H, H7a, J7a-7b = 10.9 Hz, J7a-8 = 5.4 Hz); 3.78 (dd, 1H, H7b, J7b-7a = 10.9 Hz, 
J7b-8 = 5.7 Hz); 3.79-3.63 (m, 5H, HD1, H8, H5, H3); 3.58-3.53 (m, 1H, H4); 3.49-3.41 (m, 2H, H6); 
3.01-2.82 (m, 2H, HD4, HD5); 2.05-1.85 (m, 4H, HD3, HD6). 
13C NMR (100 MHz, CD3OD): δ = 176.9, 176.6 (CONH); 141.5, 141.3 (CAr4); 139.1, 139.0 (CAr1); 
128.3, 128.3 (CAr2); 128.2, 128.2 (CAr3); 97.2 (C1); 75.1 (CD1); 75.0 (CD2); 71.3 (C5, C2); 70.7 (C7); 
69.5 (C3); 67.4 (C4); 65.1 (CH2OH); 51.3 (C6); 44.3 (C8); 43.7 (CH2NH); 41.1 (CD4, CD5); 29.08, 
28.7 (CD3, CD6). 
 
MS (ESI HRMS) calculated for [C32H42ClN5O10Na]+: 714.25124; found: 714.25095. 
 
[α]D25: -12.04 (c = 0.25 in MeOH) 
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Synthesis of (1S,2S,4S,5S) N1,N2-bis(4-(hydroxymethylene)benzyl),1,2-Cyclohexane-
dicarboxamides-4-(2-chloroethoxy)-5-[6-N-carbo-t-butoxy-α-D-6-deoxymannopyranosyloxy], 
5.27 
 
 
To a solution of 5.26 (88.8 mg, 0.128 mmol, 1 eq.) and Boc2O (42 mg, 0.192 mmol, 1.5 eq.) in dry 
MeOH (12.8 mL), Pd Lindlar was added in catalytic amount. The reaction was stirred under H2 (1 
atm) at room temperature for 5 h. TLC analysis (RP H2O:MeOH 4:6) revealed that the reaction was 
complete. The reaction was filtered through a celite pad and washed with MeOH. The filtrate was 
purified by flash chromatography (silica, CH2Cl2 with a gradient of MeOH from 10 % to 15 %). 
The crude was concentrated under reduce pressure to yield 88.2 mg of 5.27 as a white foam (yield 
90 %). 
 
1H NMR (400 MHz, CD3OD): δ = 7.27 (m, 4H, HAr3); 7.21 (m, 4H, HAr2); 4.90 (bs, 1H, H1); 4.56 
(s, 4H, CH2OH); 4.28 (s, 4H, CH2NH); 3.99-3.98 (m, 1H, HD2); 3.89-3.88 (m, 1H, H2); 3.84 (dd, 
1H, H7a, J7a-7b = 11.1 Hz, J7a-8 = 5.6 Hz); 3.78 (dd, 1H, H7b, J7b-7a = 11.1 Hz, J7b-8 = 5.4 Hz); 3.74-
3.61 (m, 4H, H3, H8, HD1); 3.59-3.43 (m, 3H, H4, H5, H6b); 3.27-3.10 (m, 1H, H6a); 3.01-3.81 (m, 
2H, HD4, HD5); 1.97-1.87 (m, 4H, HD3, HD6); 1.44 (s, 9H, tBu). 
13C NMR (100 MHz, CD3OD): δ = 177.3, 177.0 (CONH); 141.2, 141.0, (CAr4); 139.8, 139.6 
(CAr1); 128.6, 128.4 (CAr2); 127.5, 127.2 (CAr3); 100.6 (C1); 80.3 (CquattBu); 75.8 (C3); 74.7 (CD1); 
72.2 (CD2); 72.7 (CD2); 72.2 (C2); 70.4 (C7); 69.5 (C4); 64.9, 64.8 (CH2OH); 53.1 (C6); 44.4 (C8); 
43.7, 43.6 (CH2NH); 42.4, 42.2 (C6); 41.8 (CD4, CD5); 29.8, 29.4 (CD3, CD6); 28.2 (CtBu). 
 
MS (ESI) calculated for [C37H52N3O12Na]+: 788.32; found: 788.31 
 
[α]D25: +9.28 (c = 0.21 in MeOH) 
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Synthesis of (1S,2S,4S,5S) N1,N2-bis(4-(hydroxymethylene)benzyl),1,2-Cyclohexane-
dicarboxamides-4-(2-azidoethoxy)-5-[6-N-carbo-t-butoxy-α-D-6-deoxymannopyranosyloxy], 
5.28 
 
 
To a solution of 5.27 (250 mg, 0.326 mmol, 1 eq.) in dry DMF (4 mL), sodium azide (106 mg, 1.63 
mmol, 5 eq.) was added. The reaction was stirred at 50 °C under nitrogen atmosphere for 3 days. 1H 
NMR analysis assessed the completion of the reaction. The solvent was removed under reduce 
pressure and the crude was purified by flash chromatography (silica, CH3Cl:MeOH 85:15) to afford 
222.8 mg of 5.28 as a white foam (yield 88 %). 
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1H NMR (400 MHz, MeOD): δ = 7.28 (d, 4H, HAr3, J = 8.0 Hz); 7.22 (d, 4H, HAr2, J = 8.0 Hz); 
4.91 (bs, 1H, H1); 4.55 (s, 4H, CH2OH); 4.28 (s, 4H, CH2NH); 3.99-3.98 (m, 1H, HD2); 3.89-3.88 
(m, 1H, H2); 3.83-3.75 (m, 1H, H7a); 3.73-3.66 (m, 3H, H7b, H3, HD1); 3.56-3.46 (m, 3H, H6a, H4, 
H5); 3.43-3.35 (m, 2H, H8); 3.26-3.17 (m, 1H, H6b); 3.03-2.78 (m, 2H, HD4, HD5); 2.04-1.85 (m, 4H, 
HD3, HD6); 1.44 (s, 9H, tBu). 
13C NMR (100 MHz, MeOD): δ= 176.9, 176.8 (CONH); 141.5, 141.5, (CAr4); 138.9, 138.9 (CAr1); 
128.3, 128.3 (CAr2); 128.2, 128.2 (CAr3); 101.2 (C1); 80.4 (CquattBu); 76.3 (CD1); 75.1 (C5); 72.9 
(CD2); 72.3 (C2); 72.2 (C3); 70.4 (C4); 69.5 (C7); 64.7 (CH2OH); 51.9 (C8); 43.9 (CH2NH); 42.8, 
42.8 (C6); 42.4 (CD4, CD5); 29.6, 29.4 (CD3, CD6); 28.2 (CtBu). 
 
MS (ESI HRMS) calculated for [C37H52N6O12Na]+: 795.35354 ; found: 795.35211. 
 
[α]D25: + 9.94 (c = 0.90 in MeOH). 
 
Synthesis of (1S,2S,4S,5S) N1,N2-bis(4-(hydroxymethylene)benzyl)-1,2-Cyclohexane-
dicarboxamides-4-(2-azidoethoxy)-5-[6-amino-α-D-6deoxymannopyranosyloxy], 5.9 
 
 
Compound 5.28 (25.5 mg, 0.033 mmol, 1eq) was dissolved in TFA (400 µL, 5.220 mmol, 158 eq.). 
The resulting solution was stirred at 35 °C for 4h. After completion of the reaction (TLC analysis 
(CHCl3:MeOH 85:15) revealed that the reaction was complete. The solvent was removed under 
reduce pressure and the crude residue was washed and dried twice with Et2O. 25 mg of 5.9 were 
obtained as a white solid (yield 100 %). 
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1H NMR (400 MHz, D2O) δ = 7.29 (d, 4H, HAr3, J = 8.1 Hz); 7.20 (d, 4H, HAr2, J = 8.1 Hz); 5.01 
(bs, 1H, H1); 4.56 (s, 4H, CH2OH); 4.29-4.20 (m, 4H, CH2NH); 4.06-4.02 (m, 2H, HD2, H2); 3.90 
(dd, 1H, HD1, J = 8.1 Hz); 3.84-3.76 (m, 3H, H3, H5, H7a); 3.72-3.67 (m, 1H, H7b); 3.59 (t, 1H, H4, 
J4-3 = J4-5 = 9.7 Hz); 3.47 (t, 1H, H8, J8-7 = 4.8 Hz); 3.41 (dd, 1H, H6a, J6a-6b = 13.3 Hz, J6a-5 = 2.8 
Hz); 3.17 (dd, 1H, H6b, J6b-6a = 13.3 Hz, J6b-5 = 8.3 Hz); 2.86-2.83 (m, 2H, HD4, HD5); 2.07-1.88 (m, 
4H, HD3, HD6). 
13C NMR (100 MHz, D2O): δ= 176.4, 176.3 (CONH); 163.0, 163.0 (COTFA); 139.4 (CAr4), 137.7, 
137.7, (CAr1); 128.0, (CAr2); 127.5, (CAr3); 98.3 (C1); 74.5 (C3); 71.1 (C2); 70.5 (CD2); 70.1 (CD1); 
69.1 (C5); 68.1 (C4); 67.3, 67.3 (C7); 63.7 (CH2OH); 50.6 (C8); 42.8, 42.8 (CH2NH); 40.9, 40.8 
(CD4, CD5), 40.8 (C6); 27.4, 27.0 (CD3, CD6). 
 
MS (ESI HRMS) calculated for [C32H44N6O10Na]+: 695.30111, found: 695.29999. 
 
[α]D25: +2.55 (c = 0.32 in H2O) 
 
Synthesis of pseudo-disaccharide, 5.9.1 
 
 
To a stirred solution of propargyl bromide (3.9 mg, 70.0 µmol, 5 eq.) in THF (40 µL), under inert 
atmosphere atroom temperature, reagents were added as solutions in the following order: TBTA in 
THF (1.5 mg, 1.64 µmol, 0.2 eq. in 360 µL), CuSO4·5H2O in water (0.34 mg, 1.4 µmol, 0.1 eq., in 
34 µL), Sodium Ascorbate in water (1.1 mg, 5.6 µmol, 0.4 eq., in 75 µL). The reaction mixture was 
stirred under inert atmosphere, at room temperature and in the dark for 5 min, then 5.9 in H2O (11 
mg, 14.0 µmol, 1 eq.) was added as solid. The THF and water volumes were adjusted to 400 µL 
each and the mixture was stirred for 18 h, at room temperature, under nitrogen atmosphere and in 
dark. A ESI mass analysis assessed the formation of the product. Quadrasil™-MP (S/Cu 5.4:1, 5 
mg) was added to the reaction mixture, which was stirred for 10 min, and then filtered off. The 
crude was dried, then redissolved in H2O and purified by automated reverse phase chromatography 
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(H2O with a gradient of MeOH from 0 to 50 %), to give 7.9 mg of 5.9.1 as a colourless solid (yield 
77 %). 
 
1H NMR (400 MHz, D2O): δ 8.04 (s, 1H, HT5), 7.36-7.13 (m, 8H, HAr2, HAr3), 4.91 (bs, 1H, H1), 
4.65 – 4.59 (m, 8H, H8, CH2OH (Ar), HL1), 4.29 – 4.17 (m, 4H, CH2NH), 4.06 – 3.97 (m, 2H, H2, 
H7a), 3.97 – 3.90 (m, 2H, H7b), 3.90 – 3.81 (m, 2H, HD2, H3), 3.80 – 3.72 (m, 1H, H5), 3.62-3.53 (m, 
2H, HD1, H4), 3.41 (dd, 1H, H6a, J6a-6b = 13.3, J6a-5 = 2.9 Hz), 3.21 – 3.12 (m, 1H, H6b), 2.79-2.68 
(m, 1H, HD4), 2.55-2.41 (m, 1H, HD5), 1.91-1.78 (m, 3H, HD4, HD5), 1.59-1.49 (m, 1H, HD6ax). 
13C NMR (100 MHz, D2O): δ 176.40, 176.20 (CONH), 139.47, 139.44, 137.78, 137.68 (CAr1, 
CAr4), 128.06, 127.55, 127.52 (CAr2, CAr3), 125.53 (CT5), 98.33 (C1), 74.47 (CD1), 71.15 (C3), 70.62 
(CD2), 70.22 (C2), 69.33 (C5), 68.39 (C4), 67.04 (C7), 63.88 (CH2OH (Ar)), 54.85 (CL1), 50.78 (C8), 
49.17, 42.84 (CH2NH), 42.77 (C6), 40.85, 40.79 (CD4, CD6), 27.44, 26.94 (CD3, CD6). 
 
MS (ESI HRMS) calculated for [C35H49N6O11Na]+: 729.34538, found: 729.34792. 
 
[α]D25: +1.65 (c = 0.40 in H2O) 
 
Synthesis of hexavalent glycodendrimer, 5.33 
 
 
To hexavalent central scaffold 2.24 (3.96 mg, 8.21 µmol, 1 eq.) under inert atmosphere at room 
temperature, reagents were added as solutions in the following order: TBTA in THF (0.87 mg, 1.64 
µmol, 0.2 eq. in 100 µL), CuSO4·5H2O in water (0.24 mg, 0.82 µmol, 0.1 eq., in 100 µL), Sodium 
Ascorbate in water (0.65 mg, 3.28 µmol, 0.4 eq., in 100 µL). The reaction mixture was stirred under 
inert atmosphere, at room temperature and in the dark for 5 min, then 5.18 in THF (10.1 mg, 18 
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µmol, 6.6 eq., in 200 µL). The THF and water volumes were adjusted to 650 µL each and the 
mixture was stirred for 18 h, at room temperature, under nitrogen atmosphere and in dark. A 
MALDI mass analysis (DHB or sinapinic acid matrix) assessed the formation of the product. 
Quadrasil™-MP (S/Cu 9.2:1, 5 mg)  was added to the reaction mixture, which was stirred for 10 
min, and then filtered off. The crude was dried, then redissolved in MeOH and purified firstly by 
size exclusion chromatography on a Sephadex LH-20 (MeOH) column and then by automated 
reverse phase chromatography (H2O with a gradient of MeOH from 0 to 100 %), to give 27.5 mg of 
5.33 as a colourless solid (yield 86%). 
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1H-NMR (400 MHz, CD3OD): δ 7.99 (s, 6H, HTC5), 4.90 (bs, 6H, H1), 4.65-4.58 (m, 12H. H8), 
4.53 (bs, 12H, HL1), 4.03-3.91 (m, 12H, H7), 3.87-3.78 (m, 12H, H2, HD2), 3.68-3.59 (m, 48H, H3, 
HD1, HOMe), 3.55-3.41 (m, 30H, HL2, H4, H5, H6a), 3.33 (s, 4H, HL4), 3.27 – 3.17 (m, 6H, H6b), 2.82-
2.62 (m, 12H, HD4, HD5), 2.05-1.89 (m, 12H, HD3eq, HD3eq), 1.77-1.49 (m, 12H, HD3ax, HD6ax), 1.43 
(s, 54H, HtBu). 
13C-NMR (100 MHz, CD3OD): δ 176.69, 176.59 (COOMe), 158.57 (COOtBu), 146.23 (CTC4), 
125.83 (CTC5), 101.16 (C1), 80.27 (CquattBu), 75.66 (CD1), 74.16 (C5), 73.10, 72.44, 72.20 (C3, CD2, 
C2), 70.91 (CL4), 70.26 (C4), 69.63 (CL2), 68.44 (C7), 65.51 (CL1), 52.57, 52.53 (COMe), 51.62 (C8), 
46.82 (CL3), 42.66 (C6), 40.24, 40.08 (CD4, CD5), 28.94 (CtBu), 28.68 (CD3, CD6). 
 
MS (MALDI, DHB matrix): calculated for [C166H262N24O79Na]+: 3859.0, found: 3860.0 
 
[α]D25: +27 (c = 0.4 of MeOH) 
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Synthesis of hexavalent glycodendrimer, 5.32 
 
	  
To a stirred suspension of 5.33 (20.4 mg, 5.30 µmol, 1 eq.) in 1.5 mL of dry CH2Cl2, TFA (500 µL, 
6.5 mmol, 100 eq.) was added under inert atmosphere, obtaining a complete dissolution of the 
starting material. The reaction was stirred for 1.5 h, at room temperature and under nitrogen 
atmosphere. A TLC analysis (CHCl3:MeOH:H2O 8.5:1.5:0.2) revealed that the reaction was 
complete. The reaction mixture was dried and washed with Et2O (3 x 2 mL), affording 21 mg of 
final product (5.32) as a colourless oil (yield 100 %). 
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1H NMR (400 MHz, CD3OD): δ 8.04 (s, 6H, HTC5), 4.96 (bs, H6, H1), 4.68-4.57 (m, 12H, H8), 
4.53 (bs, 12H, HL1), 4.05 – 3.90 (m, 12H, H7), 3.90 – 3.83 (m, 12H, HD2, H2), 3.76 – 3.67 (m, H3, 
H5), 3.63 (s, 36H, OMe), 3.60-3.54 (m, 12H, H4, HD1), 3.51-3.43 (m, H12, CL2), 3.42 – 3.34 (m, 6H, 
H6a), 3.34 (s, HL4), 3.14 (dd, 6H, H6b J6b-6a = 13.0, J6a-5 = 7.7 Hz), 3.82-3.60 (m, 12H, CD4, CD5), 
2.05-1.92 (m, 12H, HD3eq, HD3eq), 1.77-1.49 (m, 12H, HD3ax, HD6ax). 
13C NMR (100 MHz, CD3OD): δ 176.65, 176.54 (COOMe), 125.90 (CTC5), 99.82 (C1), 75.55 
(CD1), 72.27, 72.13, 71.85, 71.03 (C2, CD2, C3, C5), 70.84 (CL4), 70.39 (CL2), 69.61 (C4), 68.12 (C7), 
52.58 (COMe), 51.71 (C8), 42.16 (C6), 40.09 (CD4, CD5), 28.52, 27.74 (CD3, CD6). 
 
MS (MALDI, DHB matrix): calculated for [C136H215N24O67]+: 3258.3, found: 3258.8 
 
[α]D25 was not performed because NMR analysis revealed the presence of a mixture of products in 
equilibrium in solution. 
 
Synthesis of hexavalent glycodendrimer, 5.34 
 
 
To a shaken solution of 5.32 (21 mg, 5.3 µmol, 1 eq.) in 2.5 mL of dry MeOH, Amberlyst A21® (60 
mg, 10 eq.) was added under inert atmosphere at room temperature; the reaction was shaken at 1500 
rpm for 3 h. Then the crude was filtered on a cotton pad to remove the resin, washed with MeOH 
and then dried. 17.3 mg of final product 5.34 were obtained as a colourless oil (yield 100 %).  
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1H-NMR (400 MHz, CD3OD): δ 8.00 (s, 6H, HTC5), 4.96 (bs, 6H, H1), 4.66-4.58 (m, 12H, H8), 
4.58-4.48 (bs, 12H, HL1), 4.05-3.91 (m, 12H, H7), 3.91-3.86 (m, 12H, H2, HD2), 3.74-3.51 (m, 60H, 
H3, H4, H5, HD1, HOMe), 3.45 (bs, HL2), 3.17-3.02 (m, 6H, H6a), 2.88-2.60 (m, 12H, HD5, HD4), 2.08-
1.91 (m, 12H, HD3eq, HD6eq), 1.78-1.48 (m, 12H, HD6ax, HD3ax). 
 
MS (ESI-HRMS): Calculated for [C136H214N24O67Na2]2+: 1651.19454, found:1651.22786. 
 
[α]D25: +33.5 (c = 0.42 in MeOH). 
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Synthesis divalent glycodendrimer, 5.35 
 
 
To a stirred solution of TIPS-2.5 (15.1 mg, 12 µmol, 1 eq.) in 300 µL of dry THF, TBAF (1M in 
THF, 24 µL, 2 eq.) was added under inert atmosphere and the mixture was stirred for 1 h; a TLC 
analysis (CHCl3:MeOH 9:1) revealed that the desilylation reaction was complete. Then reagents 
were added as solutions in the following order: TBTA in THF (1.26 mg, 2.40 µmol, 0.2 eq, in 100 
µL), CuSO4·5H2O in water (0.35 mg, 1.20 µmol, 0.1 eq., in 100 µL) and Sodium Ascorbate in 
water (0.94 mg, 4.80 µmol, 0.4 eq., in 100 µL), and the reaction mixture was stirred under inert 
atmosphere at room temperature and in the dark for 5 min. Then 5.18 in THF (14.8 mg, 26.2 µmol, 
2.2 eq., in 200 µL) was added to the mixture. THF and water volumes were adjusted to 900 µL 
each. The mixture was stirred for 18 h under inert atmosphere, at room temperature and in the dark. 
A MALDI mass analysis (DHB or synapinic matrix) assessed the formation of the product. The 
reaction was quenched by the addition of Quadrasil™-MP (S/Cu 6.2:1, 5 mg), which was added to 
the reaction mixture, stirred for 20 min and then filtered off. The crude was dried, redissolved in 
MeOH and purified firstly by size exclusion chromatography on a Sephadex LH-20 (MeOH) and 
then by automated reverse phase chromatography (H2O with a gradient of MeOH from 0 % to 100 
%), to give 13.7 mg of 5.35 as a yellow solid (yield 55 %). 
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1H-NMR (400 MHz, CD3OD): δ 8.64 (s, 2H, H11), 7.90 (s, 2H, HR3), 7.25 (s, 2H, HR5), 7.19 (s, 
2H, HR10), 4.83 (bs, 2H, H1), 4.72-4.63 (m, 4H, H8), 4.40-7.24 (m, 12H, HG1, HG5, HG9), 4.04-3.88 
(m, 16H, HG2, HG6, HG10, H7), 3.84-3.67 (m, 28H, H2, HD2, HG4, HG8, HG12, HG3, HG11, HG7), 
3.66-3.61 (m, 4H, H3, HD1), 3.60-3.42 (m, 14H, H6a, HOMe), 3.25-3.13 (m, 2H, H6a), 2.79-2.58 (m, 
4H, HD4, HD5), 2.02-1.84 (m, 4H, HD3eq, HD6eq), 1.73-1.59 (m, 4H, HD3ax, HD6ax), 1.45 (m, 18H, tBu).  
13C-NMR (100 MHz, CD3OD): δ 176.84, 176.36 (COOMe), 158.96 (COOtBu), 155.19, 154.95 
(CR10, CR5), 149.79 (CR3), 143.90 (CTC4), 127.53 (CTC5), 121.92 (CR1), 119.14, 118.68 (CR5, CR10), 
116.30, 114.11 (CR4, CR9), 111.99 (CR2), 101,02 (C1), 92.92, 91.10 (CR7, CR8), 80.33 (CquattBu), 76.84 
(CD1), 74.15 (C5), 74.15, 73.90 (CG3, CG7, CG11), 72.95, 72.41, 71.99 (CD2, C2, C3), 71.02, 70.94, 
70.89, 70.85, 70.68 (CG2, CG5, CG6, CG9, CG10), 69.57 (C4), 69.41 (CG1), 69.05 (C7), 62.38, 62.37, 
62.30 (CG4, CG8, CG12), 52.34 (COMe), 51.61 (C8), 42.47 (C6), 40.02 (CD4, CD5), 28.59, 28,02 (CtBu, 
CD6, CD3)  
 
MS (MALDI, DHB matrix): calculated for [C96H139N8O42]+: 2077,2, found: 2076.9  
 
[α]D25: +24 (c = 0.82 in MeOH) 
 
Synthesis of divalent glycodendrimer 5.36 
 
 
To a stirred solution of 5.35 (13.7 mg, 6.6 µmol, 1 eq.) in 1.8 mL of dry CH2Cl2, TFA (600 µL, 7.8 
mmol, 120 eq.) was added. The reaction mixture was stirred for 1.5 h, under inert atmosphere and at 
room temperature. A TLC analysis (CHCl3:MeOH:H2O 8.5:1.5:0.2) revealed that the cleavage of 
Boc was complete. The crude was dried coevaporating with Et2O (2 x 3 mL), to afford 13.9 mg of 
final product 5.36 as a yellow oil (yield 100 %). 
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1H-NMR (400 MHz, CD3OD): δ 8.64 (s, 2H, H11), 7.88 (s, 2H, HR3), 7.24 (s, 2H, HR6), 7.18 (s, 2H, 
HR11), 4.92 (bs, 2H, H1), 4.76-4.66 (m, 4H, H8), 4.42-4.22 (m, 12H, HG9, HG1, HG5), 4.10-3.89 (m, 
16H, HG2, HG6, HG10, H7), 3.89-3.61 (m, 32H, HD2, H2, H3, H5, HG3, HG4, HG7, HG8, HG11, HG12), 
3.61-3.49 (m, 16H, HOMe, HD1, H4), 3.42-3.36 (m, 2H, H6a), 3.19-3.07 (m, 2H, H6b), 2.81-2.64 (m, 
4H, HD5, HD4) 2.09-1.90 (m, 4H, HD3eq, HD6eq), 1.74-1.43 (m, 4H, HD3ax, HD6ax). 
13C-NMR (100 MHz, CD3OD): δ 176.94, 176.17 (COOMe), 155.41, 154.85 (CR6, CR11), 150.80 
(CR3), 143.54 (CTC5), 122.46 (CR1), 119.22, 118.49 (CR5, CR10), 116.01, 114.61 (CR4, CR9), 113.13 
(CR2), 99.72 (C1), 92.71, 91.65 (CR7, CR8), 75.60 (CD1), 74.10, 73.72 (CG3, CG7, CG11), 72.22, 71.89, 
71.81, 71.04 (CD2, C2, C3, C5), 70.99, 70.84, 70.65, 69.80 (CG2, CG5, CG6, CG9, CG10), 69.52 (C4), 
69.47 (C7), 68.55 (CG1), 62.36, 62.28 (CG4, CG8, CG12), 52.40 (COMe), 51.59 (C8), 42.17 (C6), 40.02 
(CD4, CD5), 28.74, 27.47 (CD3, CD6). 
 
MS (MALDI, DHB matrix): calculated for [C86H122N8O38]+: 1876,9, found: 1876.5 
 
[α]D25 was not performed because NMR analysis revealed the presence of a mixture of products in 
equilibrium in solution. 
 
Synthesis of divalent glycodendrimer 5.37 
 
 
To a shaken solution of 5.36 (13.9 mg, 6.6 µmol, 1 eq.) in 1.6 mL of MeOH, Amberlyst A21® (60 
mg, 50 eq.) was added, under inert atmosphere at room temperature and the reaction was shaken at 
1500 rpm for 3 h. Then the crude was filtered on a cotton pad to remove the resin, washed with 
MeOH and then dried. 10.6 mg of final product 5.37 were obtained as a yellowish oil (yield 86 %).  
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1H-NMR (400 MHz, CD3OD): δ 8.63 (s, 2H, HTC5), 7.87 (s, 2H, HR3), 7.24 (s, 2H, HR5), 7.17 (s, 
2H, HR10), 4.90 (m, 2H, H1), 4.72-4.64 (m, 4H, H8), 4.43-4.17 (m, 12H, HG9, HG1, HG5), 4.10-3.89 
(m, 16H, HG2, HG6, HG10, H7), 3.86-3.60 (m, 32H, HD2, H2, H3, H5, HG3, HG4, HG7, HG8, HG11, HG12), 
3.62-3.46 (m, 16H, HOMe, H5, HD1), 3.14-3.01 (m, 2H, H6b), 2.79-2.65 (m, 4H, HD4, HD5), 2.11-1.87 
(m, 4H, HD3eq, HD6eq), 1.72-1.4 (m, 4H, HD3ax, HD6ax). 
 
MS (ESI-HRMS): Calculated for: [C86H123N8O38Na]2+: 949.39180, found: 949.93389 
 
[α]D25: +18.1 (c = 0.53 in MeOH). 
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Synthesis of hexavalent glycodendrimer, 5.38 
 
 
To Hexa(2-propynyloxymethyl)bispentaeritritol 2.24 (2.4 mg, 4.96 µmol, 1 eq.) dissolved in THF 
(100 µL) under inert atmosphere at room temperature, reagents were added as solutions in the 
following order: TBTA in THF (0.5 mg, 1.0 µmol, 0.2 eq., in 50 µL), CuSO4·5H2O in water (0.12 
mg, 0.5 µmol, 0.1 eq., in 50 µL) and Sodium Ascorbate in water (0.4 mg, 2.0 µmol, 0.4 eq., in 50 
µL). The reaction mixture was stirred under inert atmosphere, at room temperature and in the dark 
for 5 min, then 5.28 in H2O was added (25.3 mg, 32.7 µmol, 6.6 eq., in 350 µL). The THF and 
water volumes were adjusted to 450 µL each and the mixture was stirred for 24 h. A MALDI mass 
analysis (DHB matrix) assessed the formation of the product. Quadrasil™-MP (S/Cu 15.1:1, 5 mg)  
was added to the reaction mixture, which was stirred for 10 min, and then filtered off. The crude 
was dried, then redissolved in MeOH and purified by size exclusion chromatography on a Sephadex 
LH-20 (MeOH) column. 18.9 of 5.38 were obtained as a white solid (yield 74 %). 
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1H NMR (400 MHz, CD3OD): δ 7.98 (s, 6H, HTC5), 7.32 – 7.06 (m, 48H, HAr2, HAr3), 4.84 (s, 6H, 
H1), 4.60-4.40 (m, 48H, H8, HL1, CH2OH), 4.30-4.20 (s, 24H, CH2NH), 4.00-3.74 (m, 24H; H7, H2, 
HD2), 3.73-3.58 (m, 12H, H3, HD1), 3.56-3.35 (m, 34H, H4, H5, H6a, HL2, HL4), 3.20-3.27 (m, 6H, 
H6b), 2.75-2.84 (m, 12H, HD4, HD5), 1.90-1.70 (m, 24H, HD3, HD6), 1.39 (s, 36H, tBu). 
13C NMR (100 MHz, CD3OD): δ 176.89, 176.63 (CONH), 158.58 (COOtBu), 146.16 (CTC4), 
141.58, 141.54, 139.09, 139.00 (CAr1, CAr4), 128.39 (CAr2, CAr3), 128.18 (CTC5), 101.02 (C1), 80.26 
(CquattBu), 76.23 (CD1), 74.06 (C5), 72.36, 72.24 (CD2, C2, C3), 70.27 (CL2, CL4), 69.77 (C4), 68.49 
(C7), 65.45, 64.92 (CH2OH, CL1), 51.67 (C8), 46.79 (CH2NH), 43.68 (C6), 42.69 (CD4, CD5), 41.79, 
41.69, 28.97 (CD3, CD6, CtBu). 
 
MS (MALDI, DHB matrix): calculated for [C250H346N36O79Na]+: 5142.6, found: 5145.3 
 
[α]D25: -2.3 (c = 0.24 in MeOH) 
 
Synthesis of hexavalent glycodendrimer, 5.39 
 
	  
To a stirred solution of 5.38 (4.9 mg, 0.96 µmol, 1 eq.) in 125 µL of dry CH2Cl2, 125 µL of TFA 
(170 eq.) were added under inert atmosphere. The reaction was stirred for 1 h, at room temperature 
and under nitrogen atmosphere. A TLC analysis (CHCl3:MeOH:H2O 7:3:0.5) revealed that the 
reaction was complete. The reaction mixture was dried and washed with Et2O (3 x 2 mL), affording 
5.0 mg of final product (5.39) as a whit-brownish solid (yield 100 %). 
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Synthesis of hexavalent glycodendrimer, 5.40 
 
 
To a shaken solution of 5.39 (4.9 mg, 1.0 µmol, 1 eq.) in 700 µL of ry MeOH, Amberlyst A21® (16 
mg, 100 eq.) was added, under inert atmosphere at room temperature, and the reaction was shaken 
at 1500 rpm for 3 h. Then the crude was filtered on a cotton pad to remove the resin, washed with 
MeOH and then dried. 4.5 mg of final product 5.40 were obtained as a white solid (yield 86%).  
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1H NMR (400 MHz, CD3OD): δ 7.98 (s, 6H; HTC5), 7.32 – 7.12 (m, 48H, HAr2, HAr2), 4.72 – 4.37 
(m, 48H, CH2OH, H8, HL1), 4.20-4.28 (m, 24H, CH2NH), 4.00 – 3.75 (m, 24H, H7, H2, HD2), 3.73-
3.70 (m, 12H, H3, H5), 3.60-3.39 (m, 22H, H4, HL1, HL2), 3.32 (6H, H6a), 3.05-3.20 (m, 6H, H6b), 
2.75-2.85 (m, 12H, HD4, HD5), 1.90-1.60 (m, 24H, HD3, HD6). 
13C NMR (100 MHz, CD3OD): δ 176.56 (CONH), 141.62 (CTC4), 139.46, 139.39, 138.99 (CAr1, 
CAr2), 128.41 (CAr2, CAr3), 128.21 (CTC5), 99.73 (C1), 75.75 (CD1), 72.16, 72.08, 71.90, 71.55 (C2, 
CD2, C3, C5), 70.11 (CL2, CL4), 69.64 (C4), 67.93 (C7), 65.17, 64.73 (CH2OH, CL1), 51.27 (C8), 43.73 
(CH2NH), 42.64 (C6), 41.71 (CD4, CD5), 30.85 (CD3, CD6). 
 
[α]D25: -3.9 (c = 0.15 in MeOH) 
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Synthesis of divalent glycodendrimer, 5.41 
 
 
To a stirred solution of TIPS-2.5 (8.1 mg, 6.4 µmol, 1 eq.) in 200 µL of THF, TBAF (1M in THF, 
12.8 µL, 12.8 µmol, 2 eq.) was added under inert atmosphere and the mixture was stirred for 1 h; a 
TLC analysis (CHCl3:MeOH 9:1) revealed that the desiylation reaction was complete. Then 
reagents were added as solutions in the following order: TBTA in THF (0.68 mg, 1.28 µmol, 0.2 eq, 
in 120 µL), CuSO4·5H2O in water (0.16 mg, 0.64 µmol, 0.1 eq., in 60 µL) and Sodium Ascorbate in 
water (0.51 mg, 2.56 µmol, 0.4 eq., in 60 µL). The reaction mixture was stirred, under inert 
atmosphere at room temperature in the dark, for 5 min. Then 5.28 in water (10.5 mg, 14.1 µmol, 2.2 
eq., in 200 µL) was added to the mixture; THF and water volumes were adjusted to 320 µL each. 
The mixture was stirred for 18 h under inert atmosphere, at room temperature and in the dark. A 
MALDI mass analysis (DHB matrix) assessed the formation of the product. The reaction was 
quenched by the addition of Quadrasil™-MP (S/Cu 11.8:1, 5 mg), which was added to the reaction 
mixture, stirred for 20 min and then filtered off. The crude was dried, redissolved in MeOH and 
purified first by size exclusion chromatography on a Sephadex LH-20 (MeOH) and then by 
automated reverse phase chromatography (H2O with a gradient of methanol from 0 % to 100 %), to 
give 8.7 mg of 5.41 as a yellowish solid (yield 54 %). 
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1H NMR (400 MHz, CD3OD): δ 8.63 (s, 2H, HTC5), 7.85 (s, 2H, HR2), 7.33-7.10 (m, 20H,HR10, 
HR5, HAr2, HAr3), 4.91 (bs, 2H, H1), 4.72-4.60 (m, 4H, H8), 4.59-4.50 (m, 8H, CH2OH), 4.35-4.13 
(m, 20H, CH2NH, HG1, HG5, HG9), 4.08-3.96 (m, 4H, H7), 3.95-3.80 (m, 16H, H2, HD2, HG2, HG6, 
HG10), 3.78 – 3.62 (m, 26H, H3, HG3, HG7, HG11, HG4, HG8, HG12), 3.62-3.57 (m, 1H, HD1), 3.52-3.40 
(H4, H5), 3.31 (2H, H6a), 3.30-3.22 (m, 2H, H6b), 2.85-2.70 (m, 4H, HD4, HD5), 1.90-1.70 (m, 8H, 
HD3, HD6), 1.42 (s, 18H, tBu). 
13C NMR (100 MHz, CD3OD): δ 176.95, 176.55 (COONH), 158.66 (COOtBu), 155.43, 154.98 
(CR6, CR11), 150.44 (CR3), 143.56 (CTC4), 141.58, 141.51, 139.13, 138.88 (CAr1, CAr4), 128.37, 
128.31, 128.19, 128.15 (CAr2, CAr3), 127.41 (CTC5), 122.37 (CR1), 119.15, 118.58 (CR5, CR10), 
115.98, 114.46 (CR4, CR9), 112.81 (CR2), 100.76 (C1), 92.77, 91.67 (CR7, CR8), 80.26 (CquattBu), 76.59 
(CD1), 74.13, 74.10 (CG3, CG7), 74.03 (C5), 73.65 (CG11), 72.87, 72.35, 72.21 (C2, CD2, C3), 71.01, 
70.93, 70.84, 70.65 (CG5, CG9, CG2, CG6, CG10), 69.69 (C4), 69.44 (CG1), 68.99 (C7), 64.947, 64.94 
(CH2OH), 62.40, 62.35, 62.26 (CG4, CG8, CG12), 51.74 (C8), 43.64 (CH2NH), 42.58 (C6), 41.74 (CD4, 
CD5), 30.00, 29.30 (CD3, CD6), 28.88 (CtBu). 
 
MS (MALDI, DHB matrix): calculated for [C124H166N12O42Na]+: 2519.7, found: 2517.9 
 
 [α]D25: -0.9 (c = 0.38 in MeOH) 
 
Synthesis of divalent glycodendrimer, 5.42 
 
To a stirred solution of 5.41 (8.7 mg, 3.5 µmol, 1 eq.) in 500 µL of CH2Cl2, TFA (500 µL) was 
added, under inert atmosphere at room temperature and the mixture was stirred for 1 h. TLC 
(CHCl3:MeOH:H2O 7.5:5.5:0.25) and MALDI mass (HCCA matrix) analysis revealed that the 
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reaction was complete. The crude was dried coevaporating with Et2O (3 x 1 mL), to afford 8.7 mg 
of final product 5.42 as a yellow oil (yield 100 %). 
 
MS (MALDI, HCCA matrix): calculated for [C114H150N12O38Na]+: 2319.5, found: 2319.0 
 
Synthesis of divalent glycodendrimer, 5.43 
 
 
To a shaken solution of 5.42 (8.7 mg, 3.5 µmol, 1 eq.) in 1.7 mL of dry MeOH, Amberlyst A21® 
(60 mg, 100 eq.) was added, under inert atmosphere at room temperature and the reaction was 
shaken at 1500 rpm for 3 h. Then the crude was filtered on a cotton pad to remove the resin, washed 
with MeOH and then dried. 7.3 mg of final product 5.43 were obtained as a yellowish oil (yield 91 
%).  
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1H NMR (400 MHz, CD3OD): δ 8.64 (s, 2H, HTC5), 7.85 (s, 2H, HR2), 7.28-7.10 (m, 20H, HR10, 
HR5, HAr2, HAr3), 4.91 (bs, 2H, H1), 4.72-4.50 (m, 12H, H8, CH2OH), 4.37-4.12 (m, 20H, CH2NH, 
HG1, HG5, HG9), 4.10-3.99 (m, 4H, H7), 3.95-3.80 (m, 14H, H2, HG2, HG6, HG10), 3.79 – 3.63 (m, 
30H, HD2, H3, H5, HG3, HG7, HG11, HG4, HG8, HG12), 3.58-3.45 (m, 4H, H4, HD1), 3.3-40-3.33 (m, 2H, 
H6a), 3.20-3.07 (m, 2H, H6b), 2.85-2.70 (m, 4H, HD4, HD5), 1.90-1.70 (m, 6H, HD3, HD6). 
13C NMR (100 MHz, CD3OD): δ 176.87, 176.40 (CONH), 155.46, 155.00 (CR6, CR11), 150.54 
(CR3), 141.63, 141.58, 139.07, 138.87 (CAr1, CAr4), 128.41, 128.35, 128.19, 128.16 (CAr2, CAr3), 
127.33 (CTC5), 122.24 (CR1), 119.14, 118.54 (CR5, CR10), 116.64, 115.97, 115.91, 114.68 (CR4, CR9), 
113.08 (CR2), 99.76 (C1), 92.67, 91.71 (CR7, CR8), 76.40 (CD1), 74.14, 74.09, 73.65 (CG3, CG7, CG11), 
72.40, 72.13, 71.85 (C3, C5, C2, CD2), 70.99, 70.84, 70.63 (CG5, CG9, CG2, CG6, CG10), 69.71 (C4), 
69.45 (CG1), 68.70 (C7), 64.94, 64.91 (CH2OH), 62.38, 62.36, 62.26 (CG4, CG8, CG12), 51.75 (C8), 
43.68 (CH2NH), 41.74 (CD4, CD5), 41.69 (C6), 30.77, 29.45 (CD3, CD6). 
 
MS (ESI, HRMS): calculated for: [C144H150N12O38Na2]2+: 1170.99948; found: 1171.03374 
 
[α]D25: -0.5 (c = 0.32 in MeOH) 
 
Synthesis trivalent glycodendrimer, 5.44 
 
	  
To scaffold 2.27 (7.0 mg, 19.6 µmol, 1 eq.) dissolved in THF (150 µM) under inert atmosphere at 
room temperature, reagents were added as solutions in the following order: TBTA in THF (2.1 mg, 
3.9 µmol, 0.2 eq., in 200 µL), CuSO4·5H2O in water (0.48 mg, 1.96 µmol, 0.1 eq., in 200 µL) and 
Sodium Ascorbate in water (1.55 mg, 7.84 µmol, 0.4 eq., in 200 µL). The reaction mixture was 
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stirred under inert atmosphere, at room temperature and in the dark for 5 min, then 5.28 in water 
was added (50.0 mg, 64.7 µmol, 3.3 eq., 400 µL). The THF and water volumes were adjusted to 
900 µL each and the mixture was stirred for 18 h. A MALDI mass analysis (DHB Matrix) assessed 
the formation of the product. Quadrasil™-MP (S/Cu 1.9:1, 5 mg)  was added to the reaction 
mixture, which was stirred for 20 min and then filtered off. The crude was dried, then redissolved in 
MeOH and purified by size exclusion chromatography on a Sephadex LH-20 (MeOH) column to 
give 37.2 mg of 5.44 as a colourless solid (yield 71 %). 
 
1H NMR (400 MHz, CD3OD): δ 8.01 (s, 3H, H1), 7.33 – 7.17 (m, 24H, HAr2, HAr3), 4.65-4.44 (m, 
24H, H8, HL1, CH2OH), 4.34-4.22 (m, 12H, CH2NH), 4.03-3.91 (m, 6H, H7), 3.90-3.87 (m, 3H, H2), 
3.87-3.81 (m, 3H, HD2), 3.75-3.39 (m, 28H, HD1, H3, H2, H6a, HL2, HL4, HL5, HL6, HL7, HL8), 3.30-
3.20 (m, 3H, H6b), 2.92-2.75 (m, 6H, HD4, HD5), 2.01-1.68 (m, 12H, HD3, HD6), 1.43 (s, 9H, tBu). 
13C NMR (100 MHz, CD3OD): δ 176.85, 176.63 (CONH), 158.58 (COOtBu), 146.17 (CT4), 
141.58, 139.07, 138.98 (CAr1, CAr4), 128.38, 128.16 (CAr2, CAr3), 126.07 (CT5), 100.95 (C1), 80.24 
(CquattBu), 76.25 (CD1), 74.05 (C5), 73.00 (CD2), 72.44, 72.34, 72.25, 72.09, 71.34, 70.75, 70.07 (C3, 
C2, CL2, CL4, CL5, CL6, CL7), 69.79 (C4), 68.49 (C7), 65.34, 64.92 (CL1, CH2OH), 51.69 (C8), 46.57 
(CL3), 44.10 (CL8), 43.67 (CH2NH), 42.66 (C6), 41.78, 41.70 (CD4, CD5), 29.81, 29.35 (CD3, CD6), 
28.91 (CtBu). 
 
MS (MALDI, DHB matrix): calculated for [C129H182ClN18O41]+: 2676.4, found: 2676.0 
calculated for [C129H181ClN18O41Na]+: 2698.4, found: 2698.9 
 
[α]D25: 1.6 (c = 0.75 in MeOH) 
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Synthesis of trivalent glycodendrimer, 5.45 
 
 
To a solution of 5.44 (37.2 mg, 13.9 µmol, 1 eq.) in dry DMF (200 µL), sodium azide (4.5 mg, 69 
µmol, 5 eq.) and NaI (0.2 mg, 1.4 µmol, 0.1 eq.) were added. The reaction was stirred at 50 °C for 6 
days, assessing the total conversion of the starting material by MALDI MS analysis (matrix DHB). 
The solvent was removed under reduce pressure and the crude residue was purified by size 
exclusion chromatography on a Sephadex LH-20® column to give 31.4 mg of 5.45 as a colourless 
solid (yield 84 %). 
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1H NMR (400 MHz, CD3OD): δ 8.00 (s, 1H, HT5), 7.30 – 7.15 (m, 24H, HAr2, HAr3), 4.85 (bs, 3H, 
H1), 4.65-4.45 (m, 24H; H8, HL1, CH2OH), 4.50-4.40 (m, 12H, CH2NH), 4.00-3.88 (m, 6H, H7), 
3.88-3.84 (m, 3H, H2), 3.84-3.80 (m, 3H, HD2), 3.72-3.65 (m, 3H, H3), 3.57-3.33 (m, 26H, HD1, HL2, 
HL4, HL5, HL6, HL7, H4, H5, H6b), 3.28-3.18 (m, 3H, H6b), 2.91 – 2.76 (m, 6H, HD4, HD5), 1.96-1.68 
(m, 12H, HD3, HD6), 1.41 (s, 18, tBu). 
13C NMR (100 MHz, CD3OD): δ 176.86, 176.64 (CONH), 158.58 (COOtBu), 146.13 (CT4), 
141.58, 141.53, 139.07, 138.98 (CAr1, CAr4), 128.37 (CAr2, CAr3), 128.16 (CT5), 100.96 (C1), 80.24 
(CquattBu), 76.24 (CD1), 74.05 (C5), 72.34 (CD2), 72.23, 72.15, 71.40, 71.15, 70.76, 70.12, 69.78 (C3, 
C2, CL2, CL4, CL5, CL6, CL7), 68.49 (C4), 65.32 (C7), 64.91 (CL1, CH2OH), 51.78, 51.69 (C8, CL8), 
46.57 (CL3), 43.66 (CH2NH), 42.65, 41.77 (C6), 41.69 (CD4, CD5), 29.82, 29.33 (CD3, CD6), 28.91 
(CtBu). 
 
MS (MALDI, DHB matrix): calculated for [C129H181N21O41Na]+: 2704.9, found: 2704.4 
 
[α]D25: -0.2 (c = 0.55 in MeOH) 
 
Synthesis of nonavalent glycodendrimer, 5.46 
 
 
To freshly purified scaffold (5.31) (0.54 mg, 2.26 µmol, 1 eq.) dissolved in 40 µL of THF, under 
inert atmosphere at room temperature, reagents were added as solutions in the following order: 
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TBTA in THF (0.24 mg, 0.45 µmol, 0.2 eq., in 40 µL), CuSO4·5H2O in water (0.06 mg, 0.23 µmol, 
0.1 eq., in 25 µL), Sodium Ascorbate in water (0.18 mg, 0.9 µmol, 0.4 eq., in 25 µL). The reaction 
mixture was stirred under inert atmosphere, at room temperature and in the dark for 5 min, then 
5.45 in water (20 mg, 7.5 µmol, 3.3 eq., in 100 µL). The THF and water volumes were adjusted to 
200 µL each and the mixture was stirred for 18 h. A MALDI mass analysis (DHB Matrix) assessed 
the formation of the product. Quadrasil™-MP (S/Pd 32.8:1, 5 mg) was added to the reaction 
mixture, which was stirred for 10 min, and then filtered off. The crude was dried, then redissolved 
in MeOH and purified firstly by size exclusion chromatography on a Sephadex LH-20 (MeOH) 
column to give 14.4 mg of 5.46 as a colorless solid (yield 77 %). 
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1H NMR (400 MHz, CD3OD): δ 8.02 (s, 3H, HTC5), 7.96 (s, 9H, HT5), 7.28-7.10 (m, 72H, HAr2, 
HAr3), 6.34 (s, 3H, HArC2), 4.80 (bs, 9H, H1), 4.55-4.30 (m, 78H, H8, HL1, HL8, CH2OH), 4.28-4.20 
(m, 36H, CH2NH), 4.00-3.75 (m, 42H, H7, H2, HD2, HL7), 3.70-3.68 (m, 9H, H3), 3.63 – 3.55 (m, 
9H, HD1), 3.53-3.33 (m, 9H, H5, H4, HL2, HL4, HL5, HL6, H6a), 3.29-3.20 (m, 9H, H6b), 2.80-3.70 (m, 
18H, HD4, HD5), 1.86-1.56 (m, 36H, HD3, HD6), 1.38 (s, 81H, tBu). 
13C NMR (100 MHz, CD3OD): δ 176.86, 176.62 (CONH), 146.12 (CT4, CTC4), 141.60, 141.56, 
139.09, 138.99 (CAr1, CAr4), 128.39, 128.18 (CAr2, CAr3), 101.51 (C1), 80.26 (CquattBu), 76.25 (CD1), 
74.07 (C5), 72.36-69.80 (C2, CD2, C3, C4, CL2, CL4, CL5, CL6), 68.47 (C7), 65.39, 64.92 (CL1, 
CH2OH), 51.67 (CL8, C8), 46.58 (CL3), 43.68 (CH2NH), 41.80, 41.74 (C6), 30.70 (CD3, CD6), 28.97 
(CtBu). 
 
MS (MALDI, DHB matrix): calculated for [C402H555N63O126Na]+: 8309.1, found: 8319.7 
 
[α]D25: -2.5 (c = 0.31 in MeOH) 
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Synthesis of nonavalent glycodendrimer, 5.47 
 
	  
To a stirred solution of 5.46 (6.0 mg, 0.72 µmol, 1 eq.) in 100 µL of dry CH2Cl2, 100 µL of TFA 
were added under inert atmosphere. The reaction was stirred for 2 h, at room temperature and under 
nitrogen atmosphere. A MALDI mass analysis (HCCA matrix) revealed that the reaction. The 
reaction mixture was dried and washed with Et2O (3 x 1 mL), affording 6.0 mg of final product 
(5.47) as a brownish solid (yield 100 %).	  
 
MS (MALDI, DHB matrix): calculated for [C357H484N63O108]+: 7386.0, found: 7382.6 
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Synthesis of nonavalent glycodendrimer, 5.48 
 
 
 
To a shaken solution of 5.47 (6 mg, 7.24 µmol, 1 eq.) in 550 µL of dry MeOH, Amberlyst A21® (12 
mg, 100 eq.) was added, under inert atmosphere at room temperature, and the reaction was shaken 
at 1500 rpm for 3 h. Then the crude was filtered on a cotton pad to remove the resin, washed with 
MeOH and then dried. 4.91 mg of final product 5.48 were obtained as a brownish solid (yield 92 
%).  
 
NMR (CD3OD): compound 5.48 has a too low solubility in CD3OD to acquire interpretable 1H and 
13C NMR spectra.  
 
MS (MALDI, HCCA matrix): calculated for [C357H484N63O108]+: 7386.0, found: 7384.1 
 
[α]D25: /// (5 mg of 5.48 were not soluble in 2 mL of MeOH) 
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In this thesis, the synthesis of multivalent mannose-based compounds as effective DC-SIGN 
antagonists is described. DC-SIGN is a tetrameric C-type lectin expressed on the surface of 
Dendritic Cells and responsible for the early stage of several viral infections, like the HIV one. 
Constructs here synthesised were equipped with two active pseudo-disaccharide ligands already 
developed in our laboratories: 1.7 and 1.9 (Figure 6.1), based on one mannose residue connected to 
a functionalized cyclohexane. Compound 1.9 was already demonstrated to be 3 times more active 
towards DC-SIGN than 1.7 (IC50 = 300 µM vs 1000 µM, respectively, calculated through SPR 
inhibition assays using BSA-Mannotrioside as competitor).   
 
 
Figure 6.1 Structure of pseudo-mannobioside identified as lead DC-SIGN ligands in the Bernardi group. 
 
It is well known from the literature and from previous studies conducted in the group that 
multivalent ligands are able to bind to their biological target tighter than to the corresponding 
monovalent ones. Indeed, the synthesis of tetravalent, hexavalent and nonavalent presentations of 
both 1.7 and 1.9 (Figure 6.2) led to more powerful compounds, displaying an activity that increased 
by increasing the valency. Remarkably, multivalency amplified the difference in the activity 
between the simple monovalent ligands, since multivalent compounds based on 1.9 were now one 
order of magnitude more active than those based on 1.7 (SPR competition assays).  
 
 
Figure 6.2 Schematic structure of tetravalent, hexavalemt and nonavalent compounds based on 1.7 and 1.9 previously 
synthesised in our group. 
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Nonetheless, computational studies demonstrated that the multivalent effect associated to these 
compounds can be due only to the statistical rebinding effect or to protein clustering. A chelating 
binding mechanism was excluded, since the distance between two binding sites in DC-SIGN is 
about 4 nm, whilst artificial tetravalent and hexavalent compounds were not able to cover a distance 
longer than 36 Å. Nonavalent derivatives based on 1.9 had a rather low solubility in water (≤ 1 
mM), suggesting that an approach based only on increased valency is limiting, at least for optimized 
and functionalized compounds like 1.9.  
For these reason, in this thesis we’ve strived to obtain compounds, based on 1.7 and 1.9, able to 
exploit also the chelating effect, still with a relative low valency. We therefore designed compounds 
characterized by molecular rod cores, that should be able to control the relative disposition of active 
ligands, thus allowing the overall molecule to span the distance required to bridge two DC-SIGN 
binding sites. As molecular rods, we used three phenylene-ethynylene-based molecules (Rod1-3), 
having three different lengths (Figure 6.3A). They were synthesisd starting from the commercially 
available p-dimethoxybenzene and making extensive use of Sonogashira coupling reactions with 
orthogonally protected alkynes.  
With the aim to exploit both chelation and statistical rebinding mechanisms, hexavalent compounds 
(Figure 6.3B) were synthesised by connecting two trivalent dendrons to the rods. In order to deeply 
investigate the role of valency, corresponding divalent compounds were produced (Figure 6.3C). 
They were equipped with monovalent ligands elongated with a flexible linker having the same 
length of the dendron chain. Finally, the influence of the linker flexibility was explored by 
producing also divalent compounds directly combining monovalent ligands with Rod3 (Figure 
6.3D). This library of artificial compounds was synthesised exploiting Copper-catalyzed azide-
alkyne cycloadditions to couple the biological active moieties (i.e. trivalent dendrons, elongated 
monovalent ligands and simple monovalent ligands), all equipped with an azido group, with the 
terminal alkynes of the rods. Final compounds were purified using size exclusion chromatography 
and reverse phase chromatography and characterized through NMR and MALDI spectroscopy.  
 
Chapter 6 
 
	  
297	  
 
Figure 6.3 Structures of the elongated dendrimers described in this thesis. A) Rod1, Rod2 and Rod3 are molecular 
cores used to control the overall length of final molecules: B) hexavalent ones, C) divalent ones with a long and flexible 
linker, C) divalent ones with a shirt linker. 
 
The possibility that these artificial compounds can act as DC-SIGN chelating agents was assessed 
through computational modelling, demonstrating that they can all span a distance higher than 4 nm. 
Compounds were tested through SPR inhibition assays, evaluating their ability to inhibit DC-SIGN 
anchoring to a highly mannosylated surface (Man α1-3[Manα1-6]Man-BSA, 15 trimannose 
residues, on average) and through a trans-infection inhibitions assays, using a cellular model HIV 
infection. First of all, the importance of the ligand in the overall activity was confirmed. Indeed, 
compounds based on 1.9 were always more active than those carrying 1.7, as expected. The effect 
of the Rod length clearly emerged from SPR inhibition experiments conducted on 1.7 derivatives 
and for trans-infection assays conducted on 1.9 derivatives. Indeed, compounds bearing the longest 
Rod3, displayed the highest activity in each series. Moreover, the efficient role of the statistical 
rebinding effect was demonstrated, since hexavalent compounds had higher activities than 
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corresponding divalent compounds, based on monovalent ligand concentrations. Finally, divalent 
molecules having the short linker were two times more active than the corresponding ones including 
the flexible, long linker; too flexible linkers were therefore demonstrated to have a negative effect, 
probably because of the enthalpic and entropic penalties that they have to pay to match receptor 
binding sites and to decrease their degrees of freedom. The optimal combination of compound 1.9, 
Rod3 and trivalent dendrimers led to compound PM26 (Figure 6.4); its IC50 = 24 nM in the trans-
infection inhibition assay made it one of the most powerful inhibitors of DC-SIGN mediated HIV 
adhesion on cells, relative to other constructs of much higher valency. These results therefore 
highlight that a rational design can lead to efficient binders of target proteins, even with a relatively 
low valency. 
 
 
Figure 6.4 Structure of hexavalent compound PM26, which is the hexavalent presentation of the disaccharide 1.9 using 
Rod3. It is able to inhibit the DC-SIGN-mediated HIV infection with IC50 = 24 nM. 
 
Results obtained from the SPR and the trans-infection inhibition campaign didn’t always give to 
comparable results in terms of IC50 values. Besides the different experimental set up (i.e. DC-SIGN 
is soluble in the SPR assay, whilst embedded in the membrane in the infection experiment), this 
may be due to internalization processes happening in the cellular model. Internalization of PM26 in 
Dendritic Cells was confirmed by confocal microscopy experiments, whose feasibility was linked to 
the intrinsic fluorescence behaviour of Rod3. Co-localization experiments established that, once 
internalized, PM26 is routed to lysosomes. These results make PM26 also a possible stimulator of 
the immune response. 
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The morphological behaviour of synthesised compounds, which have a clear amphiphilic structure 
(i.e. a hydrophobic core connected to hydrophilic heads and hydrophilic chains), was investigated in 
aqueous solution. The scope of this investigation was understanding if their biological performances 
depended on monomers or on aggregates self-assembled in water. Through DOSY NMR and AUC 
experiments we established that compounds are mainly monomers in solution. Nevertheless, large 
species were observed through DLS and TEM analysis; they have a RH ≈ 100-200 nm, whereas the 
one associated to monomers is ≈ 1 nm (computational studies and DOSY NMR). Since aggregates 
don’t seem to depend on temperature nor concentration, and since they can be removed through 
centrifugation without re-forming, we postulated that they are pelleting molecular nucleus that 
failed to dissolve. Performing UV-Vis spectroscopy on two selected samples before and after 
centrifugation (4000 rpm, 1-40 h), we concluded that aggregates are only a small percentage (< 10 
%) of the totality of the sample. Since SPR analysis are conducted on centrifuged samples, obtained 
results should derive mainly from monomers. Trans-infection inhibition assays, on the contrary, are 
performed solubilizing the compound first in DMSO and then diluting it in the biological buffer; 
given the good solubilizing properties of DMSO, this procedure should in principle improve the 
dissolution of samples, thus reducing the amount of formed aggregates. Further experiments will be 
conducted to evaluate the morphology of aggregates.  
Future studies will be dedicated to evaluate the immunological properties of these compounds, 
especially the most active one, PM26. They will be investigated as stimulators of cytokines, 
chemokines and other co-stimulatory molecules released in the body as a response against 
infections.  
 
Selectivity was an important topic that I’ve pursued during my project. DC-SIGN is not the only 
mannose-binding lectin expressed by DCs. Langerin is another receptor able to recognize HIV; still, 
unlike DC-SIGN, it is able to promote virus degradations. Therefore, artificial DC-SIGN ligands 
not targeting Langerin have to be produced in order not to contrast the efficient anti-pathogenic 
activity of the human body. The synthesis of cationic constructs can be a way to produce selective 
DC-SIGN ligands. Indeed, Langerin has two Lysine residues in its binding site that can establish 
electrostatic repulsions with positively-charged groups. We therefore envisaged to modify 
compounds 1.7 and 1.9 by replacing the –OH group in the 6-position of the mannose residue with 
an amino group, which should be protonated at physiological pH. For this reason, compounds 5.1 
and 5.2 (Figure 6.5) were synthesised. The selectivity of compounds 5.1 and 5.2 vs Langerin 
compared to 1.7 and 1.9 was confirmed through SPR competition assays. Compound 5.2 was totally 
unable to bind to Langerin, even at a concentration ≈ 5 mM.  
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Figure 6.5 Structure of compounds 5.1 and 5.2 with an improved selectivity for DC-SIGN vs Langerin. 
 
Compounds 5.1 and 5.2 were used to decorate multivalent scaffolds, thus potentially increasing 
their overall affinity for DC-SIGN. In principle, they should lead to polycationic species with a high 
selectivity vs Langerin. Since polycationic are known to be potentially toxic for cells, we 
investigated the cytotoxic behaviour of one selected multivalent compound based on 5.1. After 24 h 
of incubation, the tested compound was found to be cytotoxic only at concentration > 50 µM. These 
negative behaviour could therefore be overcome, assuming that all multivalent compounds based on 
5.1 and 5.2 will be active already at a concentration << 50 µM. Future studies will characterize their 
biological activity as DC-SIGN ligands and HIV-adhesion inhibitors.  
 
The results of Chapter 2 were recently published: 
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Trabattoni; M. Clerici; F. Fieschi; A. Bernardi, Designing nanomolar antagonists of DC-SIGN-
mediated HIV infection: ligand presentation using molecular rods, Chem. Commun. 2015, 3816. 
 
Manuscripts related to the results of Chapter 3 and 4 are under preparation. 
